

# EAU 24 | PARIS, FRANCE 5-8 April 2024

Cutting-edge Science at Europe's largest Urology Congress



[www.eau24.org](http://www.eau24.org)

**eau** European  
Association  
of Urology

# Urinary stone management: Exploring innovative techniques and technologies

Plenary Session

Friday 5 April  
08:00 - 10:00

**Location** Green Area, eURO Auditorium 1

**Chairs** A. Bujons Tur, Barcelona (ES)  
T. Knoll, Sindelfingen (DE)

## Learning objectives

This plenary session focuses on advancing knowledge in diagnosing and treating urolithiasis through innovative methods. It emphasizes learning about new devices, robotic tech, and minimizing procedure-related risks like radiation. Discussions on challenging cases aim to enhance safety and efficacy, improving patient care outcomes.

08:00 - 08:01

## Introduction

T. Knoll, Sindelfingen (DE)

08:01 - 08:09

## State-of-the-art lecture Radiation dose in endourology: How to achieve ALARA?

E. Emiliani, Barcelona (ES)

08:09 - 08:17

## State-of-the-art lecture Do we treat our patients right? Shared decision-making and patient-reported outcome measures in urolithiasis

E. Ventimiglia, Milan (IT)

08:17 - 08:34

## Case discussion How I evaluate and counsel high-risk stone formers

*Moderator*

M. Straub, Munich (DE)

08:17 - 08:19

## Case presentation

M. Straub, Munich (DE)

08:19 - 08:34

## Discussion

*Panel*

M. Monga, Cleveland (US)

A. Skolarikos, Athens (GR)

C.A. Wagner, Zurich (CH)

08:34 - 08:46

## American Urological Association (AUA) lecture Role and outcomes of suction devices in ureteroscopy

B. H. Eisner, Boston (US)

08:46 - 09:06

## Debate URS with modern lasers for larger stones?

*Moderator*

M. Brehmer, Stockholm (SE)

08:46 - 08:48

## Introduction

M. Brehmer, Stockholm (SE)

08:48 - 08:53

## Yes: URS for big stones

Ö. Ulvik, Bergen (NO)

08:53 - 08:58

## No: PCNL for big stones

T.E. Şener, Istanbul (TR)

08:58 - 09:06

## Discussion

09:06 - 09:16

**Case-based video presentation** PCNL troubleshooting in cases with previous renal surgery

W. Gamal, Sohag (EG)

---

09:16 - 09:43

**Case discussion** The grey zone: The best treatment for a 1.5 cm pelvic stone is...

*Moderator*

T. Taily, Ghent (BE)

---

09:16 - 09:18

**Case presentation**

T. Taily, Ghent (BE)

---

09:18 - 09:23

**Ureterscopy**

A. Sierra Del Rio, Barcelona (ES)

---

09:23 - 09:28

**Percutaneous nephrolithotomy**

J. Desai, Ahmedabad (IN)

---

09:28 - 09:33

**Shock wave lithotripsy**

M.M. Popiolek, Örebro (SE)

---

09:33 - 09:43

**Discussion**

---

09:43 - 09:51

**State-of-the-art lecture** Status of robotics in ureteroscopy

S.Y. Cho, Seoul (KR)

---

09:51 - 09:59

**State-of-the-art lecture** Follow-up imaging after stone treatment: Is standardisation of post-up imaging possible?

A. Pietropaolo, Southampton (GB)

---

09:59 - 10:00

**Closing remarks**

A. Bujons Tur, Barcelona (ES)

# Controversies on GU cancer staging: Is it only imaging?

Plenary Session

**Friday 5 April**  
**08:00 - 10:00**

**Location** Purple Area, eURO Auditorium 2  
**Chairs** M. Rouprêt, Paris (FR)  
J. Walz, Marseille (FR)

**08:00 - 08:03**

**Welcome and introduction**

**08:03 - 08:37**

**Controversies in initial staging for prostate cancer**

**Disease characterisation**

**08:03 - 08:10**

**Advantages and pitfalls of molecular imaging**

K. Herrmann, Essen (DE)

**08:10 - 08:17**

**Are biomarkers better?**

B.F. Chapin, Houston (US)

**The PSMA M1a positive patient**

**08:17 - 08:24**

**Treat as M1**

C. Sweeney, Adelaide (AU)

**08:24 - 08:31**

**Treat as M0**

H.G. Van Der Poel, Amsterdam (NL)

**08:31 - 08:37**

**Discussion**

**08:37 - 09:04**

**Controversies in initial staging for renal cell cancer**

**08:37 - 08:44**

**Evaluation with conventional imaging is enough**

J-C. Bernhard, Bordeaux (FR)

**08:44 - 08:51**

**Evaluation with molecular imaging is the way to go**

P. Mulders, Nijmegen (NL)

**08:51 - 08:58**

**Biopsy and pathology is the solution**

Y. Allory, Saint-Cloud (FR)

**08:58 - 09:04**

**Discussion**

**09:04 - 09:45**

**Controversies in initial staging for bladder cancer**

**09:04 - 09:11**

**No need for TURB, Vi-RADS makes the diagnosis**

V. Panebianco, Rome (IT)

**09:11 - 09:18**

**TURB is mandatory before any treatment**

A. Van Der Heijden, Nijmegen (NL)

**Disease characterisation**

**09:18 - 09:25**

**FDG-PET for staging, is it mandatory?**

S. Shariat, Vienna (AT)

**09:25 - 09:32**

**Histological subtypes, molecular phenotype and biomarkers are enough**

E. Compérat, Vienna (AT)

09:32 - 09:39

**MRI in evaluation after neoadjuvant chemotherapy**

A. Necchi, Milan (IT)

09:39 - 09:45

**Discussion**

---

09:45 - 09:55

**SPARC: Standardized PSMA PET Analysis and Reporting Consensus**

A.S. Bjartell, Malmö (SE)

---

09:55 - 10:00

**Enhancing access to radiotheranostics for cancer care, worldwide**

A. Viana, Auderghem (BE)

# Chronic pelvic pain in men and women

ESU Course 02

Friday 5 April  
08:30 - 11:30

**Location** Purple Area, E03

**Chair** B. Parsons, Exeter (GB)

Voting will be available via the EAU24 App or via [www.qna.at/eau](http://www.qna.at/eau)

## **Learning objectives**

The urologist is often dealing with patients having Chronic Pelvic Pain. This course will offer the urologist practical guidance in treating these patients. In the case discussion the participants will have the opportunity to help outlining the problem. In the lectures, theoretical knowledge will be translated into daily guidelines for diagnostics and treatment of patients with pelvic pain.

At the end of this course the participant will:

- Know the basic principles of treating patients with chronic pelvic pain.
- Know how to rule out well-known causes.
- Have knowledge of the myofascial and psychological aspects.
- Be able to refer patients at the right time to the right team.

## **Chronic pelvic pain, the basics: Mechanisms and terminology**

P. Abreu-Mendes, Porto (PT)

## **Chronic pelvic pain in men: Case presentation and discussion**

B. Parsons, Exeter (GB)

## **Chronic pelvic pain in men: Practical guidelines on diagnostics and treatment**

B. Parsons, Exeter (GB)

## **Chronic pelvic pain in women: Case presentation and discussion**

P. Abreu-Mendes, Porto (PT)

## **Chronic pelvic pain in women: Practical guidelines on diagnostics and treatment**

P. Abreu-Mendes, Porto (PT)

## **The interdisciplinary approach: Team members and organisation**

B. Parsons, Exeter (GB)

Friday 5 April  
08:30 - 11:30

**Location** Purple Area, E04

**Chair** S. Minhas, London (GB)

## Learning objectives

This novel and revised course will give a state-of-the-art update on the variety of genital diseases that urologists will encounter in daily clinical practice. The faculty consists of a group of internationally renowned experts in this field.

A spectrum of pathologies can affect the male genitals, from benign disorders to cancers. There will be particular focus and emphasis on interactive case-based discussions and surgical videos of the latest surgical techniques used in this evolving field. The course will also deal with the surgical management of these diseases including the surgical indications and techniques used in genital reconstructive surgery. Particular focus will be on:

- The aetiology, diagnosis and medical management of the common genital skin diseases including inflammatory conditions.
- The medical and surgical management of HPV, BXO and pre-malignant conditions of the penis, including the techniques of circumcision, skin grafting, glans resurfacing, surgery for buried penis and the correction of genital lymphoedema.
- The surgical management of Peyronie's disease including plication procedures and grafting
- The management of penile carcinoma including the aetiopathogenesis, techniques/outcome of organ-sparing surgery and ilioinguinal lymphadenectomy will be discussed and illustrated.

## Surgical management of Peyronie's disease

S. Minhas, London (GB)

## Penile and scrotal dermatology for the urologist

M. Skrodzka, London (GB)

## Circumcision, frenuloplasty and preputioplasty

A. Parnham, Manchester (GB)

## The buried penis

S. Minhas, London (GB)

## Management of genital lymphoedema

M. Skrodzka, London (GB)

## Premalignant lesions of the penis and scrotum

S. Minhas, London (GB)

## Penile cancer: Penile preserving surgery

M. Skrodzka, London (GB)

## Penile cancer: Management of lymph nodes

A. Parnham, Manchester (GB)

Friday 5 April  
08:30 - 11:30

**Location** Purple Area, E06

**Chair** E. Barret, Paris (FR)

### Learning objectives

Focal treatment (FT) is about eradicating the cancer lesion within the prostate while preserving genitourinary function. This interactive course offers delegates:

- understanding of the rationale for focal treatment and patient selection criteria.
- an update on principles, outcome and side effects of focal technologies.
- a thorough discussion of biopsy strategies and imaging in diagnostic work-up and follow-up
- information about existing registries.

As men with prostate cancer are getting younger, the side effects of whole-gland treatment are getting more important. With several new technologies available a significant development of focal treatment is expected in the coming years.

### Definition, rationale and role in the changing landscape of localised prostate cancer

C. Orczyk, London (GB)

### Patient selection tools

J.I. Martínez Salamanca, Madrid (ES)

### How to select the energy source?

E. Barret, Paris (FR)

### The post-treatment monitoring

C. Orczyk, London (GB)

### The outcomes and the ongoing trials

J.I. Martínez Salamanca, Madrid (ES)

### Clinical cases: Real-life cases, stories of success and failure

E. Barret, Paris (FR)



**Friday 5 April**  
**08:30 - 11:30**

**Location** Purple Area, E07

**Chair** A. Breda, Barcelona (ES)

### **Learning objectives**

Minimally-invasive surgery has steadily improved over the last years. Today one can approach with confidence new, difficult and challenging situations. The course is structured to evaluate and explore the increasing indications and possible complications of laparoscopic and robotic kidney surgery. This course will focus upon common and uncommon complications and how to manage and prevent them. In addition, special situations such as single port inguinal approach, zero ischaemia time, cava thrombus, accidental splenectomy and living donor nephrectomy will be presented.

### **Introduction**

A. Breda, Barcelona (ES)

---

### **Transperitoneal renal surgery: Step by step**

A. Breda, Barcelona (ES)

---

### **Retroperitoneal renal surgery: Step by step**

A. Breda, Barcelona (ES)

P.J. Zondervan, Amsterdam (NL)

---

### **Complex kidney cases**

A. Breda, Barcelona (ES)

P.J. Zondervan, Amsterdam (NL)

---

### **Intraoperative complications: Incidence and management**

P.J. Zondervan, Amsterdam (NL)

---

### **Postoperative complications: Incidence and management**

A. Breda, Barcelona (ES)

---

### **Special cases**

A. Breda, Barcelona (ES)

P.J. Zondervan, Amsterdam (NL)

Friday 5 April

08:30 - 11:30

**Location** Purple Area, E05

**Chair** F. O'Kelly, Dublin (IE)

### **Learning objectives**

Many children with congenital anomalies will present to the adult urologist with long-term sequelae, hence the importance of transition of care into adulthood. It is important to know what has been done in terms of surgical procedures so that the adult urologist knows what is expected and what should or can be done. It is also important to know how the urological follow-up of these patients should be done. The most common paediatric conditions will be explored by interactive case presentations.

### **Vesico-ureteral reflux (VUR)**

F. O'Kelly, Dublin (IE)

### **Bladder and bowel dysfunction**

R.J.M. Lammers, Groningen (NL)

### **Ureteropelvic junction (UPJ) and uterovesical junction (UVJ) obstruction**

B. Burgu, Ankara (TR)

### **Most frequent penile abnormalities and undescended testis**

B. Burgu, Ankara (TR)

### **Neurogenic bladder**

R.J.M. Lammers, Groningen (NL)

### **Transition of care into adulthood**

F. O'Kelly, Dublin (IE)

Friday 5 April  
08:30 - 11:30

**Location** Purple Area, E01

**Chair** M.M. Fode, Herlev (DK)

## Learning objectives

The course will enable participants to perform a basic diagnostic evaluation and give knowledge of advanced diagnostic methods. Participants will learn when testosterone replacement therapy is indicated and how to apply it and how to tailor PDE5-Is to the individual patient. Further, participants will gain insight into more advanced medical and mechanical ED treatments. The course will also include discussions of management/controversies regarding:

- Ejaculatory dysfunction
- Priapism
- Recurrent priapism
- Sexual rehabilitation following radical prostatectomy

## Introduction

M.M. Fode, Herlev (DK)

## Diagnostics: What is necessary?

D. Hatzichristou, Thessaloniki (GR)

## Testosterone replacement

E.C. Şerefoğlu, Istanbul (TR)

## Oral therapy for erectile dysfunction

M.M. Fode, Herlev (DK)

## Therapy of erectile dysfunction when pills fail

D. Hatzichristou, Thessaloniki (GR)

## Tips, tricks and questions from the audience

M.M. Fode, Herlev (DK)

D. Hatzichristou, Thessaloniki (GR)

E.C. Şerefoğlu, Istanbul (TR)

## Management of ejaculatory dysfunction

E.C. Şerefoğlu, Istanbul (TR)

## Peyronie's disease and priapism

D. Hatzichristou, Thessaloniki (GR)

## What to do after radical prostatectomy?

M.M. Fode, Herlev (DK)

# Urological patient presentations

Patient Office - Posters

**Friday 5 April**  
**09:00 - 10:00**

**Location** Green Area, W08

**Chair** E. Rogers, Roscommon (IE)

**Moderator** L. Makaroff, Chinnor (GB)

## **Learning objectives**

The session seeks to highlight the needs of patients with urological disease; identify innovations in patient-centred care, and to listen to patients' voices as they report the outcomes and experiences of their treatment.

Presentations have a length of 5 minutes and are followed-up by 4 minutes discussion.

[We encourage participants in this session to view the abstracts before the session. All abstract bodies, posters, videos and webcasts can be viewed on the EAU\(N\)24 Resource Centre or at the digital screens in front of the Purple Area, EGPT.](#)

**09:00 - 09:01**

## **Introduction**

**PA1**

### **How can patients be better supported when deciding on localised kidney cancer treatment?**

K. Beyer, Rotterdam (NL)

**PA2**

### **Does video-based informed consent influence peri-operative experiences in patients who had undergone renal cancer surgery?**

M. Marchetti, London (GB)

**PA3**

### **Patient treatment experience in prostate cancer: Findings from a web-based survey**

S. Moneer, Alexandria (US)

**PA4**

### **Action on shared decision-making from a multi-stakeholder collaboration on continence care**

M.L. Van Poelgeest-Pomfret, Oegstgeest (NL)

**PA5**

### **Barriers and solutions for patient engagement in oncology research: Findings from Project RISE**

J. Daly, Galway (IE)

**09:55 - 10:00**

## **Closing remarks and announcement of prize winners**

# Prime time for adjuvant treatment in locally advanced bladder cancer?

Game changing session

Friday 5 April

10:00 - 10:15

**Location**

Purple Area, eURO Auditorium 2

**Chairs**

M. Rouprêt, Paris (FR)

J. Walz, Marseille (FR)

10:00 - 10:05

**Clinical outcomes in patients with high-risk, post-cystectomy muscle-invasive bladder cancer (MIBC) with persistent circulating tumour DNA-negative (ctDNA-) status on serial testing: surveillance analysis from the IMvigor011 study**

T. Powles, London (GB)

10:05 - 10:10

**Extended follow-up from CheckMate 274 including the first report of overall survival outcomes**

M. Galsky, New York (US)

10:10 - 10:15

**Discussion**

J. Boormans, Rotterdam (NL)

# Nutrition: Patients with cancer and the importance of nutrition

Patient Office - Roundtable

Friday 5 April

10:15 - 11:15

**Location** Green Area, W08

**Chair** R. Greene, Amsterdam (NL)

## Learning objectives

The roundtable, 'The Impact of Nutrition on Urological Cancers,' will feature insights from a medical professional, dietician/nutritionist, patient, and oncology nurse. Discussions include nutrition's importance, its role in a healthy lifestyle, its link to prostate cancer, and the oncology nurse's role in nutritional support. Participants will learn about challenges due to limited nutrition understanding. The conversation will explore customizing a healthy lifestyle, potentially through a five-step plan, to address nutritional challenges during and after prostate cancer treatment. The role of oncology nurses in providing nutritional support will be a key focus.

10:15 - 10:20

## Welcome and introduction

R. Greene, Amsterdam (NL)

10:20 - 10:30

## The significance of nutrition

M. Soeters, Amsterdam (NL)

10:30 - 10:40

## Role of nutrition in a healthy lifestyle

S. Beijer, Maastricht (NL)

10:40 - 10:50

## Nutrition and prostate cancer

P.S. Huesmann, Milan (IT)

10:50 - 11:00

## Benefits of multimodal prehabilitation interventions

B. Thoft Jensen, Aarhus (DK)

11:00 - 11:15

## Q&A and closing

R. Greene, Amsterdam (NL)

# Rapid-fire debates: Common problems and controversies in bladder cancer

Thematic Session

Friday 5 April  
10:45 - 12:45

**Location** Purple Area, eURO Auditorium 2

**Chairs** A.M. Kamat, Houston (US)  
A. Stenzl, Tübingen (DE)

## Learning objectives

Participants will learn to:

1. Describe the complexities related to the diagnosis and management of bladder cancer.
2. Apply existing treatment options to appropriate patients across the spectrum of disease, from non-muscle invasive to advanced, metastatic bladder cancer.
3. Select appropriate patients for de-intensification of interventions.
4. Identify the importance of variant histology in bladder cancer management.
5. Compare management strategies in BCG-unresponsive bladder cancer.
6. Cite evidence-based approaches to surgical treatment of bladder cancer.
7. Discuss evidence supporting current bladder preservation paradigms in non-muscle invasive and muscle-invasive bladder cancer.

10:45 - 10:48

## Session introduction

A.M. Kamat, Houston (US)

10:48 - 11:07

## Rapid Fire Debate 1: Is there any role for urinary markers other than cytology in era of modern cystoscopy in surveillance of patients? What about decreasing the decrease frequency of cystoscopy?

*Moderator* J. Palou, Barcelona (ES)

10:48 - 10:50

## Case presentation

J. Palou, Barcelona (ES)

10:50 - 10:54

## No, cytology is sufficient

E. Compérat, Vienna (AT)

10:54 - 10:58

## Yes, urinary markers are needed

T. Zuiverloon, Rotterdam (NL)

10:58 - 11:07

## Discussion/Q&A

11:07 - 11:26

## Rapid Fire Debate 2: How do we manage a patient with frequent recurrence of LG papillary tumours in the bladder despite intravesical chemotherapy and BCG therapy? No clinical trial available

*Moderator* M. Babjuk, Prague (CZ)

11:07 - 11:09

## Case presentation

M. Babjuk, Prague (CZ)

11:09 - 11:13	<b>Repeated TUR +/- chemo is necessary</b> K. Chen, Singapore (SG)
11:13 - 11:17	<b>Time to do surveillance/de-escalate therapy</b> P. Spiess, Tampa (US)
11:17 - 11:26	<b>Discussion/Q&amp;A</b>
<hr/>	
11:26 - 11:45	<b>Rapid Fire Debate 3: Healthy Patient with T1HG Micropapillary NMIBC - What is the best treatment option? What if mixed histologic subtypes in addition to micropapillary?</b>  <i>Moderator</i> P. Gontero, Turin (IT)
11:26 - 11:28	<b>Case presentation</b> P. Gontero, Turin (IT)
11:28 - 11:32	<b>Intravesical therapy best option</b> B. Pradere, Toulouse (FR)
11:32 - 11:36	<b>Upfront radical cystectomy is best</b> A.M. Kamat, Houston (US)
11:36 - 11:45	<b>Discussion/Q&amp;A</b>
<hr/>	
11:45 - 12:04	<b>Rapid Fire Debate 4: Patient with MIBC after radical cystectomy – can we use ctDNA to guide decisions on adjuvant chemo/IO? What about utDNA for Bladder Sparing after NAC?</b>  <i>Moderator</i> A. Necchi, Milan (IT)
11:45 - 11:47	<b>Case presentation</b> A. Necchi, Milan (IT)
11:47 - 11:51	<b>No, ctDNA/utDNA is not ready for prime-time use</b> P. Black, Vancouver (CA)
11:51 - 11:55	<b>Yes, ctDNA/utDNA should be used to make treatment decisions</b> J. Bjerggaard Jensen, Aarhus (DK)
11:55 - 12:04	<b>Discussion/Q&amp;A</b>
<hr/>	
12:04 - 12:23	<b>Rapid Fire Debate 5: The age-old debate – what is the best treatment – oncological and QOL – for young healthy patients with MIBC? What about health care related costs?</b>  <i>Moderator</i> J.A. Witjes, Nijmegen (NL)
12:04 - 12:06	<b>Case presentation</b> J.A. Witjes, Nijmegen (NL)
12:06 - 12:10	<b>Clearly XRT</b> A.J Birtle, Preston (GB)
12:10 - 12:14	<b>Clearly, radical cystectomy</b> J.W.F. Catto, Sheffield (GB)
12:14 - 12:23	<b>Discussion/Q&amp;A</b>



12:23 - 12:42

**Rapid Fire Debate 6: Patient with non-invasive, high-grade upper tract disease in setting of prior radical cystectomy – what is optimal management? What if GFR ~ 50 instead of 80?**

*Moderator*

M. Rouprêt, Paris (FR)

12:23 - 12:25

**Case presentation**

M. Rouprêt, Paris (FR)

12:25 - 12:29

**Conservative management should be offered**

S. Psutka, Seattle (US)

12:29 - 12:33

**Nephroureterectomy is needed**

A. Stenzl, Tübingen (DE)

12:33 - 12:42

**Discussion/Q&A**

---

12:42 - 12:45

**Closing remarks**

A. Stenzl, Tübingen (DE)

# Semi-live session: PCNL updates

Thematic Session

Friday 5 April  
10:45 - 11:45

**Location** Green Area, eURO Auditorium 1

**Chairs** O. Angerri Feu, Barcelona (ES)  
A. Skolarikos, Athens (GR)

**Learning objectives**

To show PCNL procedures in different clinical scenarios and different positions.

10:45 - 10:55	<b>Semi-live video presentation Endoscopic Combined Intrarenal Surgery (ECIRS) for horseshoe kidney stones</b> C.M. Cracco, Turin (IT)
10:55 - 11:00	<b>Discussion</b>
11:00 - 11:10	<b>Semi-live video presentation Prone Combined Intrarenal Surgery (ECIRS) for diverticular stones</b> P. Kallidonis, Patras (GR)
11:10 - 11:15	<b>Discussion</b>
11:15 - 11:25	<b>Semi-live video presentation Percutaneous nephrolithotripsy in patients with severe skeletal anomalies</b> J. Desai, Ahmedabad (IN)
11:25 - 11:30	<b>Discussion</b>
11:30 - 11:40	<b>Semi-live video presentation Bilateral synchronous percutaneous nephrolithotripsy</b> E. Emiliani, Barcelona (ES)
11:40 - 11:45	<b>Discussion</b>

# ERN eUROGEN: Update on rare and complex urology

Thematic Session

**Friday 5 April**  
**10:45 - 12:15**

**Location** Purple Area, S03

**Chairs** M. Battye, Nijmegen (NL)  
W.F.J. Feitz, Nijmegen (NL)

<b>10:45 - 11:15</b>	<b>ERN eUROGEN Patient Advocacy Group (ePAG)</b>
<b>10:45 - 10:55</b>	<b>Testicular/penile cancer support from the patient perspective (WS3)</b> R. Cornes, London (GB)
<b>10:55 - 11:05</b>	<b>Interstitial cystitis: When chronic pain invades the mind (WS2)</b> A. De Santis, Rome (IT)
<b>11:05 - 11:15</b>	<b>ePAG and experts discussion: Future perspectives and patients' expectation management</b>
<b>11:15 - 11:45</b>	<b>ERN eUROGEN Workstream 1: Rare congenital uro-recto-genital anomalies</b>
<b>11:15 - 11:25</b>	<b>Urethral duplications: The complexity of diagnosis and management</b> A. El-Ghoneimi, Paris (FR)
<b>11:25 - 11:35</b>	<b>Long-term care in posterior hypospadias</b> A. Morlacco, Padova (IT)
<b>11:35 - 11:45</b>	<b>Post-hypospadias urethral strictures: The challenge is not only the surgery</b> F. Campos Juanatey, Santander (ES)
<b>11:45 - 11:55</b>	<b>ERN eUROGEN Workstream 2: Functional urogenital conditions requiring highly specialised surgery</b>
<b>11:45 - 11:55</b>	<b>Urethral stenosis in women: Diagnosis, pitfalls, management options</b> M. Mancini, Padua (IT)
<b>11:55 - 12:05</b>	<b>ERN eUROGEN Workstream 3: Rare urogenital tumours</b>
<b>11:55 - 12:05</b>	<b>Sentinel lymph-node staging in testicular cancer patients</b> Y. Che, Düsseldorf (DE)
<b>12:05 - 12:15</b>	<b>Take home message on rare urology: Practice approaches and innovations</b>

# Surgical innovations: New techniques for safer procedures

Video session 01

Friday 5 April  
10:45 - 12:15

**Location** Green Area, S04

**Chairs** E. Laukhtina, Vienna (AT)  
M. Stöckle, Homburg (DE)

We encourage participants in this session to view the abstracts before the session. All abstract bodies, posters, videos and webcasts can be viewed on the EAU(N)24 Resource Centre or at the digital screens in front of the Purple Area, EGPT.

V001 (□: 7 min.)

**Endoscopic treatment of ureteral strictures with use of self-expanding ureteral stents.**

F. Kowalski, Bydgoszcz (PL)

V002 (□: 7 min.)

**Ileal Ureter Replacement and ileocystoplasty for the Treatment of Bilateral Ureteral Strictures and bladder contracture: Technique and Outcomes**

G. Wenzhi, Beijing (CN)

V003 (□: 6 min.)

**Negative Predictive Value of Intraoperative Fluorescence-guided Surgery of PSMA-Positive Prostate Cancer During Prostatectomy**

R. Contieri, Pieve Emanuele (IT)

V004 (□: 5 min.)

**Laser Speckle Contrast Imaging to detect prostatic artery during RALP**

M. Covas Moschovas, Celebration (US)

V005 (□: 7 min.)

**Prophylactic Lymphovenous Bypass during Inguinal Lymphadenectomy for Penile Cancer: A Promising Strategy to Prevent Lymphedema of the Lower Extremities**

N. Di Nardo, Luzern (CH)

V006 (□: 8 min.)

**Utility of 3D-models in the planning and outcome assessment of laparoscopic resolution of urinary tract complications after kidney transplantation**

F.J. Burgos Revilla, Madrid (ES)

V007 (□: 6 min.)

**Robotic excision of extruded mid-urethral sling and concomitant bladder neck fascial sling placement**

C. Haudebert, Rennes (FR)

V008 (□: 6 min.)

**Robotical transperitoneal release of both pudendal and cluneal nerves for entrapment neuralgias**

O. Celhay, Bordeaux (FR)

# Joint Session of the European Association of Urology (EAU) and the Federation of ASEAN Urological Associations (FAUA)

Urology beyond Europe

**Friday 5 April**

**10:45 - 12:45**

**Location**

Green Area, W06

**Chairs**

E. Liatsikos, Patras (GR)

K.A. Mohd Ghani, Kuala Lumpur (MY)

S.V. Yrastorza, Quezon City (PH)

**10:45 - 11:00**

**FAUA: Past, present and future link between Europe and South East Asia**

S.V. Yrastorza, Quezon City (PH)

**11:00 - 11:15**

**Early radical cystectomy for high risk NMIBC. Is it better?**

N.A. Md.Yusoff, Kuala Lumpur (MY)

**11:15 - 11:30**

**Opportunities for Education, Training and Collaboration between FAUA AND EAU**

E. Liatsikos, Patras (GR)

**11:30 - 11:45**

**Application of Current recommendation and future trends of mCSPC and mCRPC treatment of Prostate Cancer in South East Asia**

L. Hakim, Surabaya (ID)

**11:45 - 12:00**

**Andropause: Perspective from Myanmar**

P. Myint, Yangon Myanmar (MM)

**12:00 - 12:15**

**Technological Exchange and Collaboration**

G. Bozzini, Como (IT)

**12:15 - 12:30**

**Advancing the treatment of penile cancer in Southeast Asia with organ-sparing techniques and sentinel node biopsy**

W. Lau, Singapore (SG)

**12:30 - 12:45**

**Traumatic urethral stricture in South East Asia**

K. Adi, Bandung (ID)

# Joint Session of the European Association of Urology (EAU) and the Canadian Urological Association (CUA)

Urology Beyond Europe

**Friday 5 April**  
**10:45 - 12:45**

**Location** Green Area, S06

**Chairs** P. Black, Vancouver (CA)  
C.R. Chapple, Sheffield (GB)

## **Learning objectives**

The learning objectives of this session are to review current evidence and indications for integrating next generation urine biomarkers and enhanced cystoscopy methods into clinical practice. Furthermore, to enhance knowledge of multidisciplinary management of high risk localized and oligometastatic prostate cancer. Lastly, to improve understanding of novel molecular imaging of kidney tumors and management of complex renal cysts.

**10:45 - 10:50**

## **Introduction**

P. Black, Vancouver (CA)  
C.R. Chapple, Sheffield (GB)

**10:50 - 11:30**

## **Bladder cancer**

*Moderator* P. Black, Vancouver (CA)

**10:50 - 11:00**

**State-of-the-art lecture** Integrating urine markers into clinical practice  
M. Roumiguie, Auradé (FR)

**Debate** Blue-light cystoscopy at the time of TURBT remains standard of care for patients with non-muscle invasive bladder cancer

**11:00 - 11:07**

## **Pro**

D.R. Siemens, Kingston, Ontario (CA)

**11:07 - 11:14**

## **Con**

R. Heer, London (GB)

**11:14 - 11:20**

## **Panel discussion**

*Moderator* P. Black, Vancouver (CA)

*Panel* R. Heer, London (GB)  
M. Roumiguie, Auradé (FR)  
D.R. Siemens, Kingston, Ontario (CA)

**11:20 - 11:30**

**State-of-the-art lecture** Pelvic lymph node dissection at the time of radical cystectomy: where do we stand?  
G. Kulkarni, Toronto (CA)

**11:30 - 12:15**

## **Prostate cancer**

*Moderator* A. De La Taille, Créteil (FR)

**11:30 - 11:40**

**State-of-the-art lecture** Neoadjuvant therapy for high risk prostate cancer  
N. Fleshner, Toronto (CA)

**11:40 - 11:45**

**Case presentation: Oligometastatic prostate cancer**  
A. De La Taille, Créteil (FR)

11:45 - 11:55

**Optimal systemic therapy**

Y.K. Ürün, Ankara (TR)

11:55 - 12:05

**Radiation of the primary and the metastases**

P. Ost, Ghent (BE)

12:05 - 12:15

**Panel discussion**

*Moderator*

A. De La Taille, Créteil (FR)

*Panel*

N. Fleshner, Toronto (CA)

P. Ost, Ghent (BE)

Y.K. Ürün, Ankara (TR)

---

12:15 - 12:45

**Kidney cancer**

*Moderator*

R. Breau, Ottawa (CA)

12:15 - 12:25

**State-of-the-art lecture Molecular imaging of kidney tumours**

M. Tran, London (GB)

**Debate Optimal management of complex renal cysts**

12:25 - 12:32

**Active surveillance**

R.A. Rendon, Halifax (CA)

12:32 - 12:39

**Surgical management**

A. Volpe, Novara (IT)

12:39 - 12:45

**Panel discussion**

*Moderator*

R. Breau, Ottawa (CA)

*Panel*

R.A. Rendon, Halifax (CA)

M. Tran, London (GB)

A. Volpe, Novara (IT)

# Joint Session of the European Association of Urology (EAU) and the Maghreb Union countries

Urology Beyond Europe

**Friday 5 April**  
**10:45 - 12:45**

**Location** Purple Area, S01

**Chairs** T. Karmouni, Rabat (MA)  
B. Malavaud, Toulouse (FR)

## **Learning objectives**

The 2024 joint session between Maghreb Urological Associations and the EAU will address three challenging aspects of clinical urology:

- 1) Stone management, first in the delicate situation of pregnancy, second in terms of financial and environmental sustainability
- 2) BPO through two pro & con debates focused on the purported sexual consequences of surgery and the risk-benefit balance of pre-emptive surgery.
- 3) Penile surgery, where video presentations will spur the discussion on the management of posterior urethral disruption, penile curvature, and address tips & tricks in challenging situations.

Looking forward a lively and thought-provoking session in a friendly atmosphere!

See you all in Paris!

Prof Bernard Malavaud & Prof Tariq Karmouni

**10:45 - 10:50**

## **Welcome and introduction**

T. Karmouni, Rabat (MA)  
B. Malavaud, Toulouse (FR)

**10:50 - 11:30**

## **Balancing ureteral stone management**

*Moderators* K. Ait El Hadj, Draria (DZ)  
P.L. Chlost, Krakow (PL)

### **Debate Stone and pregnancy**

**10:50 - 11:00**

#### **Pro**

H. Tazi, Fes (MA)

**11:00 - 11:10**

#### **Con**

P.L. Chlost, Krakow (PL)

### **Debate-Stone management, a balanced approach to sustainability**

**11:10 - 11:20**

#### **Organising care to control costs in ureteral stone management**

C.M. Cracco, Turin (IT)

**11:20 - 11:30**

#### **Taking care of the planet: Disposable vs. reusable ureteroscopes**

B.M.C. Rocco, Milan (IT)

**11:30 - 12:10**

## **Looking beyond LUTS**

*Moderators* J.L. Domínguez Escrig, Valencia (ES)  
A.S. Zribi, Tunis (TN)

### **Debate Sex and surgery for BPO**



11:30 - 11:40

**Pro**

S. Lekouaghet, Annaba (DZ)

11:40 - 11:50

**Con**

J-N.L. Cornu, Rouen (FR)

**Debate The case for pre-emptive surgery in enlarged prostate**

11:50 - 12:00

**Pro**

J.L. Domínguez Escrig, Valencia (ES)

12:00 - 12:10

**Con**

A. Chatar, Meknes (MA)

---

12:10 - 12:45

**A video collection of some challenges in penile surgery**

*Moderators*

J. Cheikhani, Nouakchott (MR)

G.Y. Robert, Bordeaux (FR)

A. Salonia, Milan (IT)

12:10 - 12:20

**Video presentation: The Management of posterior urethral disruption due to pelvic trauma**

A. Bouker, Tunis (TN)

12:20 - 12:30

**Video presentation: Challenges in the correction of penile curvature**

A. Salonia, Milan (IT)

12:30 - 12:40

**Video presentation: Challenges in the surgery of penile trauma**

A. Koutani, Rabat (MA)

12:40 - 12:45

**Concluding remarks**

T. Karmouni, Rabat (MA)

B. Malavaud, Toulouse (FR)

# Joint Session of the European Association of Urology (EAU) and the Société Internationale d'Urologie (SIU)

Urology beyond Europe

**Friday 5 April**  
**10:45 - 12:45**

**Location** Purple Area, N01

**Chairs** R. Kumar, New Delhi (IN)  
J.O.R. Sønksen, Herlev (DK)

## **Learning objectives**

At this session being conducted by speakers from around the world, attendees would learn about current open and laparoscopic urological procedures that can be performed without using robotic assistance. At the same time, they would learn about the latest advancements in urological surgery including the use of artificial intelligence in diagnosing prostate cancer and newer robots on the market.

**10:45 - 10:48**

**Welcome and introduction**

**10:48 - 11:45**

**Urology sans the robot: Semi-live techniques**

**10:48 - 10:58**

**Vesicovaginal fistulae: The African experience**

A. Abolarinwa, Lagos (NG)

**10:58 - 11:08**

**Sperm retrieval: The surgeon matters**

C.F.S. Jensen, Herlev (DK)

**11:08 - 11:18**

**Truly progressive perineal urethroplasty**

M. Fisch, Hamburg (DE)

**11:18 - 11:28**

**Safety and feasibility of ureteroscopy for paediatric stone in children under 5 Years**

A. Faure, Marseille (FR)

**11:28 - 11:38**

**Adrenalectomy: The least invasive way**

R. Kumar, New Delhi (IN)

**11:38 - 11:45**

**Discussion**

**11:45 - 12:42**

**The next decade of urology**

**11:45 - 11:55**

**Not cutting for stone: Flexible ureteroscopy for all seasons**

O. Traxer, Paris (FR)

**11:55 - 12:05**

**Invasion of the robots**

J. Lee, Seoul (KR)

**12:05 - 12:15**

**AI solutions: Will the prostate biopsy be redundant?**

C. Moore, London (GB)

**12:15 - 12:25**

**Out-patient surgery for BPH**

D. Elterman, Toronto (CA)

**12:25 - 12:35**

**The artificial bladder**

M. Fossum, Copenhagen (DK)

**12:35 - 12:42**

**Discussion**

**12:42 - 12:45**

**Closing remarks**



# Joint Session of the European Association of Urology (EAU) and the Urological Society of Australia and New Zealand (USANZ)

Urology beyond Europe

**Friday 5 April**  
**10:45 - 12:45**

**Location** Green Area, W01

**Chairs** H.E. O'Connell, Melbourne (AU)  
M.J. Ribal Caparros, Barcelona (ES)

## **Learning objectives**

In this session, participants will explore advanced techniques and best practices in mesh procedures, debate the efficacy of focal therapy in prostate cancer, and examine multidisciplinary strategies for symphyseal fistula management. The session also includes discussions on functional outcomes following prostatectomy and radiotherapy, and addresses challenges in the management of urothelial cancer, with a special focus on women's health outcomes. This comprehensive overview is designed to enhance understanding of current trends and practices in urological health care.

**10:45 - 10:47**

## **Introduction**

**10:47 - 11:10**

## **Mesh cases: Exploring recent advances and best practices**

*Moderators* C. Dowling, Melbourne (AU)  
C. Harding, Newcastle upon Tyne (GB)

**10:47 - 10:52**

## **Mesh complications and management strategies: Discuss the latest advancements in understanding and managing complications**

C. Dowling, Melbourne (AU)

**10:52 - 10:57**

## **Emerging techniques and technologies: Explore innovative approaches and technologies related to mesh procedures**

E. Fong, Auckland (NZ)

**10:57 - 11:02**

## **Regulatory updates and guidelines: Provide an overview of the current regulatory landscape and guidelines governing mesh usage**

E. Costantini, Perugia (IT)

**11:02 - 11:10**

## **Panel discussion**

**11:10 - 11:28**

## **Debate Focal therapy in prostate cancer improves functional outcomes**

*Moderators* D. Bolton, Heidelberg (AU)  
P. Cornford, Liverpool (GB)

**11:10 - 11:17**

## **Pro**

C. Varol, Sydney (AU)

**11:17 - 11:24**

## **Con**


G. Ploussard, Toulouse (FR)

**11:24 - 11:28**

## **Rebuttal**

<b>11:28 - 11:48</b>	<b>Symphyseal fistula: Diagnosis, management, and future directions</b>  <i>Moderators</i> L. Chan, Sydney (AU) V.W.M. Tse, Sydney (AU)
<b>11:28 - 11:33</b>	<b>Clinical assessment and diagnosis of urosymphyseal fistulae</b> V.W.M. Tse, Sydney (AU)
<b>11:33 - 11:38</b>	<b>Multidisciplinary management and collaboration: Emphasize the importance of a multidisciplinary approach in managing symphyseal fistula</b> L. Peri Cusi, Barcelona (ES)
<b>11:38 - 11:43</b>	<b>Surgical management</b> L. Peri Cusi, Barcelona (ES)
<b>11:43 - 11:48</b>	<b>Panel discussion</b>
<b>11:48 - 12:08</b>	<b>PPI including radiotherapy: Functional outcomes</b>  <i>Moderators</i> D. Bolton, Heidelberg (AU) E. Chartier-Kastler, Paris (FR)
<b>11:48 - 11:53</b>	<b>Functional pelvic floor US for pre and post radical prostatectomy</b> L. Chan, Sydney (AU)
<b>11:53 - 11:58</b>	<b>Role of UDS in post prostatectomy incontinence</b> M. Costa Grau, Barcelona (ES)
<b>11:58 - 12:03</b>	<b>Long term outcomes of AUS in men with prior radiotherapy</b> A. Collado Serra, Valencia (ES)
<b>12:03 - 12:08</b>	<b>Discussion including picking early diversion rather than urethral surgery</b> V.W.M. Tse, Sydney (AU)
<b>12:08 - 12:28</b>	<b>Functional aspects of urothelial cancer management</b>  <i>Moderators</i> D. Bolton, Heidelberg (AU) P. Gontero, Turin (IT)
<b>12:08 - 12:13</b>	<b>Development and evaluation of NMIBC-SYMPTOM index</b> M. Patel, Westmead (AU)
<b>12:13 - 12:18</b>	<b>PROMS and PREMS in bladder cancer</b> P. Mariappan, Edinburgh (GB)
<b>12:18 - 12:23</b>	<b>Complications of intravesical therapy for NMIBC</b> K. Zimmermann, Andernach (DE)
<b>12:23 - 12:28</b>	<b>Complications of radiotherapy for MIBC</b> N. Lawrentschuk, Victoria (AU)
<b>12:28 - 12:44</b>	<b>Women's outcome with urothelial cancer: Identifying challenges and seeking solutions</b>  <i>Moderators</i> M. Patel, Westmead (AU) J.A. Witjes, Nijmegen (NL)
<b>12:28 - 12:33</b>	<b>Diagnostic challenges and early detection</b> L.S. Mertens, Amsterdam (NL)
<b>12:33 - 12:38</b>	<b>Treatment approaches and individualized care</b> J.W.F. Catto, Sheffield (GB)

**Closing remarks**



# Joint Session of the European Association of Urology (EAU) and the Pakistan Association of Urological Surgeons (PAUS)

Urology Beyond Europe

**Friday 5 April**  
**10:45 - 12:45**

**Location** Purple Area, E02

**Chairs** M.A. Khan, Islamabad (PK)  
J.L. Vázquez, Copenhagen (DK)

## **Learning objectives**

This session will collaboratively endeavor to provide an overview of the latest developments in the training of Minimally Invasive Surgery (MIS) for BPH and management of kidney cancer (RCC) and upper tract UC with the aim of optimising patient care.

**10:45 - 10:50**

## **Welcome and introductions**

M.A. Khan, Islamabad (PK)

## **MIS for BPH**

*Moderators* I. Memon, Hyderabad (PK)  
T.A. Sami, Birmingham (GB)

**10:50 - 11:00**

## **Training models for MIS in BPH**

A. Dhanasekaran, Birmingham (GB)

**11:00 - 11:10**

## **Current best evidence for MIS in BPH**

G.I. Russo, Catania (IT)

**11:10 - 11:20**

## **Current practice pattern of BPH management in Pakistan**

M.I. Nazir, Lahore (PK)

**11:20 - 11:35**

## **Q & A**

**11:35 - 12:40**

## **Management of RCC**

*Moderators* M. Aslam, Scotland (GB)  
R. Campi, Florence (IT)

**11:35 - 11:45**

## **New technologies in the management of RCC**

N. Azawi, Havdrup (DK)

**11:45 - 11:55**

## **Management in small renal masses: An update**

M. Ather, Karachi (PK)

**11:55 - 12:05**

## **Pattern of presentation and diagnostic challenges in RCC**

N. Bin Nusrat, Galway (IE)

**12:05 - 12:15**

## **The role of partial nephrectomy in the management of RCC**

R.G. Bertolo, Verona (IT)

**12:15 - 12:25**

## **Challenging clinical case mRCC**

Y. Rasheed, Karachi (PK)

**12:25 - 12:40**

## **Debate On clinical case**

**12:40 - 12:45**

## **Conclusion**

F. Mumtaz, London (GB)





# Joint Session of the European Association of Urology (EAU) and the World Chinese Urologists

Urology beyond Europe

**Friday 5 April**  
**10:45 - 12:45**

**Location** Green Area, W03

**Chairs**  
J. Chueh, Taipei (TW)  
J. Palou, Barcelona (ES)  
K.J. Wang, Chengdu (CN)

## **Learning objectives**

In this joint session organized by the European Association of Urology (EAU), Chinese Urological Association (CUA), Taiwanese Urological Association (TUA), Hong Kong Urological Association (HKUA), and Macau Urological Association (MUA), the invited faculty will present the latest advancements in various fields of urology. Key topics of focus include advancements in stone management, innovative approaches to urothelial cancer treatment, and developments in translational urology.

**10:45 - 10:48**

**Welcome and introduction**

**10:48 - 11:12**

**Stones management**

**10:48 - 10:55**

**What's new/best in surgical stones management?**

S. Proietti, Milan (IT)

**10:55 - 11:02**

**How we clean up the residual stones during RIRS?**

C-C. Lin, Keelung City (TW)

**11:02 - 11:12**

**Discussion**

**11:12 - 11:57**

**Urothelial cancer**

**11:12 - 11:19**

**Urinary markers in 2024**

J. Palou, Barcelona (ES)

**11:19 - 11:26**

**UTUC in Taiwan: a data-driven analysis from the Taiwan UTUC collaboration group**

Y-C. Tsai, Taipei City (TW)

**11:26 - 11:33**

**New tools for the conservative management of upper urinary tract urothelial carcinoma**

A. Territo, Barcelona (ES)

**11:33 - 11:40**

**Development of Novel MIBC Classification to Predict the Response to Neoadjuvant Gemcitabine/Cisplatin plus Anti-PD-1 in Muscle-invasive Bladder Cancer**

T-X. Lin, Guangzhou (CN)

**11:40 - 11:47**

**The unique clinicopathological characteristics and oncological outcomes of Chinese UTUC and differences from Americans**

L-Q. Zhou, Beijing (CN)

**11:47 - 11:57**

**Discussion**

**11:57 - 12:42**

**Urological translation studies**

11:57 - 12:04

**Prediction of treatment efficacy of metastatic prostate cancer with morphomic analysis**

S.T. Pang, Taipei (TW)

12:04 - 12:11

**Molecular classification and bladder cancer: where are we?**

F. Liedberg, Malmö (SE)

12:11 - 12:18

**Telesurgery research and clinical trials in chinese PLA general Hospital: Results and perspective**

G. Yu, Beijing (CN)

12:18 - 12:25

**Prostate health index-Macau early experience**

L.H. Ian, Macau (MO)

12:25 - 12:32

**Novel blood and urine biomarkers for prostate cancer diagnosis: the search for the perfect candidate**

P.K-F. Chiu, Hong Kong (HK)

12:32 - 12:42

**Discussion**

---

12:42 - 12:45

**Conclusion**

*Moderator*

J. Palou, Barcelona (ES)

# Joint Session of the European Association of Urology (EAU) and the Urological Society of India (USI)

Urology beyond Europe

**Friday 5 April**  
**10:45 - 12:45**

**Location** Green Area, N03

**Chairs** L. Shah, Raipur (IN)  
P.E.V. Van Kerrebroeck, Berchem- Antwerp (BE)

## **Learning objectives**

At this session, attendees will be able to:

Learn about the latest developments in uro-oncology and reconstructive urology.

Get tips on the clinical approach to asymptomatic renal stones.

Hear from the experts on complex problems in paediatric urology.

Be informed about new possibilities for treatment in female and male urology.

## **Introduction**

**10:50 - 11:30**

### **Uro-oncology and reconstructive urology**

**10:50 - 11:00**

#### **Mantra Robot-India's Pride**

S. Rawal, Delhi (IN)

**11:00 - 11:10**

#### **Update on reconstructive surgery in uro-oncology**

L. Martínez-Piñeiro, Madrid (ES)

**11:10 - 11:20**

#### **Radical Perineal prostatectomy: revisited and improved**

H. Goel, New Delhi (IN)

**11:20 - 11:30**

#### **Challenges and intricacies in the management of pan-anterior urethral strictures**

B.T. Enganti, Hyderabad (IN)

**11:30 - 11:40**

### **Urolithiasis**

**11:30 - 11:40**

#### **Asymptomatic renal stones –when to treat?**

D. Ragoori, hyderabad (IN)

**11:40 - 12:00**

### **Paediatric Urology**

**11:40 - 11:50**

#### **Paediatric urolithiasis: a nuanced understanding**

V. Krishnamoorthy, Bangalore (IN)

**11:50 - 12:00**

#### **Valve Bladder syndrome**

A.K. Chawla, Manipal (IN)

**12:00 - 12:40**

### **Male and female urology**

**12:00 - 12:08**

#### **Prosthetics in uro-andrology**

V.S. Karthikeyan, Chennai (IN)

**12:08 - 12:16**

#### **Orthotopic ureteric meatoplasty: Shah's technique to avoid ureteric reimplant in VVF in urogynae section**

L. Shah, Raipur (IN)

**12:16 - 12:24**

#### **Varicocelectomy: improvisations for better outcomes**

V. K.V., Trivandrum (IN)

12:24 - 12:32

**Urodynamics 2024**

S. Arlandis, Valencia (ES)


12:32 - 12:40

**Complex vesico-vaginal fistulae: beyond primary repair**

S. Patwardhan, Mumbai (IN)

---

**Closing remarks**



# Meeting of the Young Academic Urologists (YAU)

Special Session

Friday 5 April

10:45 - 14:45

**Location** Green Area, N04

**Chair** J. Gómez Rivas, Madrid (ES)

## Learning objectives

In this session tailored for young academics, participants can expect to gain a comprehensive understanding of new insights in urological conditions. The session will delve into current research trends, innovative technologies, and emerging treatments in the field. Delegates will have the opportunity to explore the intersection of urology with cutting-edge medical advancements, fostering a dynamic environment for knowledge exchange and collaboration. By the end of the session, participants will be equipped with insights that bridge theoretical knowledge with practical applications in urological research and patient care.

10:45 - 11:20

## Overview of the Young Academic Urologists

*Moderator* J. Gómez Rivas, Madrid (ES)

10:45 - 11:00

## The EAU Young Academics Where are we?

J. Gómez Rivas, Madrid (ES)

11:00 - 11:10

## Non-oncology groups Update on the latest news

A. Pietropaolo, Southampton (GB)

11:10 - 11:20

## Oncology groups Update on the latest news

A. Larcher, Milan (IT)

11:20 - 11:30

## YAU awards

*Moderator* J. Gómez Rivas, Madrid (ES)

## YAU best paper published in 2023 Effectiveness of endourological management of ureteral stenosis in kidney transplant patients: EAU YAU kidney transplantation working group collaboration

A. Territo, Barcelona (ES)

## Best abstract at EAU24 by a YAU group Fluid dynamics within the renal cavities during endoscopic surgery: does the position of the flexible ureteroscope and access sheath affect the outflow rate?

A. Tsaturyan, Yerevan (AM)

## YAU reviewer of the year

R. Pichler, Innsbruck (AT)

11:30 - 13:00

## Multidisciplinary team discussion on daily cases

*Moderators* L.A. 't Hoen, Rotterdam (NL)

A. Sierra Del Rio, Barcelona (ES)

11:30 - 11:58

### **Case I Large kidney stone in paediatric patient**

*Case presenter* L.A. 't Hoen, Rotterdam (NL)

*Discussants* M.I Dönmez, Istanbul (TR)  
B. Somani, Southampton (GB)  
T.E. Şener, Istanbul (TR)

#### **Take-home messages**

L.A. 't Hoen, Rotterdam (NL)

12:00 - 12:28

### **Case II Enlarged prostate, rising PSA with negative prostate biopsies: What's next?**

*Case presenter* A. Ribeiro Morgado, Porto (PT)

*Discussants* G. Gandaglia, Milan (IT)  
C.V. Kesch, Essen (DE)  
C. Manfredi, Naples (IT)

#### **Take-home messages**

A. Ribeiro Morgado, Porto (PT)

12:30 - 12:58

### **Case III HPV-related localised penile cancer**

*Case presenter* I. Anselmo da Costa Santiago, Berlin (DE)

*Discussants* C. Fankhauser, Lucerne (CH)  
A. Muneer, London (GB)  
G.I. Russo, Catania (IT)

#### **Take-home messages**

I. Anselmo da Costa Santiago, Berlin (DE)

13:00 - 13:45

### **Artificial intelligence and new technologies**

*Moderators* M. Moschini, Milan (IT)  
I. Rivero Belenchón, Seville (ES)

13:00 - 13:10

#### **Role of AI in kidney stone disease**

B. Somani, Southampton (GB)

13:10 - 13:20

#### **Artificial intelligence applications using MRI features for detection & staging in prostate cancer**

G. Cacciamani, Los Angeles (US)

13:20 - 13:30

#### **Machine learning modeling in urothelial cancer detection and characterisation**

B. Pradere, Toulouse (FR)

13:30 - 13:45

#### **Discussion**

13:45 - 14:40

### **Training session**

*Moderators* N.I. Osman, Wirral (GB)  
M.W. Vetterlein, Hamburg (DE)

13:45 - 13:55

#### **Standardisation in academic reconstructive urology: Where are we now and where are we going?**

N. Lumen, Ghent (BE)

13:55 - 14:05

#### **Which is the best pathway for a young urologist to be trained in kidney transplant?**

A. Territo, Barcelona (ES)

14:05 - 14:15

**Surveys in clinical research: Are they worthwhile?**

K.A.O. Tikkinen, Helsinki (FI)

14:15 - 14:25

**Treatment of genitourinary tumours in 2023: A multidisciplinary perspective**

R. Campi, Florence (IT)

14:25 - 14:40


**Discussion**

---

14:40 - 14:45

**Closing remarks**

J. Gómez Rivas, Madrid (ES)



Friday 5 April  
10:45 - 12:15

**Location** Purple Area, EGPT

**Chairs** L.A. 't Hoen, Rotterdam (NL)  
M.S. Silay, Istanbul (TR)

We encourage participants in this session to view the abstracts before the session. All abstract bodies, posters, videos and webcasts can be viewed on the EAU(N)24 Resource Centre or at the digital screens in front of the Purple Area, EGPT.

10:45 - 11:03

## Screen A: Basic research & diagnosis

- P021** **Comparison of pediatric and adult patients with ureteropelvic junction obstruction in terms of nerve number, connective tissue and ganglion cell existence**  
D. Demirci, Kayseri (TR)
- P014** **Identifying infrequent genetic changes in monozygotic twins afflicted with hypospadias via targeted panel sequencing**  
H.Y. Lee, seoul (KR)
- P002** **Assessment of differences in the microvessel density(MVD) and growth factor levels between the inner and outer preputial skin in distal hypospadias**  
G. Prasad, New Delhi (IN)
- P001** **Molecular biomarkers in urine which may be useful as early markers of progressive kidney damage in congenital uropathy**  
N. Krishnan, New Delhi (IN)
- P016** **From pain onset to surgical decision: ultrasonographic insights into testicular torsion over a decade**  
H.Y. Lee, seoul (KR)
- P011** **Save the Ball: Teachers teaching teens about testicular torsion in schools**  
N.L. McCauley, Newport (GB)

11:03 - 11:21

## Screen B: Testis

- P009** **Testicular location score in the retractile testis**  
J.M. Chung, Yangsan-si (KR)
- P017** **The therapeutic effects of restoring mitochondrial biogenesis by mitochondrial transplantation and pyrroloquinoline quinone maintain therapy in testicular torsion and detorsion**  
C.B. Lin, Changhua City (TW)
- P027** **Study of abdominal testicular vessels distribution in human fetuses: anatomical basis for laparoscopic fowler-stephens surgery**  
F. Sampaio, Rio de Janeiro (BR)
- P024** **Testicular migration: when does it start the transition of the testis through the inguinal canal? Study in 169 human fetuses during the 2nd gestational trimester**  
F. Sampaio, Rio de Janeiro (BR)
- P025** **Testicular hydatides with torsion have similar anatomical features on the contra-lateral side? A morphometric study**  
F. Sampaio, Rio de Janeiro (BR)



P030	<p><b>Ultrasound for the diagnosis of testicular torsion: a systematic review and meta-analysis of diagnostic accuracy</b> C.E. Alexander, Aberdeen (GB)</p> <p><b>Study Group</b> British Urology Researchers in Surgical Training(London, United Kingdom)</p>
<hr/>	
11:21 - 11:33	<b>Screen C: VUR &amp; UTI</b>
P023	<p><b>Laparoscopic Lich Gregoire vesico-ureteral reimplantation training: a low cost non-biological simulation model.</b> R. Boulma, Tunis (TN)</p>
P006	<p><b>Post-operative Urinary Tract Infection in Children with Vesicoureteral Reflux: Does Pathogens and Antibiotics Resistance Change?</b> W. Seong, Pusan (KR)</p>
P029	<p><b>Pediatric Urinary Tract Infections Following Renal Transplantation from Deceased Donors: Insights from a Singular Medical Facility</b> A. El Helaly, Riyadh (SA)</p>
<hr/>	
	<b>Screen D: Long-term outcomes</b>
P018	<p><b>Long-term urinary and fecal outcomes in classic bladder exstrophy : what can we learn from a 20 years of experience ?</b> S. Abdellaoui, Bron (FR)</p>
P028	<p><b>Long-Term Outcomes After Isolated Epispadias Repair</b> M. Bencic, Belgrade (RS)</p>
P022	<p><b>Long-term outcomes of ileocystoplasty in children: 20 years of experience</b> E. Rovero, Paris (FR)</p>
P013	<p><b>Revisiting the vascular hitch procedure for crossing vessels in paediatric patients – a longitudinal institutional experience over 15 years</b> J. Richter, (DE)</p>
P003	<p><b>Comparison of two different approaches in the management of infants with primary obstructive megaureters and their long-term outcomes</b> M.K. Nagabhairava, bengaluru (IN)</p>
P012	<p><b>Chronic kidney disease (CKD) in children with Meningomyelocele (MMC): risk factors and clinical outcomes</b> A. El Helaly, Riyadh (SA)</p>
<hr/>	
11:51 - 12:03	<b>Screen E: Stones in children</b>
P004	<p><b>Outcomes for RIRS in the setting of multiple and large renal stones (&gt;15mm) in children: Findings from a multicenter and real-world setting</b> P. Juliebø-Jones, Bergen (NO)</p>
P010	<p><b>Mortality and burden of disease associated with kidney stone disease in children and young persons (&lt;20 years): Trends in Europe between 1990-2019</b> P. Juliebø-Jones, Bergen (NO)</p>
P007	<p><b>Quadruple-D score in the success rate of extracorporeal shock wave lithotripsy of renal stones in pediatric population</b> O. Telli, Istanbul (TR)</p>
P020	<p><b>Risk factors for the occurrence of lithiasis in the long term of pyeloplasties</b> L. Diéguez Aguirre, Barcelona (ES)</p>

12:03 - 12:15

Screen F: Miscellaneous

- P019 **Strong parental satisfaction with the use of magnetic-end double-j ureteral stent in children**  
M. Glenisson, paris (FR)
- P026 **The Effect of Botulinum Toxin A in Children with Non-Neurogenic Therapy-Refractory Dysfunctional Voiding**  
S. Hoelscher, Rotterdam (NL)
- P008 **Pediatric renal cell carcinoma: experience of a single tertiary care center**  
M. Hussiny, Mansoura (EG)
- P015 **Posterior urethral valves (PUV) and anterior urethral valves (AUV) with and without concomitant PUV: Matched cohort study at a high-risk pediatric center**  
J. Richter, (DE)

# Penile cancer: The importance of partnering with patients in procuring data

Patient Office - Roundtable

Friday 5 April

11:30 - 12:30

**Location** Green Area, W08

**Chair** R. Cornes, London (GB)

## Learning objectives

In this session we discuss:

- 1) How we can best anticipate the unmet needs of long-term survivorship for penile cancer taking in to account the unique psychological, psychosocial, and psychosexual impact that the disease will have.
- 2) How can we maintain best practice when all curative treatment will involve surgery to the penis and men may opt for less invasive treatment outside of the MDT recommendation.
- 3) A potentially ground-breaking initiative which could enable quicker identification of penile cancer via a novel algorithmic mobile phone app. How a focus group of patient advocates have helped shape this project by providing support and constructive criticism strengthening its fitness for purpose.

11:30 - 11:35

## Welcome and introduction

R. Cornes, London (GB)

11:35 - 11:50

## Procuring patient data

B.E. Ayres, London (GB)

A. Parnham, Manchester (GB)

11:50 - 12:05

## Shared decision-making

K. Manzie, Glasgow (GB)

J. Osborne, Nottingham (GB)

12:05 - 12:15

## Mobile phone app to identify potential penile cancer

L. Schneidewind, Rostock (DE)

12:15 - 12:30

## Q&A and closing

R. Cornes, London (GB)

P. Howard, Liverpool; Liverpool (GB)

# Semi-live session: Hypospadias challenges

Thematic Session

Friday 5 April  
12:00 - 13:00

**Location** Green Area, eURO Auditorium 1

**Chairs** U.K. Kennedy, Zurich (CH)  
A-F. Spinoit, Ghent (BE)

## Learning objectives

After this session, you will have gained insight into the complexity of treating complicated hypospadias. To be competent for offering this treatment to patients, an experience with and knowledge of multiple reconstructive techniques is necessary.

12:00 - 12:12

**Semi-live video presentation** **Flaps & grafts in hypospadias repair, where do we use them?**

Y.T. Soygür, Ankara (TR)

12:12 - 12:15

**Discussion**

12:15 - 12:27

**Semi-live video presentation** **Management of chordee during hypospadias repair**

M. Castagnetti, Padua (IT)

12:27 - 12:30

**Discussion**

12:30 - 12:42

**Semi-live video presentation** **Management of hypospadias complications**

A. El-Ghoneimi, Paris (FR)

12:42 - 12:45

**Discussion**

12:45 - 12:57

**Semi-live video presentation** **Management of hypospadias cripples**

M. Fisch, Hamburg (DE)

12:57 - 13:00

**Discussion**

Friday 5 April  
12:00 - 15:00

**Location** Purple Area, E01

**Chair** L. Martínez-Piñero, Madrid (ES)

Voting will be available via the EAU24 App or via [www.qna.at/eau](http://www.qna.at/eau)

### **Learning objectives**

The advanced urethral stricture course will cover the assessment and surgical treatment of strictures of the penile, bulbar and posterior urethra. General principles of assessment and follow-up, oral mucosa harvest and complications will be reviewed with evidence. Techniques of penile, bulbar and full length urethroplasty will be discussed and compared and cases reviewed with audience participation encouraged.

Pelvic fracture urethral injuries will also be discussed together with management techniques. Female urethroplasty will also be discussed and assessed.

Prior knowledge of relevant anatomy and basic endoscopic techniques will be helpful to those attending the course.

### **General principles in urethral stricture surgery. Preoperative workup and follow-up. Indications of endourological treatments.**

P. Nyirády, Budapest (HU)

### **Penile urethroplasty. Lichen sclerosus.**

P. Nyirády, Budapest (HU)

### **Bulbar urethroplasty. Grafts, anastomotic and combined techniques, Perineal urethrostomy.**

F. Campos Juanatey, Santander (ES)

### **Posterior urethroplasty (pelvic fracture distraction injuries, bladder neck contractures).**

L. Martínez-Piñero, Madrid (ES)

### **Female urethroplasty**

F. Campos Juanatey, Santander (ES)

### **Discussion / Cases**

F. Campos Juanatey, Santander (ES)

L. Martínez-Piñero, Madrid (ES)

P. Nyirády, Budapest (HU)

# Dealing with the challenge of infection in urology

ESU Course 10

Friday 5 April  
12:00 - 15:00

**Location** Purple Area, E05

**Chair** Z. Tandođdu, London (GB)

Voting will be available via the EAU24 App or via [www.qna.at/eau](http://www.qna.at/eau)

## **Learning objectives**

This ESU course on infection diseases provides a broad, up-to-date coverage of the most important and recent problems of infectious diseases in urology. Antimicrobial resistance is one of the biggest worldwide challenges in medicine and gains increasing importance in urology. The management of infections in general and of urogenital tract infections especially, has been compromised by this rapid and continuous increase of antimicrobial resistance. Basic biological principles and strategies to treat urogenital tract infections from benign infections to life-threatening infections will be discussed in this course:

- Classification of UTI and surgical field contamination categories as a basis for treatment and prophylaxis.
- Diagnosis, treatment and prophylaxis strategies of urogenital tract infections.
- Uncomplicated and recurrent cystitis.
- Complicated urinary tract infections.
- Urosepsis and Fournier gangrene.
- Male genital tract infections.

## **Introduction**

Z. Tandođdu, London (GB)

## **Classification of urinary tract infection (UTI) and surgical field contamination categories as a basis for treatment and prophylaxis**

Z. Tandođdu, London (GB)

## **Low-grade and recurrent UTI**

J. Kranz, Aachen (DE)

## **Male genital infections: Epididymitis and urethritis**

J. Medina-Polo, Madrid (ES)

## **Hospital acquired UTI and antibiotic resistance**

Z. Tandođdu, London (GB)

## **Perioperative prophylaxis with special focus on prostate biopsies**

J. Medina-Polo, Madrid (ES)

## **Sepsis and Fournier's gangrene**

J. Kranz, Aachen (DE)

Friday 5 April  
12:00 - 15:00

**Location** Purple Area, E07

**Chair** G.M. Kamphuis, Amsterdam (NL)

### Learning objectives

The course will discuss available literature and practical management options and examples treatment of urolithiasis in 'non-index' patients. The course will cover:

- Horseshoe kidney, caliceal diverticula duplicate urinary system
- Pregnancy and complex metabolic patients
- After bladder substitution/ileal conduit/reimplantation
- Transplanted kidneys and spinal malformation

### Introduction

G.M. Kamphuis, Amsterdam (NL)

### Urolithiasis in urinary system anomalies: Horseshoe kidneys

E. Emiliani, Barcelona (ES)

### Urolithiasis in urinary system anomalies: Calyceal diverticula stones

S. Doizi, Paris (FR)

### Urolithiasis in pregnancy

G.M. Kamphuis, Amsterdam (NL)

### Urolithiasis in urinary system anomalies: After bladder substitution/ ileal conduit/ ureteral reimplantation

E. Emiliani, Barcelona (ES)

### Medullary sponge kidneys

S. Doizi, Paris (FR)

### Urolithiasis in transplant kidneys

G.M. Kamphuis, Amsterdam (NL)

### Urolithiasis in urinary system anomalies: Duplicate urinary system and ectopic kidney

S. Doizi, Paris (FR)

### Bilateral stone treatment; Do's and don'ts

E. Emiliani, Barcelona (ES)

### Patients with relative contraindications: Spinal and skeletal malformations

G.M. Kamphuis, Amsterdam (NL)

Friday 5 April  
12:00 - 15:00

**Location** Purple Area, E06

**Chair** B.J. Challacombe, London (GB)

### Learning objectives

This course will cover all principal indications for robotic surgery of the upper urinary tract. The standard techniques will be explained in a video-based fashion and will be followed by discussing advanced cases as well as troubleshooting and complication management. On top of that, technical innovations and new applications will be discussed as well.

Don't miss this course, a must for all robotic surgeons expect:

- Video-based step-by-step approach
- Standard techniques
- Complex cases
- Troubleshooting and complication management
- Technical innovations: What's new in robotics?

### Introduction

B.J. Challacombe, London (GB)

### Patient positioning, trocar positioning, trans- and retroperitoneal access in renal robotic surgery

B.J. Challacombe, London (GB)

### Robotic pyeloplasty: Multichannel or single technique

A. Antonelli, Verona (IT)

### Renal surgery: Nephrectomy and nephroureterectomy: How I do it

B.J. Challacombe, London (GB)

### Partial nephrectomy I: Step 1: Isolation of renal hilum; Step 2: Mobilisation of the kidney; Step 3: Clamping of renal pedicle: Different techniques

A. Antonelli, Verona (IT)

### Partial nephrectomy II: Step 4: Different tumour resection techniques

R. De Groot, Aalst (BE)

### Partial nephrectomy III: Step 5: Different renography techniques

B.J. Challacombe, London (GB)

### Partial nephrectomy IV: Special and difficult indications

R. De Groot, Aalst (BE)

### Complications, new tools and advanced radical nephrectomy

R. De Groot, Aalst (BE)

### Wrap up and conclusions

B.J. Challacombe, London (GB)



# Surgical complications during laparoscopic/robotic urological procedures: Prevention, diagnosis, management and complications

ESU Course 08

Friday 5 April  
12:00 - 15:00

**Location** Purple Area, E03

**Chair** B.M.C. Rocco, Milan (IT)

## **Learning objectives**

- The risk of complication is a major issue for laparoscopic and robotic surgeons; the knowledge of complication is key to maximize the safety of urological procedures.  
- The course provides a comprehensive overview about the topic, summarizing how to prevent, recognize, grade and fix surgical issues. - An interactive video session will merge trainees' and experts' experience to approach minor, major and harmful drawback of common urological interventions.

## **Introduction - Aims of the course**

B.M.C. Rocco, Milan (IT)

## **Lectures: Frequency, risk factors, prevention and key aspects**

### **Vascular lesions**

A.E. Canda, Istanbul (TR)

### **Intestinal lesions**

B.M.C. Rocco, Milan (IT)

### **Urinary, neuronal and solid organ lesions**

T. Tokas, Hall In Tirol (AT)

### **How to minimize the risk of complications in robotic surgery? - Tricks of the trade**

B.M.C. Rocco, Milan (IT)

### **Risk factors and grading of complications: The patient's and the surgeon's factor**

T. Tokas, Hall In Tirol (AT)

### **How to train complications management: Tips and tricks from the training models**

A.E. Canda, Istanbul (TR)

### **Video presentation and case management - A video collection from experts**

A.E. Canda, Istanbul (TR)

T. Tokas, Hall In Tirol (AT)

### **Questions and answers**

B.M.C. Rocco, Milan (IT)

# Refining technique and technology in robotic partial nephrectomy

Video session 02

Friday 5 April  
12:30 - 14:00

**Location** Green Area, S04

**Chairs** U. Capitanio, Milan (IT)  
K-F. Kowalewski, Mannheim (DE)

We encourage participants in this session to view the abstracts before the session. All abstract bodies, posters, videos and webcasts can be viewed on the EAU(N)24 Resource Centre or at the digital screens in front of the Purple Area, EGPT.

V009 (□ 6 min.)

**Techniques for optimizing functional results of Da Vinci XI nephron sparing surgery**

E.C. Bujoreanu, Cluj Napoca (RO)

V010 (□ 6 min.)

**Technical approach for consistent outcomes for resection and reconstruction in minimally invasive partial nephrectomy**

B. Brodie, Singapore (SG)

V011 (□ 6 min.)

**The “wheelbarrow technique” for partial nephrectomy of endophytic small renal mass**

B. Brodie, Singapore (SG)

V012 (□ 8 min.)

**Challenges to the development of a surgical support system for robot-assisted partial nephrectomy using highly versatile augmented reality**

A. Sawada, Miyazaki (JP)

V013 (□ 8 min.)

**Purely Off-clamp RAPN for cT2b renal mass**

L. Misuraca, Rome (IT)

V014 (□ 7 min.)

**Sutureless robot assisted partial nephrectomy: feasibility and surgical technique (UroCCR n°158)**

G. Margue, Bordeaux (FR)

V015 (□ 7 min.)

**Sutureless Off-clamp Robotic partial Nephrectomy in solitary kidney: surgical technique, perioperative, pathologic and functional outcomes**

G. Tuderti, Roma (IT)

V016 (□ 7 min.)

**Single-port robotic retroperitoneal partial nephrectomy: initial series in Spain**

D. Vazquez-Martul , A Coruña (ES)

# Joint Session of the European Association of Urology (EAU) and Iranian Urological Association (IUA)

Urology beyond Europe

**Friday 5 April**  
**12:30 - 14:30**

**Location** Purple Area, S03

**Chairs** M. Babjuk, Prague (CZ)  
S.J. Hosseini, Tehran (IR)

**12:30 - 12:35**

**Introduction**

**12:35 - 13:10**

**Endourology**

*Moderators* A. Basiri, Tehran (IR)  
S.J. Hosseini, Tehran (IR)

**12:35 - 12:50**

**Laparoscopy in management of kidney tumors**

M.H. Radfar, Tehran (IR)

**12:50 - 13:05**

**The optimal energy source and technique of TURB**

M. Babjuk, Prague (CZ)

**13:05 - 13:10**

**Discussion**

**13:10 - 13:45**

**Andrology**

*Moderators* M. Babjuk, Prague (CZ)  
M.A. Zargar Shoushtari, Tehran (IR)

**13:10 - 13:25**

**Surgical management of penile curvatures**

S. Minhas, London (GB)

**13:25 - 13:40**

**Surgical treatments of priapism**

O. Sedigh, Torino (IT)

**13:40 - 13:45**

**Discussion**

**13:45 - 14:25**

**Paediatric urology**

*Moderators* M. Babjuk, Prague (CZ)  
S.J. Hosseini, Tehran (IR)

**13:45 - 14:00**

**The management of vesicoureteral reflux in childhood**

S. Tekgül, Ankara (TR)

**14:00 - 14:15**

**Laparoscopic extravesical ureteral reimplantation: Status, tips and tricks**

S.M. Ghahestani, Tehran (IR)

**14:15 - 14:25**

**Discussion**

**14:25 - 14:30**

**Closing remarks**

Friday 5 April  
12:30 - 14:00

**Location** Purple Area, EGPT

**Chairs** E. Linares Espinós, Madrid (ES)  
J.P. Radtke, Düsseldorf (DE)

We encourage participants in this session to view the abstracts before the session. All abstract bodies, posters, videos and webcasts can be viewed on the EAU(N)24 Resource Centre or at the digital screens in front of the Purple Area, EGPT.

## Screen A: Biopsy, imaging for detection, risk prediction, targeting and route

- P036** **Association between MRI-detected tumor ADC and risk of 5-year biochemical recurrence after radical prostatectomy.**  
M.L. Piccinelli, Milan (IT)
- P046** **The Role of Artificial Intelligence for the Detection of Clinically Significant Prostate Cancer at Multiparametric Magnetic Resonance Imaging**  
L. Quarta, Milan (IT)
- P051** **Impact of Volume Difference Between 3D Transrectal Ultrasound and MRI Segmentation on the Outcome of fusion MRI-Targeted Prostate Biopsy.**  
L. Lenfant, Paris (FR)
- P043** **Comparing the Diagnostic Accuracy of mpMRI and MicroUS for Detecting Clinically Significant Prostate Cancer in Patients with Previous Negative Prostate Biopsy**  
N. Frego, Melle (BE)
- P031** **Micro-ultrasound guided prostate biopsies: evaluation of PRI-MUS score in a high-volume experience.**  
D. Maffei, Villa Lagarina (IT)
- P035** **Can "Artificial Intelligence" improve cancer detection in transperineal MRI-TRUS fusion biopsies of the prostate?**  
K. Günzel, Berlin (DE)
- P052** **Transperineal approach is safer than transrectal approach in MRI-ultrasound fusion prostate biopsy: an analysis using propensity score matching**  
H. Tanaka, Shizuoka (JP)
- P050** **Validation of the PRIMARY system for 68Ga-PSMA-11 PET/CT interpretation for detection of intra-prostatic radiorecurrent prostate cancer**  
A. Light, London (GB)

## Screen B: Grading issues at biopsy

- P045** **Proportion of Gleason 8-10 prostate cancer found on biopsy and tumor aggressiveness in matched cohorts of men in Asia and Western countries.**  
L. Dong, Shanghai (CN)
- P041** **Predictors of Adverse Pathological Features following Robotic Radical Prostatectomy in patients with Low-risk Prostate Cancer**  
M. Covas Moschovas, Celebration (US)
- P054** **MRI-Targeted Biopsy in Biopsy-Naïve Patients and the Risk of Overtreatment: A Grading Issue**  
T. Jabbour, Bruxelles (BE)

- P042 **The quantification of GSP4 volume is superior to ISUP GG classification and %GSP4 for predicting adverse outcomes in radical prostatectomy patients**  
S.L.A. Scuderi, Milan (IT)
- P038 **Stage-specific survival among men with prostate cancer in the Nordic countries 2004-2016 - the NORDCAN survival studies**  
S.B. Larsen, Copenhagen (DK)
- P053 **Characteristics of tumor immune microenvironment in locally advanced prostate cancer not detected by imaging**  
Y. Yanai, Tokyo (JP)
- 
- Screen C: PSA as a predictor of treatment outcomes**
- P033 **Development and validation of a new personalized algorithmic model for PSA analysis : PROSTia**  
C. Larose, Vandoeuvre (FR)
- P034 **Prostate biopsy features and risk of biochemical recurrence after robot-assisted radical prostatectomy: High-Volume Tertiary Care Hospital experience**  
C. Collà Ruvolo, Napoli (IT)
- P040 **Midlife Baseline PSA as a Predictor of Lethal Prostate Cancer: Racial Differences between Black and White Men**  
G. Chiarelli, Milan (IT)
- 
- Screen D: Neoadjuvant systemic treatment to locally advanced stages**
- P059 **Association between PSMA PET response and oncological outcome following neoadjuvant hormonal therapy in high-risk prostate cancer patients.**  
G.T. Devos, Kortrijk (BE)
- P047 **Can we use immunohistochemistry as predicting factor of successful treatment with intensified neoadjuvant treatment in high-risk prostate cancer: a subanalysis of the ARNEO trial**  
A. Giesen, Leuven (BE)
- 
- Screen E: Incidence at histology, after pandemia, risks factors**
- P056 **Outcome for men diagnosed with prostate cancer at cystoprostatectomy performed for bladder cancer. Nationwide, population-based study**  
P. Scilipoti, Milan (IT)
- P048 **Incidental Prostate Cancer In Patients Treated For Benign Prostatic Hyperplasia: Analysis From A Contemporary National Dataset**  
E. Bologna, Rome (IT)
- P044 **The rebound effect of diagnosis of csPCa, after Covid-19 pandemic**  
A. Fanelli, Taranto (IT)
- P057 **Long-term Analysis of Treatment Decision Regret: Importance of the decision-making process and postoperative HRQOL after treatment for early-stage prostate cancer.**  
T. Osawa, Sapporo (JP)
- P058 **Association of proton pump inhibitors cumulative use with prostate cancer risk and adverse outcomes: A population-based analysis**  
R. Sayyid, Toronto (CA)

---

**Screen F: supportive care**

- P037 **Effect of Smoking on Prostate Cancer Survivors' Long-Term Quality of Life and Function: A longitudinal analysis of the CEASAR (Comparative Effectiveness Analysis of Surgery and Radiation) study**  
D-D. Nguyen, Boston (US)
- P032 **Smoking and Exercise are Independently Associated with Mental Health in Prostate Cancer**  
K. Alkhatib, Elmhurst (US)
- P039 **Association of Area of Deprivation Index with Prostate Cancer incidence and lethality over a contemporary North American cohort..**  
M. Finati, Foggia (IT)
- P049 **A Multi-Institutional Prospective Cohort Study Evaluating Mental Wellbeing in Prostate Cancer: The MIND-P Study**  
O. Brunckhorst, London (GB)

# Hands-on Training in Endoscopic stone treatment - Step 1

HOT 1.02

Friday 5 April  
12:45 - 13:40

**Location** Orange Area, HOT 1

**Tutors**

- V. Gauhar, Singapore (SG)
- A. Pietropaolo, Southampton (GB)
- S. Proietti, Milan (IT)
- D. Veneziano, New York (US)

## **Learning objectives**

This Basic Endoscopic Stone Treatment course is the first step in the Endoscopic Stone Treatment (EST) curriculum. It is designed to provide urologists with a fundamental understanding of endoscopic stone treatment and enhance their skills. This comprehensive training is specifically tailored for urologists who want to gain a basic level of knowledge in endoscopy and wish to improve their proficiency in key techniques for endoscopic stone management. The curriculum includes four key exercises that provide hands-on experience and practical training: Flexible Cystoscopy, Rigid Cystoscopy, Semi-Rigid Ureteroscopy, and Flexible Ureteroscopy.

The primary objective of this programme is to enhance participants' skills in the treatment of urinary stones with endoscopic techniques. By the end of the course, attendees should feel more confident and competent in their basic skills.

# Hands-on Training in Laparoscopic urological skills - Step 1

HOT 1.01

Friday 5 April  
12:45 - 13:40

**Location** Orange Area, HOT 1

**Tutors** M. Jarzowski, Bydgoszcz (PL)  
J.B. Roche, Bordeaux (FR)

## **Learning objectives**

This basic laparoscopic training course is the first step in the Laparoscopic Urological Skills (LUS) curriculum. It is designed to provide urologists with a fundamental understanding of laparoscopy and enhance their laparoscopic skills. This comprehensive training is specifically tailored for urologists who want to gain a basic level of knowledge in laparoscopy and wish to improve their proficiency in key laparoscopic techniques. The course comprises four essential exercises aimed at honing skills related to depth perception and bimanual dexterity: Peg Transfer, Circle Cut, Needle Guidance, and Knot Tying.

The primary objective of this course is to enhance participants' laparoscopic skills, focusing on key aspects such as depth perception and bimanual dexterity. By the end of the course, attendees should feel more confident and competent in their basic laparoscopic skills.



# Hands-on Training in Transurethral treatment - Step 1 & 2 (TURBT/TURP)

HOT 1.03

**Friday 5 April**  
**12:45 - 13:40**

**Location** Orange Area, HOT 1

**Tutors** D. Oliveira Reis, Lisboa (PT)  
L. Osório, Porto (PT)

## **Learning objectives**

This training course combines the first and second step of the Transurethral Treatment (TUT) curriculum. It is designed for urologists who wish to improve their proficiency in key techniques and gain a fundamental understanding of transurethral resection of the bladder and prostate. This comprehensive training covers crucial basic skills including flexible and rigid cystoscopy, resection loop handling, and direct vision internal urethrotomy, as well as the resection procedure, practiced on state-of-the-art models.

The primary objective of this course is to enhance participants' skills in transurethral resection of the prostate and bladder, focusing on key aspects such as depth perception, hand-eye coordination, control, handling, and overall technique. By the end of the course, attendees should feel more competent and confident in performing this procedure.

# Hands-on Training in Transurethral treatment - Step 3 (ThuLEP)

HOT 1.04

Friday 5 April  
12:45 - 13:40

**Location** Orange Area, HOT 2

**Tutors** L.B. Dragoş, Cambridge (GB)  
B.M. Schoensee, Berlin (DE)

## **Learning objectives**

This advanced training course is the third step in the Transurethral Treatment (TUT) curriculum. It is designed to provide urologists with a fundamental understanding of thulium laser enucleation of the prostate (ThuLEP). This comprehensive training is specifically tailored for urologists who want to become proficient in ThuLEP. Using a step by step approach, experts will lead participants through the procedure on state of the art models, to build a familiarity of the process, confidence handling the equipment, and an understanding of best practice.

## **Training aim**

The primary objective of this course is to enhance participants' skills in ThuLEP, focusing on key aspects such as control, handling, and overall technique. By the end of the course, attendees should feel more competent and confident in performing this procedure.

# Controversies in paediatric urology

Thematic Session

Friday 5 April  
13:00 - 14:30

**Location** Purple Area, N01

**Chairs** J.S.L.T. Quaedackers, Groningen (NL)  
M.S. Silay, Istanbul (TR)

## Learning objectives

Join us for an informative paediatric urology session, where experts discuss the latest advancements in diagnosing and treating urological conditions in children. Learn about innovative techniques, compassionate care, and the importance of early intervention for paediatric urology issues in this concise and engaging session.

13:00 - 13:05

## The usefulness of artificial intelligence in paediatric urology

B. Haid, Linz (AT)

13:05 - 13:10

## Urological interventions in the fetal period: What should we know?

O. Telli, Istanbul (TR)

13:10 - 13:20

## State-of-the-art lecture How can we improve treatment success of children with monosymptomatic enuresis nocturna?

G. Bogaert, Leuven (BE)

13:20 - 13:30

## European Society for Paediatric Urology (ESPU) lecture Management of sphincter insufficiency in children

A. Faure, Marseille (FR)

13:30 - 13:35

## Discussion with the audience

13:35 - 14:00

## Case discussion Undescended testis

13:35 - 13:37

## Clinical case presentation

M.I Dönmez, Istanbul (TR)

13:37 - 13:52

## Roundtable discussion

*Discussants*

G. Bogaert, Leuven (BE)  
A. Bujons Tur, Barcelona (ES)  
R.J.M. Lammers, Groningen (NL)

13:52 - 13:55

## Summary from the EAU Guidelines

A. Bujons Tur, Barcelona (ES)

13:55 - 14:00

## Discussion with the audience

14:00 - 14:30

## Debate Surgical management of duplicated ureters

*Moderator* A-F. Spinoit, Ghent (BE)

14:00 - 14:02

## Introduction

A-F. Spinoit, Ghent (BE)

14:02 - 14:07

## Heminephrectomy

M.S. Skott, Aarhus (DK)

14:07 - 14:12

**Uretero-ureterostomy**

L.A. 't Hoen, Rotterdam (NL)

14:12 - 14:17

**Ureteral reimplantation**

N. Baydilli, Kayseri (TR)

14:17 - 14:22

**Ureteral clipping**

F. O'Kelly, Dublin (IE)

14:22 - 14:25

**Expert summary**

A-F. Spinoit, Ghent (BE)

14:25 - 14:30

**Discussion with the audience**

# Challenge the EAU Guidelines: Oligometastatic bladder cancer

Thematic Session

Friday 5 April  
13:00 - 14:30

**Location** Purple Area, eURO Auditorium 2

**Chairs** A. Masson-Lecomte, Paris (FR)  
J.A. Witjes, Nijmegen (NL)

## Learning objectives

In this session a relatively new phenomenon is discussed: Oligometastatic disease in bladder cancer.

There are several issues that need attention: Is the metastasis synchronous or metachronous; what is the best imaging tool; what is the best therapeutic approach: surgery, radiation, systemic therapy or a combination; can we use markers to predict (oligo-)metastatic disease? All these issues will be discussed by experts in their field during this interesting session to provide you with the best possible insights.

13:00 - 13:02

## Introduction

A. Masson-Lecomte, Paris (FR)

13:02 - 13:12

## State-of-the-art lecture Consensus statement from ESMO, ESTRO and EAU

A. Bamias, Athens (GR)

13:12 - 13:17

## Case presentation

J.A. Witjes, Nijmegen (NL)

13:17 - 13:27

## State-of-the-art lecture What is the best imaging for diagnosis and follow up: MRI, CT, PET?

V. Panebianco, Rome (IT)

13:27 - 13:37

## State-of-the-art lecture In which cases is surgery the best option?

G. Thalmann, Bern (CH)

13:37 - 13:47

## State-of-the-art lecture In which cases we should consider radiotherapy?

N. James, London (GB)

13:47 - 13:57

## State-of-the-art lecture Should we add systemic therapy?

R. Cathomas, Chur (CH)

13:57 - 14:17

## Discussion

14:17 - 14:27

## State-of-the-art lecture Can we use markers to guide decisions regarding local or systemic treatment, systemic therapy, and follow-up?

L.S. Mertens, Amsterdam (NL)

14:27 - 14:30

## Closing remarks

J.A. Witjes, Nijmegen (NL)

# Unveiling the unseen: Management of small tumours in penile and testis cancer

Thematic Session

Friday 5 April

13:00 - 14:30

**Location** Purple Area, S01

**Chairs** O.R. Brouwer, Amsterdam (NL)  
A. Lorch, Zürich (CH)

## Learning objectives

While the focus is often on more advanced disease, adequate and early diagnosis of rare urological cancers may be equally important and challenging. This session will feature state-of-the-art lectures and discussions on small testicular masses, including fertility considerations and the potential role of miR-371a-3p for early stage testicular cancer patients. In addition, the state-of-the-art insights on how to manage a patient with a micrometastasis in the sentinel node will be debated.

13:00 - 13:25

**Case discussion** Incidental testicular mass detected in infertility work-up

13:00 - 13:05

**Case presentation**

M. Gül, Konya (TR)

13:05 - 13:10

**Radical orchidectomy**

T. Tandstad, Trondheim (NO)

13:10 - 13:15

**Partial orchidectomy**

P. Paffenholz, Cologne (DE)

13:15 - 13:20

**Monitor**

A. Terbuch, Graz (AT)

13:20 - 13:25

**Discussion**

13:25 - 13:35

**State-of-the-art lecture** Work-up of an indeterminate testicular mass

A. Muneer, London (GB)

13:35 - 13:45

**State-of-the-art lecture** Do we fully understand testicular dysgenesis syndrome yet?

M.M. Fode, Herlev (DK)

13:45 - 13:55

**State-of-the-art lecture** Fertility options and considerations in testis cancer patients

P. Sangster, London (GB)

13:55 - 14:05

**State-of-the-art lecture** miR-371a-3p in active surveillance in stage I testis cancer: Finally ready for clinical practice?

C. Fankhauser, Lucerne (CH)

14:05 - 14:10

**Discussion**

14:10 - 14:30

**Case discussion** Micrometastasis on DSNB

14:10 - 14:15

**Case presentation**

M.T.A. Vreeburg, Amsterdam (NL)

14:15 - 14:20

**Inguinal lymphadenectomy**

C. Protzel, Schwerin (DE)


14:20 - 14:25

**Monitor**

A. Parnham, Manchester (GB)

14:25 - 14:30

**Discussion**



# Counsel and improve functional results after radical prostatectomy

Abstract session 01

Friday 5 April  
13:00 - 14:30

**Location** Green Area, W03

**Chairs** T. Höfner, Linz (AT)  
I. Minčík, Presov (SK)  
K. Touijer, New York (US)

We encourage participants in this session to view the abstracts before the session. All abstract bodies, posters, videos and webcasts can be viewed on the EAU(N)24 Resource Centre or at the digital screens in front of the Purple Area, EGPT.

13:00 - 13:30

## Identify patients at risk for poor outcome

A0017

**How many procedures are necessary during the learning curve of robot-assisted radical prostatectomy to improve trifecta achievement for organ-confined prostate cancer? Results from a multicentric series**

U. Anceschi, Rome (IT)

A0005

**Self-reported comorbidities and associated psychological factors as part of patient-reported outcome measures (PROMs) in long-term survivors after radical prostatectomy**

K. Herkommer, München (DE)

A0003

**Temporal validation of an artificial intelligence tool (SEPERA) to inform nerve-sparing strategy during radical prostatectomy and comparison against urologists**

J. Kwong, Toronto (CA)

A0002

**Predictors of early continence in robot-assisted radical prostatectomy: The role of prostate lobe asymmetry**

F. Di Bello, (IT)

A0014

**Trifecta and Pentafecta after robot-assisted laparoscopic prostatectomy with bladder neck sparing and maximal urethral length preservation in patients with large prostates (>100cc)**

A. Alberti, Florence (IT)

A0016

**Stratification of potency after robotic-assisted radical prostatectomy based on age and degree of nerve-sparing**

P. Fonseca, Stevenage (GB)

13:30 - 13:55

## Prepare for the worst?

A0009

**Multimodal prehabilitation before robotic-assisted radical prostatectomy. A randomised controlled trial. Preliminary results**

J. Sureda Riera, Barcelona (ES)

A0011

**Intra-operative frozen section during robotic-assisted laparoscopic prostatectomy is associated with superior 1-year potency and continence and equivalent biochemical recurrence**

N. Kinnear, Melbourne (AU)

A0007

**Surgical Planning in Robotic Assisted Radical Prostatectomy (RALP): A Quality improvement (QI) project to improve Nerve-sparing (NS) outcomes**

E. Day, London (GB)



A0015	<p><b>Functional Outcomes of Hypothermic RARP: A Randomized, Multicenter, Single-Blinded Study</b></p> <p>J.H. Han, Seoul (KR)</p>
A0013	<p><b>Comparative Analysis of Early Functional Outcomes Following the Hood Technique vs. Standard Nerve Sparing Technique during RARP</b></p> <p>S.N. Ali, California (US)</p>
<hr/>	
13:55 - 14:25	<p><b>Tools to improve outcome</b></p>
A0004	<p><b>Short-term follow-up shows superior continence after robotic radical prostatectomy: Results from 16,839 German routine care patients.</b></p> <p>M.C. Butea-Bocu, Bad Wildungen (DE)</p>
A0010	<p><b>A Retrospective Concomitant Nonrandomized Comparison of Testosterone Replacement Therapy Versus No Treatment: Erectile Function Recovery in Older Hypogonadal Men Post-RARP.</b></p> <p>J. Tran, Orange (US)</p>
A0006	<p><b>A new approach to prostate cancer survivorship care following radical prostatectomy (RP)</b></p> <p>F.E.N. MacAskill, London (GB)</p> <p><b>Study Group</b></p> <p>Guy's Post Pelvic Surgery Research Group(London, United Kingdom)</p>
A0001	<p><b>The impact of prostate cancer ADT and EBRT follow-up treatment on patient-reported quality of life – results from the EUPROMS 2.0 follow-up study</b></p> <p>L.D.F. Venderbos, Rotterdam (NL)</p>
A0012	<p><b>Preservation of Neurovascular Bundles in High-Risk Prostate Cancer Patients: Long-Term Oncological Outcomes from a High-Volume Tertiary Center</b></p> <p>N. Frego, Melle (BE)</p>
A0008	<p><b>Impact of Nerve-Sparing on Urinary Continence following Robot-Assisted Radical Prostatectomy: results from a High-Volume Tertiary Care Hospital</b></p> <p>A. Pissavini, Bologna (IT)</p>
<hr/>	
A0412	<p><b>Current practice and unmet training needs in Robotic-assisted radical prostatectomy: investigation from the Junior ERUS / YAU working group</b></p> <p>M. Covas Moschovas, Celebration (US)</p>

# Upper urinary tract cancer: Challenges in molecular and clinical diagnosis

Abstract session 02

Friday 5 April  
13:00 - 14:30

**Location** Green Area, S06

**Chairs** B. Foerster, Zurich (CH)  
S. Füssel, Dresden (DE)  
K.A. Mohd Ghani, Kuala Lumpur (MY)

We encourage participants in this session to view the abstracts before the session. All abstract bodies, posters, videos and webcasts can be viewed on the EAU(N)24 Resource Centre or at the digital screens in front of the Purple Area, EGPT.

13:00 - 13:02

**Introduction**

13:02 - 13:27

**Staging of upper tract urothelial carcinoma**

A0018

**pT3 Upper Tract Urothelial Carcinoma of the Renal Pelvis: Validating the Prognostic Significance of Subclassification**

K. Oberneder, Vienna (AT)

A0030

**Prognostic impact of a novel pathologic T3 subclassification in patients with upper urinary tract cancer undergoing radical nephroureterectomy**

Y-J. Chou, New Taipei City (TW)

**Study Group**

Taiwan Upper Tract Urothelial Carcinoma Collaboration Group(New Taipei City, Taiwan)

A0024

**Preoperative Multivariable Model for the Prediction of Non-organ Confined Upper Tract Urothelial Carcinoma in Taiwanese population**

Y.P. Huang, Taipei (TW)

A0028

**Incidence of potential candidates for kidney-sparing surgery in upper tract urothelial carcinoma : analysis using radical nephroureterectomy specimens**

S. Matsumoto, Tokyo (JP)

A0031

**Development and validation of a novel nomogram to predict lymph node invasion in upper tract urothelial carcinoma**

M.F. Meagher, La Jolla (US)

13:27 - 13:57

**Molecular landscape of upper tract urothelial carcinoma**

A0020

**Preoperative plasma levels of transforming growth factor beta and its prognostic influence on disease outcomes after radical nephroureterectomy**

A. Alimohammadi, Vienna (AT)

A0019

**Mutational characteristics of advanced urothelial carcinoma in a high-prevalence area for aristolochic acid-associated urinary tract cancers**

H-T. Tung, Tainan (TW)

A0026

**Hematoxylin-eosin Staining Based Immune Microenvironment Subtypes to Guide Prognostic Stratification for Locally Progressive Upper Tract Urothelial Carcinoma**

C. Xu, Beijing (CN)

A0033	<p><b>The genomic landscape and clinical relevance in Chinese patients with upper tract urothelial carcinoma</b></p> <p>W. Junlong, Shanghai (CN)</p>
A0022	<p><b>Performance of Urinary Comprehensive Genomic Profiling in Patients with Upper Tract Urothelial Carcinoma</b></p> <p>M. Pallauf, Salzburg (AT)</p>
A0034	<p><b>Implication of central pathology review in multi-center study of upper tract urothelial cancer</b></p> <p>Y-J. Chou, New Taipei City (TW)</p> <p><b>Study Group</b></p> <p>Taiwan Upper Tract Urothelial Carcinoma Collaboration Group(New Taipei City, Taiwan)</p>
<b>13:57 - 14:27</b>	<b>Endoscopic management of upper tract urothelial carcinoma</b>
A0023	<p><b>Intraoperative diagnosis of upper tract urothelial carcinoma with ex-vivo confocal laser microscopy during ureteroscopy</b></p> <p>I. Sanz - Gómez, Barcelona (ES)</p>
A0032	<p><b>Stenting versus nephrostomy tubes for bladder cancer associated with hydronephrosis: Does stenting increase the incidence of upper tract urothelial carcinoma by retrograde tumor cell seeding?</b></p> <p>M.S. Wettstein, Toronto (CA)</p>
A0027	<p><b>Diagnostic role of ureteroscopy and oncological outcome in patients clinically suspected of upper tract carcinoma in situ</b></p> <p>S. Katayama, Okayama (JP)</p>
A0025	<p><b>Systematic biopsies of the upper tract: a tool to improve the diagnostic accuracy of ureteroscopy and characterization of upper tract urothelial cancer</b></p> <p>A. Galloli, Barcelona (ES)</p>
A0021	<p><b>Oncologic outcomes of endoscopic management of upper tract urothelial carcinoma: a systematic review and pooled analysis from the EAU-YAU Urothelial Working Group</b></p> <p>A. Galloli, Barcelona (ES)</p> <p><b>Study Group</b></p> <p>EAU-YAU Urothelial Working Group(Arnhem, The Netherlands)</p>
A0029	<p><b>Decisional and prognostic impact of diagnostic ureteroscopy in high-risk upper tract urothelial carcinoma: a multi-institutional collaborative analysis (ROBUUST collaborative group)</b></p> <p>F. Montanaro, Verona (IT)</p>

**14:27 - 14:30**

**Expert summary**

# Joint Session of the European Association of Urology (EAU) and the Korean Urological Association (KUA)

Urology beyond Europe

**Friday 5 April**  
**13:00 - 15:00**

**Location** Purple Area, E02

**Chairs** S.K. Hong, Seongnam (KR)  
A.S. Merseburger, Lübeck (DE)

## **Learning objectives**

This session will address a variety of hot urology topics with the help of specialists and key opinion leaders from South Korea and Europe. Delegates can expect detailed and up-to-date coverage of topics like andrology, voiding difficulty, and urological cancers including prostate cancer and urothelial cancer. In this session some of the regional similarities and differences in approaches will be explored.

## **Welcome and introduction**

J.H. Hong, Seoul (KR)

**13:00 - 13:40**

## **Urothelial cancer**

*Moderators* A. Breda, Barcelona (ES)  
S.H. Kang, Seoul (KR)

**13:00 - 13:10**

## **Is perioperative intravesical chemotherapy necessary for surgical treatment of UTUC?**

T. Choi, Seoul (KR)

**13:10 - 13:20**

## **Active surveillance in NMIBC: When and how?**

S.I. Jung, Gwangju (KR)

**13:20 - 13:30**

## **The Fundacio Puigvert Medtronic Hugo RAS experience in urothelial cancer**

A. Breda, Barcelona (ES)

**13:30 - 13:40**

## **Panel discussion**

*Panel* B.C. Jeong, Seoul (KR)  
Y.J. Kim, Cheongju (KR)  
T.H. Kim, Daegu (KR)  
E.N. Xylinas, Paris (FR)

**13:40 - 14:20**

## **Voiding dysfunction, andrology**

*Moderators* K-S. Lee, Seoul (KR)  
V. Phé, Paris (FR)

**13:40 - 13:50**

## **The appropriate grafting material in the surgical treatment of Peyronie's disease: Collagen fleece (TachoSil) vs. Bovine Pericardium vs. Saphenous Vein?**

M.G. Park, Seoul (KR)

**13:50 - 14:00**

## **Optimal evaluation and management in patients with post-prostatectomy incontinence**

H.J. Byun, Daegu (KR)

**14:00 - 14:10**

## **Current status of minimally invasive surgical therapies for BPH**

S. Gravas, Nicosia (CY)

14:10 - 14:20

**Panel discussion**

*Panel*

S. Gravas, Nicosia (CY)

J.H. Lee, Seoul (KR)

K. Park, Kwangju (KR)

J.S. Shim, Seoul (KR)

---

14:20 - 15:00

**Prostate cancer**

*Moderators*

B.A. Hadaschik, Essen (DE)

K.J. Joo, Seoul (KR)

14:20 - 14:30

**Risk-adapted strategy for screening and early detection in prostate cancer**

J. Walz, Marseille (FR)

14:30 - 14:40

**Updates and best strategy for biochemical recurrence after radical prostatectomy**

H.H. Han, Seoul (KR)

14:40 - 14:50

**How does PSMA PET-CT change our clinical practice in the management of prostate cancer?**

B.A. Hadaschik, Essen (DE)

14:50 - 15:00

**Panel discussion**

*Panel*

J.H. Han, Seoul (KR)

J.H. Hong, Seoul (KR)

P.H. Song, Daegu (KR)

J. Suh, seoul (KR)

J. Walz, Marseille (FR)

---

# Joint Session of the European Association of Urology (EAU), the Arab Association of Urology (AAU) and the Pan-African Urological Surgeons Association (PAUSA)

Urology beyond Europe

Friday 5 April  
13:00 - 15:30

**Location** Green Area, W06

**Chairs**  
M. Moussa, Beirut (LB)  
J. N'Dow, Aberdeen (GB)  
J. Rassweiler, Krems - Stein (AT)  
A.S. Zribi, Tunis (TN)

## Learning objectives

Based on the close collaboration between the EAU, PAUSA and AAU, the program of this session focuses again on main topics, which are relevant for the urological practice. This starts with the actual approaches to treat renal stones, followed by the issue of early detection of prostate cancer and its operative management. It will be interesting to hear about new research projects concerning prostate cancer in Africa. Of course, also Men's health plays an important role, thus we will here about ejaculating sperm techniques in the management of BPO as well as about penile prosthesis implantation and management of urethral strictures. Finally, renal transplantation has been chosen to emphasise the role of the urologist.

## Introduction

M. Moussa, Beirut (LB)  
J. Rassweiler, Krems - Stein (AT)  
A.S. Zribi, Tunis (TN)

13:00 - 13:40

## Urolithiasis

*Moderators*  
Y. Farahat, Umm Al Quwain (AE)  
M. Jalloh, Dakar (SN)  
J. Rassweiler, Krems - Stein (AT)

13:00 - 13:10

## ECRIS

C.M. Scoffone, Turin (IT)

13:10 - 13:20

## FURS

Y.M. Al-Hallaq, Baghdad (IQ)

13:20 - 13:30

## An analysis of Tunisian urinary calculi based on their epidemiological characteristics and chemical composition. From 2001 to 2021

K. Bouzid Ghazzi, Tunis (TN)

13:30 - 13:40

## Case presentation on urolithiasis

Y. Saeedi, Dubai (AE)

13:40 - 14:20

## Prostate cancer

*Moderators*  
M. Bulbul, Beirut (LB)  
M.J. Roobol, Rotterdam (NL)  
A.S. Zribi, Tunis (TN)

13:40 - 13:50

## Early detection of Prostate cancer

M.J. Roobol, Rotterdam (NL)

13:50 - 14:00

**Early continence after robotic radical prostatectomy**

A. El Hajj, Beirut (LB)

14:00 - 14:10

**New clinical research and clinical development in prostate cancer in Sub Saharian Africa**

M. Jalloh, Dakar (SN)

14:10 - 14:20

**Case based discussion: Pathways to diagnosis of prostate cancer**

A.S. Zribi, Tunis (TN)

---

14:20 - 15:00

**Men's health**

*Moderators*

M. Moussa, Beirut (LB)

R. Rabii, Casablanca (MA)

N. Sofikitis, Ioannina (GR)

14:20 - 14:30

**Ejaculation sparing techniques**

T. Bach, Hamburg (DE)

14:30 - 14:40

**Inflatable penile prosthesis, patient satisfaction revisited**

M. Hamdan, Amman (JO)

14:40 - 14:50

**Management of urethral strictures in Africa: Challenges and solutions**

A. Mbassi, Yaoundé (CM)

14:50 - 15:00

**Case presentation men's health**

J. Feghali, Beirut (LB)

---

15:00 - 15:30

**Renal transplantation session**

*Moderators*

A.J.H. Al-saedi, Baghdad (IQ)

J.D. Olsburgh, London (GB)

Y.M. Osman, Mansoura (EG)

15:00 - 15:10

**Patient and organ selection in renal transplantation, EAU guideline**

J.D. Olsburgh, London (GB)

15:10 - 15:20

**Multiple arteries in live donor renal transplantation**

Y.M. Osman, Mansoura (EG)

15:20 - 15:30

**Surgical complications of renal transplantation: risk factors and impact on transplant survival. Cases based discussion**

S. Zaghib, Tunis (TN)

**Conclusion**

J. Rassweiler, Krems - Stein (AT)

# Joint Session of the European Association of Urology (EAU) and the Caucasus/Central Asian countries

Urology beyond Europe

**Friday 5 April**  
**13:00 - 15:00**

**Location** Green Area, W01

**Chairs** R. Hovhannisyanyan, Yerevan (AM)  
D. Nikoleishvili, Tbilisi (GE)  
H. Van Poppel, Leuven (BE)

## Introduction

**13:03 - 13:38**

### Andrology

*Moderator* A. Khelaia, Tbilisi (GE)

**13:03 - 13:13**

### Methods of surgical sperm extraction in the assisted reproductive technology (ART) programme and the specifics of patient preparation

D. Fanarjyan, Yerevan (AM)

**13:13 - 13:23**

### Male infertility: did we learn from the past?

N. Sofikitis, Ioannina (GR)

**13:23 - 13:33**

### Our experience in penile implantation

Z. Khakimkhodzhaev, Bishkek (KG)

**13:33 - 13:38**

### Discussion

**13:38 - 14:33**

### Minimally invasive urology

*Moderator* S.V. Fanarjyan, Yerevan (AM)

**13:38 - 13:48**

### The impact of different techniques of dorsal venous complex management during laparoscopic radical prostatectomy on oncological and functional results

A. Pertia, Tbilisi (GE)

**13:48 - 13:58**

### ORSI training center: Robots, the sky is the limit?

A. Mottrie, Aalst (BE)

**13:58 - 14:08**

### Surgical recovery of long-term pelvic defects of ureters

S. Kussymzhanov, Almaty (KZ)

**14:08 - 14:18**

### Interstitial cystitis and bladder pain syndrome

A. Bayramov, Baku (AZ)

**14:18 - 14:28**

### The efficacy of using genital fasciocutaneous flaps for extended urethral strictures

I. Rofiev, Dushanbe (TJ)

**14:28 - 14:33**

### Discussion

**14:33 - 14:58**

### Screening prostate cancer

*Moderator* To be confirmed

**14:33 - 14:43**

### Screening of prostate cancer: Georgian experience

A. Chkhotua, Tbilisi (GE)



14:43 - 14:53

**EU and Council recommendation**

H. Van Poppel, Leuven (BE)


14:53 - 14:58

**Discussion**

---

14:58 - 15:00

**Closing remarks**



# Joint Session of the European Association of Urology (EAU) and the Japanese Urological Association (JUA)

Urology beyond Europe

**Friday 5 April**  
**13:00 - 15:30**

**Location** Green Area, N03

**Chairs** P. Albers, Düsseldorf (DE)  
Y. Tomita, Niigata (JP)

## **Learning objectives**

The aim of this session is to provide the audience an insight in specific topics of current clinical practice in urology. The selected themes this year are “Renal cancer” and “Renal transplantation.” For each topic, the discussion will follow two pathways: on one hand a synthesis of the most recent scientific evidence will be examined, on the other hand, complex scenarios will be discussed by top-class experts. The audience will learn how to face complex clinical decision-making in case of renal cancer and renal transplantation based on the actual EAU-Guidelines.

**13:00 - 13:05**

## **Introduction**

Y. Tomita, Niigata (JP)

**13:05 - 13:55**

## **Renal cancer**

*Moderators* C.K. Bensalah, Rennes (FR)  
H. Miyake, Kobe (JP)

**13:05 - 13:15**

## **Robot-assisted partial nephrectomy**

A. Minervini, Florence (IT)

**13:15 - 13:25**

## **Presurgical systemic therapy and subsequent cytoreductive nephrectomy**

H. Tanaka, Tokyo (JP)

**13:25 - 13:50**

## **Panel discussion**

*Panel* A. Bex, London (GB)  
S. Ishikawa, Niigata (JP)  
M.C. Mir Maresma, Valencia (ES)  
R. Tomida, Tokushima (JP)

**13:50 - 13:55**

## **Break**

**13:55 - 14:40**

## **JUA Abstract presentations**

*Moderators* P. Albers, Düsseldorf (DE)  
Y. Tomita, Niigata (JP)

**13:55 - 14:00**

## **Efficacy of a hydrogel spacer for improving quality of life in patients with prostate cancer undergoing low-dose-rate brachytherapy alone or in combination with intensity-modulated radiotherapy: A retrospective observational study using propensity score matching**

*Presenter* Y. Nakai, Kashihara-Shi (JP)

14:00 - 14:05	<b>Delta-radiomics analysis in comparison to radiomics analysis using dynamic computed tomography for preoperative risk stratification in upper urinary tract urothelial carcinoma</b>
	<i>Presenter</i> H. Tanaka, Tokyo (JP)
14:05 - 14:10	<b>Geriatric nutritional risk index predicts postoperative complications in elderly patients undergoing robot-assisted radical cystectomy</b>
	<i>Presenter</i> K. Fukuta, Tokushima (JP)
14:10 - 14:15	<b>Serum serotonin levels as a potential risk factor for overactive bladder in a community-dwelling population</b>
	<i>Presenter</i> T. Hamaya, Hirosaki (JP)
14:15 - 14:20	<b>Analysis of ctDNA hotspot mutations in non-coding lesion improves early prediction of recurrence in muscle-invasive bladder cancer (MIBC)</b>
	<i>Presenter</i> S. Tsukahara, Fukuoka (JP)
14:20 - 14:25	<b>Procedural safety of aquablation for benign prostatic hyperplasia in japanese men</b>
	<i>Presenter</i> T. Miyauchi, Oita (JP)
14:25 - 14:30	<b>Contralateral patent processus vaginalis in pediatric patients with a unilateral nonpalpable testis</b>
	<i>Presenter</i> H. Nishio, Nagoya (JP)
14:30 - 14:35	<b>Summary by moderators</b>
14:35 - 14:40	<b>Break</b>
<hr/>	
14:40 - 15:25	<b>Renal transplantation</b>
	<i>Moderators</i> A. Alcaraz, Barcelona (ES) M. Tasaki, Niigata (JP)
14:40 - 14:50	<b>New tools for rejection diagnosis</b> T. Hirai, Tokyo (JP)
14:50 - 15:00	<b>Update in robotic assisted kidney transplantation</b> A. Breda, Barcelona (ES)
15:00 - 15:10	<b>Kidney transplant in complex vascular patients</b> A. Alcaraz, Barcelona (ES)
15:10 - 15:25	<b>Panel discussion</b>
	<i>Panel</i> Y. Abe, Kagawa (JP) A. Alcaraz, Barcelona (ES) A. Breda, Barcelona (ES) T. Hirose, Sapporo (JP)
<hr/>	
15:25 - 15:30	<b>Closing remarks by JUA President</b> M. Eto, Fukuoka (JP)

# Updates and controversies - Urolithiasis, female and male LUTS Guidelines 2024: What has changed?

ESU Course 09

**Friday 5 April**  
**13:00 - 15:00**

**Location** Purple Area, E04

**Chair** A.K. Nambiar, Newcastle-upon-Tyne (GB)

## **Learning objectives**

This course will focus on three non-oncology Guidelines (Non-Neurogenic Female and Male LUTS, and Urolithiasis) and there will be a brief review of the EAU Guidelines methodology and process of guideline development.

The course will then involve an interactive discussion of the main new changes to these guidelines, challenges in development, areas of inconsistency and opportunities for further research.

## **Welcome and introduction**

A.K. Nambiar, Newcastle-upon-Tyne (GB)

---

## **Urolithiasis guideline: New diagnostic algorithms, best clinical practice in urinary stone intervention, how and how often to follow up and time to discharge urinary stone patients after treatment**

R. Geraghty, Newcastle upon Tyne (GB)

---

## **Non-neurogenic male LUTS guideline: Updates and controversies**

J-N.L. Cornu, Rouen (FR)

---

## **Female Non-neurogenic LUTS: A re-birth, revamp and re-naming. Changes to expect in 2024**

A.K. Nambiar, Newcastle-upon-Tyne (GB)

# Hands-on Training in PSMA/PET image reading for urologists

HOT 1.18

Friday 5 April

13:00 - 16:30

**Location** Orange Area, HOT 5

## Learning objectives

The Hands-on Training in PSMA/PET image reading for urologists provides training in PET imaging for prostate cancer with an emphasis on PSMA. The course aims to help urologists understand the role PET imaging plays in the management of patients with prostate cancer and how to interpret the images. The training addresses how prostate PET imaging works, what different tracers might be used for prostate cancer, and how to use the information generated by PET (i.e. in clinical decision making or modifying management of patients). The course will cover initial staging, staging at recurrence, and the use of PET imaging for radioligand treatment. The current limitations and pitfalls of PET imaging will be critically assessed and discussed.

## Training aim

The primary objective of this course is to develop practical skills needed to implement PSMA/PET into practice.

13:00 - 13:10	<b>Importance of PSMA/PET imaging to the Urologist and introduction to the course</b> V. Kasivisvanathan, London (GB)
13:10 - 13:25	<b>Overview of PET-tracers and radioligands</b> K. Herrmann, Essen (DE)
13:25 - 13:40	<b>Principles of PET reading in Prostate Cancer</b> R. Mei, Modena (IT)
13:40 - 13:55	<b>Current data on PET imaging in newly diagnosed prostate cancer</b> V. Kasivisvanathan, London (GB)
13:55 - 14:15	<b>Review of PSMA/PET images for initial prostate cancer staging</b> R. Mei, Modena (IT)
14:15 - 14:25	<b>Discussion of Role of PSMA/PET for initial staging</b> V. Kasivisvanathan, London (GB)
14:25 - 14:40	<b>Current data on PET imaging in recurrent prostate cancer</b> K. Herrmann, Essen (DE)
14:40 - 15:20	<b>Review of PSMA/PET images of prostate cancer recurrence</b> R. Mei, Modena (IT)
15:20 - 15:30	<b>Discussion of Role of PSMA/PET for Recurrence</b> F. Sanguedolce, Barcelona (ES)
15:30 - 15:45	<b>Current data on the role of PET imaging for selection of radioligand therapy</b> K. Herrmann, Essen (DE)
15:45 - 16:05	<b>Review of PSMA/PET images of advanced prostate cancer</b> R. Mei, Modena (IT)

**16:05 - 16:15**

**Discussion of Role of PSMA/PET and radioligand therapy for advanced disease**

F. Sanguedolce, Barcelona (ES)

---

**16:15 - 16:25**

**Pitfalls and limitations of PSMA/PET**

K. Herrmann, Essen (DE)

---

**16:25 - 16:30**

**Summary and Close**

F. Sanguedolce, Barcelona (ES)

# Inflammatory bladder

Patient Office - Roundtable

**Friday 5 April**  
**13:30 - 14:30**

**Location** Green Area, W08

**Chairs** A. De Santis, Rome (IT)  
D.A.W. Janssen, Nijmegen (NL)

## **Learning objectives**

We want to generate attention for the burden and lack of guidelines for inflammatory bladder diseases. We will focus on BPS/IC, chronic radiation induced cystitis and ketamine induced cystitis. The burden, experienced by patients and the nuances in healthcare management will be discussed. This roundtable will give patients and clinical care experts in this field a platform on how to improve healthcare for these underdiagnosed and often sub optimally treated patients.

**13:30 - 13:35**

## **Welcome & introduction**

D.A.W. Janssen, Nijmegen (NL)

**13:35 - 13:50**

## **IC/BPS**

A. De Santis, Rome (IT)  
D.A.W. Janssen, Nijmegen (NL)

**13:50 - 14:05**

## **Radiotherapy/radiation cystitis**

**13:50 - 13:55**

## **A patient view to talk about their experience**

M. Koivuneva, Nurmijärvi (FI)

**13:55 - 14:05**

## **An expert view on treatments**

L.M. Renström Koskela, Stockholm (SE)

**14:05 - 14:20**

## **Ketamine cystitis: Affects and addiction**

W. Van Der Sanden, Utrecht (NL)

**14:20 - 14:30**

## **Q&A and closing**

D.A.W. Janssen, Nijmegen (NL)

**Friday 5 April**  
**13:30 - 16:45**

**Location** Orange Area, HOT 3

**Chair** L. Budäus, Hamburg (DE)

### **Learning objectives**

MRI is increasingly used in patients undergoing prostate biopsies. Different MRI Ultrasound fusion devices allow integrating the MRI information into the daily clinical workflow. Moreover, transperineal biopsies are increasingly used even in the outpatient setting.

The Hands-on Training in MRI Fusion Biopsy is designed to help participants understand the advantages, handling and limitations of MRI Ultrasound fusion biopsies.

Therefore, the course provides an overview on technical basics and different prostate biopsy approaches. Technical considerations, the transrectal or transperineal approach will be critically reviewed and discussed. Additionally, performing transperineal biopsies in the office based setting by using local anesthesia will be presented. During the second half of the course, the participants are able to try out different Fusion biopsy machines in small groups.

The training is designed to be 2 hours, including a short introduction, presentation of different approaches, and a rotation of training at each station, ensuring contact of every participant to each machine.

**13:30 - 13:35**

### **Introduction**

L. Budäus, Hamburg (DE)

**13:35 - 13:50**

### **Different MRI-Ultrasound technical approaches available**

L. Budäus, Hamburg (DE)

**13:50 - 14:05**

### **Demonstration: How to perform a transperineal biopsy**

C. Kastner, Cambridge (GB)

**14:05 - 16:35**

### **Hands-on training at stations**

#### *Tutors*

R. Diamand, Brussels (BE)  
F. Falkenbach, Hamburg (DE)  
P.C. Henry, Besançon (FR)  
M. Jahnen, Munich (DE)  
C. Kastner, Cambridge (GB)  
F. Lavagno, Turin (IT)  
P.L Pfitzinger, Munich (DE)

**16:35 - 16:45**

### **Closing Remarks and Q&A**



# Hands-on Training in Endoscopic stone treatment - Step 1

HOT 1.06

Friday 5 April  
13:45 - 14:40

**Location** Orange Area, HOT 1

**Tutors**  
K. Ahmed, London (GB)  
V. Gauhar, Singapore (SG)  
A. Pietropaolo, Southampton (GB)  
D. Veneziano, New York (US)

## **Learning objectives**

This Basic Endoscopic Stone Treatment course is the first step in the Endoscopic Stone Treatment (EST) curriculum. It is designed to provide urologists with a fundamental understanding of endoscopic stone treatment and enhance their skills. This comprehensive training is specifically tailored for urologists who want to gain a basic level of knowledge in endoscopy and wish to improve their proficiency in key techniques for endoscopic stone management. The curriculum includes four key exercises that provide hands-on experience and practical training: Flexible Cystoscopy, Rigid Cystoscopy, Semi-Rigid Ureteroscopy, and Flexible Ureteroscopy.

The primary objective of this programme is to enhance participants' skills in the treatment of urinary stones with endoscopic techniques. By the end of the course, attendees should feel more confident and competent in their basic skills.

# Hands-on Training in Laparoscopic urological skills - Step 1

HOT 1.05

Friday 5 April

13:45 - 14:40

**Location** Orange Area, HOT 1

**Tutors** M. Jarzowski, Bydgoszcz (PL)

J.B. Roche, Bordeaux (FR)

## **Learning objectives**

This basic laparoscopic training course is the first step in the Laparoscopic Urological Skills (LUS) curriculum. It is designed to provide urologists with a fundamental understanding of laparoscopy and enhance their laparoscopic skills. This comprehensive training is specifically tailored for urologists who want to gain a basic level of knowledge in laparoscopy and wish to improve their proficiency in key laparoscopic techniques. The course comprises four essential exercises aimed at honing skills related to depth perception and bimanual dexterity: Peg Transfer, Circle Cut, Needle Guidance, and Knot Tying.

The primary objective of this course is to enhance participants' laparoscopic skills, focusing on key aspects such as depth perception and bimanual dexterity. By the end of the course, attendees should feel more confident and competent in their basic laparoscopic skills.

# Hands-on Training in Transurethral treatment - Step 1 & 2 (TURBT/TURP)

HOT 1.07

Friday 5 April

13:45 - 14:40

**Location** Orange Area, HOT 1

**Tutors** D. Oliveira Reis, Lisboa (PT)  
L. Osório, Porto (PT)

## **Learning objectives**

This training course combines the first and second step of the Transurethral Treatment (TUT) curriculum. It is designed for urologists who wish to improve their proficiency in key techniques and gain a fundamental understanding of transurethral resection of the bladder and prostate. This comprehensive training covers crucial basic skills including flexible and rigid cystoscopy, resection loop handling, and direct vision internal urethrotomy, as well as the resection procedure, practiced on state-of-the-art models.

The primary objective of this course is to enhance participants' skills in transurethral resection of the prostate and bladder, focusing on key aspects such as depth perception, hand-eye coordination, control, handling, and overall technique. By the end of the course, attendees should feel more competent and confident in performing this procedure.

# Hands-on Training in Transurethral treatment - Step 3 (ThuLEP)

HOT 1.08

Friday 5 April

13:45 - 14:40

**Location** Orange Area, HOT 2

**Tutors** L.B. Dragoş, Cambridge (GB)

B.M. Schoensee, Berlin (DE)

## **Learning objectives**

This advanced training course is the third step in the Transurethral Treatment (TUT) curriculum. It is designed to provide urologists with a fundamental understanding of thulium laser enucleation of the prostate (ThuLEP). This comprehensive training is specifically tailored for urologists who want to become proficient in ThuLEP. Using a step by step approach, experts will lead participants through the procedure on state of the art models, to build a familiarity of the process, confidence handling the equipment, and an understanding of best practice.

## **Training aim**

The primary objective of this course is to enhance participants' skills in ThuLEP, focusing on key aspects such as control, handling, and overall technique. By the end of the course, attendees should feel more competent and confident in performing this procedure.

# Harnessing technology in urology: From remote monitoring to AI-enhanced robotic interventions

Video session 03

**Friday 5 April**  
**14:15 - 15:45**

**Location** Green Area, S04

**Chairs** J.W. Collins, London (GB)  
F. Porpiglia, Turin (IT)

We encourage participants in this session to view the abstracts before the session. All abstract bodies, posters, videos and webcasts can be viewed on the EAU(N)24 Resource Centre or at the digital screens in front of the Purple Area, EGPT.

V017 (□: 8 min.)

**Use of TYTOCARE device for home telemonitoring in patients undergoing radical cystectomy: Comparative analysis of early post-operative outcomes**  
A. Quarà, Baldissero Torinese (IT)

V018 (□: 6 min.)

**Artificial Intelligence 3D Augmented Reality guided RARP v.s. Artificial Intelligence 3D Augmented Reality guided RARP v.s. Cognitive MRI intervention: ad interim analysis of RIDERS Trial**  
E. Checcucci, Candiolo (IT)

V019 (□: 7 min.)

**3D-models assistance during robot-assisted renal artery aneurysm removal**  
D. Amparore, Turin (IT)

V020 (□: 9 min.)

**Robotic ureteroplasty for retrocaval ureter with three-dimensional images navigation: technique and outcomes**  
W. Xiang, Beijing (CN)

V021 (□: 8 min.)

**Robot assisted 3D model & indocyanine guided ureteral reimplantation in renal transplant patients: 4 emblematic cases from our series.**  
F. Lavagno, Turin (IT)

V022 (□: 8 min.)

**Feasibility of image-guided navigation during robotic-assisted surgery: a prospective study**  
L. Aguilera Saiz, Amsterdam (NL)

V086 (□: 7 min.)

**A preliminary experience with metaverse surgical planning for robotic partial nephrectomy**  
E. Checcucci, Candiolo (IT)

V024 (□: 5 min.)

**Super-selective clamping guided by 3D augmented reality during robot assisted partial nephrectomy: A single center experience**  
G. Spena, Napoli (IT)

Friday 5 April  
14:15 - 15:45

**Location** Purple Area, EGPT

**Chairs** J. Heesakkers, Maastricht (NL)  
T.L.C. Kuo, Singapore (SG)

We encourage participants in this session to view the abstracts before the session. All abstract bodies, posters, videos and webcasts can be viewed on the EAU(N)24 Resource Centre or at the digital screens in front of the Purple Area, EGPT.

14:15 - 14:36

## Screen A: Urethral strictures

- P084** **Delineating functional outcomes and patient-reported treatment satisfaction after perineal urethrostomy as last resort management of complex anterior urethral strictures**  
J. Klemm, Hamburg (DE)
- P064** **Management Patterns of Male Urethral Stricture Disease Among Urologists: What Do the Guidelines Say? What Do Urologists Do?**  
O. Bozkurt, Izmir (TR)
- P061** **Efficacy analysis of robot-assisted laparoscopic Y-V cystoplasty for anastomotic stricture after radical prostatectomy for prostate cancer—experience from a single urinary tract repair center**  
Q. Fu, Shanghai (CN)
- P069** **Non-bulb transecting vessel - sparing excision and primary anastomosis (EPA). Dorsal approach for proximal bulbar and membranous strictures.**  
M. Dahamshy, Kfar kanna (IL)
- P072** **Mucosal sparing augmented non-transecting urethroplasty (msANTA) : Game changer In the management of non traumatic Bulbar urethral strictures**  
S. Bafna, Ayanavaram Chennai (IN)
- P077** **Long-term Follow-up and Success Rate of Ventral Inlay Buccal Mucosal Graft Urethroplasty vs Dorsal onlay Buccal Mucosal Graft Urethroplasty for Female Urethral Stricture Disease.**  
V. Tarigopula, Bhubaneswar (IN)
- P076** **Does tobacco exposure, preoperative oral health, and buccal mucosal graft histology have a effect on postoperative pain scores at harvest site? A Prospective Observational**  
V. Tarigopula, Bhubaneswar (IN)

14:36 - 14:54

## Screen B: Sexual dysfunction

- P080** **Qualitative assessment of patient-reported outcomes in urinary and sexual function in patient after perineal urethrostomy**  
P. Neuville, Lyon (FR)
- P087** **Our outcomes of an improved penile venous surgery in patients with venogenic erectile dysfunction**  
B.R. Gvasalia, Tbilisi (GE)

P067	<b>Efficacy of transobturator vaginal tape (TVT-O) in the treatment of Coital Incontinence.</b> M. Gubbiotti, Perugia (IT)
P081	<b>Does a separate blood supply to the urethra decrease complications in transmasculine gender affirmation surgery? Outcomes of radial artery urethroplasty in a large cohort</b> W.G. Lee, London (GB)
P088	<b>Novel strategy for Combining penile erection restoration and factual girth enhancement based on de novo penile fibrovascular assembly</b> C-H. Chung, New Taipei City (TW)
P089	<b>Effect of alpha-adrenoceptor antagonists on sexual function: A systematic review and meta-analysis</b> N. Gherabi, Algiers (DZ)  <b>Study Group</b> U-merge Ltd.(London, United Kingdom)
<hr/>	
<b>14:54 - 15:06</b>	<b>Screen C: Urogenital reconstruction: preclinical</b>
P068	<b>Shared genetic etiology and causality between Hunner-type interstitial cystitis and autoimmune disorders: A large-scale genome-wide cross-trait analysis</b> X.Y. Lyu, Chengdu (CN)
P063	<b>Functionality and tolerability of magnetic artificial urinary sphincter in canine incontinence model</b> S. Tabatabaei, Newton (US)
P078	<b>Paclitaxel coated ureteral balloon for ureteroscopic thermal injury induced ureteral stenosis in porcine model: a preclinical study.</b> X. Li, Beijing (CN)
P083	<b>Decellularization and recellularization of human foreskin for tissue engineering applications</b> S. Žiaran, Bratislava (SK)
<hr/>	
<b>15:06 - 15:30</b>	<b>Screen D: Urogenital reconstruction: miscellaneous</b>
P070	<b>Systematic review and meta-analysis of the outcomes of robot-assisted surgery in complex neuro-uological interventions</b> P. Geretto, torino (IT)
P079	<b>Combined endoscopic and robot-assisted repair of vescicovaginal fistula and bladder endometriosis: Role of peritoneal flap</b> G. Albo, Milan (IT)
P074	<b>Combined robot-assisted and endoscopic treatment of ureteral strictures: functional outcomes in a single center experience</b> M. Berra, Buscate (IT)
P065	<b>Bladder elongation psoas hitch does not negatively affect voiding function</b> L. Grimaud, Durham (US)
P082	<b>Short-term Morbidity and Long-term Functional Outcomes of the T Plasty for Salvage Reconstruction of Recalcitrant Bladder Neck Stenosis</b> F. König, Hamburg (DE)
P085	<b>Long-term results of Subtrigonal Inlay Patch (SIP) Technique for recurrent bladder neck contractures</b> O. Bozkurt, Izmir (TR)

- P075 **Iatrogenic or recurrent Bladder Neck contracture treated by the Palminteri Ferrari technique: a new way to approach a frustrating condition**  
S. Morselli, San Felice Sul Panaro (IT)
- P073 **Pudendal entrapment syndrome: the earliest diagnosis, the best surgical result**  
A. Piana, Turin (IT)
- 
- 15:30 - 15:45** **Screen E: Complex reconstructive pathology**
- P060 **The Portuguese Navy Radiation-induced Cystitis (PNRC) scale: Validation of a novel clinical radiation-induced cystitis classification**  
T.M. Ribeiro De Oliveira, Lisbon (PT)
- P062 **Prior radiotherapy is an independent predictor for major postoperative complications in patients undergoing urinary diversion for non-malignant indications**  
J. Haugland, Bergen (NO)
- P071 **Urosymphyseal fistula and pubic osteomyelitis in prostate cancer survivors – a complex disease requiring extensive and specialized treatment**  
L. Smeyers, Kasterlee (BE)
- P086 **Comparing Lifespan of Artificial Urinary Sphincters in Preirradiated Patients: Transcorporal vs. Standard Placement**  
K. Malshy, Providence, Rhode Island (US)
- P066 **Correlation between early recovery of urinary continence and length of spared urethra after robotic assisted radical prostatectomy: a prospective multicenter study**  
F.M. Valenzi, Latina LT (IT)



**Friday 5 April**  
**14:45 - 16:15**

**Location** Purple Area, N01  
**Chairs** P. Black, Vancouver (CA)  
S.K. Pal, Duarte (US)

**14:45 - 15:25**

## **Kidney cancer**

**14:45 - 14:55**

### **Immune checkpoint therapy in kidney cancer: Have we reached the limit?**

U. Vogl, Bellinzona (CH)

**14:55 - 15:05**

### **Selecting patients for immunotherapy: Tissue-based biomarkers vs. IMDC classification**

Z. Tippu, London (GB)

**15:05 - 15:15**

### **What is new in perioperative therapy in kidney cancer**

A. Bex, London (GB)

**15:15 - 15:17**

### **Case presentation**

R. Flippot, Villejuif (FR)

**15:17 - 15:25**

### **Panel discussion**

---

**15:25 - 15:55**

## **Bladder cancer**

**15:25 - 15:35**

### **Immunotherapy beyond BCG in NMIBC**

D. Raggi, Milan (IT)

**15:35 - 15:45**

### **Perioperative immune checkpoint inhibition in MIBC**

B. Szabados, London (GB)

**15:45 - 15:55**

### **Response to immune checkpoints in different histological and molecular subtypes**

Y. Loriot, Villejuif (FR)

---

**15:55 - 16:05**

### **Biomarkers beyond PDL1 for predicting response to checkpoint inhibition in bladder cancer**

A. Necchi, Milan (IT)

---

**16:05 - 16:15**

### **Novel approaches to immunotherapy in GU cancers: What comes next?**

V. Grünwald, Essen (DE)

Friday 5 April  
14:45 - 16:15

**Location** Purple Area, S03

**Chairs** A. Briganti, Milan (IT)  
K.A.O. Tikkinen, Helsinki (FI)

### Learning objectives

In this session featuring urologic examples, attendees will learn about:

1. Advantages and disadvantages of surrogate endpoints
2. How to assess the certainty of evidence and its impact on decision-making
3. Analysing heterogeneity and conducting subgroup analyses
4. The significance of non-inferiority trials and network meta-analyses
5. Understanding the principles and applications of platform trials
6. Patients' values & preferences, and the importance of trustworthy guidelines

14:45 - 14:46

**Introduction**

14:46 - 15:00

**Debate Surrogate endpoints**

14:46 - 14:51

**Pro**

A. Martini, Houston (US)

14:51 - 14:56

**Con**

R. Breau, Ottawa (CA)

14:56 - 14:58

**Rebuttal - pro**

A. Martini, Houston (US)

14:58 - 15:00

**Rebuttal - con**

R. Breau, Ottawa (CA)

15:00 - 15:07

**Certainty of evidence**

D.A. González-Padilla, Madrid (ES)

15:07 - 15:14

**Moving from evidence to the decisions**

P. Dahm, Minneapolis (US)

15:14 - 15:21

**Heterogeneity in systematic reviews**

A.K. Puerto Niño, Bogota (CO)

15:21 - 15:28

**Subgroup analysis in randomised trials**

T.P. Kilpeläinen, Helsinki (FI)

15:28 - 15:35

**Non-inferiority trial**

S.V. Tornberg, Helsinki (FI)

15:35 - 15:42

**Platform trials**

N. James, London (GB)

---

15:42 - 15:49

**Network meta-analysis**

A.K. Puerto Niño, Bogota (CO)

---

15:49 - 15:58

**Fixed-effect vs. random-effects models for meta-analysis**

A. Halme, Helsinki (FI)

---

15:58 - 16:05

**Patients' values and preferences**

S. Malde, London (GB)

---

16:05 - 16:12

**Trustworthy guidelines**

P.D. Violette, Woodstock (CA)

---

16:12 - 16:15

**Closing remarks**

K.A.O. Tikkinen, Helsinki (FI)

---



# Navigating the landscape: Testicular carcinoma across stages

Abstract session 03

Friday 5 April

14:45 - 16:15

**Location** Purple Area, S01

**Chairs** T. Kuliš, Zagreb (HR)  
C. Oing, Newcastle upon Tyne (GB)  
P. Paffenholz, Cologne (DE)

We encourage participants in this session to view the abstracts before the session. All abstract bodies, posters, videos and webcasts can be viewed on the EAU(N)24 Resource Centre or at the digital screens in front of the Purple Area, EGPT.

14:45 - 15:05

## Tumor micro-environment

A0039

### New definition of the "Growing teratoma syndrome" based on molecular subtyping and novel biomarkers

P. Pongratanakul, Düsseldorf (DE)

A0044

### A single-cell analysis reveals intra-tumor heterogeneity and immune environment of testicular seminoma

W. Wang, Chengdu (CN)

A0043

### Predictive value of immune genes related to RAS/KIT mutations in the response of TGCT to cisplatin-based chemotherapy and immunotherapy

N. Song, Nanjing (CN)

A0041

### Primary retroperitoneal germ-cell tumors (pR-GCT): Evaluation of treatment outcomes of an international collaboration (PRIMERE study-IGG05)

S. Nazzani, Milan (IT)

15:05 - 15:35

## Optimizing diagnosis and management of stage I and indeterminate lesions

A0040

### MRI in the diagnosis of indeterminate testicular lesions- a game changer?

S. Deininger, Salzburg (AT)

A0046

### miRNA as a liquid biomarker to detect malignancy in small testicular masses.

J. Chavarriaga, TORONTO (CA)

A0051

### Predicting metastatic relapse in clinical stage I seminoma germ cell tumors using artificial intelligence on histopathological slides

A. Alberts, Bleiswijk (NL)

A0038

### Long-term outcomes of surveillance of clinical stage I pure teratoma of the testicle

J. Chavarriaga, TORONTO (CA)

A0037

### Inconsistency in the assessment of retroperitoneal lymph node metastasis in testicular cancer patients: influence on clinical stage, therapy and relapse rate

T. Nestler, Koblenz (DE)

15:35 - 16:00

## The role and impact of RPLND in metastatic germ cell tumors

A0035

### Outcomes after primary retroperitoneal lymph node dissection in men with stage 2 non-seminomatous germ cell tumour, a multicenter retrospective cohort study

L. Antonelli, bovezzo (IT)

- A0045 **Primary retroperitoneal lymph node dissection in marker positive testicular cancer**  
J. Chavarriaga , TORONTO (CA)
- A0048 **Association of radiographic and pulmonary functional changes in patients receiving polychemotherapy including bleomycin**  
L. Frey, Mainz (DE)
- A0047 **Retrospective analysis on oncological results of postchemotherapeutic residual tumor resection in patients with metastatic seminoma following systemic chemotherapy**  
C. Steinbach, Cologne (DE)
- A0036 **Risk factors for relapse in non-seminomatous testicular cancer after post-chemotherapy retroperitoneal lymph node dissection with viable residual cancer**  
L. Antonelli, bovezzo (IT)
- 

**16:00 - 16:15**

**Testis cancer survival and survivorship**

- A0042 **Ejaculatory dysfunction (EJD) after retroperitoneal lymph node dissection (RPLND) for testicular cancer (TC)**  
C. Conduit, Melbourne (AU)
- A0049 **The Empower Pathway: an innovative approach to delivering personalised care for testicular cancer survivors**  
R. Holwell, London (GB)
- A0052 **Hospital anxiety and depression scale (HADS) scores trends among testicular cancer patients, a single institute longitudinal study**  
K. Alkhatib, Elmhurst (US)

# Urolithiasis: Imaging and conservative management

Abstract session 05

Friday 5 April  
14:45 - 16:15

**Location** Green Area, W03

**Chairs** N. Abid, Lyon (FR)  
R.G. Atis, İstanbul (TR)  
F. Pauchard, Vina del Mar (CL)

We encourage participants in this session to view the abstracts before the session. All abstract bodies, posters, videos and webcasts can be viewed on the EAU(N)24 Resource Centre or at the digital screens in front of the Purple Area, EGPT.

- 
- A0072** **Comparison of automated kidney stone size measurement and volumetry in photon counting CT compared to 3rd generation dual energy CT and physically measurements**  
T. Nestler, Koblenz (DE)
- 
- A0077** **Trends in Kidney Stone Prevalence among US Adults from the NHANES Database**  
N. Bhojani, Montreal (CA)
- 
- A0073** **The impact of kidney stone disease on quality of life in high-risk stone formers**  
A. Assad, Montreal (CA)
- 
- A0075** **Utilizing artificial intelligence to anticipate urolithiasis risk in general population**  
B. Gimenez, Santiago (CL)
- 
- A0071** **Dose optimization by deep learning tool in various CT protocols for urolithiasis: a physical human phantom study**  
S.Y. Choi, Seoul (KR)
- 
- A0083** **Quality of information and appropriateness of Open AI outputs for lithiasis management**  
A. Guercio, Latina (IT)
- 
- A0085** **Radiomics-based Multi-class Classification for Composition of Urolithiasis on Non-Contrast Computed Tomography.**  
S. Jeong, Seoul (KR)
- 
- A0087** **Multi-Energy Photon-Counting Computed Tomography: A Novel Technique to Determine Kidney Calculi Composition**  
B. Wang, Beijing (CN)
- 
- A0076** **Evaluation of the clinical significance of radiological signs of stone impaction in predicting spontaneous stone passage**  
M.M. Popiolek, Örebro (SE)
- 
- A0078** **Factors Affecting Radiation Exposure In Patients Undergoing Endoscopic Treatment For Urolithiasis**  
D.D. Sugrue, Dublin (IE)

- A0079 **Caveats against the use of ultrasound as the primary imaging modality in pediatric urolithiasis.**  
M. Abbas, Kfar cana (IL)
- 
- A0080 **Acoustic Radiation Force Impulse Image for Evaluation of Parenchyma Elasticity in Acute Hydronephrotic Kidney: A Preliminary Report**  
Y-L. Wu, Taipei City (TW)
- 
- A0081 **Screening for Clinically Significant Nephrolithiasis Based on Simple Health Checkup Clinical and Urine Parameters in General Populations: Machine Learning Models and Multi-hospital Study**  
H. Chen, Kaohsiung (TW)
- 
- A0070 **Optimal timing of surgical intervention after diagnosis of upper urinary tract stones: a perspective from renal function preservation**  
W. Yuma, Tokyo (JP)
- 
- A0086 **Decision Regret Analysis of patients opting for early Ureteroscopy versus a trial of Medical Expulsive Therapy after Shared Decision Making for management of ureteric calculi  $\leq 10\text{mm}$ : Final results from the DRAUMET study**  
A.K. Chawla, Manipal (IN)
- 
- A0084 **Histopathological evaluation of Holmium:YAG Laser Injury to human ureter during urolithiasis surgery**  
S.M. Croghan, Dublin (IE)
- 
- A0074 **Kidney stone analysis: An EAU section of urolithiasis (EULIS) survey on current practices and perspectives worldwide**  
S. Stoots, Amsterdam (NL)

Friday 5 April  
14:45 - 16:15

**Location** Green Area, S06

**Chairs** J.L. Domínguez Escrig, Valencia (ES)  
To be confirmed  
E.N. Xylinas, Paris (FR)

We encourage participants in this session to view the abstracts before the session. All abstract bodies, posters, videos and webcasts can be viewed on the EAU(N)24 Resource Centre or at the digital screens in front of the Purple Area, EGPT.

14:45 - 15:10

## Minimal invasive surgery of upper tract urothelial carcinoma

A0093

### Change in Kidney Function after Endoscopic Management of Upper Tract Urothelial Cancer – Results from the EndoUTUC Collaboration

M. Pallauf, Salzburg (AT)

#### Study Group

EndoUTUC Collaboration(United States of America, United States of America)

A0095

### "Twenty-Year Follow-Up of Large-Volume Low-Grade Urothelial Carcinoma: Long-Term Outcomes in Patients Undergoing Ureteroscopic versus Nephroureterectomy Therapy"

G. Verhovsky, New York (US)

A0089

### Open versus Minimally Invasive Nephroureterectomy in Octogenarians: An Analysis of Surgical Approach Trends, Outcomes and Survival Analysis with Propensity Matching

S. Trecarten, San Antonio (US)

A0104

### Robotic distal ureterectomy for high-risk distal ureteral urothelial carcinoma: a retrospective multicenter comparative analysis (ROBUUST collaborative analysis)

F. Ditonno, Verona (IT)

A0092

### Robot-assisted radical nephroureterectomy for locally advanced upper tract urothelial carcinoma. Is it ready for prime time? A snapshot from the Junior ERUS/Young Academic Urologist Working Group on Robot-assisted Surgery

F. Di Maida, Florence (IT)

15:10 - 15:35

## Systemic treatment for upper tract urothelial carcinoma

A0094

### Neoadjuvant disitamab vedotin combined with tislelizumab for locally advanced upper urinary tract carcinoma: A pilot study for a phase II trial.

Y. Bao, Chengdu (CN)

A0090

### Real-world data: call for paradigm shift towards neoadjuvant chemotherapy in patients with Upper Tract Urothelial Carcinoma treated with Nephroureterectomy - Analysis of the ROBUUST Registry

G. Tuderti, Roma (IT)

A0096

### Genomic Tumor Correlates of Clinical Outcomes Following Kidney-Sparing Chemoradiation Therapy for upper tract urothelial carcinoma

C. Gu, Shanghai (CN)



A0101	<b>Real-world outcomes of first-line systematic treatment in advanced Upper Urinary Tract Urothelial Carcinoma patients with renal impairment: YUSHIMA-04 study</b> T. Kimura, Tokyo (JP)
A0088	<b>Survival benefit of nephroureterectomy in systemic therapy exposed metastatic upper tract urinary urothelial carcinoma patients</b> S. Morra, napoli (IT)
<hr/>	
<b>15:35 - 15:55</b>	<b>Outcomes after treatment for upper tract urothelial carcinoma</b>
A0091	<b>Real-world management of high-risk Upper Tract Urothelial Carcinoma: level of adherence to EAU guidelines- Analysis of the ROBUUST Registry</b> G. Tuderti, Roma (IT)
A0099	<b>The Long-term Outcome of Nephron-Sparing Surgery versus Radical Nephroureterectomy for Organ-Localized Upper Urinary Tract Urothelial Carcinoma: A Population-based Study of 1969 Patients</b> R.Y. Deng, Beijing (CN)
A0098	<b>Validating and extending pre-operative renal scintigraphy predictions for post-nephrectomy renal function changes beyond upper urinary tract urothelial carcinoma</b> K-S. Su, Taipei City (TW)
A0102	<b>Oncological outcomes and preoperative predictors of disease recurrence in upper tract urothelial carcinoma patients treated with distal ureterectomy: results from a large national cohort</b> M. Rosazza, Torino (IT)
<hr/>	
<b>15:55 - 16:15</b>	<b>Risk stratification of upper tract urothelial carcinoma</b>
A0100	<b>Risk of upper tract urothelial carcinoma recurrence following non-muscle invasive bladder cancer: A retrospective, multi-institutional analysis of 3,036 patients</b> J. Kwong, Toronto (CA)
A0103	<b>Head-to-head comparison of the American Urological Association and European Association of Urology risk stratification models of upper tract urothelial carcinoma</b> G. Basile, Milan (IT)
A0097	<b>Interleukin-6 and its soluble receptor as predictors of disease outcomes after radical nephroureterectomy in patients with upper tract urothelial carcinoma</b> H. Ofner, Vienna (AT)
A0105	<b>Impact of lymphovascular invasion on survival of surgically treated patients with Upper Tract Urothelial Carcinoma: A nationwide analysis</b> G.O. Cirulli, Roma (IT)

# Joint Session of the European Association of Urology (EAU) and the Confederación Americana de Urología (CAU)

Urology Beyond Europe

**Friday 5 April**  
**14:45 - 16:45**

**Location** Purple Area, eURO Auditorium 2

**Chairs** A.R. Rodriguez, Winston Salem (US)  
A. Stenzl, Tübingen (DE)

## **Learning objectives**

The session provides an update including interactive discussion of the present imaging, diagnosis, staging and management of prostate cancer, bladder cancer, and kidney cancer, as well as, demonstration of new techniques related to the surgical treatment of benign prostatic hyperplasia and renal stones. All these topics will be presented and discussed by recognized experts representatives from both the EAU and CAU. The session aims to show aspects from different health care systems with respect to the management of malignant and benign genitourinary diseases.

**14:45 - 14:46**

## **Introduction**

A.R. Rodriguez, Winston Salem (US)  
A. Stenzl, Tübingen (DE)

## **Prostate cancer: Diagnosis – Staging**

**14:46 - 14:56**

## **Prostate MRI the new gold standard: How, when, in whom**

M. Wroclawski, Sao Paulo (BR)

**14:56 - 15:06**

## **Update on PSMA PET/CT: When does its use in staging have an impact on survival?**

W. Fendler, Essen (DE)

## **Debate Transperineal prostate biopsy the new gold standard**

**15:06 - 15:11**

## **Pro**

C. Gratzke, Freiburg (DE)

**15:11 - 15:16**

## **Con**

R.R. Tourinho Barbosa, Paris (FR)

**15:16 - 15:31**

## **Prostate cancer: Treatment**

**15:16 - 15:21**

## **Indications, advantages and disadvantages of focal treatment modalities**

R. Sanchez-Salas, Montreal (CA)

**15:21 - 15:26**

## **How reliable are imaging modalities for focal treatment**

J. Walz, Marseille (FR)

**15:26 - 15:31**

## **Discussion**

**15:31 - 15:56**

## **Discussion Bladder Cancer**

## **Debate Extended lymphadenectomy for bladder cancer is not necessary**

15:31 - 15:36

**Pro**

J.E. Gschwend, Munich (DE)

15:36 - 15:41

**Con**

R. Sanchez-Salas, Montreal (CA)

15:41 - 15:51

**Role of immunotherapy in bladder cancer**

M. Babjuk, Prague (CZ)

15:51 - 15:56

**Discussion**

---

15:56 - 16:21

**Tips and tricks: Kidney cancer**

15:56 - 16:06

**Laparoscopic partial nephrectomy**

G. Vitagliano, Buenos Aires (AR)

16:06 - 16:16

**Robotic partial nephrectomy**

V. Ficarra, Messina (IT)

16:16 - 16:21

**Discussion**

---

16:21 - 16:31

**Tips and tricks: BPH**

16:21 - 16:31

**Pitfalls in laser enucleation**

T. Bach, Hamburg (DE)

---

16:31 - 16:41

**Tips and tricks: Endourology**

16:31 - 16:41

**Mini percutaneous nephrolithotomy**

N. Bernardo, Buenos Aires (AR)

---

16:41 - 16:45

**Conclusion**

# Use of digital technology & data-driven shared decision making

Patient Office - Roundtable

**Friday 5 April**  
**14:45 - 15:45**

**Location** Green Area, W08

**Chairs** E. Rogers, Roscommon (IE)  
M.R. Van Balken, Arnhem (NL)

## **Learning objectives**

- 1) Participants will learn about the transformative impact of digital technology and artificial intelligence on patient advocacy and decision-making.
- 2) The roundtable will explain how using multiple communication channels (digital, face-to-face, print, etc.) can support informed patient decisions, and optimise communication using AI and digital innovations.
- 3) Attendees will learn about the legal challenges and considerations in digital health and data usage.

**14:45 - 14:50**

## **Introduction**

E. Rogers, Roscommon (IE)

**14:50 - 15:00**

## **Digital technology in patient advocacy and decision-making**

L. Makaroff, Chinnor (GB)

**15:00 - 15:05**

## **The role of data-driven SDM**

J. Ghith, New York (US)

**15:05 - 15:10**

## **Enhancing patient empowerment through digital platforms**

M.L. Van Poelgeest-Pomfret, Oegstgeest (NL)

**15:10 - 15:15**

## **Empowering patients in health management via digital tools**

J. Phillips, (GB)

**15:15 - 15:25**

## **Legal considerations in digital health and data usage**

B. Leigh, London (GB)

**15:25 - 15:40**

## **Interactive discussion and Q&A**

*Moderator* E. Rogers, Roscommon (IE)

**15:40 - 15:45**

## **Concluding remarks and future directions**

E. Rogers, Roscommon (IE)

# Hands-on Training in Laparoscopic urological skills - Step 1

HOT 1.09

Friday 5 April  
14:45 - 15:40

<b>Location</b>	Orange Area, HOT 1
<b>Tutors</b>	F. Greco, Bergamo (IT) M. Jarzemski, Bydgoszcz (PL)

## Learning objectives

This basic laparoscopic training course is the first step in the Laparoscopic Urological Skills (LUS) curriculum. It designed to provide urologists with a fundamental understanding of laparoscopy and enhance their laparoscopic skills. This comprehensive training is specifically tailored for urologists who want to gain a basic level of knowledge in laparoscopy and wish to improve their proficiency in key laparoscopic techniques. The course comprises four essential exercises aimed at honing skills related to depth perception and bimanual dexterity: Peg Transfer, Circle Cut, Needle Guidance, and Knot Tying.

The primary objective of this course is to enhance participants' laparoscopic skills, focusing on key aspects such as depth perception and bimanual dexterity. By the end of the course, attendees should feel more confident and competent in their basic laparoscopic skills.

# Hands-on Training in Endoscopic stone treatment - Step 1

HOT 1.10

Friday 5 April  
14:45 - 15:40

**Location** Orange Area, HOT 1

**Tutors**  
K. Ahmed, London (GB)  
V. Gauhar, Singapore (SG)  
I.M. Tjiam, Poortugaal (NL)  
D. Veneziano, New York (US)

## **Learning objectives**

This Basic Endoscopic Stone Treatment course is the first step in the Endoscopic Stone Treatment (EST) curriculum. It is designed to provide urologists with a fundamental understanding of endoscopic stone treatment and enhance their skills. This comprehensive training is specifically tailored for urologists who want to gain a basic level of knowledge in endoscopy and wish to improve their proficiency in key techniques for endoscopic stone management. The curriculum includes four key exercises that provide hands-on experience and practical training: Flexible Cystoscopy, Rigid Cystoscopy, Semi-Rigid Ureteroscopy, and Flexible Ureteroscopy.

The primary objective of this programme is to enhance participants' skills in the treatment of urinary stones with endoscopic techniques. By the end of the course, attendees should feel more confident and competent in their basic skills.

# Hands-on Training in Transurethral treatment - Step 1 & 2 (TURBT/TURP)

HOT 1.11

Friday 5 April

14:45 - 15:40

**Location**

Orange Area, HOT 1

**Tutors**

P. Kallidonis, Patras (GR)

D. Oliveira Reis, Lisboa (PT)

**Learning objectives**

This training course combines the first and second step of the Transurethral Treatment (TUT) curriculum. It is designed for urologists who wish to improve their proficiency in key techniques and gain a fundamental understanding of transurethral resection of the bladder and prostate. This comprehensive training covers crucial basic skills including flexible and rigid cystoscopy, resection loop handling, and direct vision internal urethrotomy, as well as the resection procedure, practiced on state-of-the-art models.

The primary objective of this course is to enhance participants' skills in transurethral resection of the prostate and bladder, focusing on key aspects such as depth perception, hand-eye coordination, control, handling, and overall technique. By the end of the course, attendees should feel more competent and confident in performing this procedure.

# Hands-on Training in Transurethral treatment - Step 3 (ThuLEP)

HOT 1.12

Friday 5 April

14:45 - 15:40

**Location**

Orange Area, HOT 2

**Tutors**

G. Bozzini, Como (IT)

L.B. Dragoş, Cambridge (GB)

**Learning objectives**

This advanced training course is the third step in the Transurethral Treatment (TUT) curriculum. It is designed to provide urologists with a fundamental understanding of thulium laser enucleation of the prostate (ThuLEP). This comprehensive training is specifically tailored for urologists who want to become proficient in ThuLEP. Using a step by step approach, experts will lead participants through the procedure on state of the art models, to build a familiarity of the process, confidence handling the equipment, and an understanding of best practice.

**Training aim**

The primary objective of this course is to enhance participants' skills in ThuLEP, focusing on key aspects such as control, handling, and overall technique. By the end of the course, attendees should feel more competent and confident in performing this procedure.



# Biopsy strategy: Targeted only or along with systematic?

Abstract session 04

Friday 5 April

15:15 - 16:45

**Location** Purple Area, E06

**Chairs** J.M. Norris, London (GB)  
G.Y. Robert, Bordeaux (FR)  
L-Q. Zhou, Beijing (CN)

We encourage participants in this session to view the abstracts before the session. All abstract bodies, posters, videos and webcasts can be viewed on the EAU(N)24 Resource Centre or at the digital screens in front of the Purple Area, EGPT.

15:15 - 15:17

**Introduction**

15:17 - 15:37

**Targeted biopsy only**

A0066

**Prostate cancer detection rate with MRI-targeted biopsy alone using outpatient transperineal prostate biopsy.**

P.P. Avolio, Pieve Emanuele (IT)

A0054

**Targeted Biopsy and Overgrading of MRI lesions in Prostate Cancer: Does it Lead to Overtreatment?**

A. Uleri, Barcelona (ES)

A0053

**Can we avoid systematic biopsies for prostate cancer diagnosis in multiparametric magnetic resonance imaging (mpMRI) targeted biopsies?**

C. Calzas Montalvo, Pinto (ES)

A0056

**Diagnostic performance of transperineal prostate targeted biopsy alone according to the PI-RADS score based on bi-parametric magnetic resonance imaging**

S.W. Yun, Seoul (KR)

15:37 - 16:42

**Along with systematic biopsies**

A0063

**The clinical utility of contralateral systematic biopsies in men with unilateral MRI foci undergoing office-based transperineal MRI-guided biopsies**

L. Boesen, Herlev (DK)

A0065

**Targeted with perilesional biopsy should be considered as the new standard for the diagnosis of clinically significant prostate cancer. A Systemic Review & Meta-analysis**

A.C. Bravo Balado, Barcelona (ES)

A0058

**Is Ipsilateral Systematic Biopsy Combined With Targeted Biopsy the Optimal Substitute for Bilateral Systematic Biopsy Combined With Targeted Biopsy? A Systematic Review and Meta-analysis.**

Q. Wu, Chengdu (CN)

A0069

**The impact of systematic sampling on prostate biopsy results**

H.C. Ayerra Pérez, Vitoria (ES)

A0068

**The added value of side specific systematic biopsy in patients diagnosed by magnetic resonance imaging-targeted prostate biopsy**

H-A. Bourgeno, Uccle (BE)

- A0060 **The suitability of hemi-ablation for patients diagnosed with localised prostate cancer following multiparametric MRI targeted and non-targeted transperineal prostate biopsy**  
D.T. Reddy, London (GB)
- A0062 **The POET Trial – PrOspective Evaluation of a new perilesional Template for systematic prostate biopsy**  
A. Sigle, Freiburg (DE)
- A0055 **Optimizing the Number of Systematic Cores During MRI Target Biopsy. Preliminary results from the prospective, paired-cohort SCOT Trial**  
D. Cannoletta, Milano (IT)
- A0061 **When Does Systematic Biopsy Information Matter The Most? Identifying Independent Predictors Of Disease Downgrading At Radical Prostatectomy In high grade Prostate Cancer Based On A Large Multi-Institutional Series.**  
G. Sorce, Milan (IT)
- A0057 **The significant added value of concomitant systematic prostate biopsies in addition to targeted sampling in patients with previous negative biopsies. Implications for accurate staging predictions from a large multi-institutional series.**  
D. Robesti, Milan (IT)
- A0067 **The role of ipsilateral and contralateral systematic biopsy in MRI-ultrasound fusion biopsy**  
H. Guo, Hong Kong (HK)
- A0064 **Diagnostic accuracy of Multiparametric Magnetic Resonance Imaging (mpMRI), Targeted and Systematic Prostate Biopsy for the Detection of Cribriform Growth Pattern in Patients with Clinical-Localized Prostate Cancer**  
A. Piasentin, Trieste (IT)
- A0059 **A nomogram to predict lymphnode involvement in candidates to robot-assisted radical prostatectomy with iT3 prostate cancer on preoperative multiparametric MRI as unique high-risk feature**  
C.A. Bravi, London (GB)

---

16:42 - 16:45

Expert summary

Friday 5 April  
15:45 - 17:15

**Location** Green Area, W01

**Chairs** A. Bujons Tur, Barcelona (ES)  
J.M. Chung, Yangsan-si (KR)  
R.J.M. Lammers, Groningen (NL)

We encourage participants in this session to view the abstracts before the session. All abstract bodies, posters, videos and webcasts can be viewed on the EAU(N)24 Resource Centre or at the digital screens in front of the Purple Area, EGPT.

- 
- A0113** **Descent: Departmental evaluation of scrotal imaging considering european and national testicle guidelines**  
D.E. Bernstein, London (GB)
- 
- A0108** **The impact of health care on outcomes of suspected testicular torsion: Results from the GRAND study**  
Y. Volz, München (DE)
- 
- A0107** **Role of different urinary biomarkers in the differentiation of ureteropelvic junction obstruction from transient hydronephrosis**  
A. Banerjee, Kolkata (IN)
- 
- A0116** **Early prenatal detection of LUTO is associated with increased risk of kidney transplantation - a multi-institutional trans-atlantic experience**  
J. Richter, (DE)
- 
- A0106** **Effect of overnight bladder drainage on posterior urethral valve sequelae: A randomized controlled trial**  
A. Elkashef, Mansoura (EG)
- 
- A0119** **The Optimal Urethral Coverage in Hypospadias repair: Dartos Fascia versus Tunica Vaginalis Flap? A Randomized Controlled Trial**  
Y.M. Osman, Mansoura (EG)
- 
- A0122** **Long-term functional outcomes of voiding after hypospadias repair: A single-center retrospective comparative study**  
H. Nishio, Nagoya (JP)
- 
- A0123** **Long-term outcomes and genotype to phenotype correlation in children with Denys Drash syndrome: a national cohort study**  
M. Glenisson, paris (FR)
- 
- A0115** **Transitional outcomes of children who have undergone Cohen ureteroneocystostomy for the treatment of vesicoureteral reflux to adulthood**  
I. Selvi, Istanbul (TR)
- 
- A0120** **Mitrofanoff's channel procedure : what can we learn from a 20-year experience ?**  
S. Amar, TOURS (FR)

A0112	<b>Day surgery for transperitoneal versus retroperitoneal robotic-assisted laparoscopic pyeloplasty for ureteropelvic junction obstruction in children. A multicentre study</b> A. Trypens, Paris (FR)
A0117	<b>Robotic-assisted laparoscopy surgery (RALS) in children weighing 10kg or less: results of a multicentric study</b> A. Faure, Marseille (FR)
A0109	<b>Major factors contributing to surgical success in pediatric patients with VUR who underwent laparoscopic or robot-assisted extravesical ureteral reimplantation</b> Y.H. Hayashi, Nagoya (JP)
A0110	<b>Retroperitoneal versus transperitoneal robotic-assisted laparoscopic nephron sparing surgery for renal tumor in children. A multicentre study.</b> J. Grosman, Paris (FR)
A0118	<b>Maximizing robotic extravesical ureteral reimplantation success: the synergistic impact of ureteral adventitia inclusion and robust distal end detrusorraphy sutures</b> H.Y. Lee, seoul (KR)
A0121	<b>Robot-assisted laparoscopic adrenalectomy: extended application in children</b> M. Glenisson, paris (FR)
A0114	<b>Pediatric obesity and development of the penis and testi</b> J.M. Chung, Yangsan-si (KR)
A0111	<b>Efficacy and safety of mirabegron compared with solifenacin in treatment of non-neurogenic voiding dysfunction in children: A randomized controlled trial</b> Y.M. Osman, Mansoura (EG)

# Hands-on Training in Endoscopic stone treatment - Step 1

HOT 1.14

**Friday 5 April**  
**15:45 - 16:40**

**Location** Orange Area, HOT 1

**Tutors**

- K. Ahmed, London (GB)
- A. Papatsoris, Athens (GR)
- I.M. Tjiam, Poortugaal (NL)
- D. Veneziano, New York (US)

## **Learning objectives**

This Basic Endoscopic Stone Treatment course is the first step in the Endoscopic Stone Treatment (EST) curriculum. It is designed to provide urologists with a fundamental understanding of endoscopic stone treatment and enhance their skills. This comprehensive training is specifically tailored for urologists who want to gain a basic level of knowledge in endoscopy and wish to improve their proficiency in key techniques for endoscopic stone management. The curriculum includes four key exercises that provide hands-on experience and practical training: Flexible Cystoscopy, Rigid Cystoscopy, Semi-Rigid Ureteroscopy, and Flexible Ureteroscopy.

The primary objective of this programme is to enhance participants' skills in the treatment of urinary stones with endoscopic techniques. By the end of the course, attendees should feel more confident and competent in their basic skills.

# Hands-on Training in Laparoscopic urological skills - Step 1

HOT 1.13

Friday 5 April

15:45 - 16:40

**Location** Orange Area, HOT 1

**Tutors** F. Greco, Bergamo (IT)  
M. Jarzemski, Bydgoszcz (PL)

## **Learning objectives**

This basic laparoscopic training course is the first step in the Laparoscopic Urological Skills (LUS) curriculum. It designed to provide urologists with a fundamental understanding of laparoscopy and enhance their laparoscopic skills. This comprehensive training is specifically tailored for urologists who want to gain a basic level of knowledge in laparoscopy and wish to improve their proficiency in key laparoscopic techniques. The course comprises four essential exercises aimed at honing skills related to depth perception and bimanual dexterity: Peg Transfer, Circle Cut, Needle Guidance, and Knot Tying.

The primary objective of this course is to enhance participants' laparoscopic skills, focusing on key aspects such as depth perception and bimanual dexterity. By the end of the course, attendees should feel more confident and competent in their basic laparoscopic skills.

# Hands-on Training in Transurethral treatment - Step 1 & 2 (TURBT/TURP)

HOT 1.15

Friday 5 April

15:45 - 16:40

**Location** Orange Area, HOT 1

**Tutors** P. Kallidonis, Patras (GR)  
D. Oliveira Reis, Lisboa (PT)

## **Learning objectives**

This training course combines the first and second step of the Transurethral Treatment (TUT) curriculum. It is designed for urologists who wish to improve their proficiency in key techniques and gain a fundamental understanding of transurethral resection of the bladder and prostate. This comprehensive training covers crucial basic skills including flexible and rigid cystoscopy, resection loop handling, and direct vision internal urethrotomy, as well as the resection procedure, practiced on state-of-the-art models.

The primary objective of this course is to enhance participants' skills in transurethral resection of the prostate and bladder, focusing on key aspects such as depth perception, hand-eye coordination, control, handling, and overall technique. By the end of the course, attendees should feel more competent and confident in performing this procedure.

# Hands-on Training in Transurethral treatment - Step 3 (ThuLEP)

HOT 1.16

**Friday 5 April**  
**15:45 - 16:40**

**Location** Orange Area, HOT 2

**Tutors** G. Bozzini, Como (IT)  
L.B. Dragoş, Cambridge (GB)

## **Learning objectives**

This advanced training course is the third step in the Transurethral Treatment (TUT) curriculum. It is designed to provide urologists with a fundamental understanding of thulium laser enucleation of the prostate (ThuLEP). This comprehensive training is specifically tailored for urologists who want to become proficient in ThuLEP. Using a step by step approach, experts will lead participants through the procedure on state of the art models, to build a familiarity of the process, confidence handling the equipment, and an understanding of best practice.

## **Training aim**

The primary objective of this course is to enhance participants' skills in ThuLEP, focusing on key aspects such as control, handling, and overall technique. By the end of the course, attendees should feel more competent and confident in performing this procedure.



# EAU Opening Ceremony

Opening ceremony

**Friday 5 April**  
**18:00 - 19:30**

**Location** Green Area, eURO Auditorium 1

**Opening performance by the Cabaret Dance Show**

**Opening address**

**Announcement of the new EAU Honorary Members**

**Presentation of the EAU Willy Gregoir Medal 2024**

**Presentation of the EAU Frans Debryne Life Time Achievement Award 2024**

**Presentation of the EAU Crystal Matula Award 2024**

**Presentation of the EAU Hans Marberger Award 2024**

**Presentation of the EAU Innovators in Urology Award 2024**

**Presentation of the EAU Ernest Desnos Prize 2024**

**Presentation of the EAU Prostate Cancer Research Award 2024**

**Presentation of the EAU Patient Advocacy Medal of Excellence 2024**

**Closing performance by the Cabaret Dance Show**

**Saturday 6 April**  
**07:00 - 08:00**

**Location** Green Area, N04

---

**1. Opening and communications by the Secretary General**

---

**2. Approval minutes General Assembly of 11 March 2023, Milan, Italy**

---

**3. General report by the EAU Secretary General**

A. Stenzl, Tübingen (DE)

---

**4. Report by the EAU Treasurer**

J.O.R. Sønksen, Herlev (DK)

---

**5. Specific reports on the EAU Offices by the EAU Executive**

---

**6. Report by the Secretary General on the EAU Membership**

**Announcement new EAU members**

**Announcement new Honorary members**

---

**7. Report of the Chairman of the EAU Research Foundation (EAURF)**

A.S. Bjartell, Malmö (SE)

---

**8. Nominations EAU Office Chair positions**

**Approval Nomination Chair Scientific Congress Office**

**Approval Nomination Chair Section Office**

---

**9. Other business**

# Risk-adapted screening and treatment of screen-detected prostate cancer

Plenary Session

**Saturday 6 April**  
**08:00 - 09:55**

**Location** Purple Area, eURO Auditorium 2

**Chairs** P. Albers, Düsseldorf (DE)  
A. Villers, Lille (FR)

## **Learning objectives**

Since the European Commission decided to extend a recommendation of organised cancer screening programs also to prostate cancer, EU member states started to implement this recommendation in their populations. Which risk-adapted strategies are preferred? Include genetics, biomarkers or age groups? Which primary tests and reflex tests should be used: PSA, MRI, biomarkers or a combination? In this session the latest results will be presented and discussed.

**08:00 - 08:05**

## **Patients' perspective of a risk-adapted screening strategy in Europe**

E-G. Carl, Tornesch (DE)

**08:05 - 08:13**

## **Different ways of risk-adapted screening in Europe**

H.J. De Koning, Rotterdam (NL)

**08:13 - 08:21**

## **Implementation of risk-adapted screening strategy in Europe - PRAISE-U**

M.J. Roobol, Rotterdam (NL)

**08:21 - 08:29**

## **Prostate cancer predisposition genes**

D. Stoppa-Lyonnet, Paris (FR)

**08:29 - 08:37**

## **Society of Urologic Oncology (SUO) lecture Update on biomarkers and US risk-adapted screening strategy**

A.S. Kibel, Boston (US)

**08:37 - 08:50**

## **Prostate cancer: Are we poised for screening? 15-y outcomes of the CAP trial**

F.C. Hamdy, Oxford (GB)

R. Martin, Bristol (GB)

**08:50 - 09:27**

## **Risk-adapted screening for prostate cancer in Europe**

**08:50 - 08:52**

## **Case presentation: 50 year-old man asks for prostate cancer early detection**

M. Maggi, Rome (IT)

**08:52 - 08:59**

## **MRI-led screening: The UK perspective**

C. Moore, London (GB)

**08:59 - 09:02**

## **PSA only (PROBASE - the German Screening Trial in young men)**

B.A. Hadaschik, Essen (DE)

**09:02 - 09:07**

## **PSA + MRI (OPT - the Swedish nationwide screening strategy)**

J. Hugosson, Gothenburg (SE)

**09:07 - 09:12**

## **PSA + Risk calculators + MRI (the EAU screening algorithm)**

K. Beyer, Rotterdam (NL)

**09:12 - 09:17**

## **PSA+MRI+targeted biopsies only (Gothenburg-2 trial)**

J. Hugosson, Gothenburg (SE)

09:17 - 09:27

**The best and pragmatic way of personalised diagnosis of prostate cancer**

C.H. Bangma, Rotterdam (NL)

---

09:27 - 09:55

**Case-based discussion Management of elevated PSA in conjunction with hereditary risk**

09:27 - 09:29

**Case presentation: 50 yrs, MCCL < 6mm ISUP GG 2, 10% GP4, BRCA2 +**

E. Linares Espinós, Madrid (ES)

09:29 - 09:34

**Active surveillance**

O. Yossepowitch, Tel-Aviv (IL)

09:34 - 09:39

**Curative treatment**

R. Coelho, Sao Paulo (BR)

09:39 - 09:47

**Familial prostate cancer: Does it influence the screening and management?**

A. Morgans, Boston (US)

09:47 - 09:55

**Discussion**

# The future of urology: From carbon footprint to artificial intelligence

Plenary Session

Saturday 6 April  
08:00 - 10:00

**Location** Green Area, eURO Auditorium 1

**Chairs** T. Knoll, Sindelfingen (DE)  
A. Stenzl, Tübingen (DE)

## Learning objectives

In urology we are facing an increasing challenge with more and more non-reusable material applied in surgery and other interventional techniques. This will cause a considerable use of resources for production and transportation. Thus, possible advantages for patients as well as treating physicians outweigh the burden on climate and use of raw materials? Will, on the other hand, better education, application of artificial intelligence lead to a better indication of certain interventions? Leaders in the field of training, education, digitalisation and other aspects of future changes in urology will give you a nice perspective of what is coming up over the next 10 years.

08:00 - 08:02

## Introduction

T. Knoll, Sindelfingen (DE)

08:02 - 08:12

## State-of-the-art lecture Training in urology: How do we adapt to the changing future?

A. Gallagher, Melle (BE)

08:12 - 08:22

## State-of-the-art lecture Female perspective in urology: How are the residency programmes changing?

V. Phé, Paris (FR)

08:22 - 08:32

## State-of-the-art lecture How should I prepare to become a leader in urology?

F. Montorsi, Milan (IT)

08:32 - 09:37

## Artificial intelligence in urology: Where are now?

*Moderator* M.R. Cooperberg, San Francisco (US)

08:32 - 08:42

## State-of-the-art lecture Using digital twins to support multiple stages of the patient journey

S. Franke, Leipzig (DE)

08:42 - 08:52

## State-of-the-art lecture Image-guided navigation systems in urological surgery

A. Breda, Barcelona (ES)

08:52 - 09:02

## State-of-the-art lecture Artificial Intelligence in prostate cancer imaging

M. De Rooij, Nijmegen (NL)

09:02 - 09:12

## State-of-the-art lecture Metaverse in urology: Fiction or reality

F. Porpiglia, Turin (IT)

09:12 - 09:22

## State-of-the-art lecture How do I see the urology theatre of 2030?

P. Dasgupta, London (GB)

09:22 - 09:37

## Discussion: The role of AI

09:37 - 09:57

**Best way to reduce carbon footprint in urology**

*Moderator*

K.A.O. Tikkinen, Helsinki (FI)

09:37 - 09:42

**US perspective**

S. Loeb, New York (US)

09:42 - 09:47

**EU perspective**

A. Leliveld-Kors, Groningen (NL)

09:47 - 09:57

**Discussion**

09:57 - 10:00

**Closing remarks**

---

**Saturday 6 April**  
**08:30 - 11:30**

**Location** Purple Area, E07

**Chair** V.M.J. De Coninck, Brasschaat (BE)

Voting will be available via the EAU24 App or via [www.qna.at/eau](http://www.qna.at/eau)

## **Learning objectives**

The aims and objectives of this course are to provide a complete overview of complications related to endourological procedures.

- Extracorporeal shock wave lithotripsy (ESWL)
- Retrograde intrarenal surgery (RIRS)
- Percutaneous nephrolithotomy (PCNL)
- Transurethral resection of the bladder (TURB) and prostate (TURP), anatomical endoscopic enucleation of the prostate (AEEP), cystolithotripsy/cystolitholapaxy, internal urethrotomy/urethral dilation

This ESU course has the goal to fill the knowledge gap for early identification of complications during endourological procedures and to describe their management, in order to prevent further harm. At the end of the course, the participants will be able to increase their knowledge about complications in endourology and to identify them according to their etiology. They will also know how most endourological complications can be managed and prevented. Lastly, clinicians will use the increased knowledge to provide better care to their patients.

## **Extracorporeal shock wave lithotripsy**

E.X. Keller, Zürich (CH)

## **RIRS**

V.M.J. De Coninck, Brasschaat (BE)

## **PCNL**

E.X. Keller, Zürich (CH)

## **TURB, TURP, AEEP, cystolithotripsy/cystolitholapaxy**

K. Lehrich, Berlin (DE)

## **Internal urethrotomy, urethral dilation**

K. Lehrich, Berlin (DE)

## **Complications related to fluoroscopy and imaging**

V.M.J. De Coninck, Brasschaat (BE)

# 2024 EAU Guidelines update - Renal, bladder and prostate cancer: What has changed?

ESU Course 15

**Saturday 6 April**  
**08:30 - 11:30**

**Location** Purple Area, E03

**Chair** H.G. Van Der Poel, Amsterdam (NL)

## **Learning objectives**

During the course, recent practice changing alterations in the EAU Guidelines will be discussed. Based on the clinical recommendations, the highlights of the guidelines on prostate, renal and bladder cancer changed in the 2022 updates, will be presented and illustrated by clinical cases. A basic knowledge of the guidelines information is assumed for participating trainees.

## **Introduction**

H.G. Van Der Poel, Amsterdam (NL)

---

## **Update renal cancer: Localised**

A. Volpe, Novara (IT)

---

## **Discussion**

---

## **Update renal cancer: Metastasised**

A. Volpe, Novara (IT)

---

## **Discussion**

---

## **Update bladder cancer: Non-muscle invasive**

J.L. Domínguez Escrig, Valencia (ES)

---

## **Discussion**

---

## **Update bladder cancer: Muscle invasive**

J.L. Domínguez Escrig, Valencia (ES)

---

## **Discussion**

---

## **Update prostate cancer: Localised**

N. Grivas, Ioannina (GR)

---

## **Discussion**

---

## **Update prostate cancer: Metastasised**

N. Grivas, Ioannina (GR)

---

## **Discussion**



**Saturday 6 April**  
**08:30 - 10:30**

**Location** Purple Area, E01

**Chair** S. Joniau, Leuven (BE)

### **Learning objectives**

- Provide an introduction to working definition(s), background, and biology of oligometastatic prostate cancer.
- Update the current molecular imaging to provide such a diagnosis.
- Review the potential roles of surgery and/or radiation as metastasis-directed therapy.
- Understand opportunities and challenges in individualising care of the oligometastatic prostate cancer patient.

### **Introduction: Oligometastatic prostate cancer as a diagnosis**

S. Joniau, Leuven (BE)

### **Surgery of primary oligometastatic prostate cancer (N1/M1)**

S. Joniau, Leuven (BE)

### **Surgery for recurrent nodal metastasis with updates on molecular/PET imaging**

A. Briganti, Milan (IT)

### **Radiation in oligometastatic prostate cancer (primary and recurrent) and clinical trial updates**

T. Zilli, Genève (CH)

### **Further cases (case illustrations throughout)**

A. Briganti, Milan (IT)

S. Joniau, Leuven (BE)

T. Zilli, Genève (CH)

### **Discussion and conclusion**

S. Joniau, Leuven (BE)

**Saturday 6 April**  
**08:30 - 11:30**

**Location** Purple Area, E04

**Chair** A. Muneer, London (GB)

### **Learning objectives**

This is a state of the art course on the use of prosthetics in the management of erectile dysfunction and urinary incontinence. The main learning objectives are:

- Step-by-step preparation and insertion of a penile prosthesis
- Complications and difficult situations for IPP
- Step-by-step options and techniques in the surgical management of incontinence
- Complications and difficult situations for GSI management

### **Introduction to the course**

A. Muneer, London (GB)

### **Penile prosthesis**

#### **Development of different types of penile prosthesis**

J. Romero-Otero, Madrid (ES)

#### **Selection of patients for penile prosthesis surgery**

I. Moncada Iribarren, Madrid (ES)

#### **Theatre set-up and preparation of patients**

I. Moncada Iribarren, Madrid (ES)

#### **Surgical techniques and intraoperative complications**

A. Muneer, London (GB)

#### **Penile prosthesis training - role of modular training and training tools**

A. Muneer, London (GB)

#### **The difficult implant: Peyronie's, priapism, fibrotic penis**

J. Romero-Otero, Madrid (ES)

#### **Revision surgery and managing post operative complications**

I. Moncada Iribarren, Madrid (ES)

### **Prosthetic surgery for male urinary incontinence**

#### **AUS: Indications, types, techniques and complications**

S. Malde, London (GB)

#### **Slings: Indications, types, techniques and complications**

S. Malde, London (GB)

#### **Future of prosthetic urology**

A. Muneer, London (GB)

**Saturday 6 April**  
**08:30 - 11:30**

**Location** Purple Area, E06

**Chair** A. Minervini, Florence (IT)

### **Learning objectives**

- Learn tips and tricks for successfully managing challenging cases of localised renal tumours through interactive case discussion
- Become familiar with the current standards of minimally-invasive surgical techniques and ablative therapies for localized renal tumours
- Understand the benefits of robotics and 3D reconstruction for surgical conservative treatment in challenging scenarios through interactive cases and surgical videos
- Review and analyse the patterns and predictors of recurrence in localized RCC through analysis of clinical trial evidence

### **Partial nephrectomy: Indications and surgical steps**

M.J. Ribal Caparros, Barcelona (ES)

### **Radical Nephrectomy: Indications and surgical steps**

A. Minervini, Florence (IT)

### **Ablative treatment: Technologies, indications and results**

D. Enikeev, Vienna (AT)

### **Discussion**

### **Surgical treatment in challenging cases and bilateral renal tumours**

A. Minervini, Florence (IT)

### **Ablative treatment in challenging cases: Tips and tricks**

D. Enikeev, Vienna (AT)

### **Adjuvant therapy in localised RCC: Patterns and predictors of recurrence and evidences from clinical trials**

M.J. Ribal Caparros, Barcelona (ES)

### **Interactive case reports discussion**

D. Enikeev, Vienna (AT)

A. Minervini, Florence (IT)

M.J. Ribal Caparros, Barcelona (ES)

# Urinary tract and genital trauma

ESU Course 14

Saturday 6 April  
08:30 - 11:30

**Location** Purple Area, E02

**Chair** N. Kitrey, Ramat Gan (IL)

Voting will be available via the EAU24 App or via [www.qna.at/eau](http://www.qna.at/eau)

## Learning objectives

Trauma is a leading cause of morbidity and death. Most urologists are involved in the management of trauma patients, therefore to understand and follow the basic principles is needed.

The ESU urological trauma course details the epidemiology, mechanism of action, diagnosis, and management of urogenital trauma (renal, ureteric, bladder, urethra, and external genitalia). The course is based on the peer-reviewed annually-updated EAU Guidelines on urological trauma. Interactive case-based discussion will highlight the key points of trauma management.

## Introduction

N. Kitrey, Ramat Gan (IL)

## General trauma

N. Kitrey, Ramat Gan (IL)

## Renal trauma

E.K. Mayer, London (GB)

## Ureteral trauma

N. Lumen, Ghent (BE)

## Bladder trauma

E.K. Mayer, London (GB)

## Urethral trauma

N. Lumen, Ghent (BE)

## Genital trauma

N. Kitrey, Ramat Gan (IL)

## Questions and answers

# Robotic-assisted laparoscopic prostatectomy

ESU Course 17

Saturday 6 April

08:30 - 11:30

**Location** Purple Area, E05

**Chair** A. De La Taille, Créteil (FR)

## Learning objectives

The objectives are to explain, using videos and step-by-step explanations, robotic assisted radical prostatectomy with three presenters using three different approaches: Transperitoneal, preperitoneal and retzius-sparing techniques.

General principles regarding port placement, prostate anatomy and surgical landmarks will be also reminded considering the different possible options and the different types of robotic systems used. Finally, the course will present the possible intraoperative risks of complications and how-to-manage-them strategies.

This course will be interactive including direct and/or multichoice questions to the audience.

## Introduction

A. De La Taille, Créteil (FR)

## Anatomical remainders

F. Annino, Arezzo (IT)

## RALP by steps: Anterior transperitoneal

A. Haese, Hamburg (DE)

## RALP by steps: Retius sparing

F. Annino, Arezzo (IT)

## Tips and Tricks

### How to avoid positive margins during nerve-sparing

A. Haese, Hamburg (DE)

### How to preserve bladder neck

F. Annino, Arezzo (IT)

### How to avoid and manage urine leakage

A. De La Taille, Créteil (FR)

## Tricky cases

### Prostatectomy after TURP/Enucleation

A. Haese, Hamburg (DE)

### How to manage median lobe and prostate > 100 grms

F. Annino, Arezzo (IT)

### Salvage prostatectomy

A. De La Taille, Créteil (FR)

## Beware of complications

### Bleeding

A. Haese, Hamburg (DE)

**Ureteral lesion**

F. Annino, Arezzo (IT)

**Manage bladder strictures**

A. De La Taille, Créteil (FR)

---

**Discussion: Quality control during the learning curve**

A. Haese, Hamburg (DE)

---

**Conclusion**

A. De La Taille, Créteil (FR)



**Saturday 6 April**

**09:00 - 12:15**

**Location** Orange Area, HOT 3

**Chair** L. Budäus, Hamburg (DE)

### **Learning objectives**

MRI is increasingly used in patients undergoing prostate biopsies. Different MRI Ultrasound fusion devices allow integrating the MRI information into the daily clinical workflow. Moreover, transperineal biopsies are increasingly used even in the outpatient setting.

The Hands-on Training in MRI Fusion Biopsy is designed to help participants understand the advantages, handling and limitations of MRI Ultrasound fusion biopsies.

Therefore, the course provides an overview on technical basics and different prostate biopsy approaches. Technical considerations, the transrectal or transperineal approach will be critically reviewed and discussed. Additionally, performing transperineal biopsies in the office based setting by using local anesthesia will be presented. During the second half of the course, the participants are able to try out different Fusion biopsy machines in small groups.

The training is designed to be 2 hours, including a short introduction, presentation of different approaches, and a rotation of training at each station, ensuring contact of every participant to each machine.

**09:00 - 09:05**

### **Introduction**

L. Budäus, Hamburg (DE)

**09:05 - 09:20**

### **Different MRI-Ultrasound technical approaches available**

L. Budäus, Hamburg (DE)

**09:20 - 09:35**

### **Demonstration: How to perform a transperineal biopsy**

C. Kastner, Cambridge (GB)

**09:35 - 12:05**

### **Hands-on training at stations**

#### *Tutors*

F. Falkenbach, Hamburg (DE)

P.C. Henry, Besançon (FR)

M. Jahnen, Munich (DE)

C. Kastner, Cambridge (GB)

F. Lavagno, Turin (IT)

L. Lenfant, Paris (FR)

T. Loch, Flensburg (DE)

**12:05 - 12:15**

### **Closing Remarks and Q&A**

# Hands-on Training in Endoscopic stone treatment - Step 1

HOT 2.02

**Saturday 6 April**

**09:00 - 09:55**

**Location**

Orange Area, HOT 1

**Tutors**

B. Ballesta Martinez, Alicante (ES)

O.R. Durutovic, Belgrade (RS)

N. Macchione, Milan (IT)

A. Tsaturyan, Yerevan (AM)

**Learning objectives**

This Basic Endoscopic Stone Treatment course is the first step in the Endoscopic Stone Treatment (EST) curriculum. It is designed to provide urologists with a fundamental understanding of endoscopic stone treatment and enhance their skills. This comprehensive training is specifically tailored for urologists who want to gain a basic level of knowledge in endoscopy and wish to improve their proficiency in key techniques for endoscopic stone management. The curriculum includes four key exercises that provide hands-on experience and practical training: Flexible Cystoscopy, Rigid Cystoscopy, Semi-Rigid Ureteroscopy, and Flexible Ureteroscopy.

The primary objective of this programme is to enhance participants' skills in the treatment of urinary stones with endoscopic techniques. By the end of the course, attendees should feel more confident and competent in their basic skills.



# Hands-on Training in Laparoscopic urological skills - Step 1

HOT 2.01

Saturday 6 April

09:00 - 09:55

**Location** Orange Area, HOT 1

**Tutors** T. Kalogeropoulos, Athens (GR)  
A. Papatsoris, Athens (GR)

## **Learning objectives**

This basic laparoscopic training course is the first step in the Laparoscopic Urological Skills (LUS) curriculum. It designed to provide urologists with a fundamental understanding of laparoscopy and enhance their laparoscopic skills. This comprehensive training is specifically tailored for urologists who want to gain a basic level of knowledge in laparoscopy and wish to improve their proficiency in key laparoscopic techniques. The course comprises four essential exercises aimed at honing skills related to depth perception and bimanual dexterity: Peg Transfer, Circle Cut, Needle Guidance, and Knot Tying.

The primary objective of this course is to enhance participants' laparoscopic skills, focusing on key aspects such as depth perception and bimanual dexterity. By the end of the course, attendees should feel more confident and competent in their basic laparoscopic skills.

# Hands-on Training in Transurethral treatment - Step 1 & 2 (TURBT/TURP)

HOT 2.03

**Saturday 6 April**

**09:00 - 09:55**

**Location** Orange Area, HOT 1

**Tutors** P. Mariappan, Edinburgh (GB)  
A. Sousa Castro, Lisboa (PT)

## **Learning objectives**

This training course combines the first and second step of the Transurethral Treatment (TUT) curriculum. It is designed for urologists who wish to improve their proficiency in key techniques and gain a fundamental understanding of transurethral resection of the bladder and prostate. This comprehensive training covers crucial basic skills including flexible and rigid cystoscopy, resection loop handling, and direct vision internal urethrotomy, as well as the resection procedure, practiced on state-of-the-art models.

The primary objective of this course is to enhance participants' skills in transurethral resection of the prostate and bladder, focusing on key aspects such as depth perception, hand-eye coordination, control, handling, and overall technique. By the end of the course, attendees should feel more competent and confident in performing this procedure.

# Hands-on Training in Transurethral treatment - Step 3 (ThuLEP)

HOT 2.04

**Saturday 6 April**

**09:00 - 09:55**

**Location** Orange Area, HOT 2

**Tutors** L.B. Dragoş, Cambridge (GB)

B.M. Schoensee, Berlin (DE)

## **Learning objectives**

This advanced training course is the third step in the Transurethral Treatment (TUT) curriculum. It is designed to provide urologists with a fundamental understanding of thulium laser enucleation of the prostate (ThuLEP). This comprehensive training is specifically tailored for urologists who want to become proficient in ThuLEP. Using a step by step approach, experts will lead participants through the procedure on state of the art models, to build a familiarity of the process, confidence handling the equipment, and an understanding of best practice.

## **Training aim**

The primary objective of this course is to enhance participants' skills in ThuLEP, focusing on key aspects such as control, handling, and overall technique. By the end of the course, attendees should feel more competent and confident in performing this procedure.

**Saturday 6 April**  
**09:30 - 13:00**

**Location** Orange Area, HOT 5

**Chair** V. Kasivisvanathan, London (GB)

### **Learning objectives**

The MRI Reading Course is designed as a half-day or full-day live or online training. This course will provide interactive teaching from expert faculty in prostate MRI reading and interpretation and help urologists to understand the role MRI plays in the management of patients with prostate cancer and how to use the information generated by prostate MRI. The course will address how to use an imaging workstation, how to understand the basic concepts/principles behind different MRI sequences (T2-weighted imaging, DWI-imaging and DCE-imaging), in which order to view the different sequences when interpreting prostate MRI, how to use the PI-RADS scoring system to score MRIs, and finally to understand what are the standards for a prostate MRI and what quality criteria need to be fulfilled. The participants will do hands on reading and assessment of prostate MRI scans on their computer via MIM-software followed by a reference reading provided by expert radiologists and pathological verification.

**09:30 - 09:35**

### **Course Overview**

V. Kasivisvanathan, London (GB)

**09:35 - 09:45**

### **Lecture: The importance of prostate MRI to the Urologist**

J. Walz, Marseille (FR)

**09:45 - 10:15**

### **Lecture: Introduction to MRI sequences, scoring systems, PI-RADS**

M. Pecoraro, Rome (IT)

**10:15 - 10:45**

### **Lecture: Interactive case discussion – reporting MRI using PI-RADS**

F. Giganti, London (GB)

**10:45 - 10:50**

### **Introduction to the software for MRI interpretation**

J. Walz, Marseille (FR)

**10:50 - 11:20**

### **Diagnosis I: Practical MRI diagnosis**

**11:20 - 11:50**

### **Review of the findings I**

M. Pecoraro, Rome (IT)

**11:50 - 12:20**

### **Diagnosis II: Practical MRI diagnosis**

**12:20 - 12:50**

### **Review of the findings II**

F. Giganti, London (GB)

**12:50 - 13:00**

### **Discussion, feedback, & closure**

V. Kasivisvanathan, London (GB)

# Hands-on Training in Sacral Neuromodulation (SNM)

HOT 2.26

**Saturday 6 April**  
**09:30 - 11:00**

**Location** Orange Area, HOT 4

**Chair** V. Phé, Paris (FR)

## **Learning objectives**

This Hands-on Training is designed to equip participants with the fundamental skills to perform sacral neuromodulation (SNM) procedures effectively. Participants will have the opportunity to practice each step of the SNM procedure, including primary percutaneous nerve evaluation, tined lead and battery implantation, programming, and troubleshooting.

## **Training aim**

The primary objective of this course is to enhance participants' skills in sacral neuromodulation, focusing on key aspects of the procedure. By the end of the course, attendees should feel more confident and competent in SNM procedures.

- Hands-on Training.
- Operating area setup and organization.
- The management of equipment
- Standardized technical approach of a urological procedure.
- Management of critical details related to an urological procedure.

**09:30 - 09:30**

## **Introduction**

**09:30 - 11:00**

## **Percutaneous Nerve Evaluation Station 1**

*Tutor* C. Harding, Newcastle upon Tyne (GB)

**09:30 - 11:00**

## **Percutaneous Nerve Evaluation Station 2**

*Tutor* C. Ochoa Vargas, Bristol (GB)

**09:30 - 11:00**

## **Percutaneous Nerve Evaluation Station 3**

*Tutor* M.A. Perrouin Verbe, Nantes (FR)

**09:30 - 11:00**

## **Advanced Station 1**

*Tutor* M.G. Çulha, Istanbul (TR)

**09:30 - 11:00**

## **Advanced Station 2**

*Tutor* S. Arlandis, Valencia (ES)

**09:30 - 11:00**

## **Advanced Station 3**

*Tutor* M. Tutolo, Milan (IT)

**09:30 - 11:00**

## **Programming Station**

*Tutor* L. Thomas, Bristol (GB)

# Guideline changes in screening and diagnosis for prostate cancer?

Game changing session

**Saturday 6 April**  
**09:55 - 10:30**

**Location** Purple Area, eURO Auditorium 2

**Chairs** P. Albers, Düsseldorf (DE)  
A. Villers, Lille (FR)

## **Learning objectives**

Prostate MRI has a central role in prostate cancer diagnosis. Should it be performed with or without contrast? Can we identify a group of men who do not need frequent screening? And what about using MRI and blood-based biomarkers as a reflex tests in the screening setting? Authors will present and discuss their results for the first time.

**09:55 - 10:08**

## **Part I**

**09:55 - 10:03**

### **Comparison of biparametric and multiparametric magnetic resonance imaging for prostate cancer detection: the PRIME Study (NCT04571840)**

V. Kasivisvanathan, London (GB)

**10:03 - 10:08**

### **Discussant**

G. Gandaglia, Milan (IT)

**10:08 - 10:30**

## **Part II**

**10:08 - 10:16**

### **Challenging EAU Guidelines on Prostate Cancer Risk Definition in the Screening Setting: Insights from the PROBASE Trial**

P. Albers, Düsseldorf (DE)

**10:16 - 10:24**

### **Results from the first screening round of the ProScreen screening trial with PSA, kallikrein panel and MRI**

A.P. Auvinen, Tampere (FI)

**10:24 - 10:30**

### **Discussant**

T. Nordström, Stockholm (SE)

# YUORDay24: EAU Young Urologists Office (YUO) & European Society of Residents in Urology (ESRU) - Part I

Special Session

**Saturday 6 April**  
**10:00 - 14:00**

**Location** Green Area, W06

**Chairs** E. Checcucci, Candiolo (IT)  
J.L. Vásquez, Copenhagen (DK)

## **Learning objectives**

The purpose of this session is to bring young urologists closer to experts by discussing topics chosen specifically for their potential relevance to the new generations of urologists. Among these topics are surgical tips & tricks, new technologies, and clinical nightmares.

**10:00 - 10:15**

**Welcome and introduction**

**10:15 - 11:00**

**European Urology Scholarship Programme (EUSP)**

*Moderators* Y. Abu Ghanem, London (GB)  
U.G. Falagario, Foggia (IT)  
A.S. Merseburger, Lübeck (DE)

**10:15 - 10:25**

**Updates on the EUSP programmes and how to apply**

A.S. Merseburger, Lübeck (DE)

**10:25 - 10:35**

**How to successfully apply for a one-year scholarship**

G. Jenster, Rotterdam (NL)

**10:35 - 10:45**

**What is the value proposition of a scholarship programme for the YUO, EAU, and our patients?**

J.L. Vásquez, Copenhagen (DK)

**10:45 - 10:50**

**Report of the best scholars in clinical and basic research**

A.S. Merseburger, Lübeck (DE)

**10:50 - 10:55**

**Best scholar winner: Basic research Radical prostatectomy for high-risk and oligometastatic prostate cancer: Histopathological assessment, novel imaging techniques, and pathogenic gene mutations**

P. Rajwa, Zabrze (PL)

**10:55 - 11:00**

**Best scholar winner: Clinical research A population study evaluating biochemical recurrence patterns after primary curative treatment for prostate cancer**

U.G. Falagario, Foggia (IT)

**11:00 - 12:00**

**Surgery tips and tricks**

*Moderators* A. Goujon, Paris (FR)  
A. Khelif, Mons (BE)  
A. Sachdeva, Manchester (GB)

**11:00 - 11:10**

**Gain the access to the retroperitoneum with retroperitoneoscopic approach**

F. Porpiglia, Turin (IT)

**11:10 - 11:15**

**Discussion**

11:15 - 11:25	<b>How to maximise the quality of TURB and avoid intraoperative risks</b> J. Palou, Barcelona (ES)
11:25 - 11:30	<b>Discussion</b>
11:30 - 11:40	<b>Percutaneous kidney puncture: Tips and tricks for an efficient and safe procedure</b> M. Cepeda, Valladolid (ES)
11:40 - 11:45	<b>Discussion</b>
11:45 - 11:55	<b>Testicular cancer surgery</b> C. Fankhauser, Lucerne (CH)
11:55 - 12:00	<b>Discussion</b>
<hr/>	
<b>12:00 - 13:00</b>	<b>New technologies for young surgeons and scientists</b> <i>Moderators</i> L. Baekelandt, Leuven (BE) E. Checcucci, Candiolo (IT) A. Rautio, Tallinn (EE)
12:00 - 12:10	<b>The importance of 3D models for planning and navigation in kidney surgery</b> D. Amparore, Turin (IT)
12:10 - 12:15	<b>Discussion</b>
12:15 - 12:25	<b>Aquablation: Advantages and drawbacks of a new instrument</b> J-T. Klein, Münsterlingen (CH)
12:25 - 12:30	<b>Discussion</b>
12:30 - 12:40	<b>Artificial intelligence for prostate cancer: From imaging to histology</b> K. Kaulanjan, Rennes (FR)
12:40 - 12:45	<b>Discussion</b>
12:45 - 12:55	<b>ChatGPT for clinics and academics</b> G. Cacciamani, Los Angeles (US)
12:55 - 13:00	<b>Discussion</b>
<hr/>	
<b>13:00 - 14:00</b>	<b>Nightmare cases: Clinical case discussion</b> <i>Moderators</i> L. Afferi, Luzern (CH) D.M. Carrión Monsalve, Madrid (ES) V. Quaresma, Coimbra (PT)
13:00 - 13:20	<b>Case I: Complete obstruction of a double-layered polytetrafluoroethylene membrane – covered self-expandable segmental metallic stent (UVENTA) due to encrustation</b> <i>Speaker</i> E. Papadimitriou, Athens (GR) <i>Expert</i> A. Pietropaolo, Southampton (GB)
13:20 - 13:40	<b>Case II: Fournier's Gangrene after circumcision – if you not only lose your prepuce</b> <i>Speaker</i> F. Aschwanden, Lucerne (CH) <i>Expert</i> M. Vallée, Poitiers (FR)



13:40 - 14:00

**Case III: Laparoscopic radical prostatectomy - it's never too late for a complication**

*Speaker*

K. Gkeka, Patras (GR)

*Expert*

E. Liatsikos, Patras (GR)

# Hands-on Training in Laparoscopic urological skills - Step 1

HOT 2.05

Saturday 6 April

10:00 - 10:55

**Location**

Orange Area, HOT 1

**Tutors**

T. Kalogeropoulos, Athens (GR)

A. Papatsoris, Athens (GR)

**Learning objectives**

This basic laparoscopic training course is the first step in the Laparoscopic Urological Skills (LUS) curriculum. It designed to provide urologists with a fundamental understanding of laparoscopy and enhance their laparoscopic skills. This comprehensive training is specifically tailored for urologists who want to gain a basic level of knowledge in laparoscopy and wish to improve their proficiency in key laparoscopic techniques. The course comprises four essential exercises aimed at honing skills related to depth perception and bimanual dexterity: Peg Transfer, Circle Cut, Needle Guidance, and Knot Tying.

The primary objective of this course is to enhance participants' laparoscopic skills, focusing on key aspects such as depth perception and bimanual dexterity. By the end of the course, attendees should feel more confident and competent in their basic laparoscopic skills.

# Hands-on Training in Endoscopic stone treatment - Step 1

HOT 2.06

**Saturday 6 April**

**10:00 - 10:55**

**Location** Orange Area, HOT 1

**Tutors**

- B. Ballesta Martinez, Alicante (ES)
- O.R. Durutovic, Belgrade (RS)
- N. Macchione, Milan (IT)
- A. Tsaturyan, Yerevan (AM)

## **Learning objectives**

This Basic Endoscopic Stone Treatment course is the first step in the Endoscopic Stone Treatment (EST) curriculum. It is designed to provide urologists with a fundamental understanding of endoscopic stone treatment and enhance their skills. This comprehensive training is specifically tailored for urologists who want to gain a basic level of knowledge in endoscopy and wish to improve their proficiency in key techniques for endoscopic stone management. The curriculum includes four key exercises that provide hands-on experience and practical training: Flexible Cystoscopy, Rigid Cystoscopy, Semi-Rigid Ureteroscopy, and Flexible Ureteroscopy.

The primary objective of this programme is to enhance participants' skills in the treatment of urinary stones with endoscopic techniques. By the end of the course, attendees should feel more confident and competent in their basic skills.

# Hands-on Training in Transurethral treatment - Step 1 & 2 (TURBT/TURP)

HOT 2.07

**Saturday 6 April**

**10:00 - 10:55**

**Location** Orange Area, HOT 1

**Tutors** P. Mariappan, Edinburgh (GB)  
A. Sousa Castro, Lisboa (PT)

## **Learning objectives**

This training course combines the first and second step of the Transurethral Treatment (TUT) curriculum. It is designed for urologists who wish to improve their proficiency in key techniques and gain a fundamental understanding of transurethral resection of the bladder and prostate. This comprehensive training covers crucial basic skills including flexible and rigid cystoscopy, resection loop handling, and direct vision internal urethrotomy, as well as the resection procedure, practiced on state-of-the-art models.

The primary objective of this course is to enhance participants' skills in transurethral resection of the prostate and bladder, focusing on key aspects such as depth perception, hand-eye coordination, control, handling, and overall technique. By the end of the course, attendees should feel more competent and confident in performing this procedure.

# Hands-on Training in Transurethral treatment - Step 3 (ThuLEP)

HOT 2.08

**Saturday 6 April**

**10:00 - 10:55**

**Location** Orange Area, HOT 2

**Tutors** L.B. Dragoş, Cambridge (GB)  
B.M. Schoensee, Berlin (DE)

## **Learning objectives**

This advanced training course is the third step in the Transurethral Treatment (TUT) curriculum. It is designed to provide urologists with a fundamental understanding of thulium laser enucleation of the prostate (ThuLEP). This comprehensive training is specifically tailored for urologists who want to become proficient in ThuLEP. Using a step by step approach, experts will lead participants through the procedure on state of the art models, to build a familiarity of the process, confidence handling the equipment, and an understanding of best practice.

## **Training aim**

The primary objective of this course is to enhance participants' skills in ThuLEP, focusing on key aspects such as control, handling, and overall technique. By the end of the course, attendees should feel more competent and confident in performing this procedure.

**Saturday 6 April**  
**10:15 - 11:45**

**Location** Purple Area, S01

**Chairs** P. De Backer, Ghent (BE)  
A. Ghose, Kolkata (IN)  
J. Gómez Rivas, Madrid (ES)

We encourage participants in this session to view the abstracts before the session. All abstract bodies, posters, videos and webcasts can be viewed on the EAU(N)24 Resource Centre or at the digital screens in front of the Purple Area, EGPT.

**10:15 - 10:45**

**Affordable medicine and accessible care**

A0140

**Cost comparison of reusable and single-use cystoscopes: A systematic literature review and meta-analysis**

A.C.O. Birkedal, Cambridgeshire (GB)

A0137

**Office-based endoscopic urological procedures under local anesthesia: Evaluation of feasibility, pain, and patient preference**

A. Ricapito, Foggia (IT)

A0125

**A Cost-Consequence Analysis of the Man Van Project: Comparing Prostate-specific Antigen Testing on a Nurse-led Mobile Service with Primary Care**

M. Moghul, London (GB)

A0131

**Virtual care as a tool to improve health equity? A U.S. national racial and ethnic analysis of telemedicine utilization among cancer patients and survivors during COVID-19**

R. Talwar, Nashville (US)

A0126

**Current Expectations And Opinions On Single Port Robotic Surgery: Preliminary Analysis Of a Survey Among European Experts (SPARC Collaborative Group)**

F. Ditonno, Verona (IT)

A0127

**Characteristics and trends of industry-sponsored research funding to urologists in the United States between 2014 and 2022**

D-D. Nguyen, Boston (US)

**10:45 - 11:00**

**AI in diagnosis: pathology**

A0138

**Multi-modal deep learning model for predicting homologous recombination deficiency in prostate cancer: an international multi-cohort study**

R. Chen, Shanghai (CN)

A0129

**Deep Learning Unveils Molecular Footprints in Histology: Predicting Molecular Subtypes from Bladder Cancer Histology Slides**

F. Khoraminia, Rotterdam (NL)

A0132

**Intelligent discrimination between Normal and Cancerous Human Urothelial Cells by using Electrical Impedance analyzed by Combination of Microflow Cytometry and Machine Learning**

H.W. Kim, Busan (KR)

**11:00 - 11:30**

**AI in diagnosis: imaging and other**

- A0141 **Harnessing artificial intelligence for enhanced renal analysis: automated detection of hydronephrosis and precise kidney segmentation**  
R. Alexa, Aachen (DE)
- A0136 **Can artificial neural network models improve estimation of glomerular filtration rate?**  
T. Zafari, Melbourne (AU)
- A0128 **Detection of Prostate Cancer Extracapsular Extension with MRI Using Deep Learning Methods**  
M. Covas Moschovas, Celebration (US)
- A0133 **Data processing pipeline and artificial intelligence (AI) for autonomous fusion in transperineal prostate biopsies**  
F. Cianflone, Milan (IT)
- A0130 **Development of pT classification prediction system in UTUC using deep-learning**  
R. Tomida, Tokushima (JP)
- A0135 **Artificial Intelligence Based Personalized Oncological Outcome Prediction Model for Upper Urinary Tract Urothelial Carcinoma After Radical Nephroureterectomy: Development and Multi-Center Validation**  
H.Y. Lee, seoul (KR)
- 

11:30 - 11:45

**AI facilitating surgery**

- A0134 **AI-based classification and segmentation method for bladder cancer from cystoscopic image: preliminary study**  
M. Oh, Seoul (KR)
- A0124 **A.I. instrument tracking during proficiency-based progression training: Does instrument velocity really matter?**  
P. De Backer, Ghent (BE)
- A0139 **Evaluation of an extended reality (XR) headset designed for remote training, resident surgery observation and as a wearable monitor for minimally invasive surgery (MIS)**  
N. Stone, Vail (US)

# Penile cancer treatment and penile reconstruction

Video session 04

**Saturday 6 April**  
**10:15 - 11:45**

**Location** Green Area, S04

**Chairs** H.M. Alnajjar, London (GB)  
L. Barreto, Nitra (SK)

We encourage participants in this session to view the abstracts before the session. All abstract bodies, posters, videos and webcasts can be viewed on the EAU(N)24 Resource Centre or at the digital screens in front of the Purple Area, EGPT.

V025 (□ 7 min.)

**Hyperrealistic 3D models for the practice of andrological surgical procedures. A new paradigm?**

F. Campos Juanatey, Santander (ES)

V026 (□ 8 min.)

**No Scalpel Nesbit. Novel method of Nesbit's procedure with a carbon dioxide (CO2) laser.**

E.K. Pawlowska-Krajka, Warsaw (PL)

V027 (□ 7 min.)

**A Novel Technique of Penile Preservation: Local Excision of Proximal Corporal Sarcoma and Left to Right Corporo-corporostomy.**

S.K. Bhagat, Mumbai (IN)

V028 (□ 6 min.)

**Perineoscopic urethrostomy in penile cancer patients**

A.C. Bravo Balado, Barcelona (ES)

V029 (□ 8 min.)

**Fused Double-Cylinder Penile Prosthesis Placement After Phalloplasty Without Urethral Lengthening: A Novel Technique Using A 2-Piece IPP**

M. Garcia, San Francisco (US)

V030 (□ 4 min.)

**Video Comparative Analysis of Modern Dynamic Sentinel Node Biopsy Techniques in European Referral Centres: Practices, Variations, and Opportunities for Research**

S. Yan, London (GB)

V031 (□ 5 min.)

**Robot-Assisted Video-Endoscopic Inguinal Lymph Node Dissection (RAVEIL): Description of Technique**

R. Diamand, Brussels (BE)

V032 (□ 7 min.)

**Robot-assisted Inguinal Lymphadenectomy with the Hugo™ RAS System: surgical set-up and initial experience.**

C. Berquin, Gent (BE)



# Understanding tumour and patient biology for optimised treatment

Thematic Session

**Saturday 6 April**  
**10:30 - 12:00**

**Location** Green Area, N04  
**Chairs** L. Dyrskjøt, Aarhus (DK)  
K. Junker, Homburg (DE)

**10:30 - 10:34**

**Welcome and introduction**

**10:34 - 10:46**

**State-of-the-art lecture Perspectives of antibody-drug conjugates for specific tumour targeting: An overview**  
P. Black, Vancouver (CA)

**10:46 - 11:43**

**Tumour focused**

**10:46 - 10:56**

**Nectin-4—drug conjugates (in metastatic urothelial carcinomas): The right drug for everyone?**  
N. Klümper, Bonn (DE)

**10:56 - 11:06**

**Rationale of PARP inhibitors in combination with novel hormonal agents in PC: Do we still need BRCA testing?**  
J. Linxweiler, Homburg/saar (DE)

**11:06 - 11:16**

**miRNAs: New biomarkers for tailored treatment of testicular germ cell tumours?**  
J. Lobo, Porto (PT)

**11:16 - 11:26**

**Molecular imaging: From diagnostics to theranostics (general overview)**  
W. Fendler, Essen (DE)

**11:26 - 11:43**

**Discussion**

**11:43 - 11:55**

**State-of-the-art lecture The impact of ageing on cancer progression and therapeutic response**  
A. Gomes, Tampa (US)

**11:55 - 12:00**

**Discussion**

# Advancing urothelial cancer care: From molecular subtyping to enhanced imaging techniques

Abstract session 09

**Saturday 6 April**  
**10:30 - 12:00**

**Location** Green Area, W03

**Chairs** S. Crabb, Southampton (GB)  
T-X. Lin, Guangzhou (CN)  
S.V. Lindsborg, Aarhus (DK)

We encourage participants in this session to view the abstracts before the session. All abstract bodies, posters, videos and webcasts can be viewed on the EAU(N)24 Resource Centre or at the digital screens in front of the Purple Area, EGPT.

**10:30 - 10:32**

**Introduction**

**10:32 - 11:07**

**Improving diagnostic modalities in MIBC**

A0143

**The Optimal Way to Determine Kidney Function for Cisplatin-based Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer: A European Association of Urology Young Academic Urologists Urothelial Cancer Working Group Multi-institutional Study**

R. Pichler, Innsbruck (AT)

A0158

**MBC Trial – MRI before cystoscopy incorporating novel diffusion kurtosis imaging and tumour contact length**

R. Shanmugasundaram, South Wentworthville (AU)

A0149

**Theranostics in chemotherapy resistant MIBC by instillation of FAP & CXCR4 radioligands into the bladder - the Bladder BRIDGister experience**

R. Wirtz, Cologne (DE)

A0150

**MRI-based machine learning radiomics for preoperative prediction of HER2 status in urothelial bladder carcinoma**

Q. Cao, Nanjing (CN)

A0142

**Quantitative MRI Parameters Providing the Novel Value in Discriminating Muscle-Invasive Bladder Cancer**

S. Yoshida, Saitama (JP)

A0151

**Inclusion of apparent diffusion coefficient value in Vesical Imaging Reporting and Data System improves accuracy of diagnosis of muscle-invasive bladder cancer**

Q. Cao, Nanjing (CN)

A0155

**Assessment of the value of frozen section analysis if the macroscopic appearance of the ureter is normal: Case-control study**

S. Kerroumi, Oran (DZ)

**11:07 - 11:22**

**Variant histologies of MIBC**

A0145

**Molecular, immunohistochemical and clinical determinants of urothelial carcinoma of the bladder with nested subtype**

F.J. Koll, Frankfurt (DE)

A0144

**Squamous Metaplasia: A risk we should factor into bladder cancer follow up?**

J. Leighton, Newcastle upon Tyne (GB)

A0153

**Clinical characteristics and oncologic outcomes of bladder neuroendocrine carcinoma in a contemporary, multi-institutional cohort**

E. Zaffuto, Milan (IT)

---

11:22 - 11:57

**Refining the prognosis of MIBC**

A0154

**Evaluating the use of One-Step Nucleic Acid Amplification (OSNA) for detecting lymph node metastases in urothelial carcinoma of the bladder – First results of an ongoing, self-controlled study**

B. Michalik, Oldenburg (DE)

A0152

**The prognostic significance of the presence of Lead, Cadmium, Aluminum and Zinc and expression of FGFR3, GATA3 and Cytokeratin 5/6 markers in bladder cancer tissue**

B. Ali-El-Dein, Mansoura (EG)

A0146

**Prognostic Influence of Preoperative Plasma Levels of Epidermal Growth Factor Receptor (EGFR) and Human Epidermal Growth Factor Receptor 2 (HER2) on Disease Outcomes Following Radical Cystectomy**

K. Oberneder, Vienna (AT)

A0147

**Positive ctDNA Status Before Radical Cystectomy Predicts Lymph Node Status and Pathological Upstaging**

P. Wiklund, Stockholm (SE)

A0148

**Development and validation of a highly specific digital PCR test using hypermethylated circulating tumor DNA in invasive urothelial carcinoma**

D. Prost, PARIS (FR)

---

11:57 - 12:00

**Expert summary**

# Benign prostatic hyperplasia and Female incontinence

Meeting of the EAU Section of Functional Urology (ESFU)

Saturday 6 April

10:30 - 13:30

**Location** Purple Area, S03

**Chair** F. Cruz, Porto (PT)

## Learning objectives

The most prevalent conditions urologists involved in functional urology will come across are Benign Prostatic Hyperplasia and Urinary Incontinence. BPH will be the object of in-depth scrutiny including diagnosis, different forms of treatments and respective long-term outcomes. The information will be applied in a debate of two cases. Urinary incontinence will be the object of a lecture that will examine health policies in Europe. Artificial Urinary Sphincter use in men and women and Posterior Tibial Nerve Stimulation will also be addressed in the session.

10:30 - 10:35

## Welcome and introduction

*Moderators* F. Cruz, Porto (PT)  
C. Konstantinidis, Ilion (GR)

10:35 - 10:45

## Female urinary incontinence in Europe

P.E.V. Van Kerrebroeck, Berchem- Antwerp (BE)

10:45 - 11:45

## BPH Session: One treatment fits all or personalised medicine?

*Moderators* F. Cruz, Porto (PT)  
C. Konstantinidis, Ilion (GR)

10:45 - 10:55

## Why are so many patients are on medical treatment after BPH/BPE surgery?

V. Phé, Paris (FR)

10:55 - 11:05

## How can we anticipate we are pushing medical treatment too far, in monotherapy or combination?

B.Y. Padilla Fernandez, San Cristóbal De La Laguna (ES)

11:05 - 11:15

## Do we have long-terms results to say that minimally-invasive urethral stents have come of age?

N. Mangir, Ankara (TR)

11:15 - 11:25

## Rezum, aquablation or the good old TURP?

A.K. Nambiar, Newcastle-upon-Tyne (GB)

11:25 - 11:35

## Doctor, tell me about the risk of incontinence after HOLEP vs. other forms of pro enucleation

T. Antunes Lopes, Porto (PT)

11:35 - 11:45

## When do we need urodynamics to study a male patient with BPE and LUTS?

M. Tutolo, Milan (IT)

## Case presentation with a debate

*Moderator* J. Heesakkers, Maastricht (NL)

11:45 - 11:50

## Case 1

J. Heesakkers, Maastricht (NL)

11:50 - 11:55

**Case 2**

J. Heesakkers, Maastricht (NL)

11:55 - 12:15

**Debate/discussion**

---

12:15 - 13:00

**ESFU invites other Societies**

*Moderators*

S. Arlandis, Valencia (ES)

T. Tarcan, Üsküdar/ İstanbul (TR)

12:15 - 12:30

**ICS lecture AUS and urinary incontinence: are we arriving at the end of gender discrimination?**

E. Chartier-Kastler, Paris (FR)

12:30 - 12:45

**SUFU Lecture What is new in the treatment of BPS/IC?**

R. Moldwin, New York (US)

12:45 - 13:00

**SINUG Lecture Cognitive dysfunction with long-term anticholinergic medication: Real or a hype?**

P. Blasco Hernández, Sevilla (ES)

---

**Debate Botulinum toxin A or posterior tibial nerve stimulation to treat incontinence in my multiple sclerosis patient?**

*Moderators*

F.C. Burkhard, Bern (CH)

E. Finazzi Agrò, Rome (IT)

13:00 - 13:10

**Botulinum toxin A**

A. Apostolidis, Thessaloniki (GR)

13:10 - 13:20

**Posterior tibial nerve stimulation**

K-D. Sievert, Detmold (DE)

13:20 - 13:25

**Discussion**

---

13:25 - 13:30

**Closing remarks**

F. Cruz, Porto (PT)

# Controversies and dilemmas in reproductive and sexual medicine: From the laboratory to the clinic and from the operating theater back to the laboratory

Meeting of the EAU Section of Andrological Urology (ESAU)

**Saturday 6 April**  
**10:30 - 13:30**

**Location** Green Area, N03

**Chair** N. Sofikitis, Ioannina (GR)

## **Learning objectives**

The ESAU of The EAU invites you to participate actively in The ESAU Scientific Meeting. The scientific trip, an exciting odyssey passing through unknown paths, from the basic research efforts to the employment of the research results and conclusions in Andrology Clinics and The Operating Theater, will allow us to have a scientific interaction discussing controversies and dilemmas in male infertility, male endocrinology, and sexual medicine.

**10:30 - 10:31**

## **Welcome**

N. Sofikitis, Ioannina (GR)

**10:31 - 11:01**

## **State-of-the-art lectures in reproductive medicine**

*Moderators*  
G. Corona, Bologna (IT)  
M.M. Fode, Herlev (DK)

**10:31 - 10:41**

## **Are there any evidence-based lifestyle recommendations we can give to men from infertile couples?**

A. Salonia, Milan (IT)

**10:41 - 10:51**

## **Which pharmaceutical treatments are contraindicated in men who wish to become fathers?**

A. Giwercman, Malmö (SE)

**10:51 - 11:01**

## **Sparing surgery of the testis: Indications, techniques and outcomes**

S. Minhas, London (GB)

**11:01 - 11:11**

## **State-of-the-art lectures in sexual medicine**

*Moderators*  
C. Bettocchi, Foggia (IT)  
D.J. Ralph, London (GB)

**11:01 - 11:11**

## **The role of extracorporeal shock wave therapy in andrology**

J. Rassweiler, Krems - Stein (AT)

**11:11 - 11:21**

## **State-of-the-art lectures in male endocrinology**

*Moderators*  
H. Nguyen Phuc Cam, Ho Chi Minh Ville (VN)  
P. Verze, Salerno (IT)

**11:11 - 11:21**

## **Is testosterone first-choice therapy in obese hypogonadal men?**

H. Behre, Halle (DE)

**11:21 - 11:31**

## **State-of-the-art debates in reconstructive surgery**

*Moderators*  
G.I. Russo, Catania (IT)  
A. Salonia, Milan (IT)

11:21 - 11:31	<b>Penile surgery can increase the penile length: Aesthetic fact?</b> J. Romero-Otero, Madrid (ES)
11:31 - 11:41	<b>State-of-the-art lectures in assisted reproductive technology for the treatment of azoospermia</b> <i>Moderators</i> M. Moussa, Beirut (LB) P. Sangster, London (GB)
11:31 - 11:41	<b>Do we really need spermatozoa to generate healthy human offspring?</b> N. Sofikitis, Ioannina (GR)
11:41 - 12:05	<b>Surgery in motion 1: Surgery for the treatment of male infertility</b> <i>Moderators</i> F. Dimitriadis, Thessaloniki (GR) F. Fusco, Naples (IT)
11:41 - 11:48	<b>Does micro-TESE remain the gold standard for testicular sperm recovery in non-obstructed azoospermic males?</b> M. Dinkelman-Smit, Rotterdam (NL)
11:48 - 11:55	<b>Microsurgical aspiration of epididymal sperm from obstructed azoospermic males</b> A.B. Altay, Izmir (TR)
11:55 - 12:02	<b>Tips and tricks on the surgical treatment of recurrent varicocele</b> S. Çayan, Mersin (TR)
12:02 - 12:05	<b>Discussion</b>
12:05 - 12:23	<b>Surgery in motion 2: Surgery for the treatment of male infertility</b> <i>Moderators</i> M. Boiko, Kyiv (UA) A. Khelaia, Tbilisi (GE)
12:05 - 12:12	<b>Surgery of the ejaculatory ducts: Indications and results</b> A. Muneer, London (GB)
12:12 - 12:19	<b>Microsurgical aspiration of sperm from the vas deferens</b> A. Zachariou, Ioannina (GR)
12:19 - 12:23	<b>Discussion</b>
12:23 - 12:54	<b>Testicular cancer and male reproductive health-optimising outcomes</b> <i>Moderators</i> M.B.T. Dung, Ho Chi Minh City (VN) S. Minhas, London (GB)
12:23 - 12:32	<b>Testicular dysgenesis: Its role in male reproductive health and testicular cancer - what is the evidence?</b> A. Cocci, Florence (IT)
12:32 - 12:40	<b>Fertility preservation in men with testis cancer: The onco TESE, technique and outcomes</b> Z. Kopa, Budapest (HU)
12:40 - 12:49	<b>The hypothalamo-pituitary testicular axis in men with testicular cancer</b> G. Corona, Bologna (IT)
12:49 - 12:54	<b>Discussion</b>

12:54 - 13:28

**Lectures and surgery in motion 3: Penile surgery**

*Moderator* P.A.S. Vendeira, Porto (PT)

12:54 - 13:01

**Indications for longitudinal incision of the tunica for Peyronie's disease**

A. Kadioglu, Istanbul (TR)

13:01 - 13:08

**Ischemic priapism: Placement of the IPP at an early stage**

C. Bettocchi, Foggia (IT)

13:08 - 13:17

**Ischemic priapism: Placement of the IPP at a late stage/complications**

D.J. Ralph, London (GB)

13:17 - 13:24

**Ischemic priapism: Tips and tricks in diagnosis and treatment**

D. Hatzichristou, Thessaloniki (GR)

13:24 - 13:28


**Discussion**

---

13:28 - 13:30

**Conclusions**

N. Sofikitis, Ioannina (GR)





# Progress and controversies in oncological urology

Meeting of the EAU Section of Oncological Urology (ESOU)

**Saturday 6 April**  
**10:30 - 13:10**

**Location** Purple Area, N01

**Chair** M. Rouprêt, Paris (FR)

## Learning objectives

- To strengthen the leading role of European urologists in providing care to patients with genitourinary malignancies.
- To recognise the value of multidisciplinary collaborations between urologists, medical oncologists, radiation oncologists, and other stakeholders involved in the multifaceted care of patients with genitourinary malignancies.
- To navigate the evolving landscape of multimodal, minimally-invasive and technologically advanced therapeutic options with the aim to implement personalised pathways of care across the wide spectrum of genitourinary malignancies stage by stage.

**10:30 - 10:35**

## Welcome and introduction

G. Giannarini, Udine (IT)

M. Rouprêt, Paris (FR)

**10:35 - 11:20**

## Session I: Hot topics in oncological urology

*Moderators*

G. Giannarini, Udine (IT)

M. Rouprêt, Paris (FR)

**10:35 - 10:45**

## Prostate: Options and challenges in the management of oligometastatic prostate cancer in the PSMA-PET era

C. Sweeney, Adelaide (AU)

**10:45 - 10:50**

## Questions & answers

**10:50 - 11:00**

## Which future for immunotherapy in localised kidney cancer?

R. Campi, Florence (IT)

**11:00 - 11:05**

## Questions & answers

**11:05 - 11:15**

## The current role of surgery in metastatic testicular cancer

C. Fankhauser, Lucerne (CH)

**11:15 - 11:20**

## Questions & answers

**11:20 - 11:35**

## European Urology Oncology lecture

**11:20 - 11:23**

## Introduction

M. Rouprêt, Paris (FR)

**11:23 - 11:35**

## Survivorship considerations across the spectrum of genitourinary oncology

A. Morgans, Boston (US)

## Session II: Common problems in oncological urology

Moderators

G. Giannarini, Udine (IT)

M.C. Mir Maresma, Valencia (ES)

---

11:35 - 12:05

**Case-based debate** Clear cell renal carcinoma T3c with lung micronodules

11:35 - 11:40

**Case presentation**

M. von Deimling, Hamburg (DE)

11:40 - 11:50

**Systemic treatment first**

R. Flippot, Villejuif (FR)

11:50 - 12:00

**Surgery first**

M.C. Mir Maresma, Valencia (ES)

12:00 - 12:05

**Discussion**

---

12:05 - 12:35

**Case-based debate** Metastatic bladder cancer at diagnosis: Complete response after systemic treatment and subsequent bladder recurrence pT1 High Grade

12:05 - 12:10

**Case presentation**

M. Moschini, Milan (IT)

12:10 - 12:20

**Cystectomy**

P. Gontero, Turin (IT)

12:20 - 12:30

**2nd line metastatic treatment**

R. Flippot, Villejuif (FR)

12:30 - 12:35

**Discussion**

---

12:35 - 13:05

**Case-based debate** High-risk biochemical recurrence after radical prostatectomy

12:35 - 12:40

**Case presentation**

C.V. Kesch, Essen (DE)

12:40 - 12:50

**Treat without imaging**

B. Tombal, Brussels (BE)

12:50 - 13:00

**Treat after imaging**

A. De La Taille, Créteil (FR)

13:00 - 13:05

**Discussion**

---

13:05 - 13:10

**Closing remarks**

G. Giannarini, Udine (IT)

M.C. Mir Maresma, Valencia (ES)

# Urinary tract and prostatic infections in the office and outpatient setting: Realistic guidance for everyday practice

Meeting of the EAU Section of Urologists in Office (ESUO)

**Saturday 6 April**  
**10:30 - 13:30**

**Location** Green Area, W01

**Chairs** H. Brenneis, Pirmasens (DE)  
F. Dimitriadis, Thessaloniki (GR)

## **Learning objectives**

Urinary tract and prostatic infections (UTPIs) are the most frequent cause of office and outpatient clinic visits accounting for numerous hospitalisations. Distinguished clinical physicians and scientists have joined forces to present a comprehensive resource guide to current diagnostic and treatment modalities for a broad spectrum of clinical issues relevant to UTPIs. State-of-the-art lectures on novel strategies such as the Artificial Intelligence-guided antibiotic choices, low-risk pregnant women with UTIs, and a realistic guidance to handle bacterial and non-bacterial prostatitis in the office and outpatient setting will be presented. Finally, the relationship between chronic prostatitis and male sexual function and fertility will be discussed.

**10:30 - 10:33**

## **Welcome and introduction**

F. Dimitriadis, Thessaloniki (GR)

**10:33 - 11:46**

## **Urinary Tract Infections in the office and the outpatient setting**

*Moderators* A. Zachariou, Ioannina (GR)  
L.P. Zapala, Warsaw (PL)

**10:33 - 10:46**

## **State-Of-The-Art lecture: Can novel strategies guide antibiotic choice in recurrent UTIs and improve antimicrobial stewardship?**

F.M.E. Wagenlehner, Giessen (DE)

**10:46 - 10:56**

## **Markers and the most common pathogens of male genital infections**

M. Benyó, Debrecen (HU)

**10:56 - 11:06**

## **UTIs in everyday urology practice: Practical guidance**

J. Keehnen, Rotterdam (NL)

**11:06 - 11:16**

## **The real "face" of E.coli: Why it is so problematic to finally "kill" it!**

A. Khelaia, Tbilisi (GE)

**11:16 - 11:26**

## **Catheter-associated urinary tract infections and how to handle them**

P. Tsafrakidis, Limassol (CY)

**11:26 - 11:39**

## **State-Of-The-Art lecture: Low-risk pregnant women with asymptomatic bacteriuria and urinary tract infections**

S.E. Geerlings, Amsterdam (NL)

**11:39 - 11:46**

## **Discussion**

**11:46 - 12:06**

## **Chronic prostatitis in the office and the outpatient setting**

*Moderators* M. Benyó, Debrecen (HU)  
T.H. Kuru, Köln (DE)

**11:46 - 11:56**

## **Chronic prostatitis: Does it really exist and what can we do?**

H. Brenneis, Pirmasens (DE)

11:56 - 12:06

**Sexual function consequences in patients with chronic prostatitis**

A. Zachariou, Ioannina (GR)

---

12:06 - 12:45

**Debate Does Evidence-Based Medicine suggest a connection between chronic prostatitis and male infertility?**

12:06 - 12:16

**No, there is no significant connection**

T. De Vringer, Rotterdam (NL)

12:16 - 12:26

**Yes, there is a connection**

F. Dimitriadis, Thessaloniki (GR)

12:26 - 12:38

**State-Of-The-Art lecture: Bacterial and non-bacterial prostatitis in the office and outpatient setting: A realistic guidance for everyday practice**

R. Bartoletti, Pisa (IT)

12:38 - 12:45

**Discussion**

---

12:45 - 13:22

**Infective complications in office-based urological interventions**

*Moderators*

S.M. Haensel, Rotterdam (NL)

A. Verit, Istanbul (TR)

12:45 - 12:55

**Prostate biopsy: With or without antibiotic prophylaxis?**

T.H. Kuru, Köln (DE)

12:55 - 13:05

**Lowering the risk of infections in patients undergoing urologic procedures in the office setting**

L.P. Zapala, Warsaw (PL)

13:05 - 13:15

**UTI associated with stents, stones, or foreign bodies that cannot be urgently removed**

W. Krajewski, Wrocław (PL)

13:15 - 13:22

**Discussion**

---

13:22 - 13:29

**Helmut Haas Award**

*Moderator*

S.M. Haensel, Rotterdam (NL)

13:22 - 13:27

**Presentation of the award-winning work by the winner**

H. Chen, Kaohsiung (TW)

13:27 - 13:30

**Closing remarks**

H. Brenneis, Pirmasens (DE)

**Saturday 6 April**  
**10:30 - 18:00**

**Location** Green Area, eURO Auditorium 1  
**Chair** A. Breda, Barcelona (ES)

## **Ghent University Hospital**

*Coordinator* T. Taily, Ghent (BE)

## **Erasmus Hospital Brussels**

*Coordinator* T. Roumeguere, Brussels (BE)

## **Onze-Lieve-Vrouwe Hospital (OLV) Aalst**

*Coordinators* G. De Naeyer, Aalst (BE)  
A. Mottrie, Aalst (BE)

## **AZ Maria Middelaes Ghent**

*Coordinator* K. Decaestecker, Ghent (BE)

## **Algemeen Stedelijk Ziekenhuis Aalst**

*Coordinator* B. Rappe, Aalst (BE)

**10:30 - 11:00**

## **Part 1a**

### **Channel 1**

*Moderators* G. Bozzini, Como (IT)  
J.B. Roche, Bordeaux (FR)

### **Channel 2**

*Moderators* A. Gallioli, Barcelona (ES)  
J-T. Klein, Münsterlingen (CH)

### **Channel 3**

*Moderators* B. Geavlete, Bucharest (RO)  
A. Skolarikos, Athens (GR)

### **Channel 4**

*Moderators* M. Brehmer, Stockholm (SE)  
E. Ventimiglia, Milan (IT)

### **Channel 1 70 gr HOLEP with dual-pulse technology**

P. Schatteman, Aalst (BE)

### **Channel 2 Semi-live: RIRS procedure LithoVue SU scope and Moses Technology**

S. Proietti, Milan (IT)

**Channel 3 MiniECIRS for multiple calyceal stones in a challenging anatomy**

C. Manso Aparicio, Valladolid (ES)

D.A. Pérez Fentes, Santiago de Compostela (ES)

**Channel 4 Part I: Full dusting with Thulium Fiber Laser (TFL). No need to use high frequency to go fast and fine!**

O. Traxer, Paris (FR)

---

11:00 - 11:30

**Part 1b****Channel 1**

*Moderators*

G. Bozzini, Como (IT)

J.B. Roche, Bordeaux (FR)

**Channel 2**

*Moderators*

J-T. Klein, Münsterlingen (CH)

A. Papatsoris, Athens (GR)

**Channel 3**

*Moderators*

B. Geavlete, Bucharest (RO)

A. Skolarikos, Athens (GR)

**Channel 4**

*Moderators*

M. Brehmer, Stockholm (SE)

E. Ventimiglia, Milan (IT)

**Channel 1 Photoselective Vaporization of the Prostate (PVP) with Greenlight Laser for 70 cc obstructive BPH**

H. Cash, Berlin (DE)

**Channel 2 Semi-live: Rezum**

M. Fourmarier, Aix-en-Provence (FR)

**Channel 3 Dual implant (penile inflatable prosthesis and artificial urinary sphincter) through single penoscrotal incision**

*Speakers*

K. Van Renterghem, Hasselt (BE)

M. Waterloos, Gent (BE)

**Channel 4 Part II: Full dusting with Thulium Fiber Laser (TFL). No need to use high frequency to go fast and fine!**

O. Traxer, Paris (FR)

---

11:30 - 12:00

**Part 2a****Channel 1**

*Moderators*

E. Liatsikos, Patras (GR)

U. Nagele, Hall in Tirol (AT)

**Channel 2**

*Moderators*

S. Bechis, San Diego (US)

B. Malavaud, Toulouse (FR)

### Channel 3

*Moderators* P. Diana, Barcelona (ES)  
M.C. Rassweiler-Seyfried, Mannheim (DE)

### Channel 4

*Moderators* P. Juárez Del Dago Anaya, Las Palmas de G.C. (ES)  
A. Miernik, Freiburg (DE)

### Channel 1 Part I: ECIRS for right kidney 30mm cystine stone

C.M. Cracco, Turin (IT)  
C.M. Scoffone, Turin (IT)

### Channel 2 Pre-recorded: BPH

*Speaker* M. Straub, Munich (DE)

*Case moderator* T. Amiel, Munich (DE)

### Channel 3 Small tools with great effect - double laser power in an ECIRS

E.K. Bres-Niewada, Pruszkow (PL)  
A. Secker, Münster (DE)

### Channel 4 Semi-live: BPH HoLEP - Virtual Basket (Cyber Ho 150)

F. Gomez Sancha, Madrid (ES)

---

12:00 - 12:30

### Part 2b

#### Channel 1

*Moderators* E. Liatsikos, Patras (GR)  
U. Nagele, Hall in Tirol (AT)

#### Channel 2

*Moderators* S. Bechis, San Diego (US)  
B. Malavaud, Toulouse (FR)

#### Channel 3

*Moderators* P. Diana, Barcelona (ES)  
M.C. Rassweiler-Seyfried, Mannheim (DE)

#### Channel 4

*Moderators* P. Juárez Del Dago Anaya, Las Palmas de G.C. (ES)  
A. Miernik, Freiburg (DE)

### Channel 1 Part II: ECIRS for right kidney 30mm cystine stone

C.M. Cracco, Turin (IT)  
C.M. Scoffone, Turin (IT)

### Channel 2 Semi-live: Bladder tumour

R. Mallet, Périgueux (FR)

### Channel 3 Holmium laser pulse modulation - to dust or to bust

L. Ajayi, London (GB)

### Channel 4 ThuFlep - TFL (Fiber Dust)

M.A. Zawadzki, Warsaw (PL)

---

12:30 - 13:00

### Part 3

### **Channel 1**

*Moderators*

C. Berquin, Gent (BE)  
G. Mazzon, Bassano del Grappa (IT)

### **Channel 2**

*Moderators*

L. Cindolo, Salerno (IT)  
S. Micali, Modena (IT)

### **Channel 3**

*Moderators*

P.J.S. Osther, Vejle (DK)  
B. Petrut, Cluj Napoca (RO)

### **Channel 4**

*Moderators*

S. Choong, London (GB)  
L. Lusuardi, Salzburg (AT)

### **Channel 1 Thulium Laser Enucleation of the Prostate (ThuFLEP) with SOLTIVE™ System**

J. Sanchez Macias, Barcelona (ES)

### **Channel 2 Semi-live: Minimally-invasive BPH treatment with iTind**

S. Secco, Milan (IT)

### **Channel 3 Supine MiniEcirs with Thulium Fiber Laser (TFL)**

O. Angerri Feu, Barcelona (ES)  
E. Emiliani, Barcelona (ES)

### **Channel 4 Pre-recorded: New technology (15 min.)**

*Speaker*

O. Traxer, Paris (FR)

*Case moderator*

E. Ventimiglia, Milan (IT)

### **Channel 4 Semi-live: Mini-PCNL - TFL (Fiber Dust) - (15 min.)**

I. Kartalas Goumas, Milan (IT)

---

**13:00 - 13:30**

### **Part 4**

#### **Channel 1**

*Moderators*

C. Berquin, Gent (BE)  
G. Mazzon, Bassano del Grappa (IT)

#### **Channel 2**

*Moderators*

L. Cindolo, Salerno (IT)  
S. Micali, Modena (IT)

#### **Channel 3**

*Moderators*

P.J.S. Osther, Vejle (DK)  
B. Petrut, Cluj Napoca (RO)

#### **Channel 4**

*Moderators*

S. Choong, London (GB)  
L. Lusuardi, Salzburg (AT)



**Channel 1 Retrograde intra renal surgery for kidney stones Thulium Fiber Laser (TFL)**

G.M. Kamphuis, Amsterdam (NL)

**Channel 2 Semi-live: NMIBC treatment with Narrow Band Imaging (NBI) & Plasma+**

B. Malavaud, Toulouse (FR)

**Channel 3 Laparoscopic partial nephrectomy**

R. Bollens, Lomme (FR)

**Channel 4 Semi-live: BPH - TFL Vs Holmium - TFL (Fiber Dust) + Holmium (Cyber Ho 100) - (15 min.)**

P. Kallidonis, Patras (GR)

**Channel 4 Pre-recorded: Mini-ECIRS -TFL (Fiber Dust) + Holmium (Cyber Ho) - (15 min.)**

*Speakers*

O. Angerri Feu, Barcelona (ES)

E. Emiliani, Barcelona (ES)

*Case moderator*

S. Ferretti, Modena (IT)

---

**13:30 - 14:00**

**Part 5**

**Channel 1**

*Moderators*

R. Boissier, Marseille (FR)

A. Skolarikos, Athens (GR)

**Channel 2**

*Moderators*

E. Barret, Paris (FR)

A. Pietropaolo, Southampton (GB)

**Channel 3**

*Moderators*

P. Kallidonis, Patras (GR)

T. Knoll, Sindelfingen (DE)

**Channel 4**

*Moderators*

A. Bujons Tur, Barcelona (ES)

C.C. Seitz, Vienna (AT)

**Channel 1 Circumferential apical urethra sparing en bloc BipoLEP**

T.R.W. Herrmann, Frauenfeld (CH)

**Channel 2 Semi-live: UTUC using Flex-XC1 and MultiLASE TFL**

G. Giusti, Basiglio (IT)

**Channel 3 Flexible ureterorenoscopy of a lower pole stone**

T. Taily, Ghent (BE)

**Channel 4 Semi-live: DISS (Direct-in-scope-suction) RIRS with SUCTION scope**

B. Somani, Southampton (GB)

---

**14:00 - 14:15**

**Break**

---

**14:15 - 15:00**

**Part 6**

**Channel 1 Nerve Sparing Radical Prostatectomy for intermediate risk PCa**

R. Gaston, Bordeaux (FR)

**Channel 2 Pre-recorded: Navigating Complex Reconstructions with the Hugo™ RAS System (1) - (20 min.)**

B. Peyronnet, Rennes (FR)

**Channel 2 Pre-recorded: Navigating Complex Reconstructions with the Hugo™ RAS System (2) - (20 min.)**

R. Papalia, Rome (IT)

**Channel 3 RAPN for right sided cT1a RCC with 3-D reconstruction**

R. De Groot, Aalst (BE)

---

**15:00 - 15:30**

**Part 7**

**Channel 1**

*Moderators*

P. Juárez Del Dago Anaya, Las Palmas de G.C. (ES)

R. Papalia, Rome (IT)

**Channel 2**

*Moderators*

B.J. Challacombe, London (GB)

A. Minervini, Florence (IT)

**Channel 3**

*Moderators*

P. Dasgupta, London (GB)

S. Secco, Milan (IT)

**Channel 4**

*Moderators*

J.M. Gaya Sopena, Barcelona (ES)

R. Schiavina, Bologna (IT)

**Channel 1 Nerve Sparing Radical Prostatectomy for intermediate risk PCa**

R. Gaston, Bordeaux (FR)

**Channel 2 Semi-live: Cystectomy - (15 min.)**

*Speakers*

B.M.C. Rocco, Milan (IT)

M.C. Sighinolfi, Milan (IT)

**Channel 2 Semi-live: Partial nephrectomy - (15 min.)**

V. Hevia Palacios, Madrid (ES)

**Channel 3 RAPN for right sided cT1a RCC with 3-D reconstruction**

R. De Groot, Aalst (BE)

**Channel 4 Semi-live: RARP**

A. Haese, Hamburg (DE)

---

**15:30 - 17:00**

**Part 8**

**Channel 1**

*Moderators*

N.N. Harke, Hannover (DE)

D. Tilki, Hamburg (DE)

## **Channel 2**

*Moderators* C. Wijburg, Arnhem (NL)  
P. Wiklund, Stockholm (SE)

## **Channel 3**

*Moderators* F. Porpiglia, Turin (IT)  
C. Wagner, Gronau (DE)

## **Channel 4**

*Moderators* A. Minervini, Florence (IT)  
H.G. Van Der Poel, Amsterdam (NL)

## **Channel 1 Partial nephrectomy, multiport system, digital twin**

K. Decaestecker, Ghent (BE)

## **Channel 2 Semi-live: Radical prostatectomy - extraperitoneal approach with single port system - (45 min.)**

K. Badani, New York (US)

## **Channel 2 Semi-live: Benign prostatectomy (transvesical approach) - (45 min.)**

J.H. Kaouk, Cleveland (US)

## **Channel 3 Multiport RARP for locally advanced PCa**

A. Mottrie, Aalst (BE)

## **Channel 4 Semi-live: Retroperitoneal partial nephrectomy – single port system**

S. Crivellaro, Chicago (US)

---

**17:00 - 17:30**

## **Part 9**

### **Channel 1**

*Moderators* A. Budía Alba, Valencia (ES)  
A. Bujons Tur, Barcelona (ES)

### **Channel 2**

*Moderators* O.R. Durutovic, Belgrade (RS)  
J. Vesper, Vienna (AT)

### **Channel 3**

*Moderators* M. Cepeda, Valladolid (ES)  
E. Montanari, Milan (IT)

### **Channel 4**

*Moderators* R. Cansino, Madrid (ES)  
A. Neisius, Trier (DE)

## **Channel 1 Semi-live: First animal test in Europe with IRP monitoring f-URS (Zebra Scope) and Chinese clinical experience**

J.X. Li, Beijing (CN)  
E. Liatsikos, Patras (GR)

## **Channel 2 Semi-live: Laser EEP with Thulio®, an advanced Thulium:YAG Laser with RealPulse® technology**

G. De Naeyer, Aalst (BE)

## **Channel 3 Invisible PNL**

M. Straub, Munich (DE)

**Channel 4 Semi-live: The Hydrogel Method - On the way to stone-free patients after RIRS**

T. Amiel, Munich (DE)

---

**17:30 - 18:00**

**Part 10**

**Channel 2**

*Moderators*

O.R. Durutovic, Belgrade (RS)

J. Veser, Vienna (AT)

**Channel 4**

*Moderators*

R. Cansino, Madrid (ES)

A. Neisius, Trier (DE)

**Channel 2 Semi-live: Advanced AEEP with TFL and Piranha Morcellator**

C. Netsch, Hamburg (DE)

**Channel 4 Semi-live: PCNL with Trilogy**

T. Knoll, Sindelfingen (DE)

# EAU24: Live surgery - Channel 1

Special Session

**Saturday 6 April**  
**10:30 - 18:00**

**Location**

Live surgery Channel 1

# EAU24: Live surgery - Channel 2

Special Session

**Saturday 6 April**  
**10:30 - 18:00**

**Location**

Live surgery Channel 2

# EAU24: Live surgery - Channel 3

Special Session

**Saturday 6 April**  
**10:30 - 18:00**

**Location**

Live surgery Channel 3

# EAU24: Live surgery - Channel 4

Special Session

**Saturday 6 April**  
**10:30 - 18:00**

**Location**

Live surgery Channel 4



**Saturday 6 April**  
**10:30 - 12:00**

**Location** Purple Area, EGPT

**Chairs** K.A.O. Tikkinen, Helsinki (FI)  
M. Vallée, Poitiers (FR)

We encourage participants in this session to view the abstracts before the session. All abstract bodies, posters, videos and webcasts can be viewed on the EAU(N)24 Resource Centre or at the digital screens in front of the Purple Area, EGPT.

**10:30 - 10:42**

**Screen A: Basic research**

- P093** **The postmenopausal urinary metabolome is associated with recurrent UTI and urobiome ecology.**  
M. Neugent, Richardson (US)
- P094** **Associations between potential renal acid load and urine PH in postmenopausal women with recurrent UTI**  
P.E. Zimmern, Dallas (US)
- P092** **Identification of urinary cytokines to distinguish between asymptomatic bacteriuria and urinary tract infection**  
P.E. Zimmern, Dallas (US)
- P095** **Tissue distribution of Ceftazidime-Avibactam in kidney tissue in healthy rats and pigs using a microdialysis technique.**  
M. Vallée, Poitiers (FR)

**10:42 - 11:00**

**Screen B: Markers**

- P113** **Association between elevated plasma thrombin-antithrombin complex levels and severe acute kidney injury development in urological sepsis**  
N. Fujita, Hirosaki (JP)
- P112** **Endothelial glycocalyx injury is a risk factor for disseminated intravascular coagulation development in urological sepsis**  
N. Fujita, Hirosaki (JP)
- P114** **Comparison of qSOFA score and SIRS criteria for assessing the risk for severe acute kidney injury development and mortality in febrile urinary tract infection**  
N. Fujita, Hirosaki (JP)
- P117** **Persistently elevated urinary inflammatory biomarkers may predict recurrence of recurrent urinary tract infection in women**  
M-C. Liu, Hualien (TW)
- P091** **Prediction of urinary tract infection combining sysmex UF-5000I urine fluorescence flow cytometry with urinalysis – a single center study in Vietnam**  
V.A.V. Trang, Ho Chi Minh (VN)
- P097** **Plasma hyaluronan levels predict major adverse cardiovascular events in urological sepsis**  
M. Momota, Hirosaki (JP)

**11:00 - 11:12**

**Screen C: Diagnosis**

P107	<b>Comparing the accuracy of UTISA and ACSS questionnaires in diagnosing acute uncomplicated cystitis in women</b> Y-J. Chou, New Taipei City (TW)
P110	<b>Bacteriuria and urosepsis in patients with stented ureters: predictors of infection &amp; when not to treat</b> D. Batura, London (GB)
P115	<b>Why underrepresentation costs lives: First results from a high-volume multi-institutional study in Germany about risk factors for mortality in Fournier gangrene</b> C. Rieger, Cologne (DE)
P102	<b>Reduction of antibiotic use around prostatic biopsy in a prostate cancer network</b> C.H. Bangma, Rotterdam (NL) <b>Study Group</b> Anser Prostate Network(Rotterdam, The Netherlands)
<hr/>	
<b>11:12 - 11:24</b>	<b>Screen D: Screening</b>
P104	<b>Asymptomatic Bacteriuria prior to Partial and Radical nephrectomy: To screen or not to screen?</b> E. Ayoub, Poitiers (FR)
P116	<b>Reducing infectious complications after transrectal prostate biopsy: significance of rectal swab ESBL/MRGN screening and tailored antibiotic treatment</b> G. Ortner, Innsbruck (AT)
<hr/>	
<b>11:24 - 11:39</b>	<b>Screen E: Miscellaneous</b>
P103	<b>Catheter Associated Urinary Tract Infections-Online questionnaire (CAUTI-On): status quo in central European urological care</b> E. Arbelaez, Basel (CH)
P098	<b>Radiomics analysis using non-contrast computed tomography for predicting HDU admission in patients with acute pyelonephritis</b> T. Horie, Bunkyo-ku (JP)
P119	<b>Real time urinary tract infection diagnosis and antimicrobial susceptibility testing within &lt;90 Minutes</b> Z. Bahouth, Shefa-amer (IL)
P105	<b>Quality of information and appropriateness of Open AI outputs for urinary tract infections</b> M. Romagnoli, Orte (IT)
P096	<b>Propolis - a natural material for antimicrobial and anti-encrustation coating on ureteral stents</b> L. Yang, Chengdu (CN)
<hr/>	
<b>11:39 - 12:00</b>	<b>Screen F: Complications</b>
P106	<b>Assessing the Influence of Recurrent Urinary Tract Infections on Sexual Function: A case-control study</b> J. Medina-Polo, Madrid (ES)
P118	<b>Pathogen Species Are the Risk Factors for Postoperative Infection of Patients with Transurethral Resection of the Prostate: A Retrospective Study</b> L. Ye, Beijing (CN)

- P111 **Role of serum immunoglobulin N-glycans in endothelial glycocalyx injury in urological sepsis**  
N. Fujita, Hirosaki (JP)
- P100 **Comparison of Urinary Tract Infection Rates with and without Prophylactic Antibiotics in Transperineal Prostate Biopsy: An Updated Systematic Review and Meta-Analysis**  
D.Y. Jun, Seoul (KR)
- P101 **The impact of exposure to ileal feces during intracorporeal urinary diversion: cultivable microbiota of the distal ileum**  
K. Zennami, Nagakute (JP)
- P099 **Antimicrobial Prophylaxis in Robot assisted laparoscopic radical Prostatectomy: A Systematic Review**  
E. Falkensammer, Salzburg (AT)
- P090 **Analysis of Urinary Tract Infections (UTI) complications after Radical Cystectomy: Results from a single center study and Improvement of ERAS protocol**  
V. Lorusso, Milan (IT)

**Saturday 6 April**  
**10:45 - 12:15**

**Location** Purple Area, eURO Auditorium 2

**Chairs** P. Albers, Düsseldorf (DE)  
H. Van Poppel, Leuven (BE)

### **Learning objectives**

A project was submitted, by the EAU and a consortium of 25 institutions from 12 countries, to the European Commission: PRostate cancer Awareness and Initiative for Screening in the European Union (PRAISE-U). It has been granted funding under the EU4Health programme. This session will clarify the aims of the project, highlight the challenges and explain the role of EAU and its membership in contributing to a comprehensive living knowledge platform on prostate cancer screening in the EU and in Europe, to get better insight into policy making and governance of urological care in the field of early detection.

**10:45 - 11:00**

### **State of play of PCa early detection across the EU including the new European Joint Action on Cancer Screening**

M.J. Roobol, Rotterdam (NL)

**11:00 - 11:10**

### **Results of European needs assessment: What countries require in terms of early detection**

K. Beyer, Rotterdam (NL)

**11:10 - 11:20**

### **Tailoring success: Strategies for prostate cancer screening implementation across diverse health systems in Europe**

A. Chandran, Lyon (FR)

**11:20 - 11:40**

### **Piloting early detection programmes: The opportunities and challenges**

M. Otero Garcia, Vigo (ES)

A. Patasius, Vilnius (LT)

**11:40 - 11:50**

### **The importance of data needed to inform cancer early detection policy: The Czech experience**

O. Majek, Brno (CZ)

**11:50 - 12:00**

### **What role for the EAU Evidence Hub?**

P. Cornford, Liverpool (GB)

**12:00 - 12:10**

### **Joining the dots from diagnosis to treatment: Update from EU initiatives on comprehensive cancer centres**

T. Albreht, Ljubljana (SI)

**12:10 - 12:15**

### **Session take home messages**

P. Albers, Düsseldorf (DE)

H. Van Poppel, Leuven (BE)

# Living with the burden of OAB

Patient Office - Round table

**Saturday 6 April**

**10:45 - 11:45**

**Location** Purple Area, E01

## **Learning objectives**

Managing patient expectations: OAB patients are often times unaware of the risk of the condition becoming chronic due to the fact that they do not complete their drug regimen. Managing a patient's expectations may help with adherence to drug treatment; resulting in better outcomes and reducing the burden on the healthcare system(s).

**10:45 - 10:50**

## **Introduction**

*Moderator* D. Elterman, Toronto (CA)

**10:50 - 11:05**

## **Case story: from early symptoms to diagnosis to treatment to living with**

M. Daly, Athlone (IE)

**11:05 - 11:15**

## **OAB diagnosis? What does this mean for the patient and family?**

M.L. Van Poelgeest-Pomfret, Oegstgeest (NL)

**11:15 - 11:25**

## **Empowering patients to manage their wee wee woes**

E. Wallace, Dublin (IE)

**11:25 - 11:35**

## **Impact of OAB on mental health**

D. Elterman, Toronto (CA)

**11:35 - 11:45**

## **Q&A and closing**

*Moderator* D. Elterman, Toronto (CA)

# Hands-on Training in Laparoscopic urological skills - Step 1

HOT 2.09

Saturday 6 April

11:00 - 11:55

**Location** Orange Area, HOT 1

**Tutors** F. Greco, Bergamo (IT)  
T.M. Ribeiro De Oliveira, Lisbon (PT)

## Learning objectives

This basic laparoscopic training course is the first step in the Laparoscopic Urological Skills (LUS) curriculum. It designed to provide urologists with a fundamental understanding of laparoscopy and enhance their laparoscopic skills. This comprehensive training is specifically tailored for urologists who want to gain a basic level of knowledge in laparoscopy and wish to improve their proficiency in key laparoscopic techniques. The course comprises four essential exercises aimed at honing skills related to depth perception and bimanual dexterity: Peg Transfer, Circle Cut, Needle Guidance, and Knot Tying.

The primary objective of this course is to enhance participants' laparoscopic skills, focusing on key aspects such as depth perception and bimanual dexterity. By the end of the course, attendees should feel more confident and competent in their basic laparoscopic skills.

# Hands-on Training in Endoscopic stone treatment - Step 1

HOT 2.10

**Saturday 6 April**

**11:00 - 11:55**

**Location** Orange Area, HOT 1

**Tutors**

- B. Ballesta Martinez, Alicante (ES)
- O.R. Durutovic, Belgrade (RS)
- N. Macchione, Milan (IT)
- A. Tsaturyan, Yerevan (AM)

## **Learning objectives**

This Basic Endoscopic Stone Treatment course is the first step in the Endoscopic Stone Treatment (EST) curriculum. It is designed to provide urologists with a fundamental understanding of endoscopic stone treatment and enhance their skills. This comprehensive training is specifically tailored for urologists who want to gain a basic level of knowledge in endoscopy and wish to improve their proficiency in key techniques for endoscopic stone management. The curriculum includes four key exercises that provide hands-on experience and practical training: Flexible Cystoscopy, Rigid Cystoscopy, Semi-Rigid Ureteroscopy, and Flexible Ureteroscopy.

The primary objective of this programme is to enhance participants' skills in the treatment of urinary stones with endoscopic techniques. By the end of the course, attendees should feel more confident and competent in their basic skills.

# Hands-on Training in Transurethral treatment - Step 1 & 2 (TURBT/TURP)

HOT 2.11

**Saturday 6 April**

**11:00 - 11:55**

**Location** Orange Area, HOT 1

**Tutors** P. Mariappan, Edinburgh (GB)  
A. Sousa Castro, Lisboa (PT)

## **Learning objectives**

This training course combines the first and second step of the Transurethral Treatment (TUT) curriculum. It is designed for urologists who wish to improve their proficiency in key techniques and gain a fundamental understanding of transurethral resection of the bladder and prostate. This comprehensive training covers crucial basic skills including flexible and rigid cystoscopy, resection loop handling, and direct vision internal urethrotomy, as well as the resection procedure, practiced on state-of-the-art models.

The primary objective of this course is to enhance participants' skills in transurethral resection of the prostate and bladder, focusing on key aspects such as depth perception, hand-eye coordination, control, handling, and overall technique. By the end of the course, attendees should feel more competent and confident in performing this procedure.



# Hands-on Training in Transurethral treatment - Step 3 (ThuLEP)

HOT 2.12

**Saturday 6 April**

**11:00 - 11:55**

**Location** Orange Area, HOT 2

**Tutors** L.B. Dragoş, Cambridge (GB)

B.M. Schoensee, Berlin (DE)

## **Learning objectives**

This advanced training course is the third step in the Transurethral Treatment (TUT) curriculum. It is designed to provide urologists with a fundamental understanding of thulium laser enucleation of the prostate (ThuLEP). This comprehensive training is specifically tailored for urologists who want to become proficient in ThuLEP. Using a step by step approach, experts will lead participants through the procedure on state of the art models, to build a familiarity of the process, confidence handling the equipment, and an understanding of best practice.

## **Training aim**

The primary objective of this course is to enhance participants' skills in ThuLEP, focusing on key aspects such as control, handling, and overall technique. By the end of the course, attendees should feel more competent and confident in performing this procedure.

# Hands-on Training in Sacral Neuromodulation (SNM)

HOT 2.27

Saturday 6 April

11:15 - 12:45

**Location** Orange Area, HOT 4

**Chair** V. Phé, Paris (FR)

## Learning objectives

This Hands-on Training is designed to equip participants with the fundamental skills to perform sacral neuromodulation (SNM) procedures effectively. Participants will have the opportunity to practice each step of the SNM procedure, including primary percutaneous nerve evaluation, tined lead and battery implantation, programming, and troubleshooting.

## Training aim

The primary objective of this course is to enhance participants' skills in sacral neuromodulation, focusing on key aspects of the procedure. By the end of the course, attendees should feel more confident and competent in SNM procedures.

- Hands-on Training.
- Operating area setup and organization.
- The management of equipment
- Standardized technical approach of a urological procedure.
- Management of critical details related to an urological procedure.

11:15 - 12:45

## Introduction

11:15 - 12:45

## Percutaneous Nerve Evaluation Station 1

*Tutor* G. Sampogna, Milan (IT)

11:15 - 12:45

## Percutaneous Nerve Evaluation Station 2

*Tutor* C. Ochoa Vargas, Bristol (GB)

11:15 - 12:45

## Percutaneous Nerve Evaluation Station 3

*Tutor* M.A. Perrouin Verbe, Nantes (FR)

11:15 - 12:45

## Advanced Station 1

*Tutor* M.G. Çulha, Istanbul (TR)

11:15 - 12:45

## Advanced Station 2

*Tutor* A. Kaufmann, Nottwil (CH)

11:15 - 12:45

## Advanced Station 3

*Tutor* J-N.L. Cornu, Rouen (FR)

11:15 - 12:45

## Programming Station

*Tutor* L. Thomas, Bristol (GB)

# BPO surgery: Ablative surgical options

Abstract session 10

**Saturday 6 April**  
**12:00 - 13:30**

**Location** Purple Area, S01

**Chairs** S. Madersbacher, Vienna (AT)  
J. Romero-Otero, Madrid (ES)  
To be confirmed

We encourage participants in this session to view the abstracts before the session. All abstract bodies, posters, videos and webcasts can be viewed on the EAU(N)24 Resource Centre or at the digital screens in front of the Purple Area, EGPT.

- 
- A0172** **Benign prostatic hyperplasia surgery: A contemporary ten-year analysis of usage trends and costs from a large US database**  
C. Manfredi, Naples (IT)
- 
- A0165** **Changing trends in the surgical management of BPO in Europe**  
L. Bruno, Düsseldorf (DE)
- 
- A0163** **The impact of the surgical waiting list for transurethral resection of the prostate on patient's clinical course: a single center investigation**  
L. Boeri, Milan (IT)
- 
- A0160** **Holmium Laser Enucleation of the Prostate (HoLEP) for very large benign prostatic hyperplasia (>200 ml): long term outcome of a large series.**  
M. Tallè, Ancona (IT)
- 
- A0170** **Day-case HOLEP : succes rate and predictive factor of D0 discharge after 10 years of clinical experience**  
X. Lacroix, Bordeaux (FR)
- 
- A0168** **Impact of Laser energy and rate of enucleated prostate tissue in the early functional outcomes of Holmium Laser Enucleation of Prostate (HOLEP).**  
S. Fernández-Pello Montes, Gijón (ES)
- 
- A0175** **Impact of total laser energy on functional outcome following Holmium Laser Enucleation of the prostate**  
T. Westhofen, Munich (DE)
- 
- A0174** **Moses 2.0 Technology for holmium laser enucleation of the prostate in the treatment of BPH: Prospective randomized double-blind study**  
T. Tricard, Strasbourg (FR)
- 
- A0162** **Analysis of the morcellation efficiency after HoLEP of the Multicut® device: the new standard of care?**  
B. García Gómez, Madrid (ES)
- 
- A0171** **Thulium Fiber Laser vs Thulium:YAG en-block laser enucleation of the prostate. A comparison of perioperative outcomes**  
A. Pacchetti, Como (IT)

A0169	<p><b>Thulium Laser energy versus Bipolar current in transurethral enucleation of large prostates; a multicenter prospective randomized study</b></p> <p>M.S. Eladawy, Giza (EG)</p>
A0176	<p><b>Real-world complications of anatomical endoscopic enucleation of the prostate: Lessons from the 6193 patients from the Refinement in Endoscopic Anatomical enucleation of Prostate (REAP) registry</b></p> <p>E.J. Lim, Singapore (SG)</p>
A0173	<p><b>Endoscopic enucleation of large prostates &gt; 80 cc in men aged 80 years and older. Double trouble? Outcomes from a global multicentre experience using different energy sources and techniques.</b></p> <p>V. Gauhar, Singapore (SG)</p>
A0166	<p><b>Risk of Acute Urinary Retention After-HoLEP – Results from a Prospective Trial</b></p> <p>P. Capogrosso, Varese (IT)</p>
A0164	<p><b>Aquablation at 4-years: the largest, real world, single-center study and longest follow-up data for this innovative BPH treatment</b></p> <p>S.A. Kaplan, New York (US)</p>
A0159	<p><b>Waterjet ablation therapy (aquabeam) vs. urethral-sparing robot-assisted simple prostatectomy for large prostate volumes (&gt;80 mL): results of a multicentric series according to the standardized BPH-6 achievement</b></p> <p>U. Anceschi, Rome (IT)</p>
A0167	<p><b>Water vs. Water II 5-year update: comparing aquablation therapy for benign prostatic hyperplasia in 30-80 cc and 80-150 cc prostates</b></p> <p>M.B. Berjaoui, Toronto (CA)</p>
A0161	<p><b>Robot-Assisted Simple Prostatectomy versus Holmium Laser Enucleation for the Treatment of Benign Prostatic Hyperplasia in Large (&gt;100 ml) Prostates: Updated Comparative Analysis from a High-Volume Center</b></p> <p>A. Mottaran, Bologna (IT)</p>

**Saturday 6 April**  
**12:00 - 13:30**

**Location** Purple Area, E01

**Chairs** L. Bukavina, Philadelphia (US)  
K-F. Kowalewski, Mannheim (DE)  
R. Pereira Mestre, Bellinzona (CH)

We encourage participants in this session to view the abstracts before the session. All abstract bodies, posters, videos and webcasts can be viewed on the EAU(N)24 Resource Centre or at the digital screens in front of the Purple Area, EGPT.

**12:00 - 12:30**

**E-health**

A0183

**Digital remote monitoring and machine learning (ML) modeling to predict survival following radical cystectomy for bladder cancer – a secondary outcome analysis of the iROC trial**

P. Khetrapal, London (GB)

**Study Group**

iROC Study Team(London, United Kingdom)

A0178

**Electronic Patient Reported Outcome Measures (ePROM) collected via smartphone text messages**

L. Munk, Aarhus (DK)

A0189

**Opportunities of home uroflowmetry enabled by digital health technologies.**

E. Van Beeck Morales, Edegem (BE)

A0177

**Challenges in E-health: the effect of digitalisation of frequency voiding charts on compliance in paediatric patients. Randomised controlled trial comparing digital and paper frequency voiding charts.**

E.H.M. van de Wetering, Nijmegen (NL)

A0186

**Use of a Novel Smartphone App for Audio Recording Consultations of Patients Seeking Genital Gender-Affirming Surgery: An Opportunity for Broader Application Throughout Urology**

M. Garcia, San Francisco (US)

**12:30 - 13:00**

**Large language models 1: Harnessing ChatGPT for enhanced clinical expertise**

A0181

**Evaluating the efficacy of ChatGPT in answering e-consults from general practitioners to urologists: A pilot study**

M. Kommers, Amsterdam (NL)

A0179

**Performance of ChatGPT on the Fellow of the European Board of Urology (FEBU) Exams: A Comparative Analysis**

J. Schoch, Koblenz (DE)

A0180

**RARPKB: A Knowledge-guide Decision Support Platform for Personalized Robot-Assisted Surgery in Prostate Cancer**

J. Li, Chengdu (CN)

A0187

**Automated Operative Reports for Robotic Radical Prostatectomy using Artificial Intelligence**

A. Khanna, Rochester (US)

A0184

**Large Language Models: The New AI-Powered Kidney Stone Experts? Comparative Study of Chat GPT 3.5, Chat GPT 4, Bard, and Bing AI**

R. Kalbit, Marikina (PH)

---

13:00 - 13:30

**Large language models 2: Enhancing the quality of patient-centered communication**

A0190

**Evaluation of the effectiveness of Smart Consent® in improving understanding of informed consent. Initial experience.**

N. Herrera Aranda, Vitoria-Gasteiz (ES)

A0188

**Artificial Intelligence in Advancing Prostate Cancer Patient Care**

S.N. Ali, California (US)

A0185

**Characterizing the impact of novel patient-centered pathology reports: A randomized controlled trial of patients undergoing prostate biopsy**

R. Kumar, Toronto (CA)

A0191

**Effectiveness of the medical chatbot PROSCA to inform patients about prostate cancer: Results of a randomized controlled trial**

M. Görtz, Heidelberg (DE)

A0192

**Evaluating the effectiveness of ChatGPT in disseminating accurate and readable prostate cancer information**

L. Storino Ramacciotti, Pasadena (US)

A0193

**Exploring the Efficiency of Generative Artificial Intelligence in Rapidly and Accurately Producing Patient Information for Urological Malignancy Treatments Aligned with the Latest EAU Guidelines**

S. Rodler, Munich (DE)

# Urology & beyond: Inclusivity and healthy work environment

Abstract session 52

**Saturday 6 April**  
**12:00 - 13:30**

**Location** Purple Area, E02

**Chairs** J. Baard, Amsterdam (NL)  
H.E. O'Connell, Melbourne (AU)  
I. Rivero Belenchón, Seville (ES)

We encourage participants in this session to view the abstracts before the session. All abstract bodies, posters, videos and webcasts can be viewed on the EAU(N)24 Resource Centre or at the digital screens in front of the Purple Area, EGPT.

**12:00 - 12:02**

**Introduction**

- 
- A0196** **Train the Trainers for the delivery of proficiency based progression training by the European Robotic Surgical Section Fellowship Centers**  
N. Frego, Melle (BE)
- 
- A0203** **Trends of European School of Urology (ESU) Training and Resident Education: An overview of 2 decades of EAU Education Programme**  
B. Somani, Southampton (GB)
- 
- A0210** **Emergency Urology Crash Course: Teaching Frontline Non-Urologists Pays Back**  
E. Desouky, Chicago (US)
- 
- A0208** **The Learning Styles of Graduating Canadian Urology Residents**  
N. Touma, Kingston (CA)
- 
- A0204** **No Pressure: The Impact of Theatre Staff Education on Lithotomy Positioning**  
J. Xu, Melbourne (AU)
- 
- A0200** **External validation of the Sexual Minorities and Prostate Cancer Scale (SMACS) in a sexual majority and minority population following robotic prostatectomy (RARP): NCT05772598**  
F.E.N. MacAskill, London (GB)
- 
- A0199** **Adverse Childhood Experiences and Prostate Cancer Screening**  
M. Nguy, Sacramento (US)
- 
- A0206** **Clinical impact of Social Determinants of Health (SDOH): Analysis of major uro-oncology surgical procedures using large national dataset**  
A. Franco, Rome (IT)
- 
- A0211** **Care associated adverse events related to the use of laser in urological interventions: The French experience**  
M. Abdessater, Pontoise (FR)
- 
- A0209** **Forgotten Antegrade Ureteric Stent: What can we do? – Inter-departmental safety net**  
E. Desouky, Chicago (US)

---

A0198	<b>The practice of reflection by urologists on surgical mortality and the lessons learnt</b> S. Qin, Heidelberg (AU)
A0207	<b>Trial of a Self-TWOC pathway to reduce carbon footprint</b> H. Loudon, Bristol (GB)
A0195	<b>The Carbon Footprint of Reusable Versus Single Use Flexible Cystoscopes</b> S. McDonald, Murdoch (AU)
A0197	<b>Parenthood among French urologists</b> N. Stivalet Schoentgen, Paris (FR)
A0202	<b>Family planning, pregnancy and parenthood during surgical training: experiences and perspectives from trainees and early career surgeons in Australia and New Zealand</b> J. Xu, Melbourne (AU)
A0201	<b>Clinical hypnosis in urology: preliminary experience in the daily practice</b> E. Vercelli, Turin (IT)
<b>13:27 - 13:30</b>	<b>Expert summary</b>

---



# Adrenal tumour and trauma

Abstract session 53

**Saturday 6 April**  
**12:00 - 13:30**

**Location** Purple Area, E03

**Chairs** V. Gomez Dos Santos, Madrid (ES)  
S.J. Hosseini, Tehran (IR)  
A. Mattei, Luzern (CH)

We encourage participants in this session to view the abstracts before the session. All abstract bodies, posters, videos and webcasts can be viewed on the EAU(N)24 Resource Centre or at the digital screens in front of the Purple Area, EGPT.

**12:00 - 12:50**

## **Adrenal tumour**

A0214

### **BRAF V600E mutation promoted excess of cortisol secretion in adrenal cortical adenoma**

K. Numakura, Akita (JP)

A0225

### **Is size of an adrenal mass enough to indicate surgical examination?**

C. García Fuentes, Alcorcón (ES)

A0212

### **Intratumor bacteria is associated with prognosis in adrenocortical carcinoma**

C. Feng, Shanghai (CN)

A0217

### **The European Network for the Study of Adrenal Tumors staging system (2015): a North American validation**

L.M.I. Jannello, Milan (IT)

A0219

### **Minimally invasive adrenalectomy: Trends and outcomes analysis from a large population-based database**

F. Ditonno, Verona (IT)

A0221

### **Is Partial Adrenalectomy a Viable Option in Treating Unilateral Primary Aldosteronism?**

T.N. Lee, Taipei (TW)

#### **Study Group**

TAIPAI Study Group(Taipei City, Taiwan)

A0220

### **Prognostic significance of lymph node count in surgically treated patients with T2-4 stage non-metastatic adrenocortical carcinoma**

A. Assad, Montreal (CA)

A0222

### **Factors regarding metastasis risk of pheochromocytoma and paraganglioma**

T.T.C. Wei, Taipei City (TW)

A0218

### **Influence of surgical technique on hemodynamic instability during minimally invasive surgery for pheochromocytoma**

A.H. Chaman Baz, Nijmegen (NL)

A0228

### **Prognostic predictors of hypertension outcomes after adrenalectomy in primary aldosteronism**

H. Fukushima, Nagasaki (JP)

**12:50 - 13:30**

## **Trauma**

A0215

**The seasonality of penile fractures: Results from the GRAND study**

N. Pyrgidis, München (DE)

A0216

**Ureteral injuries in cytoreductive and hyperthermic intraperitoneal chemotherapy surgery: An analysis of incidence and risk factors**

M. Alonso Grandes, Fuenlabrada (ES)

A0223

**Intermittent catheters with integrated amphiphilic surfactant associated with less urethral microtrauma in ex vivo model**

L. Barbieri, Deeside (GB)

A0224

**An integrated guidewire Urethral Catheterisation Device (UCD®) for Difficult Urethral Catheterisation in the Emergency department**

A. Combes, Sydney (AU)

A0226

**Acute imaging practices after pediatric renal trauma: the Multi-Institutional Pediatric Acute Renal Trauma Study (Mi-PARTS) experience**

P. Neuville, Lyon (FR)

**Study Group**

Mi-PARTS Study Group(Multi-Institutional, United States of America)

A0229

**Renal preservation in patients undergoing surgical exploration for grade IV renal trauma.**

C. Fragkoulis, Athens (GR)

A0227

**EmERgency UrEteric InJury Management: A Year LOng NatIoNal Audit (BAUS REJOIN AUDIT)**

F.E.N. MacAskill, London (GB)

**Study Group**

BAUS Section of FNUU(London, United Kingdom)

A0213

**When Urologists go to war – Workload of German Urological Surgeons in a deployed U.S. Facility in Afghanistan**

J. Schoch, Koblenz (DE)

# Chronic pelvic pain & male stress incontinence

Abstract session 54

**Saturday 6 April**  
**12:00 - 13:30**

**Location** Purple Area, E04

**Chairs** M. Gacci, Florence (IT)  
W.A. Hübner, Korneuburg (AT)  
H-C. Kuo, Hualien (TW)

We encourage participants in this session to view the abstracts before the session. All abstract bodies, posters, videos and webcasts can be viewed on the EAU(N)24 Resource Centre or at the digital screens in front of the Purple Area, EGPT.

**12:00 - 12:25**

## **Chronic pelvic pain: basic research & epidemiology**

A0235

### **Metagenomic Sequencing of the Urinary Microbiome of Postmenopausal Women with Recurrent Urinary Tract Infection and Type 2 Diabetes**

P.E. Zimmern, Dallas (US)

A0233

### **Controlled release of microorganisms from engineered living materials for the treatment of urinary tract infections**

M. Sivaperuman Kalairaj, College Station (US)

A0239

### **Intradetrusor plasmid VEGF165-gene therapy in comparison with botulinum toxin type A in rats with cyclophosphamide-induced cystitis.**

B. Grigoryan, Moscow (RU)

A0234

### **The potential role of macrophage polarization in the progression of Hunner type interstitial cystitis**

S. Lee, Changwon (KR)

A0243

### **Chronic prostatitis enhances the incidence of the subsequent benign prostatic hyperplasia: A population-based cohort study**

Y-C. Huang, Tainan (TW)

**12:25 - 12:50**

## **Chronic pelvic pain: clinic**

A0236

### **Clinical significance of interstitial cystitis/bladder pain syndrome with metabotropic glutamate receptor**

J. Park, Seoul (KR)

A0245

### **Brimapitide (BRM), potential novel treatment for bladder pain syndrome (BPS/IC), is safe and well tolerated. Report from a phase 1/2a study**

J. Heesakkers, Maastricht (NL)

A0244

### **Classification of non-Hunner's interstitial cystitis by maximal bladder capacity and grade of glomerulation – association with urinary inflammatory biomarker levels and implication of treatment outcome**

Y-H. Jiang, Hualien (TW)

A0237

### **Efficacy and Safety of Intravesical Interferon Instillation for Women with Refractory Bladder Pain Syndrome/Interstitial Cystitis: A Prospective Study**

S.H. Shen, Chengdu (CN)

**12:50 - 13:30**

## **Male stress incontinence**

A0242

**Early continence recovery after robot-assisted radical prostatectomy: a multicenter analysis on the role of prostatic shape**

M. Carilli, Roma (IT)

A0240

**Unveiling the Long-term Survival Outcomes of Artificial Urinary Sphincter: A Twelve-Year Study from the French National Health Insurance Database**

L. Lenfant, Paris (FR)

A0231

**Artificial urinary sphincter (AUS) Implantation with Transcorporal versus Standard technique: an international multicenter retrospective study on high-risk patients**

A. Fraile Poblador, Madrid (ES)

A0246

**Artificial urinary sphincter with or without prior male slings in patients with post-prostatectomy incontinence: 15-year experience from a referral center**

P-M. Chow, Taipei (TW)

A0230

**Effect of action and feedback observation training (AFOT) in the achievement of urinary continence in men after robot-assisted laparoscopic prostatectomy (RALP): a randomized controlled trial**

F. Russo, Pieve Emanuele MI (IT)

A0247

**The new artificial urinary sphincter UroActive™: results of the first in man study at 3 months post-activation (SOPHIA study)**

E. Chartier-Kastler, Paris (FR)

A0232

**Third implantation of artificial urinary sphincter in male patients with two previous explantations : is it doomed to failure?**

F. Meyer, PARIS (FR)

A0238

**SATURN 1 year follow-up: European prospective multicentre registry for surgical procedures in males with stress urinary incontinence.**

F. Martens, Nijmegen (NL)

**Study Group**

SATURN study group(Arnhem, The Netherlands)

# Combatting urological infections: Advances in treatment and prophylaxis strategies

Abstract session 55

**Saturday 6 April**  
**12:00 - 13:30**

**Location** Purple Area, E05

**Chairs** G. Bonkat, Basel (CH)  
J. Kranz, Aachen (DE)  
To be confirmed

We encourage participants in this session to view the abstracts before the session. All abstract bodies, posters, videos and webcasts can be viewed on the EAU(N)24 Resource Centre or at the digital screens in front of the Purple Area, EGPT.

- 
- A0254** **Assessing the long-term efficacy and safety of MV140 sublingual bacterial vaccine in the initial cohort: A 9-year study in the UK for treating recurrent urinary tract infections in men and women**  
S. Kanabar, Reading (GB)
- 
- A0257** **Comparison of the clinical efficacy of guideline-based and culture-based antibiotic therapy for chronic bacterial prostatitis**  
K. Naber, Straubing (DE)
- 
- A0256** **Computer-assisted optimisation of perioperative antibiotic prophylaxis in urologic surgery**  
L. Haeuser, Bordeaux (FR)
- 
- A0258** **Prediction of Antibiotic Prescription for Acute Uncomplicated Cystitis: Insights from Two Randomized Clinical Trials**  
J.F. Alidjanov, Giessen (DE)
- 
- A0255** **Antibiotic therapy for pre-operative positive urine culture: how can we improve our practice?**  
T. Garnier, (FR)
- 
- A0263** **Efficacy and safety of cefepime/enmetazobactam as compared to frequently used antibiotics in patients with complicated urinary tract infections including acute pyelonephritis: A Bayesian network meta analysis**  
F.M.E. Wagenlehner, Giessen (DE)
- 
- A0264** **Elevating quality of life: Autovaccination strategies for reducing hospitalizations and emergency visits in neurogenic bladder patients**  
J.B. Ortiz Salvador, Valencia (ES)
- 
- A0260** **Ureterostomy vs ileal conduit : comparative study of Urinary tract infections (UTIs) after external urinary diversion for radical cystectomy.**  
M.A. Bedoui, Soukra (TN)
- 
- A0253** **Predictors of Additional Intervention in Prostate Abscess: A Multicenter Study and Prostate Abscess Complexity Score Proposal**  
R. Pallares-Mendez, Rome (IT)

A0252

**The Outcomes of Three Different Techniques of Prostatic Abscess Drainage: A Retrospective Single Center Experience.**

A. Zoair, TANTA (EG)

---

A0261

**Predicting the risk factors for severity and long-term ICU stay in patients with emphysematous pyelonephritis: a five-year experience from a tertiary center**

A. Kumar Pal, Kolkata (IN)

---

A0249

**Treatment outcome of intravesical platelet rich plasma injections in patients with interstitial cystitis/bladder pain syndrome of different clinical phenotype**

W-R. Yu, Hualien (TW)

---

A0250

**Intravesical instillation of epidermal growth factor could ameliorate urothelial inflammation and down-regulate oxidative stress in rats with LPS-induced interstitial cystitis**

C.H. Yang, Taipei (TW)

---

A0259

**Intravesical Gentamicin: Is it the new Gold Standard to manage Refractory Urinary Tract infections? – Experience from a dedicated complex UTI clinic**

P. Chitteti, Middlesborough (GB)

---

A0248

**Bladder-pain predominance is associated with satisfactory outcome to intravesical botulinum toxin A injection for patients with interstitial cystitis/bladder pain syndrome**

W-R. Yu, Hualien (TW)

# Basic research and trials: Renal tumours

Abstract session 56

**Saturday 6 April**  
**12:00 - 13:30**

**Location** Purple Area, E06

**Chairs** K. Junker, Homburg (DE)  
G. Lucarelli, Bari (IT)  
Y. Tomita, Niigata (JP)

We encourage participants in this session to view the abstracts before the session. All abstract bodies, posters, videos and webcasts can be viewed on the EAU(N)24 Resource Centre or at the digital screens in front of the Purple Area, EGPT.

**12:00 - 12:02**

**Introduction**

- 
- A0276** **Establishment of intratumor bacteria as biomarkers in renal clear cell carcinoma**  
C. Feng, Shanghai (CN)
- 
- A0278** **Molecular correlates of clinical response to combination immunotherapy in advanced fumarate hydratase deficient renal cell carcinoma**  
Y. Xu, Shanghai (CN)
- 
- A0279** **Commensal Lachnospiraceae bacterium-derived Propionate Inhibites Tumorigenesis in Clear cell renal cell carcinoma**  
W. Zhai, shanghai (CN)
- 
- A0280** **A preliminary study on the prognostic effects of aging microenvironment on clear cell renal cell cancer based on transcriptomic data analysis**  
J. Zou, Ganzhou (CN)
- 
- A0281** **A randomized controlled trial assessing the release of circulating tumor and mesenchymal cells in no-touch radical nephrectomy**  
T.M. Palmela Leitão, Lisbon (PT)
- 
- A0269** **FOXM1D interacts with HCFC1 to regulate YY1-mediated transcription of immune checkpoint molecules in renal cancer**  
Y. Wang, Shanghai (CN)
- 
- A0267** **Clinical and biohumoral markers of AKI predictive of mid-term renal function after kidney surgery**  
R. La Mura, Perugia (IT)
- 
- A0270** **A potential tumor-marker from urinary microbiota – focusing on renal cell carcinoma**  
S. Kajioka, Fukuoka (JP)
- 
- A0274** **ARPP19 a key lactylation-related gene, associated with prognosis and immunogenicity of clear cell renal cell carcinoma**  
N. Song, Nanjing (CN)

A0275	<b>Impact of heavy metals, trace elements, and oxidative stress in the pathogenesis of renal cell carcinoma</b> K. Arulraj, New Delhi (IN)
A0268	<b>Construction of Cuproptosis Signature based on bioinformatics and experimental validation in Clear Cell Renal Cell Carcinoma</b> X. Tian, Shanghai (CN)
A0271	<b>Enhancing immunotherapy in renal cell carcinoma by engineering cytotoxic T lymphocytes with chimeric costimulatory switch proteins</b> J. Linxweiler, Homburg/saar (DE)
A0277	<b>Untargeted Metabolomics Study of Plasma and Tissue in Renal Cell Carcinoma Patients with Von Hippel-Lindau Syndrome</b> Z. Zhang, Beijing (CN)
A0272	<b>Evaluation of genetic mutations in clear cell renal cell carcinoma with tumor necrosis</b> L. Davis, Cleveland (US)
A0266	<b>Protein Arginine Methyltransferases Refine the Classification of Clear Cell Renal Cell Carcinoma with Distinct Prognosis and Tumor Microenvironment Characteristics</b> Y. Shiqi, Shanghai (CN)
A0265	<b>Multi-omics profiling demonstrates dynamic changes of cancer-associated fibroblasts and their derived extracellular vesicles during prostate cancer progression</b> C. Hu, Shanghai (CN)
<b>13:27 - 13:30</b>	<b>Expert summary</b>  <i>Speaker</i> K. Junker, Homburg (DE)



# Pathology at biopsy: Grade group assignment, risk prediction

Abstract session 57

**Saturday 6 April**  
**12:00 - 13:30**

**Location** Purple Area, E07

**Chairs** J.P. Radtke, Düsseldorf (DE)  
R.C.N. Van Den Bergh, Utrecht (NL)  
D.T.S. Woon, (AU)

We encourage participants in this session to view the abstracts before the session. All abstract bodies, posters, videos and webcasts can be viewed on the EAU(N)24 Resource Centre or at the digital screens in front of the Purple Area, EGPT.

**12:00 - 12:02**

**Introduction**

**12:02 - 12:22**

**Cribriform and Intraductal subtypes**

A0286

**Undetected Cribriform and Intraductal Prostate Cancer in Grade Group 2 False Negative Biopsies and Their Impact on Post-Prostatectomy Pathological Results**  
R.M. Marques Bernardino, TORONTO (CA)

A0290

**The presence of intraductal carcinoma of prostate is a risk factor for poor pathologic response in men with high-risk prostate cancer receiving neoadjuvant therapy**  
W. Binyu, Nanjing (CN)

A0284

**Is prostate biopsy a reliable method for detecting cribriform and intraductal carcinoma?**  
R.M. Marques Bernardino, TORONTO (CA)

A0292

**The Clinical Trajectory of Patients Afflicted by Rare Histological Variants of Prostate Carcinoma**  
N. Artamonova, Innsbruck (AT)

**12:22 - 12:47**

**Risk prognosis**

A0283

**Comparison of the utility of worst vs. global Gleason grade group in MRI-US fusion biopsy for predicting postprostatectomy biochemical recurrence**  
M. Kobayashi, Tokyo (JP)

A0288

**Quantification of perineural cancer invasion on systematic needle core biopsy of the prostate is useful for risk stratification in patients with Grade Group 2 or 3 cancer, but not in those with Grade Group 4-5 cancer**  
H. Miyamoto, Rochester (US)

A0291

**The Highest Grade Group Does Not Drive the Risk of Advanced Stage when Systematic and Multiparametric Magnetic Resonance Imaging (MRI)-targeted Biopsies are Discordant: Results from a Large Multi-Institutional Series**  
S.L.A. Scuderi, Milan (IT)

A0285

**Risk estimation of metastatic recurrence after prostatectomy : new preoperative risk stratification tools including cancer location and size at MRI, targeted biopsy and percent of grade 4/5.**  
J. Olivier, Lille (FR)

A0298	<b>Peritumoral inflammation in prostate biopsy core predict Biochemical recurrence after active treatment for prostate cancer.</b> F. Guzzi, (IT)
<b>12:47 - 13:27</b>	<b>Pathologic examination</b>
A0282	<b>An assessment of WHO Group 1 Prostate Cancer in Irish Hospitals, an analysis of 6816 newly diagnosed prostate cancer cases using the IPCOR database.</b> D.J. Galvin, Dublin 4 (IE)
A0297	<b>Interim Analysis of the FAST – Study Frozen section Analysis assisted MRI-Targeted Biopsy for Prostate Cancer Diagnosis – a Prospective, Randomized Study</b> M. Jahnen, Munich (DE)
A0293	<b>A “green biopsy” expedited prostate cancer diagnostic pathway: Carbon footprint assessment and clinical outcomes</b> L. Storino Ramacciotti, Pasadena (US)
A0289	<b>Defining Prostate Cancer with High Gleason Score by Prostate fluid Metabolic Fingerprint Based Multi-Modal Recognition</b> Z. Peng, shanghai (CN)
A0296	<b>Upgrading risk in prostate cancer after combined prostate biopsy according to the site of positive cores: results in 658 patients treated with robot-assisted radical prostatectomy in tertiary referral centers</b> C. Collà Ruvolo, Napoli (IT)
A0287	<b>Optimizing Detection and Prediction of Prostate Cancer After Positive MRI and Negative Biopsies.</b> F. Zattoni, Verona (IT)
A0294	<b>Predicting pathological tumor and prostate volume in prostate cancer patients based on micro-ultrasound and MRI findings</b> A. Rakauskas, Lausanne (CH)
A0295	<b>Pathological features of prostatic false-positive lesions on 68Ga-PSMA-11 PET/CT</b> R. Li, Nanjing (CN)
<b>13:27 - 13:30</b>	<b>Expert summary</b>

**Saturday 6 April**  
**12:00 - 13:30**

**Location** Green Area, S04

**Chairs** V. Jahrreiss, Vienna (AT)  
W. Krajewski, Wrocław (PL)

We encourage participants in this session to view the abstracts before the session. All abstract bodies, posters, videos and webcasts can be viewed on the EAU(N)24 Resource Centre or at the digital screens in front of the Purple Area, EGPT.

V033 (□ 6 min.)

**Ureterorenoscopic Thulium Laser Lithotripsy in the Treatment of Staghorn Calculi (TUNNEL's Technique)**

M. Nouri, Oujda (MA)

V034 (□ 8 min.)

**Laser for Stones Thulium is The Best?**

A.G. Martov, Moscow (RU)

V035 (□ 7 min.)

**Bilateral mini-percutaneous nephrolitotomy in a single surgical time: Step-by-step guided surgery and results from the experience of a high volume center**

I. Sanz - Gómez, Barcelona (ES)

V036 (□ 6 min.)

**Step-by-Step guide to Flexible And Navigable suction ureteric access Sheath (FANS)**

D. Ragoori, hyderabad (IN)

V037 (□ 5 min.)

**Percutaneous cystolithotomy in an augmentation cystoplasty with Mitrofanoff**

L. Diéguez Aguirre, Barcelona (ES)

V038 (□ 7 min.)

**Robotic retrograde intrarenal surgery for urolithiasis**

A. Farré Alejo, Barcelona (ES)

V039 (□ 8 min.)

**The ILY Robotic Flexible Ureteroscopy: A comprehensive operative guide and demonstration**

A. El Hajj, Beirut (LB)

V040 (□ 5 min.)

**Robot-assisted flexible reno-ureteroscopy with the ILY® robot: First italian clinical experience**

A. Quarà, Baldissero Torinese (IT)

# Hands-on Training in Laparoscopic urological skills - Step 1

HOT 2.13

**Saturday 6 April**

**12:00 - 12:55**

**Location** Orange Area, HOT 1

**Tutors** G. Bozzini, Como (IT)  
F. Greco, Bergamo (IT)

## **Learning objectives**

This basic laparoscopic training course is the first step in the Laparoscopic Urological Skills (LUS) curriculum. It designed to provide urologists with a fundamental understanding of laparoscopy and enhance their laparoscopic skills. This comprehensive training is specifically tailored for urologists who want to gain a basic level of knowledge in laparoscopy and wish to improve their proficiency in key laparoscopic techniques. The course comprises four essential exercises aimed at honing skills related to depth perception and bimanual dexterity: Peg Transfer, Circle Cut, Needle Guidance, and Knot Tying.

The primary objective of this course is to enhance participants' laparoscopic skills, focusing on key aspects such as depth perception and bimanual dexterity. By the end of the course, attendees should feel more confident and competent in their basic laparoscopic skills.

# Hands-on Training in Endoscopic stone treatment - Step 1

HOT 2.14

**Saturday 6 April**

**12:00 - 12:55**

**Location** Orange Area, HOT 1

**Tutors** O.R. Durutovic, Belgrade (RS)  
F. Esperto, Rome (IT)  
S. Güven, Konya (TR)  
N. Macchione, Milan (IT)

## **Learning objectives**

This Basic Endoscopic Stone Treatment course is the first step in the Endoscopic Stone Treatment (EST) curriculum. It is designed to provide urologists with a fundamental understanding of endoscopic stone treatment and enhance their skills. This comprehensive training is specifically tailored for urologists who want to gain a basic level of knowledge in endoscopy and wish to improve their proficiency in key techniques for endoscopic stone management. The curriculum includes four key exercises that provide hands-on experience and practical training: Flexible Cystoscopy, Rigid Cystoscopy, Semi-Rigid Ureteroscopy, and Flexible Ureteroscopy.

The primary objective of this programme is to enhance participants' skills in the treatment of urinary stones with endoscopic techniques. By the end of the course, attendees should feel more confident and competent in their basic skills.

# Hands-on Training in Transurethral treatment - Step 1 & 2 (TURBT/TURP)

HOT 2.15

**Saturday 6 April**

**12:00 - 12:55**

**Location** Orange Area, HOT 1

**Tutors** R.N. Brito Ramos, Lisbon (PT)

D. Oliveira Reis, Lisboa (PT)

## **Learning objectives**

This training course combines the first and second step of the Transurethral Treatment (TUT) curriculum. It is designed for urologists who wish to improve their proficiency in key techniques and gain a fundamental understanding of transurethral resection of the bladder and prostate. This comprehensive training covers crucial basic skills including flexible and rigid cystoscopy, resection loop handling, and direct vision internal urethrotomy, as well as the resection procedure, practiced on state-of-the-art models.

The primary objective of this course is to enhance participants' skills in transurethral resection of the prostate and bladder, focusing on key aspects such as depth perception, hand-eye coordination, control, handling, and overall technique. By the end of the course, attendees should feel more competent and confident in performing this procedure.

# Hands-on Training in Transurethral treatment - Step 3 (ThuLEP)

HOT 2.16

**Saturday 6 April**

**12:00 - 12:55**

**Location**

Orange Area, HOT 2

**Tutors**

L.B. Dragoş, Cambridge (GB)

B.M. Schoensee, Berlin (DE)

**Learning objectives**

This advanced training course is the third step in the Transurethral Treatment (TUT) curriculum. It is designed to provide urologists with a fundamental understanding of thulium laser enucleation of the prostate (ThuLEP). This comprehensive training is specifically tailored for urologists who want to become proficient in ThuLEP. Using a step by step approach, experts will lead participants through the procedure on state of the art models, to build a familiarity of the process, confidence handling the equipment, and an understanding of best practice.

**Training aim**

The primary objective of this course is to enhance participants' skills in ThuLEP, focusing on key aspects such as control, handling, and overall technique. By the end of the course, attendees should feel more competent and confident in performing this procedure.

**Saturday 6 April**  
**12:15 - 13:45**

**Location** Green Area, N04

**Chairs** J. N'Dow, Aberdeen (GB)  
V. Sakalis, Thessaloniki (GR)

### **Learning objectives**

The objective of this session is to investigate the current state of data initiatives in urology, including registries, databases, and collaborative research efforts. The impact of the EAU UroEvidence Hub and real-world evidence on clinical decision-making, treatment guidelines, and patient outcomes will be discussed. Additionally, it will attempt to identify potential challenges and limitations of real-world evidence analysis and acknowledge the ethical and regulatory considerations involved in data collection and use.

**12:15 - 12:25**

### **EAU Data Initiatives: Foundations and looking to the future**

J. N'Dow, Aberdeen (GB)

**12:25 - 12:40**

### **EAU UroEvidenceHub: Building a platform for future RWE research**

P. Cornford, Liverpool (GB)

**12:40 - 12:50**

### **Patient engagement in EAU data initiatives: Why it is essential**

E. Briers, Hasselt (BE)

**12:50 - 13:05**

### **How real-world evidence can complement traditional evidence synthesis & guideline development**

P. Rijnbeek, Rotterdam (NL)

**13:05 - 13:15**

### **Real-world evidence analysis of the adverse events of systemic treatment in patients with mHSPC: Results of the 3rd PIONEER Studyathon**

P. Rajwa, Zabrze (PL)

**13:15 - 13:25**

### **Guidelines-based decision support tools & their impact on guidelines adherence**

M.J. Roobol, Rotterdam (NL)

**13:25 - 13:40**

### **Piloting the European Health Data Space: Methods, challenges and opportunities encountered**

N. Bellière, Paris (FR)

**13:40 - 13:45**

### **Session take home messages**

V. Sakalis, Thessaloniki (GR)



**Saturday 6 April**  
**12:15 - 13:45**

**Location** Green Area, W03

**Chairs** N. Fossati, Lugano (CH)  
To be confirmed  
D.R. Siemens, Kingston, Ontario (CA)

We encourage participants in this session to view the abstracts before the session. All abstract bodies, posters, videos and webcasts can be viewed on the EAU(N)24 Resource Centre or at the digital screens in front of the Purple Area, EGPT.

**12:15 - 13:00**

**MRI**

A0315

**Can systemic biopsies be avoided in biopsy-naïve patients with very high suspicious lesion at multiparametric MRI? A single institution analysis**

P.P. Avolio, Pieve Emanuele (IT)

A0307

**Incidence of significant prostate cancer after positive MRI and negative targeted and systematic biopsies.**

C. Siebert, (FR)

A0313

**The Impact of Multiple Lesions in Prostate MRI – Insights from the YAU Prostate Cancer Group**

F. Zattoni, Verona (IT)

**Study Group**

EAU-YAU Prostate Cancer Working Party.(Padua, Italy)

A0309

**Bimodal imaging: Detection Rate of clinically significant Prostate Cancer is higher in MRI lesions visible by transrectal ultrasound**

F. Falkenbach, Hamburg (DE)

A0299

**Predicting clinically significant prostate cancer following mpMRI - Analyses from a high-volume center**

M. Jahnen, Munich (DE)

A0303

**Clinically significant MRI-negative prostate cancer: a matched-paired analysis to evaluate radiological, histological and molecular features**

M. Oderda, Turin (IT)

A0302

**Diagnostic value of the Prostate Health Index and ADC values based on PI-RADSv2.1 in prostate cancer with PSA4-20ng/ml**

W. Yong, Tianjin (CN)

A0312

**Mid-term follow up analysis of a cohort of patients with initial MRI at suspicion of prostate cancer. How it can be useful for exclusion of PC and avoid unnecessary biopsies.**

A.C. Tagalos Munoz, Madrid (ES)

A0301

**NMR-based metabolomics discriminate between prostate biopsy-positive and biopsy-negative patients suspicious for prostate cancer.**

M. Ladurner, Innsbruck (AT)

**13:00 - 13:25**

**Micro-US**

A0304	<p><b>Retrospective Analysis of Microultrasound Accuracy in Prostate Cancer diagnosis: Results from a High-Volume Referral Center</b></p> <p>N. Frego, Melle (BE)</p>
A0305	<p><b>Pathologic Gleason Upgrading Following High-resolution Micro-Ultrasound, Conventional Ultrasound and MRI Fusion Biopsy Techniques: A Comparative Study</b></p> <p>M. Michael, New Haven (US)</p>
A0308	<p><b>“Histofusion” biopsy of the prostate: analysis of multicenter national data in real-life settings</b></p> <p>A. Govorov, Moscow (RU)</p>
A0300	<p><b>Clinically significant prostate cancer detection rate in biopsy-naïve patients with mpMRI and microultrasound topographically discordant lesions: a single-center prospective analysis</b></p> <p>F. Dagnino, Pieve Emanuele (IT)</p>
A0314	<p><b>Prostate cancer detection rate with the ExactVu System in biopsy-naive patients with high clinical suspicion and negative multiparametric MRI: Update from a large single-center experience.</b></p> <p>P.P. Avolio, Pieve Emanuele (IT)</p>
<hr/>	
13:25 - 13:45	<p><b>PET/CT</b></p>
A0310	<p><b>Use of PSMA PET/CT in Detecting Primary Prostate Cancer: evaluation of the diagnostic accuracy in prebiopsy setting</b></p> <p>E. Cisero, Orbassano (IT)</p>
A0311	<p><b>Comparing detection rates of PSMA PET/CT target biopsy vs. mpMRI targeted biopsy in detection of clinically significant prostate cancer</b></p> <p>F. Piramide, Turin (IT)</p>
A0306	<p><b>The new long-half-life probe 123I-PSMA-7 guided real-time intraoperatively biopsy in patients with suspected prostate cancer</b></p> <p>S. Niu, Beijing (CN)</p>
A0316	<p><b>Additive utility of 68Ga-prostate-specific membrane antigen positron emission tomography/computed tomography in prostate cancer diagnosis: Is there a case for “seeing is believing”?</b></p> <p>J. Chin, Singapore (SG)</p>

**Saturday 6 April**  
**12:15 - 13:45**

**Location** Purple Area, EGPT

**Chairs** M.C. Mir Maresma, Valencia (ES)  
S. Psutka, Seattle (US)

We encourage participants in this session to view the abstracts before the session. All abstract bodies, posters, videos and webcasts can be viewed on the EAU(N)24 Resource Centre or at the digital screens in front of the Purple Area, EGPT.

**12:15 - 12:29**

**Screen A:**

P142

**Anti-inflammatory dietary index and risk of renal cell carcinoma**

H. Ugge, Örebro (SE)

P129

**Prognostic significance of body mass index in patients with metastatic renal cell carcinoma treated with first-line therapies**

K. Sato, Tokyo (JP)

P136

**Risk factors for kidney cancer and socio-occupational category: Significant impact of chlorinated solvents (ProCCR 111 study)**

M. Ferragu, Angers (FR)

P381

**Results of the Yorkshire Kidney Screening Trial, a feasibility study of adding abdominal non-contrast CT scanning to screen for kidney cancer and other abdominal pathology to CT-based screening for lung cancer**

G.D. Stewart, Cambridge (GB)

**Study Group**

YKST Study Group(Multi-centre, United Kingdom)

**12:29 - 12:44**

**Screen B:**

P145

**Preoperative or intraoperative renal biopsy increases the accuracy in predicting lymph node invasion in patients with renal cell carcinoma**

F. Belladelli, Milan (IT)

P144

**Renal Biopsy does not affect mortality in Renal Mass Patients When Confronted with Upfront Surgery: a Propensity Score Adjusted Analysis**

F. Belladelli, Milan (IT)

P124

**Shifting the Paradigm: Improving Renal Cell Carcinoma Staging Within the AJCC System by Adding C-Reactive Protein-Analysis of the INMARC Registry**

C. Saitta, Pieve Emanuele (IT)

P135

**Mismatch between clinical and pathological T stage among patients with suspected renal cell carcinoma undergoing surgery: potential implications for target volume delineation and stereotactic body radiotherapy (SBRT) implementation for localized renal masses.**

G. Francolini, Florence (IT)

P126

**Diagnostic Performance of Multiparametric Magnetic Resonance Imaging before Renal Biopsy using Clear Cell Likelihood Score (ccLS)**

C. Re, Albairate (IT)

12:44 - 12:56

**Screen C:**

- P143 **Postoperative recurrence factors in patients with pT3N0M0 clear cell renal cell carcinoma, called the M0 intermediate-high-risk group of the KEYNOTE 564 trial**  
H. Naito, Kagawa (JP)
- P139 **Predicting positive surgical margins in patients treated with robot-assisted partial nephrectomy: results from a prospectively maintained dataset of a single tertiary referral center**  
V. Salamone, Florence (IT)
- P130 **Incremental value of Radiomics with Machine learning to the existing prognostic models for predicting outcome in renal cell carcinoma**  
Z.J. Wang, Nanjing (CN)
- P121 **Development and validation of prognostic nomograms and integrated software incorporating preoperative CRP level for predicting survival outcomes in patients with nonmetastatic clear cell renal cell carcinoma: INMARC study**  
W. Chen, Tokyo (JP)
- 

12:56 - 13:11

**Screen D:**

- P128 **Surveillance interruption and need for active treatment in Von Hippel-Lindau disease: implications for clinical management and trial design**  
F. Cei, Segrate (IT)
- P140 **The new 2019 Bosniak classification of complicated renal cysts. Radiopathological correlation and critical review**  
H. Alfambra Fernandez, Barcelona (ES)
- P125 **Revealing patterns in spontaneous hemorrhagic risks and growth of angiomyolipomas: Is strict follow-up warranted?**  
D. Lopez Curtis, Madrid (ES)
- P138 **Epithelioid renal angiomyolipoma: clinical features, treatment modalities, and oncologic outcomes – a systematic review of 221 case reports**  
F. Haselhoff, Kriens (CH)
- P141 **Growth Kinetics of Oncocytic Neoplasms on Active Surveillance and Impact on Renal Function**  
L. Raveendran, Toronto (CA)
- 

13:11 - 13:23

**Screen E:**

- P133 **Urologists & Kidney Transplantation: The residents' perspective**  
A. Pecoraro, Firenze (IT)
- P131 **Perioperative Surgical Complications in Robot-Assisted vs. Pure Laparoscopic Living Donor Nephrectomy: A European Robotic Urology Section (ERUS) RAKT working group study**  
R. Campi, Florence (IT)
- P132 **Outcomes of robot-assisted kidney transplantation (RAKT) using right- vs left grafts from living donors: update from the ERUS-RAKT working group**  
A. Pecoraro, Firenze (IT)
- P134 **Deceased Donor Robotic-Assisted Kidney Transplantation: The ERUS-RAKT Experience**  
T. Prudhomme, Toulouse (FR)
- 

13:23 - 13:35

**Screen F:**

P137

**Renal allograft management with urolithiasis: A multicentric study. On behalf of the Renal Transplant group of the Spanish Urological Association**

A. Sierra Del Rio, Barcelona (ES)

P122

**Native nephrectomy and arterial embolization of native kidney in autosomal dominant polycystic kidney disease patients: indications, timing and postoperative outcomes. A systematic review by the EAU-YAU Kidney Transplantation working group**

T. Prudhomme, Toulouse (FR)

P123

**Impact of donating the larger kidney by CT volumetry on the kidney function, 5-years after living donation**

S. Ong, Singapore (SG)

P127

**Renal volumetry as a predictor of residual renal function after nephrectomy in living donors**

D. Simón Nieto, Seville (ES)

# Joint Session of the EAU, EANM, ESMO and ESTRO: A collaborative approach - Multidisciplinary tumour boards in stage II seminoma

Thematic Session

**Saturday 6 April**  
**12:30 - 14:00**

**Location** Purple Area, eURO Auditorium 2

**Chairs**  
M. Albersen, Leuven (BE)  
N. Naoun, Villejuif (FR)  
D. Oprea-Lager, Amsterdam (NL)  
P. Ost, Ghent (BE)

### **Learning objectives**

To understand the clinical utility of PET in the management of testicular seminoma.

To learn how to detect viable residual tumour on PET.

To guide clinicians to accurately diagnose recurrence of seminoma.

**12:30 - 13:25**

**Case discussion Stage IIb seminoma (3-5cm): Spoilt for choice?**

**12:30 - 12:35**

**Case presentation**

I. Anselmo da Costa Santiago, Berlin (DE)

**12:35 - 12:42**

**Standard of care: BEP**

C. Oing, Newcastle upon Tyne (GB)

**12:42 - 12:49**

**Role of PET-imaging in seminoma**

D. Oprea-Lager, Amsterdam (NL)

**12:49 - 12:56**

**mi-RPLND + carbo**

W. Cazzaniga, London (GB)

**12:56 - 13:03**

**Modern radiotherapy to affected node + carbo**

A. Papachristofilou, Basel (CH)

**13:03 - 13:10**

**Surgery first, primum non nocere**

Y. Che, Düsseldorf (DE)

**13:10 - 13:25**

**Panel discussion**

**13:25 - 13:35**

**State-of-the-art lecture Is progression-free survival a correct endpoint in stage II seminoma trials?**

L. Nappi, Vancouver (CA)

**13:35 - 13:45**

**State-of-the-art lecture Long-term toxicity in testicular cancer and AYA: Premature mortality and morbidity illustrated**

Z. Klaassen, Augusta (US)

**13:45 - 13:55**

**State-of-the-art lecture Ongoing trials and novel tools in the toolbox for metastatic TGCT**

L. Nappi, Vancouver (CA)

**13:55 - 14:00**

**Discussion**

# 10th ESO Prostate Cancer Observatory 2024

Thematic Session

**Saturday 6 April**

**15:00 - 17:00**

**Location**

Purple Area, eURO Auditorium 2

**Chairs**

P. Cornford, Liverpool (GB)

F. Peccatori, Bellinzona (CH)

U. Vogl, Bellinzona (CH)

**15:00 - 15:05**

**Welcome and introduction**

P. Cornford, Liverpool (GB)

F. Peccatori, Bellinzona (CH)

U. Vogl, Bellinzona (CH)

**15:05 - 15:13**

**The nurse's perspective**

C.N. Tillier, Amsterdam (NL)

**15:13 - 15:21**

**The urologist's perspective on active surveillance**

P. Cornford, Liverpool (GB)

**15:21 - 15:29**

**The imaging specialist's perspective on MRI**

N. Tunariu, London (GB)

**15:29 - 15:37**

**The imaging specialist's perspective on PSMA-PET/CT**

I. Burger, Baden (CH)

**15:37 - 15:45**

**The pathologist's perspective**

E. Compérat, Vienna (AT)

**15:45 - 15:53**

**The urologist's perspective on surgery**

S. Joniau, Leuven (BE)

**15:53 - 16:01**

**The radiation oncologist's perspective**

K. Rans, Leuven (BE)

**16:01 - 16:09**

**The urologist's perspective on focal therapy**

R. Sanchez-Salas, Montreal (CA)

**16:09 - 16:17**

**The medical oncologist's perspective**

U. Vogl, Bellinzona (CH)

**16:17 - 16:25**

**The geneticist's perspective**

E. Castro, Madrid (ES)

**16:25 - 16:33**

**The patient advocate's perspective**

E-G. Carl, Tornesch (DE)

**16:33 - 16:58**

**Panel discussion Hottest topics in Prostate cancer 2024**

**16:58 - 17:00**

**Closing remarks**





# French contributions to urology

Special Session

**Saturday 6 April**  
**15:00 - 17:00**

**Location** Purple Area, N01

**Chairs** E. Cuenant, Sète (FR)  
P.E.V. Van Kerrebroeck, Berchem- Antwerp (BE)

## **Learning objectives**

Several major innovations in urology were developed in France. These still have impact on on current urological practice, and hence are still relevant today. Different aspects of these developments will be presented and discussed.

**15:00 - 15:10**

**Introduction**

**15:10 - 15:25**

**Stone cutters of old France**

E. Chartier-Kastler, Paris (FR)

**15:25 - 15:30**

**Discussion**

**15:30 - 15:45**

**Urology as a surgical specialty: A French revolution?**

P.E.V. Van Kerrebroeck, Berchem- Antwerp (BE)

**15:45 - 15:50**

**Discussion**

**15:50 - 16:05**

**'Mon cher collègue...': French influence on Britain's most famous urologist**

J.C. Goddard, Leicester (GB)

**16:05 - 16:10**

**Discussion**

**16:10 - 16:25**

**Famous French urologic patients**

D. Schultheiss, Giessen (DE)

**16:25 - 16:30**

**Discussion**

**16:30 - 16:45**

**The 'Belle Epoque' of Urology**

J. Mattelaer, Kortrijk (BE)

**16:45 - 16:50**

**Discussion**

**16:50 - 17:00**

**Conclusions and closure**

P.E.V. Van Kerrebroeck, Berchem- Antwerp (BE)

# YUORDay24: EAU Young Urologists Office (YUO) & European Society of Residents in Urology (ESRU) - Part II

Special Session

**Saturday 6 April**  
**15:00 - 17:00**

**Location** Green Area, W06

**Chairs** E. Checcucci, Candiolo (IT)  
J.L. Vásquez, Copenhagen (DK)

## **Learning objectives**

The purpose of this session is to bring young urologists closer to experts in the field. Particularly, importance is given to guidelines by discussing current topics in the "Challenging Guidelines" session, followed by the Guidelines Cup. Lastly, the best scientific contributions prepared by residents will be awarded.

## **Challenging the guidelines: Controversial topics**

**Moderators** E.C. Bujoreanu, Cluj Napoca (RO)  
S.T. De Cillis, Turin (IT)  
B. Pradere, Toulouse (FR)

**15:00 - 15:20**

## **PSMA for prostate cancer diagnosis**

15:00 - 15:08

### **Pro**

F. Ceci, Milano (IT)

15:08 - 15:16

### **Con**

M. Emberton, London (GB)

15:16 - 15:20

### **Conclusion by expert**

S. Shariat, Vienna (AT)

**15:20 - 15:40**

## **Robotic surgery for functional urology**

15:20 - 15:28

### **Pro**

V. Phé, Paris (FR)

15:28 - 15:36

### **Con**

A. Sahai, London (GB)

15:36 - 15:40

### **Conclusion by expert**

J. Heesakkers, Maastricht (NL)

**15:40 - 16:00**

## **PDD for bladder cancer diagnosis**

15:40 - 15:48

### **Pro**

A. Masson-Lecomte, Paris (FR)

15:48 - 15:56

### **Con**

R. Heer, London (GB)

15:56 - 16:00

### **Conclusion by expert**

M. Rouprêt, Paris (FR)

**16:00 - 16:45**

## **Guidelines cup**

### **Guidelines masters**

M.J. Ribal Caparros, Barcelona (ES)

J.L. Vázquez, Copenhagen (DK)

### **Guidelinescup finalists**

M. Czerwaty, Warszawa (PL)

J. Devos, Antwerpen (BE)

J. Mendes Carvalho, Porto (PT)

---

**16:45 - 17:00**

### **Prizes and awards**

#### *Moderators*

L. Afferi, Luzern (CH)

E. Checcucci, Candiolo (IT)

J.L. Vázquez, Copenhagen (DK)

**16:45 - 16:50**

**First prize: Best abstract by a resident** **The Trans-Atlantic recommendations for prostate gland evaluation with MRI after focal therapy (TARGET) international consensus recommendations**

A. Light, London (GB)

**16:50 - 16:55**

**Second prize: Best abstract by a resident** **Duration of untreated ED is associated with overall impoverishment of male sexual function**

F. Belladelli, Milan (IT)

**16:55 - 17:00**

**Third prize: Best abstract by a resident** **Water vs. Water II 5-year update: comparing aquablation therapy for benign prostatic hyperplasia in 30-80 cc and 80-150 cc prostates**

M.B. Berjaoui, Toronto (CA)

# The infertile couple: Urological aspects

ESU Course 26

**Saturday 6 April**  
**15:00 - 18:00**

**Location** Purple Area, E07

**Chair** M. Dinkelman-Smit, Rotterdam (NL)

Voting will be available via the EAU24 App or via [www.qna.at/eau](http://www.qna.at/eau)

## **Learning objectives**

This course provides state-of-the-art information on urological aspects of diagnosis and therapy of modern reproductive medicine. Diagnostic procedures should be standardised and coordinated in a timely fashion for both partners, focusing on the possible urological, hormonal and genetic causes of male infertility.

In terms of therapy, this course will provide updated information on evidence-based data and discuss the importance of varicoceles in male infertility. We will show microsurgical techniques on video and explain why proper training and skills perfection is key to successful case management. A successful IVF/ICSI outcome depends upon the use of state-of-the-art techniques for sperm retrieval and sperm preparation.

We will also provide information on genetic aspects and stress the responsibility of the urologist as an adviser and gatekeeper for the treatment of the infertile couple.

## **Diagnostic work-up, medical treatment**

A. Salonia, Milan (IT)

## **Pathophysiology, diagnosis and treatment of varicocele**

M. Dinkelman-Smit, Rotterdam (NL)

## **Microsurgical refertilisation**

M. Dinkelman-Smit, Rotterdam (NL)

## **Sperm retrieval techniques and genetic aspects of IVF/ICSI**

A. Salonia, Milan (IT)

# Influence of ChatGPT and AI in urology

Thematic Session

**Saturday 6 April**  
**15:15 - 16:45**

**Location** Green Area, N04

**Chairs** K.A.O. Tikkinen, Helsinki (FI)  
J. Walz, Marseille (FR)

## **Learning objectives**

1. Understand AI's role in decision support, data analysis, and prediction tools
2. Explore AI's applications in diagnostic assistance, emphasising AI diagnostics in imaging and pathology
3. Learn about AI's integration into surgical planning through augmented reality and robotics for enhanced surgical precision
4. Discover AI's, specifically ChatGPT's, role in patient education and support
5. Learn about AI's and chatGPT's role in grant applications, scientific publications and congresses

This programme was developed with the help of ChatGPT.

**15:15 - 15:34**

## **Decision support**

**15:15 - 15:22**

## **AI analysis of data and AI prediction tools**

I. Bentellis, Nice (FR)

**15:22 - 15:29**

## **Literature research with AI/ChatGPT**

G. Cacciamani, Los Angeles (US)

**15:29 - 15:34**

## **Discussion**

**15:34 - 15:53**

## **Diagnostic assistance**

**15:34 - 15:41**

## **AI diagnostics imaging**

J.J. Futterer, Nijmegen (NL)

**15:41 - 15:48**

## **AI diagnostics pathology**

Y. Allory, Saint-Cloud (FR)

**15:48 - 15:53**

## **Discussion**

**15:53 - 16:12**

## **Surgical planning and guidance**

**15:53 - 16:00**

## **AI and augmented reality**

R. Autorino, Chicago (US)

**16:00 - 16:07**

## **AI and robotics**

S. Secco, Milan (IT)

**16:07 - 16:12**

## **Discussion**

**16:12 - 16:19**

## **Patient education and support**

**16:12 - 16:19**

## **ChatGPT and the patient**

J. Ghith, New York (US)

**16:19 - 16:45**

## **Research and data analysis**

16:19 - 16:26

**Grant application**

A.S. Bjartell, Malmö (SE)

16:26 - 16:33

**Communication: Scientific publication**

A. Briganti, Milan (IT)

16:33 - 16:40

**Communication: Scientific congress**

M. Albersen, Leuven (BE)

16:40 - 16:45

**Discussion**

# Female urology: Stress urinary incontinence and more

Abstract session 12

**Saturday 6 April**  
**15:15 - 16:45**

**Location** Purple Area, S01

**Chairs** S. Arlandis, Valencia (ES)  
E. Costantini, Perugia (IT)  
M. Wong, Singapore (SG)

We encourage participants in this session to view the abstracts before the session. All abstract bodies, posters, videos and webcasts can be viewed on the EAU(N)24 Resource Centre or at the digital screens in front of the Purple Area, EGPT.

- 
- A0326** **Direct comparison of novel vaginal meshes developed for use in the treatment of stress urinary incontinence in an improved pre- clinical rabbit model**  
N. Mangir, Ankara (TR)
- 
- A0321** **Treatment of Female Stress Urinary Incontinence with Allograft slings from Human Umbilical Vessels in Patients with complicated mid-urethral synthetic slings: intermediate Analysis**  
U. Pinar, Paris (FR)
- 
- A0320** **Low-intensity pulsed ultrasound promotes urethral smooth muscle regeneration by modulating the immune microenvironment**  
C. Song, Shanghai (CN)
- 
- A0331** **Design and Prototyping of a Shape-Adjustable Sling for the Treatment of Stress Urinary Incontinence**  
S. Tasmim, College Station (US)
- 
- A0330** **A randomized controlled trial: TOT and transurethral bulking agent in naive stress incontinence**  
E. Illiano, PERUGIA (IT)
- 
- A0329** **Adjustable continence therapy device versus polyacrylamide hydrogel peri-urethral injections in elderly women with non-neurogenic stress urinary incontinence**  
M. Chapuis, Pointe À Pitre (GP)
- 
- A0324** **Outpatient periurethral injections of polyacrylamide hydrogel under local anesthesia in the office: a prospective single-center series**  
B. Faurie, Bordeaux (FR)
- 
- A0323** **Long-term Midurethral Mesh Sling Survival For Women With Stress Urinary Incontinence**  
M. Laude, Saint-Priest-en-Jarez (FR)
- 
- A0317** **Have I placed the single incision sling correctly? Transperineal ultrasound could have the answer**  
J. Espinosa, Valencia (ES)

A0318	<b>The long-term rate of re-operation after mid-urethral sling insertion among women with urinary incontinence: Population-based study</b> J.Y. Cho, Sonpa-gu (KR)
A0325	<b>Late presentation of complications of mid-urethral sling and outcomes after sub-urethral sling removal</b> P.E. Zimmern, Dallas (US)
A0328	<b>The Impact of the Colposacropexy Learning Curve on Mesh Complications</b> E. Illiano, PERUGIA (IT)
A0332	<b>Robotic assisted colposuspension for female stress urinary incontinence (SUI). A 2-year multicentre prospective study</b> C. Clark, Harpenden (GB)
A0334	<b>Trends in the use of female artificial urinary sphincter in Europe: preliminary data from the VENUS study</b> To be confirmed
A0333	<b>Impact of robotic artificial urinary sphincter implantation in female patients on quality of life and patients-reported outcomes</b> A. Dubois, Loon Plage (FR)
A0322	<b>Use Cluster Analysis to Develop an Accurate and Practical Diagnostic Method for Detrusor Underactivity in Female Patient without Bladder Outlet Obstruction</b> J-C. Chen, Taichung City 403 (TW)
A0327	<b>Inter-observer reproducibility for determination of female urethral narrowing on voiding cystourethrogram</b> P.E. Zimmern, Dallas (US)
A0319	<b>Therapeutic efficacy of transurethral bladder neck incisions for female voiding dysfunction</b> H-C. Kuo, Hualien (TW)



**Saturday 6 April**  
**15:15 - 16:45**

**Location** Green Area, W01

**Chairs** O.R. Brouwer, Amsterdam (NL)  
C. Jeronimo, Porto (PT)  
A. Necchi, Milan (IT)

We encourage participants in this session to view the abstracts before the session. All abstract bodies, posters, videos and webcasts can be viewed on the EAU(N)24 Resource Centre or at the digital screens in front of the Purple Area, EGPT.

**15:15 - 15:17**

**Introduction**

**15:17 - 15:37**

**Tumor micro-environment, liquid biopsies and new targets**

A0345

**Single-cell trajectory analysis reveals distinct differentiation of epithelial cells highlighting a more aggressive phenotype in HPV-negative and TP53 mutated penile cancer**

L. Elst, Leuven (BE)

A0346

**Single-cell transcriptomics reveals B cells-IgA-PIGR axis improving overall survival in HPV-associated penile squamous cell carcinomas**

T. Tao, Hefei (CN)

A0350

**Checkpoint-related proteins in liquid biopsies and their association with prognostic factors in penile cancer**

D. Glombik, Örebro (SE)

A0342

**TROP-2 – a promising new therapeutic target in penile squamous cell carcinoma**

R. Weiten, Bonn (DE)

**15:37 - 16:07**

**Evolutions in diagnosis**

A0344

**Snap diagnosis: pilot study of artificial intelligence powered smartphone application for penile cancer detection from the comfort of your home**

J. Liu, Melbourne (AU)

A0351

**First evaluation of one-step nucleic acid amplification (OSNA) for rapid molecular detection of lymph node metastases in penile cancer patients**

S. Engels, Oldenburg (DE)

A0339

**Evaluation of the use of serum Squamous cell carcinoma Antigen for staging of penile cancer**

M.T.A. Vreeburg, Amsterdam (NL)

A0340

**Assessment and outcome of intraoperative frozen section examination of surgical resection margins in the management of penile cancer**

M. Yunis, Watford (GB)

A0348

**Comprehensive Evaluation of MRI Accuracy in Local Staging of Penile Cancer**

M. Shendy, cardiff (GB)

A0335

**Does the “10% rule” apply to sentinel node biopsies for penile squamous cell carcinoma?**

S. Yan, London (GB)

16:07 - 16:22

## Epidemiology and prognosis

A0343

**Human papillomavirus (HPV) does not modify the prognostic significance of tumour stage and grade of differentiation in penile carcinoma. A retrospective study spanning 50 years from a Norwegian tertiary centre.**

C.A. Moen, Bergen (NO)

A0337

**Penile Intraepitheliale Neoplasia (PeIN) in the Netherlands: A Comprehensive 15-Year Study on Incidence, Recurrence, and Progression to Invasive Malignancy**

O. Avitan, Haifa (IL)

A0341

**Penile cancer, epidemiological data can determine the disease trend and how to conduct prevention and treatment?**

A.F. Rodrigues, Goiania (BR)

---

16:22 - 16:42

## Therapy & outcomes

A0349

**Outcome of videoendoscopic inguinal lymphadenectomy versus open radical inguinal lymphadenectomy in patients with penile Cancer: A retrospective comparative study**

A. Jalan, Bharatpur (NP)

A0347

**Organ Preservation and Oncological Efficacy of Peniscopically Controlled CO2 Laser Excision of Penile Squamous Cell Carcinoma: Early and Late Results in a High-Volume Center**

C. Silvani, San Donato Mse Milano (IT)

A0338

**Quality of life after penile cancer surgery: comparison between amputative and penile-sparing surgery.**

M.T.A. Vreeburg, Amsterdam (NL)

A0336

**Optimising surveillance imaging in high risk nodal (N+) penile cancer: Proposal of an updated surveillance protocol**

B.E. Ayres, London (GB)

---

16:42 - 16:45

## Expert summary

# Enucleation is enucleation is enucleation

Video session 06

**Saturday 6 April**  
**15:15 - 16:45**

**Location** Green Area, S04

**Chairs** J-T. Klein, Münsterlingen (CH)  
K. Lehrich, Berlin (DE)

We encourage participants in this session to view the abstracts before the session. All abstract bodies, posters, videos and webcasts can be viewed on the EAU(N)24 Resource Centre or at the digital screens in front of the Purple Area, EGPT.

V041 (□: 7 min.)

**STAR-P – Suprapubic Transvesical Adenoma Resection of the Prostate - original technique for surgical treatment of BPH: A novel urethra-sparing strategy for any prostatic volume**

B. Bucca, Rome (IT)

V042 (□: 7 min.)

**En Bloc enucleation for large prostates (>150 gr), Tips and tricks for success. En Bloc enucleation for large prostates (>150 gr), Tips and tricks for success. En Bloc enucleation for large prostates (>150 gr), Tips and tricks for success.**

M.E. Rodríguez Socarrás, Madrid (ES)

V043 (□: 5 min.)

**Combined HoLEP and transvesical Single port robotic simple prostatectomy**

C.G. Rogers, Detroit (US)

V044 (□: 8 min.)

**Plasmakinetic enucleation of the prostate with apical precut (APC-PKEP): a modified electrode and en bloc technique for anatomic transurethral prostatectomy**

J. Wu, Fuzhou, Fujian Province (CN)

V045 (□: 8 min.)

**Robotic anatomical enucleation of the prostate (RAEP) without irrigation and with suprapubic tube only for massively enlarged obstructive prostate**

J-T. Klein, Münsterlingen (CH)

V046 (□: 7 min.)

**Robotic Single port Transvesical Enucleation of the Prostate (STEP): technique and early single center experience**

A. Franco, Rome (IT)

V047 (□: 8 min.)

**Robot-Assisted Simple Prostatectomy (RASP): step by step technique, complications and peri-operative results**

O. Blezien, Milan (IT)

# The management of genitourethral complications

Meeting of the EAU Section of Genitourinary Reconstructive Surgeons (ESGURS)

**Saturday 6 April**  
**15:15 - 18:15**

**Location** Green Area, N03

**Chair** D.J. Ralph, London (GB)

## **Learning objectives**

This year we have lectures on the management of complications of penile prosthesis implantation from our associates. This is followed by straightening the penis in different congenital conditions. We all have nightmare cases in reconstruction and some will be presented here. Can balloon dilatation replace urethroplasty? We will debate this. There will also be updates in male incontinence and urethral strictures together with the problems of mesh in females.

**15:15 - 16:11**

## **Penile prosthesis 101**

*Moderators*  
A. Cocci, Florence (IT)  
D.J. Ralph, London (GB)

**15:15 - 15:22**

## **Antibiotics to be replaced by antiseptics during penile prosthesis implantation?**

J. Romero-Otero, Madrid (ES)

**15:22 - 15:29**

## **Extra tunical grafting with IPP in treating Peyronie's disease wasting**

E. Lledó García, Madrid (ES)

**15:29 - 15:36**

## **Techniques to prevent IPP reservoir herniation**

D. Osmonov, Kiel (DE)

**15:36 - 15:43**

## **The management of penile prosthesis aneurysms**

F-X.M. Madec, Suresnes (FR)

**15:43 - 15:50**

## **Total vs single component change for IPP mechanical failure**

L.A. Micol, Lausanne (CH)

**15:50 - 15:57**

## **Is the mini jupette still a good option to treat climaturia?**

F. Chierigo, Genova (IT)

**15:57 - 16:04**

## **The use of mesh in penile prosthesis insertion**

W.G. Lee, London (GB)

**16:04 - 16:11**

## **The management of intraoperative and post-operative tunical perforation in IPP surgery**

P. Gordon, Leeds (GB)

**16:11 - 16:39**

## **Penile reconstruction: Making it straight but not narrow**

*Moderators*  
I. Moncada Iribarren, Madrid (ES)  
J. Romero-Otero, Madrid (ES)

**16:11 - 16:18**

## **Straightening the congenital penile curvature**

D. Schlager, Freiburg (DE)

**16:18 - 16:25**

## **Straightening the extrophy penis**

G. De Win, Edegem (BE)

**16:25 - 16:32**

## **Straightening the hypospadias penis**

D. Hernández Hernández, San Cristóbal de La Laguna (ES)

16:32 - 16:39

**The current grafts used in Peyronie's disease: What has changed?**

S.C. Morgenstern, Frankfurt am Main (DE)

---

16:39 - 17:07

**Reconstruction nightmares**

*Moderators*

R. Dahlem, Hamburg (DE)

E. Kocjancic, Chicago (US)

16:39 - 16:46

**Total/partial loss of phallus after penile prosthesis**

W.G. Lee, London (GB)

16:46 - 16:53

**Recurrence of bulbar urethral stricture**

P. Anderson, Dudley (GB)

16:53 - 17:00

**Fistulae after robotic surgery**

T.J. Greenwell, London (GB)

17:00 - 17:07

**Medico-legal aspects of reconstruction: in-depth medico-legal cross examination of case 6**

L. De Kort, Utrecht (NL)

---

17:07 - 17:49

**Lower urinary tract hot topics**

*Moderators*

T.J. Greenwell, London (GB)

L.G. Smyth, Dublin (IE)

17:07 - 17:17

**Debate Paclitaxel balloon dilatation of recurrent bulbar urethral stricture versus urethroplasty**

*Panel*

F. Campos Juanatey, Santander (ES)

M.W. Vetterlein, Hamburg (DE)

17:17 - 17:25

**Mesh-related urinary tract injuries and their management**

H. Gresty, London (GB)

17:25 - 17:33

**The outcomes of female urethroplasty from the EFG collaborative and future research directions**

M. Waterloos, Gent (BE)

17:33 - 17:41

**Acute and long-term management of the obstructed ureter**

J. Sairanen, Helsinki (FI)

17:41 - 17:49

**Setting up a GURS practice in a low-middle income health care setting**

M.J. Abalajon, Antipolo City (PH)

---

17:49 - 18:13

**Decision-making in reconstructive urology**

*Moderators*

O. Kose, Sakarya (TR)

A.O. Noah, London (GB)

17:49 - 17:57

**Artificial urinary sphincter or sling in men with stress urinary incontinence**

W. Verla, Ghent (BE)

17:57 - 18:05

**Urethroplasty for men with bulbar artificial urinary sphincter**

A.E. Zumrutbas, Denizli (TR)

18:05 - 18:13

**Fistula repair in women**

J. Ockrim, London (GB)

---

18:13 - 18:15

**Discussion and closing remarks**

D.J. Ralph, London (GB)

# Infections in urology

Meeting of the EAU Section of Infections in Urology (ESIU)

**Saturday 6 April**  
**15:15 - 18:15**

**Location** Purple Area, S03

**Chairs** T. Cai, Trento (IT)  
F.M.E. Wagenlehner, Giessen (DE)

Voting will be available via the EAU24 App or via [www.qna.at/eau](http://www.qna.at/eau)

## **Learning objectives**

Infections of the urogenital tract are amongst the most frequent infections inside the hospital but also in outpatients. This session on infections in urology combines urgent and ongoing topics, highly relevant for practicing urologists. Participants will learn strategies how to prevent infections, how to deal with infections in kidney transplant patients, and how to deal with the most severe infections in urology, namely urosepsis.

**15:15 - 15:16**

## **Introduction**

F.M.E. Wagenlehner, Giessen (DE)

**15:16 - 15:55**

## **Kidney transplant: Resolving the myths about catheters - lively debate and development of a consensus**

*Chair* V. Gomez Dos Santos, Madrid (ES)

*Moderator* C. Ohyama, Hiroasaki (JP)

**15:16 - 15:24**

## **Introduction and findings from national registries**

T.E. Bjerklund Johansen, Oslo (NO)

**15:24 - 15:29**

## **Is early removal of catheters a must?**

F. McCaig, London (GB)

**15:29 - 15:34**

## **What about ureteral catheters: are they mandatory and when to remove them?**

V. Díez Nicolás, Madrid (ES)

**15:34 - 15:39**

## **Use a SPC and have no problems!**

J. Medina-Polo, Madrid (ES)

**15:39 - 15:52**

## **Roundtable discussion: Can we reach a pragmatic consensus? (voting)**

*Discussants* T. Cai, Trento (IT)

L. Schneidewind, Rostock (DE)

**15:52 - 15:55**

## **Closing remarks and summary of the session**

T.E. Bjerklund Johansen, Oslo (NO)

**15:55 - 16:55**

## **How do I do it to prevent and deal with infections in urological surgery?**

*Moderators* R. Bartoletti, Pisa (IT)

M. Vallée, Poitiers (FR)

F.M.E. Wagenlehner, Giessen (DE)

**15:55 - 16:00**

## **Introduction and background**

F.M.E. Wagenlehner, Giessen (DE)

16:00 - 16:10	<b>Penile implantation: Can antibiotics be removed?</b> H.M. Alnajjar, London (GB)
16:10 - 16:20	<b>Fascial Sling: Do I need to use antibiotics? (5 min. presentation + 5 min. video)</b> E. Costantini, Perugia (IT)
16:20 - 16:30	<b>Prostate biopsies without antibiotics (5 min. presentation + 5 min. video)</b> A. Pilatz, Giessen (DE)
16:30 - 16:40	<b>PCNL: Who are patients that don't need antibiotic prophylaxis? (5 min. presentation + 5 min. video)</b> B. Somani, Southampton (GB)
16:40 - 16:55	<b>Debate all Can we agree to reduce antibiotics around prophylaxis? (voting)</b>  <i>Moderator</i> M. Vallée, Poitiers (FR)
16:55 - 17:21	<b>Vaccines - Immunomodulation in urology: Is this the future?</b>  <i>Moderators</i> F. Bruyere, Tours (FR) T. Cai, Trento (IT)
16:55 - 17:03	<b>Host response to UTIs: The basics</b> B. Wullt, Helsingborg (SE)
17:03 - 17:11	<b>Immunoprophylaxis of UTIs basics: Let's go to the drawing board</b> R. Calin, Paris (FR)
17:11 - 17:16	<b>How will immunoprophylaxis reshape the management of UTIs?</b> F. Bruyere, Tours (FR)
17:16 - 17:21	<b>Wrap up and key points</b> T. Cai, Trento (IT)
17:21 - 18:15	<b>Severe infections in Urology: Early detection and management?</b>  <i>Moderators</i> S.E. Geerlings, Amsterdam (NL) J. Kranz, Aachen (DE) Z. Tandoğdu, London (GB)
17:21 - 17:26	<b>Introduction</b> Z. Tandoğdu, London (GB)
17:26 - 17:34	<b>Updates from the latest guidelines on management of urosepsis</b> J. Kranz, Aachen (DE)
17:34 - 17:42	<b>Biomarkers role in urosepsis</b> F.M.E. Wagenlehner, Giessen (DE)
17:42 - 17:50	<b>How and when is rapid point of diagnostic tools to arrive and reshape management of urosepsis?</b> R. Ahmad, Hamar (NO)
17:50 - 17:58	<b>From PCNL to Sepsis? Why? How? Can we prevent? Can we predict?</b> E. De Lorenzis, Milan (IT)
17:58 - 18:06	<b>Tackling complexity: Approaches to UTI management in pregnancy</b> J. Currie, Bristol (GB)
18:06 - 18:15	<b>Q&amp;A and closing remarks</b> T. Cai, Trento (IT)

# Imaging-guided surgeries

Meeting of the EAU Section of Urological Imaging (ESUI)

**Saturday 6 April**  
**15:15 - 18:15**

**Location** Green Area, W03

**Chair** F. Sanguedolce, Barcelona (ES)

## **Learning objectives**

What are the latest advances in imaging technology that will support urological surgical training, surgical planning, and real-time intervention guidance? As imaging is going to play a major role in nearly all fields and aspects of our surgical practice, the audience will learn how and which imaging modality could be used to optimise their surgical performance, as well as which are those innovative technologies fully embodying imaging for undertaking precision urological surgeries. Each session will consist of a unique experience thanks to the participation of world-class innovative surgeons, as a collaboration of ESUI with the main EAU Sections in urological surgery, namely EULIS (stone disease), ESUT (technology) and ERUS (robotics).

**15:15 - 15:19**

## **Welcome and introduction**

F. Sanguedolce, Barcelona (ES)

**15:19 - 16:16**

## **Joint session with EULIS**

*Moderators*

P. Martino, Bari (IT)

V. Scattoni, Milan (IT)

C.C. Seitz, Vienna (AT)

**15:19 - 15:30**

## **Dual energy CT scan for stone characterisation**

E.X. Keller, Zürich (CH)

**15:30 - 15:41**

## **Training in urolithiasis interventions: from simulation to virtual reality**

K. Ahmed, London (GB)

**15:41 - 15:52**

## **Image-tracked renal puncture for PCNL**

E.A. Rodrigues De Lima, Braga (PT)

**15:52 - 16:03**

## **Augmented reality for renal puncture during PCNL**

E. Checcucci, Candiolo (IT)

**16:03 - 16:16**

## **Discussion**

**16:16 - 17:13**

## **Joint session with ESUT**

*Moderators*

L. Budäus, Hamburg (DE)

C. Fiori, Orbassano (IT)

**16:16 - 16:27**

## **BPH: Aquablation, the WATER trials**

N. Barber, Camberley (GB)

**16:27 - 16:38**

## **BPH/focal therapy: TULSA, an option for several indications**

L.H. Klotz, Toronto, ON (CA)

**16:38 - 16:49**

## **Surgical planning and fusion guidance technologies for precise focal therapy of PCa**

F. Sanguedolce, Barcelona (ES)

**16:49 - 17:00**

## **Focal therapy Registry: A European call**

E. Barret, Paris (FR)



17:00 - 17:13

**Discussion**

---

**17:13 - 18:10**

**Joint session with ERUS**

*Moderators*

A. Breda, Barcelona (ES)

M.C. Kriegmair, Planegg (DE)

17:13 - 17:24

**Surgical planning and augmented reality during partial nephrectomy**

A. Breda, Barcelona (ES)

17:24 - 17:35

**PSMA-guided salvage lymphadenectomy**

T. Maurer, Hamburg (DE)

17:35 - 17:46

**Sentinel lymphadenectomy in PCa with 99mTcnanocolloid: Myth or reality?**

C.D. Vera Donoso, Valencia (ES)

17:46 - 17:57

**Real-time assessment of surgical margins after robotic radical prostatectomy:  
Confocal microscopy vs. Histolog scanner**

G. Shaw, London (GB)

17:57 - 18:10

**Discussion**

---

**18:10 - 18:15**

**Closing remarks**

F. Sanguedolce, Barcelona (ES)

**Saturday 6 April**  
**15:15 - 18:45**

**Location** Orange Area, HOT 5

**Chair** V. Kasivisvanathan, London (GB)

### **Learning objectives**

The MRI Reading Course is designed as a half-day or full-day live or online training. This course will provide interactive teaching from expert faculty in prostate MRI reading and interpretation and help urologists to understand the role MRI plays in the management of patients with prostate cancer and how to use the information generated by prostate MRI. The course will address how to use an imaging workstation, how to understand the basic concepts/principles behind different MRI sequences (T2-weighted imaging, DWI-imaging and DCE-imaging), in which order to view the different sequences when interpreting prostate MRI, how to use the PI-RADS scoring system to score MRIs, and finally to understand what are the standards for a prostate MRI and what quality criteria need to be fulfilled. The participants will do hands on reading and assessment of prostate MRI scans on their computer via MIM-software followed by a reference reading provided by expert radiologists and pathological verification.

**15:15 - 15:20**

### **Course Overview**

V. Kasivisvanathan, London (GB)

**15:20 - 15:30**

### **Lecture: The importance of prostate MRI to the Urologist**

V. Kasivisvanathan, London (GB)

**15:30 - 16:00**

### **Lecture: Introduction to MRI sequences, scoring systems, PI-RADS**

M. De Rooij, Nijmegen (NL)

**16:00 - 16:30**

### **Lecture: Interactive case discussion – reporting MRI using PI-RADS**

F. Giganti, London (GB)

**16:30 - 16:35**

### **Introduction to the software for MRI interpretation**

J. Gómez Rivas, Madrid (ES)

**16:35 - 17:05**

### **Diagnosis I: Practical MRI diagnosis**

**17:05 - 17:35**

### **Review of the findings I**

M. De Rooij, Nijmegen (NL)

**17:35 - 18:05**

### **Diagnosis II: Practical MRI diagnosis**

**18:05 - 18:35**

### **Review of the findings II**

F. Giganti, London (GB)

**18:35 - 18:45**

### **Discussion, feedback, & closure**

V. Kasivisvanathan, London (GB)

# Hands-on Training in Urodynamics

HOT 2.28

**Saturday 6 April**

**15:15 - 18:15**

**Location** Orange Area, HOT 4

**Chair** A. Garcia Mora, Mexico City (MX)

## **Learning objectives**

Description:

This Hands-on Training is designed for participants to improve their skills in urodynamics, with an emphasis on practical aspects. Participants will have the opportunity to practice each step of the UDS procedure, including set up, running a test, troubleshooting, and interpretation.

## **Training aim**

The primary objective of this course is to enhance participants' skills in urodynamics, focusing on key aspects of the procedure. By the end of the course, attendees should feel more confident and competent in UDS procedures.

Voting will be available via the EAU24 App or via [www.qna.at/eau](http://www.qna.at/eau)

**15:15 - 15:35**

## **Introduction**

A. Garcia Mora, Mexico City (MX)

**15:35 - 15:55**

## **Hands-on Training: Rotation**

A. Gammie, Bristol (GB)

**15:55 - 16:25**

## **Setting Up**

A. Gammie, Bristol (GB)

**16:25 - 16:55**

## **Running a test**

P. Geretto, torino (IT)

**16:55 - 17:15**

## **Hands-on Training: Rotation**

**17:15 - 17:45**

## **Troubleshooting**

A. Garcia Mora, Mexico City (MX)

**17:45 - 18:15**

## **Interpretation**

C. Ochoa Vargas, Bristol (GB)

**Saturday 6 April**  
**15:15 - 16:45**

**Location** Purple Area, EGPT

**Chairs** R.T. Bryan, Birmingham (GB)  
G. Niegisch, Düsseldorf (DE)

We encourage participants in this session to view the abstracts before the session. All abstract bodies, posters, videos and webcasts can be viewed on the EAU(N)24 Resource Centre or at the digital screens in front of the Purple Area, EGPT.

**15:15 - 15:27**

**Screen A: Bladder cancer**

P146

**Urinary proteomics for microbiome identification and its implication in bladder cancer pathogenesis**

P.V. Stamatakos, Piraeus (GR)

P164

**Bladder cancer organoids serve as a useful system to mirror the characteristics of parental tumours**

H. Zhao, Hongkong (HK)

P172

**A zebrafish xenograft model for evaluating efficacy of cisplatin in muscle-invasive bladder cancer**

Y. Sugino, Tsu (JP)

P155

**Low-absent expression of TROP-2 in sarcomatoid subtype of bladder cancer: immunohistochemical evaluation of TROP-2 in a series of muscle invasive bladder cancer**

G. Giannarini, Udine (IT)

**15:27 - 15:39**

**Screen B: Bladder cancer**

P163

**Expression of CYTOR in Cancer-Associated Fibroblasts Is Associated with the Prognosis and Immunotherapeutic Response in Bladder Cancer**

Y. Wu, Beijing (CN)

P152

**Combined analysis of molecular patterns and clinical factors for the prediction of immune checkpoint inhibitor therapy in advanced urothelial carcinoma**

T. Szarvas, Budapest (HU)

P171

**Cancer-derived exosomal prothymosin- $\alpha$  triggers muscle wasting via regulating TLR4-NF- $\kappa$ B-E3 ubiquitin ligase signaling pathway**

C-Y. Hu, Tainan (TW)

**15:39 - 15:54**

**Screen C: Bladder cancer**

P149

**PHF6 promotes bladder cancer malignant progression via facilitating P53 ubiquitination**

Q. Zhang, Nanjing (CN)

P154

**AIRD1A Knockouts in Bladder Cancer Cell Lines Leads to MYC and E2F Activation Implicated in More Aggressive Tumor Behavior**

C.J. Magnani, Boston (US)

P153	<b>The m6A reader IGF2BP3 promotes bladder cancer progression via enhancing HSP90AB1 expression</b> Q. Zhang, Nanjing (CN)
P159	<b>The histone methyltransferase KMT9 regulates proliferation and migration of bladder cancer cells and is a novel target for treatment of muscle invasive bladder cancer (MIBC)</b> S. Totonji, Freiburg (DE)
P158	<b>YTHDC1 reduces M2 macrophage infiltration by regulating tumor senescence to suppress lymph node metastasis of bladder cancer</b> Y. Su, Qingdao (CN)
<hr/>	
<b>15:54 - 16:09</b>	<b>Screen D: Prostate cancer</b>
P160	<b>Generation of a new transgenic mouse model to explore the role of oncofetal CRIPTO in lethal prostate cancer</b> G. Thalmann, Bern (CH)
P150	<b>Investigating prostate cancer cellular heterogeneity and treatment response at single-cell level</b> R. Parmentier, Basel (CH)
P169	<b>Exploring the genomic blueprint of de novo neuroendocrine prostate cancer: Insights for innovative therapies from spatial gene expression analysis</b> R. Watanabe, Seattle (US)
P162	<b>Melatonin Induces P53 Phosphorylation to Enhance SLC7A11-Mediated Ferroptosis and Inhibit Prostate Cancer Progression</b> H. Huang, Guangzhou (CN)
P161	<b>Androgen receptor mediated tumor-associated macrophages drives prostate cancer progression to castration-resistant prostate cancer.</b> H. Huang, Guangzhou (CN)
<hr/>	
<b>16:09 - 16:21</b>	<b>Screen E: Prostate cancer</b>
P151	<b>Enzalutamide (enza) with or without leuprolide in patients (pts) with European Association of Urology (EAU)-guideline-defined high-risk biochemically recurrent prostate cancer (BCR) following radical prostatectomy (RP) or radiation therapy (RT): EMBARK post hoc analysis</b> U. De Giorgi, Meldola (IT)
P168	<b>Uncovering somatic genetic susceptibility factors in prostate cancer through comprehensive genome-wide analysis</b> L. Lin, Chengdu (CN)
P148	<b>Unveiling the Hidden Role of Spermine: Targeting HMOX1-induced Mitophagy in Prostate Cancer Therapy</b> J. Sun, Hong Kong (HK)
P166	<b>T cells subset in tumor-draining lymph nodes and blood from patients with prostate cancer</b> A.Z.S. Saudi, Norrköping (SE)
<hr/>	
<b>16:21 - 16:36</b>	<b>Screen F: Kidney cancer</b>
P167	<b>Targeting glutamine addiction to induce ferroptosis with potent drug combination therapy for renal cell carcinoma</b> A. Takeuchi, Aichi (JP)

- P156 **Carbonic anhydrase IX in renal cell carcinoma: a relevant biomarker and promising therapeutic target**  
J. Breza Sr., Bratislava (SK)
- P157 **Prognostic role of PD-L1 in tumor tissue and liquid biopsy in clear cell renal cell carcinoma**  
P. Zeuschner, Homburg (DE)
- P170 **Effect of HLA genotype on anti-PD-1 antibody treatment for advanced renal cell carcinoma**  
T. Tanegashima, Fukuokashi Higashiku (JP)
- P147 **Metallothionein 1 X is a tumor suppressor gene and inhibits metastasis in clear cell renal cell carcinoma**  
R. Rui, Beijing (CN)

# Hands-on Training in Laparoscopic urological skills - Step 1

HOT 2.17

Saturday 6 April

15:30 - 16:25

**Location** Orange Area, HOT 1

**Tutors** S. García Barreras, Madrid (ES)  
A. Papatsoris, Athens (GR)

## **Learning objectives**

This basic laparoscopic training course is the first step in the Laparoscopic Urological Skills (LUS) curriculum. It designed to provide urologists with a fundamental understanding of laparoscopy and enhance their laparoscopic skills. This comprehensive training is specifically tailored for urologists who want to gain a basic level of knowledge in laparoscopy and wish to improve their proficiency in key laparoscopic techniques. The course comprises four essential exercises aimed at honing skills related to depth perception and bimanual dexterity: Peg Transfer, Circle Cut, Needle Guidance, and Knot Tying.

The primary objective of this course is to enhance participants' laparoscopic skills, focusing on key aspects such as depth perception and bimanual dexterity. By the end of the course, attendees should feel more confident and competent in their basic laparoscopic skills.

# Hands-on Training in Endoscopic stone treatment - Step 1

HOT 2.18

**Saturday 6 April**

**15:30 - 16:25**

**Location** Orange Area, HOT 1

**Tutors** A.C. Bouma - Houwert, Laren (NL)  
F. Esperto, Rome (IT)  
S. Güven, Konya (TR)  
T. Tokas, Hall In Tirol (AT)

## **Learning objectives**

This Basic Endoscopic Stone Treatment course is the first step in the Endoscopic Stone Treatment (EST) curriculum. It is designed to provide urologists with a fundamental understanding of endoscopic stone treatment and enhance their skills. This comprehensive training is specifically tailored for urologists who want to gain a basic level of knowledge in endoscopy and wish to improve their proficiency in key techniques for endoscopic stone management. The curriculum includes four key exercises that provide hands-on experience and practical training: Flexible Cystoscopy, Rigid Cystoscopy, Semi-Rigid Ureteroscopy, and Flexible Ureteroscopy.

The primary objective of this programme is to enhance participants' skills in the treatment of urinary stones with endoscopic techniques. By the end of the course, attendees should feel more confident and competent in their basic skills.



# Hands-on Training in Transurethral treatment - Step 1 & 2 (TURBT/TURP)

HOT 2.19

**Saturday 6 April**

**15:30 - 16:25**

**Location** Orange Area, HOT 1

**Tutors** R.N. Brito Ramos, Lisbon (PT)

D. Oliveira Reis, Lisboa (PT)

## **Learning objectives**

This training course combines the first and second step of the Transurethral Treatment (TUT) curriculum. It is designed for urologists who wish to improve their proficiency in key techniques and gain a fundamental understanding of transurethral resection of the bladder and prostate. This comprehensive training covers crucial basic skills including flexible and rigid cystoscopy, resection loop handling, and direct vision internal urethrotomy, as well as the resection procedure, practiced on state-of-the-art models.

The primary objective of this course is to enhance participants' skills in transurethral resection of the prostate and bladder, focusing on key aspects such as depth perception, hand-eye coordination, control, handling, and overall technique. By the end of the course, attendees should feel more competent and confident in performing this procedure.

# Hands-on Training in Transurethral treatment - Step 3 (ThuLEP)

HOT 2.20

Saturday 6 April

15:30 - 16:25

**Location** Orange Area, HOT 2

**Tutors** G. Bozzini, Como (IT)  
T.E. Şener, Istanbul (TR)

## **Learning objectives**

This advanced training course is the third step in the Transurethral Treatment (TUT) curriculum. It is designed to provide urologists with a fundamental understanding of thulium laser enucleation of the prostate (ThuLEP). This comprehensive training is specifically tailored for urologists who want to become proficient in ThuLEP. Using a step by step approach, experts will lead participants through the procedure on state of the art models, to build a familiarity of the process, confidence handling the equipment, and an understanding of best practice.

## **Training aim**

The primary objective of this course is to enhance participants' skills in ThuLEP, focusing on key aspects such as control, handling, and overall technique. By the end of the course, attendees should feel more competent and confident in performing this procedure.

# Medical writing for urologists: An interactive workshop on how to write, publish and promote the “perfect” manuscript

ESU Course 20

**Saturday 6 April**  
**16:00 - 18:00**

<b>Location</b>	Purple Area, E01
<b>Chairs</b>	A. Briganti, Milan (IT) D.R. Siemens, Kingston, Ontario (CA)

## **Learning objectives**

This ESU course is a collaboration between *European Urology* and the *Journal of Urology*

This course will offer an expansive and interactive overview of the entire scholarly publishing procedure, specifically focusing on the writing process and what it means to be an outstanding author. The Faculty will offer instruction on how to construct a well-written introduction and methods section for your manuscript, learn how to present statistical analyses, understand key points when writing and how to use Social Media to best promote important work. Participants will obtain insight directly from editors on what they expect to see. The course will be structured into two modules including lectures and breakout sessions.

- To learn how to write a full length article from the Author and Editor perspective
- To understand systematic reviews and meta-analysis.
- Using Social Media platforms in a responsible and successful manner.
- To learn from experienced editors.

## **Welcome and introduction**

A. Briganti, Milan (IT)

---

## **How to capture the Editor's attention**

D.R. Siemens, Kingston, Ontario (CA)

---

## **Performing and reporting the perfect statistics**

R. L. Dunn, Ann Arbor (US)

---

## **Beyond the scientific manuscript: The role of social media in 2024**

D. Murphy, Melbourne (AU)

---

## **Small group sessions (20 minutes per group)**

---

### **What did I do wrong? Practical examples on "How to improve the methodological approach to your research question"**

R. L. Dunn, Ann Arbor (US)

---

### **Captivating the reader: Unlocking the power of abstracts and introductions**

L. Bukavina, Philadelphia (US)

---

### **Contextualising results and crafting impactful conclusions in discussion**

B.F. Chapin, Houston (US)

---

## **Conclusion Reports from the group**

# Modern treatment in testicular cancer

ESU Course 22

**Saturday 6 April**  
**16:00 - 18:00**

**Location** Purple Area, E03

**Chair** D. Nicol, London (GB)

## **Learning objectives**

This course will cover the diagnosis and treatment of germ cell tumours of the testis. Lectures will cover the potential role of the new marker miRNA-371 in testicular cancer and provide an overview of both early stage and advanced disease. Case based discussions with audience interaction will cover common scenarios and issues in clinical practice. Learning objectives will be to understand the promise and current limitations on a new marker in testicular cancer, management of early stage disease including adjuvant treatments, the role and use of chemotherapy and surgery in advanced and relapsed disease.

## **Introduction**

D. Nicol, London (GB)

## **Whats new? The role of the new diagnostic marker miR-371**

R. Leão, Coimbra (PT)

## **Testis cancer: Early stages**

D. Nicol, London (GB)

## **Testis cancer: Case discussion**

R. Leão, Coimbra (PT)

D. Nicol, London (GB)

T. Tandstad, Trondheim (NO)

## **Testis cancer: Advanced stages**

T. Tandstad, Trondheim (NO)

## **Testis cancer: Case discussion**

R. Leão, Coimbra (PT)

D. Nicol, London (GB)

T. Tandstad, Trondheim (NO)

## **Discussion and conclusion**

D. Nicol, London (GB)

# 2024 EAU Guidelines update – Sexual health, infections and penile and testicular cancer: What has changed?

ESU Course 25

**Saturday 6 April**  
**16:00 - 18:00**

**Location** Purple Area, E06  
**Chair** G. Bonkat, Basel (CH)

## **Urological infections**

### **Updated from the 2024 Infections Guidelines – recurrent UTI, ABU and the EMA stance on fluoroquinolones**

G. Bonkat, Basel (CH)

## **Testicular cancer**

### **Principles of systemic therapy in testicular cancer across disease stages**

A. Patrikidou, Villejuif (FR)

## **Penile cancer**

### **EAU ASCO Penile Cancer guidelines one year on – key recommendations and questions**

O.R. Brouwer, Amsterdam (NL)

## **Sexual and reproductive health panel**

### **Penile size abnormalities and dysmorphophobia – does size matter? Summary of the Guidelines**

M. Falcone, Torino (IT)

# Practical tips for pelvic laparoscopic surgery: Cystectomy, radical prostatectomy adenomectomy and sacrocolpopexy

ESU Course 23

**Saturday 6 April**  
**16:00 - 18:00**

**Location** Purple Area, E04

**Chair** J.M. Gaya Sopena, Barcelona (ES)

## **Learning objectives**

### **Patient positioning and trocar placement**

J.M. Gaya Sopena, Barcelona (ES)

### **Laparoscopic adenomectomy and radical prostatectomy**

P. Kallidonis, Patras (GR)

### **Laparoscopic radical cystectomy**

J.M. Gaya Sopena, Barcelona (ES)

### **Laparoscopic reconstructive surgery of the pelvic floor and sacrocolpopexy**

P. Kallidonis, Patras (GR)

### **Identify and solve complications**

J.M. Gaya Sopena, Barcelona (ES)

# How we manage upper tract tumours

ESU Course 24

**Saturday 6 April**  
**16:00 - 18:00**

**Location** Purple Area, E05

**Chair** S. Shariat, Vienna (AT)

## **Learning objectives**

This course will address contemporary concepts and controversies in UTUC such as:

- Accurate staging and its role in clinical decision-making/risk stratification.
- Risks, benefits, and side effects of current and novel therapeutic approaches including endoscopic and minimal-invasive surgery.
- Optimal management of the bladder cuff as well as indication and extent of lymphadenectomy.
- Systemic therapy for high-risk and metastatic patients.

## **Epidemiology, diagnosis, evaluation**

A. Masson-Lecomte, Paris (FR)

## **Prognostic and predictive factors, pathology**

S. Shariat, Vienna (AT)

## **Treatment of low-risk cancer (high grade Ta, T1 and carcinoma in situ (CIS))**

A. Masson-Lecomte, Paris (FR)

## **Treatment of localised high-risk (invasive) and metastatic cancer**

S. Shariat, Vienna (AT)

**Saturday 6 April**  
**16:00 - 18:00**

**Location** Purple Area, E02

**Chair** D. Veneziano, New York (US)

### **Learning objectives**

Over the past decades laparoscopy has played a major role in the therapeutic options of most urological conditions. Nevertheless, the steep learning curve associated with laparoscopic surgery makes it a challenging technique to master.

The aim of this ESU course is to provide you not only the basics of laparoscopic surgery, but also the tips and tricks to develop your laparoscopic skills.

- Peritoneal access and pneumoperitoneum
- How to choose and use the best laparoscopic instruments
- Indications and contraindications of the laparoscopic approach
- How to prevent and manage complications

Video and lively discussions will aid beginners shortening their learning curve and optimizing the success of their laparoscopic procedures.

---

### **Laparoscopy: Historical perspective**

D. Veneziano, New York (US)

---

### **Basic principles of laparoscopic surgery and pneumoperitoneum**

T.M. Ribeiro De Oliveira, Lisbon (PT)

---

### **Laparoscopic equipment and trocar placement**

D. Veneziano, New York (US)

---

### **Indications for laparoscopic surgery in urology**

T.M. Ribeiro De Oliveira, Lisbon (PT)

---

### **Managing complications in laparoscopic surgery**

D. Veneziano, New York (US)



# Hands-on Training in Laparoscopic urological skills - Step 1

HOT 2.21

Saturday 6 April

16:30 - 17:25

**Location** Orange Area, HOT 1

**Tutors** S. García Barreras, Madrid (ES)

A. Papatsoris, Athens (GR)

## **Learning objectives**

This basic laparoscopic training course is the first step in the Laparoscopic Urological Skills (LUS) curriculum. It designed to provide urologists with a fundamental understanding of laparoscopy and enhance their laparoscopic skills. This comprehensive training is specifically tailored for urologists who want to gain a basic level of knowledge in laparoscopy and wish to improve their proficiency in key laparoscopic techniques. The course comprises four essential exercises aimed at honing skills related to depth perception and bimanual dexterity: Peg Transfer, Circle Cut, Needle Guidance, and Knot Tying.

The primary objective of this course is to enhance participants' laparoscopic skills, focusing on key aspects such as depth perception and bimanual dexterity. By the end of the course, attendees should feel more confident and competent in their basic laparoscopic skills.

# Hands-on Training in Endoscopic stone treatment - Step 1

HOT 2.22

**Saturday 6 April**

**16:30 - 17:25**

**Location** Orange Area, HOT 1

**Tutors** A.C. Bouma - Houwert, Laren (NL)  
F. Esperto, Rome (IT)  
S. Güven, Konya (TR)  
T. Tokas, Hall In Tirol (AT)

## **Learning objectives**

This Basic Endoscopic Stone Treatment course is the first step in the Endoscopic Stone Treatment (EST) curriculum. It is designed to provide urologists with a fundamental understanding of endoscopic stone treatment and enhance their skills. This comprehensive training is specifically tailored for urologists who want to gain a basic level of knowledge in endoscopy and wish to improve their proficiency in key techniques for endoscopic stone management. The curriculum includes four key exercises that provide hands-on experience and practical training: Flexible Cystoscopy, Rigid Cystoscopy, Semi-Rigid Ureteroscopy, and Flexible Ureteroscopy.

The primary objective of this programme is to enhance participants' skills in the treatment of urinary stones with endoscopic techniques. By the end of the course, attendees should feel more confident and competent in their basic skills.

# Hands-on Training in Transurethral treatment - Step 1 & 2 (TURBT/TURP)

HOT 2.23

**Saturday 6 April**

**16:30 - 17:25**

**Location** Orange Area, HOT 1

**Tutors** R.N. Brito Ramos, Lisbon (PT)

D. Oliveira Reis, Lisboa (PT)

## **Learning objectives**

This training course combines the first and second step of the Transurethral Treatment (TUT) curriculum. It is designed for urologists who wish to improve their proficiency in key techniques and gain a fundamental understanding of transurethral resection of the bladder and prostate. This comprehensive training covers crucial basic skills including flexible and rigid cystoscopy, resection loop handling, and direct vision internal urethrotomy, as well as the resection procedure, practiced on state-of-the-art models.

The primary objective of this course is to enhance participants' skills in transurethral resection of the prostate and bladder, focusing on key aspects such as depth perception, hand-eye coordination, control, handling, and overall technique. By the end of the course, attendees should feel more competent and confident in performing this procedure.

# Hands-on Training in Transurethral treatment - Step 3 (ThuLEP)

HOT 2.24

**Saturday 6 April**

**16:30 - 17:25**

**Location** Orange Area, HOT 2

**Tutors** G. Bozzini, Como (IT)  
T.E. Şener, Istanbul (TR)

## **Learning objectives**

This advanced training course is the third step in the Transurethral Treatment (TUT) curriculum. It is designed to provide urologists with a fundamental understanding of thulium laser enucleation of the prostate (ThuLEP). This comprehensive training is specifically tailored for urologists who want to become proficient in ThuLEP. Using a step by step approach, experts will lead participants through the procedure on state of the art models, to build a familiarity of the process, confidence handling the equipment, and an understanding of best practice.

## **Training aim**

The primary objective of this course is to enhance participants' skills in ThuLEP, focusing on key aspects such as control, handling, and overall technique. By the end of the course, attendees should feel more competent and confident in performing this procedure.

# From diagnosis to management: Comprehensive insights into non-muscle invasive bladder cancer

Abstract session 14

**Saturday 6 April**  
**17:00 - 18:30**

**Location** Green Area, N04  
**Chairs** M. Bandini, Milan (IT)  
A. Van Der Heijden, Nijmegen (NL)  
To be confirmed

We encourage participants in this session to view the abstracts before the session. All abstract bodies, posters, videos and webcasts can be viewed on the EAU(N)24 Resource Centre or at the digital screens in front of the Purple Area, EGPT.

**17:00 - 17:02**

**Introduction**

**17:02 - 17:27**

**Quality of life of patients with non-muscle invasive bladder cancer**

A0368

**Development of the Bladder Utility Symptom Scale (BUSS Utility): A novel tool to measure utilities and quality of life in bladder cancer patients**

G. Kulkarni, Toronto (CA)

A0356

**Quality of life and utility measurement in bladder cancer patients**

M. Papasideris, Toronto (CA)

A0364

**Effect of pregabalin on catheter-related bladder discomfort in patients undergoing transurethral resection of bladder tumor**

B. Mosbahi, Tunis (TN)

A0367

**Effect of Intravesical Bacillus Calmette-Guerin (BCG) Induction Therapy on Sperm Parameters in Sexually Active Male Patients Diagnosed With Non Muscle Invasive Bladder Cancer**

I.O. Canitez, İstanbul (TR)

A0355

**Impact of chronic kidney disease on prognosis in patients with high-risk non-muscle-invasive bladder cancer who underwent adjuvant induction bacillus Calmette-Guérin therapy**

N. Fujita, Hirosaki (JP)

**17:27 - 17:42**

**Urinary markers in the surveillance setting of non-muscle invasive bladder cancer**

A0359

**Clinical Validation and Performance Assessment of a TERT/FGFR3/KRAS Mutation screening urinary biomarker test for recurrence surveillance in non-muscle invasive bladder cancer**

P. Ramos, Porto (PT)

A0358

**Reducing the number of flexible cystoscopies in patients undergoing follow-up for non-muscle invasive bladder cancer with either flexible cystoscopy or the urinary biomarker test Bladder Cancer Monitor: a secondary outcome from a randomised clinical trial**

T. Karmark Dreyer, Aarhus (DK)

A0361

**Results from the prospective randomized UroFollow trial comparing marker-guided vs. cystoscopy-based standard follow-up in patients with low/intermediate risk bladder cancer.**

B. Schmitz-Dräger, Erlangen (DE)

17:42 - 18:27

**Oncological outcome of patients with non-muscle invasive bladder cancer**

A0366

**Long-term oncological outcomes of de novo bladder cancer in kidney transplant recipients: results from a large multicenter international cohort**

S. Livoti, Moncalieri (IT)

A0362

**Evaluation of the long term recurrence risk, metastatic potential and length of cystoscopic surveillance of low-grade non-muscle invasive bladder cancer.**

A. Chan, Toronto (CA)

A0360

**Defining intermediate-risk non-Muscle invasive bladder cancer: a comparative study of EAU and IBCG criteria**

G. Avesani, Milan (IT)

A0354

**Towards Defining Follow-up Strategies for Patients with Primary (First Diagnosis) EAU2021 Intermediate-Risk Non-Muscle Invasive Bladder Cancer**

R. Contieri, Pieve Emanuele (IT)

**Study Group**

On behalf of the Multi-center EAU Non-Muscle-Invasive Bladder Cancer Guidelines Panel Study Consortium on the WHO1973 and WHO2004-2016 Classification Systems for Grade(Arnhem, The Netherlands)

A0363

**Real-world outcomes of bladder sparing treatments (BSTs) in patients with high-risk non-muscle invasive bladder cancer, who failed or were intolerant to BCG therapy**

E. Day, London (GB)

A0365

**Cancer control rates in adequate versus inadequate treatment with adjuvant immunotherapy instillations with BCG**

M. De Angelis, Milan (IT)

A0352

**Development and external validation of an artificial intelligence-based tool for PROgression Risk assessment in Non-muscle invasive Bladder CAncer (PROGRxN-BCa)**

J. Kwong, Toronto (CA)

A0357

**TERT C228T and KDM6A alterations are potential predictive biomarkers in non muscle-invasive bladder cancer treated with Bacillus Calmette–Guérin**

Q-D. Xia, Wuhan (CN)

A0353

**En bloc vs. conventional transurethral resection of bladder tumor: Two-year oncological follow-up of a single-center prospective, randomized, controlled, non-inferiority trial**

P. Diana, Barcelona (ES)

18:27 - 18:30

**Expert summary**

**Saturday 6 April**  
**17:00 - 18:30**

**Location** Purple Area, S01

**Chairs** M.A. Averbeck, Porto Alegre (BR)  
G. Karsenty, Marseille (FR)  
L.M. Liao, Beijing (CN)

We encourage participants in this session to view the abstracts before the session. All abstract bodies, posters, videos and webcasts can be viewed on the EAU(N)24 Resource Centre or at the digital screens in front of the Purple Area, EGPT.

**17:00 - 17:10**

## Neurourology: basic research

A0386

### The role of 5-hydroxytryptamine neurons in the mouse raphe nucleus for controlling the micturition reflex

M. Li, Shanghai (CN)

A0380

### 5-HT<sub>2A/2C</sub> receptor agonist DOI improve detrusor sphincter dyssynergia by inhibiting L-type voltage-gated calcium channels in spinal cord injury rats

R. Lv, shanghai (CN)

**17:10 - 17:45**

## Neurourology clinical

A0382

### HAP-PEE, a Danish national registry study of women with neuromuscular diseases 's ability to urinate when away from home, prevalence of lower urinary tract symptoms and the impact on quality of life

B. Thoft Jensen, Aarhus (DK)

A0376

### Remote Programming in Phase I Sacral Neuromodulation: A Multi-Center Feasibility Study

J. Jing, Beijing (CN)

A0377

### Survey in a young autism spectrum disorder population on bladder and bowel dysfunctions.

M. Gubbiotti, Perugia (IT)

A0375

### Positive Impact of a Patient Support Programme on Intermittent Catheterisation Outcomes

J.N.J. Azuero Perdomo, Bogotá (CO)

A0370

### Comparative cost-consequence study between supra pubic catheter and cystectomy with ileal conduit derivation for patients with neurogenic bladder

C. de Broucker, Nice (FR)

A0373

### Urodynamics: Imposition or not as bad as it seems? Secondary analyses from a randomized controlled trial

O. Gross, Zürich (CH)

A0379

### A prospective paired comparison trial on mirabegron and anticholinergics in patients with low bladder compliance

H.S. Son, Seoul (KR)

**17:45 - 18:00**

## Neuromodulation in neurogenic patients

A0385	<b>Efficacy of sacral nerve modulation in the treatment of neurogenic overactive bladder in patients with multiple sclerosis.</b> B. Carolus, Lille (FR)
A0384	<b>Wearable dorsal genital nerve stimulation to control neurogenic detrusor over-activity after spinal cord injury</b> S.L. Knight, London (GB)
A0372	<b>Transcutaneous spinal cord stimulation and pelvic floor rehabilitation: a randomised controlled trial to investigate effect on lower urinary tract function after spinal cord injury</b> S.L. Knight, London (GB)
<b>18:00 - 18:30</b>	<b>Female urology: miscellaneous topics</b>
A0381	<b>Voiding diary data, patient-reported outcomes and safety through 6 months after sacral neuromodulation implantation in non-obstructive urinary retention patients</b> S. Malde, London (GB)
A0374	<b>Natural Orifice Uterine Suspension (NOUS): An easier way to treat advanced uterine prolapse in elderly patients (IDEAL Phase 2a)</b> C. Zhang, Chengdu (CN)
A0383	<b>Using urinary biomarkers and machine learning models to develop predictive factors for long-term treatment outcome in the patients with interstitial cystitis/bladder pain syndrome</b> M-C. Liu, Hualien (TW)
A0369	<b>A Mussel Inspired Bio-Adhesive for Early Correction of Pelvic Floor Detachment</b> P.E. Zimmern, Dallas (US)
A0378	<b>Robot-assisted sacrocolpopexy versus trans-vaginal prolapse repair: impact on lower bowel tract function</b> A.L. Pastore, Rome (IT)
A0371	<b>Erogenous and Aversive Sensation Throughout the Vulva, Vagina, and Breasts in Cis-Gender Women: Anatomic "Heat-Maps" to Assess Effect of Treatment on Erogenous Sensation</b> M. Garcia, San Francisco (US)



**Saturday 6 April**  
**17:00 - 18:30**

**Location** Green Area, W01

**Chairs** B. Geavlete, Bucharest (RO)  
C.A. Wagner, Zurich (CH)  
K.J. Wang, Chengdu (CN)

We encourage participants in this session to view the abstracts before the session. All abstract bodies, posters, videos and webcasts can be viewed on the EAU(N)24 Resource Centre or at the digital screens in front of the Purple Area, EGPT.

- 
- A0396** **Microplastics exposure influence the formation of calcium oxalate kidney stone through inducing renal injury**  
Y. Chen, Tianjin (CN)
- 
- A0395** **Urinary Metabolic Disturbances and VDR Gene Polymorphisms as Prognostic Factors for Recurrence of Calcium Oxalate Renal Calculi: A prospective controlled trial.**  
A.E. Abolazm, Mansoura (EG)
- 
- A0400** **Comparison of the intestinal microbiota of patients with primary hyperparathyroidism with and without urinary system stone disease**  
A. Gudeloglu, Ankara (TR)
- 
- A0403** **Fecal microbiome in patients with staghorn calcium oxalate stones treated with percutaneous nephrolithotomy: a comparative study with stone-free subjects**  
Y. Lu, Singapore (SG)
- 
- A0393** **Cross-species multi-omics analysis using human GWAS and a mouse model reveals novel urolithiasis-associated molecules CRYAB and SHROOM3 acting in collecting duct principal cells**  
R. Chaya, Nagoya (JP)
- 
- A0391** **Long-term sodium deficiency reduces sodium excretion but impairs renal function and increases stone formation in hyperoxaluric calcium oxalate rats**  
Y-C. Huang, Tainan (TW)
- 
- A0390** **Preliminary study on PKA/STAT3 in the formation mechanism of kidney stones induced by nanobacteria mediated by CaSR-Claudin-14 pathway**  
J. Zou, Ganzhou (CN)
- 
- A0399** **Exosomal miR-146a-5p, the hope within Pandora's Box for CaOx stones**  
Y. Yang, Wuhan (CN)
- 
- A0401** **Exploring the Pandora's box—exosomes derived from HK2 cells**  
Y. Yang, Wuhan (CN)
- 
- A0402** **Urinary glycated uromodulin of diabetic nephropathy patients accelerate more crystal aggregation and kidney stone formation**  
Y-S. Tseng, Taipei (TW)



# The cutting edge of prostate surgery: New techniques and technologies

Video session 07

**Saturday 6 April**  
**17:00 - 18:30**

**Location** Green Area, S04

**Chairs** F. Gómez Veiga, Salamanca (ES)  
K. Maes, Lisbon (PT)

We encourage participants in this session to view the abstracts before the session. All abstract bodies, posters, videos and webcasts can be viewed on the EAU(N)24 Resource Centre or at the digital screens in front of the Purple Area, EGPT.

V048 (□ 5 min.)

**Peritoneal flap following lymph node dissection in robotic radical prostatectomy: A novel "Bunching" technique**

M. Covas Moschovas, Celebration (US)

V049 (□ 8 min.)

**Robot-assisted transperineal radical prostatectomy: Surgical technique and analysis of intraoperative and postoperative outcomes**

R. Almeida-Magana, London (GB)

V050 (□ 6 min.)

**Robotic assisted prostatectomy in a patient with a pre-existing inflatable penile prosthesis –a novel suspensory technique**

J. McDonald, Melbourne (AU)

V051 (□ 6 min.)

**Impact of a novel anterior suspension stitch on return of urinary continence after Robotic Radical Prostatectomy (RRP), with description of surgical technique**

S. Arora, Detroit (US)

V052 (□ 7 min.)

**Surgical and new generation imaging tips and tricks to maximize robotic radical prostatectomy outcomes**

F. Piramide, Turin (IT)

V053 (□ 6 min.)

**IP8-FLUORESCENCE: Fluorescence Confocal Microscopy for Rapid Evaluation of Surgical Margins**

N. Mayor, London (GB)

V054 (□ 7 min.)

**Lateral versus anterior approach for bladder neck dissection during robot-assisted radical prostatectomy: impact on surgical margins and early urinary continence.**

F. Lavagno, Turin (IT)

V055 (□ 8 min.)

**Robot assisted radical prostatectomy: SSI Mantra**

S.K. Pratihar, (IN)

**Saturday 6 April**  
**17:00 - 18:30**

**Location** Purple Area, EGPT

**Chairs** A. Cocci, Florence (IT)  
S. Minhas, London (GB)

We encourage participants in this session to view the abstracts before the session. All abstract bodies, posters, videos and webcasts can be viewed on the EAU(N)24 Resource Centre or at the digital screens in front of the Purple Area, EGPT.

**17:00 - 17:21**

## **Screen A: Surgical approaches for male infertility**

- P188** **Microscopic surgery for the repair of painful varicocele—efficacy, and predictors of successful outcomes**  
S. Bercovich, Petah-tikva (IL)
- P177** **Day-Case Vasectomy Reversal Under Local Anaesthesia: Evaluating Feasibility, Safety and Effectiveness**  
A. Mukherjee, Newcastle Upon Tyne (GB)
- P179** **Risk factor analysis including ductus deferens lavage for lingering sperm post vasectomy**  
C-H. Lu, Taichung (TW)
- P185** **The Necessity of Improvement in Micro-TESE for Male Infertility based on Current Literature: the Clinical Investigation of a New Imaging Modality**  
M. Cetin, İstanbul (TR)
- P197** **Hormonal changes following microdissection testicular sperm extraction in men with non-obstructive azoospermia - findings from a real-life multi-centric study**  
E. Pozzi, Milan (IT)
- P201** **Predictive factors in the success of surgical sperm retrieval techniques**  
H.R. Ayllón, Alcobendas-Madrid (ES)
- P183** **Clinical outcomes of intracytoplasmic sperm injection using ejaculated or testicular sperm in patients with AZFc deletions**  
Y. Fang, Beijing (CN)

**17:21 - 17:39**

## **Screen B: Erectile restoration with penile prosthesis**

- P180** **"Comparing Chlorhexidine 0.05% Antiseptic Monotherapy to Conventional Combined Antibiotic Irrigation During Penile Prosthesis Implantation: A Two-Center Prospective Randomized Controlled Non-Inferiority Study" (Preliminary Data)**  
E. Desouky, Chicago (US)
- P189** **The Road to Penile Prosthesis: Unveiling Factors Linked to Early Surgery - Insights from a Real-Life Cross-Sectional Study**  
E. Pozzi, Milan (IT)
- P173** **Perioperative outcomes and evolution of penile prosthesis implantation in Germany: Results from the GRAND study**  
N. Pyrgidis, München (DE)

P200	<b>Penile prosthesis with contemporary plastic procedures in obese patients: complication and satisfaction rate in day case surgery setting</b> G. Maiolino, Perugia (IT)
P192	<b>Long-term outcomes and risk factors for reintervention after Penile Prosthesis Implantation</b> S. Zouari, Nice (FR)
P176	<b>Male genital image and quality of life after penile prosthesis implantation: a patient perspective</b> N. García Formoso, Santander (ES)
<hr/>	
<b>17:39 - 18:00</b>	<b>Screen C: Peyronie's disease and priapism</b>
P175	<b>What do patients with Peyronie's disease expect from therapy? A prospective multi-center study</b> A. Soave, Hamburg (DE)
P182	<b>Severity of penile curvature in patients with Peyronie's disease and erectile dysfunction does not correlate with dynamic colour Doppler duplex ultrasound parameters: findings from a real-life cross-sectional study</b> F. Negri, Milan (IT)
P199	<b>Multicenter evaluation of Multi-Incision Technique (MIT) with Malleable Prosthesis in Peyronie's Disease: a Lengthening Strategy in patients with or without Erectile Dysfunction</b> G. Maiolino, Perugia (IT)
P187	<b>Lengthening Corporoplasty with TachoSil® in Peyronie's Disease – A National Multicentric Analysis</b> A. Costa Silva, Porto (PT)
P191	<b>Shockwave therapy and Platelet Rich Plasma for the treatment of Peyronie's disease</b> M.V. Epifanova, Moscow (RU)
P198	<b>Outcomes of superselective transcatheter embolization in high-flow priapism</b> A. Biasatti, Trieste (IT)
P184	<b>Quality of life outcomes for penile prosthesis insertion post-priapism – Satisfaction guaranteed?</b> I. Dighero, London (GB)
<hr/>	
<b>18:00 - 18:18</b>	<b>Screen D: Post-prostatectomy ED and rehabilitation</b>
P181	<b>An exploratory clinical trial of alginate gel combined with polyglycolic acid nerve sheets for restoring erectile function following cavernous nerve injury during radical prostatectomy</b> N. Narita, Aktia (JP)
P178	<b>Transcutaneous mechanical nerve stimulation as rehabilitation of sexual function following nerve-sparing radical prostatectomy: A pilot study</b> M.M. Fode, Herlev (DK)
P194	<b>Evaluation of the consequences of direct current stimulation (DCS) treatment in patients undergoing robot-assisted radical prostatectomy with nerve-sparing technique</b> F.P. Bizzarri, Roma (IT)

- P195** **Low-intensity extracorporeal shockwave therapy is safe immediately following robotic-assisted radical prostatectomy (NCT03862599)**  
F.E.N. MacAskill, London (GB)  
**Study Group**  
Guy's Post Pelvic Surgery Research Group(London, United Kingdom)
- P196** **Preoperative prostatic urethral length in MRI is associated with the risk of climacturia after robotic radical prostatectomy**  
C. Munoz Calahorro, Seville (ES)
- 
- 18:18 - 18:30** **Screen E: ESWT**
- P193** **Comparison of three focal shockwave protocols for the treatment of erectile dysfunction**  
H.A. Corredor Ayala, Bogota (CO)
- P190** **Erectile dysfunction treatment by platelet-rich plasma and extracorporeal shock wave therapy**  
M.V. Epifanova, Moscow (RU)
- P202** **Correlation between comorbidities and the response of erectile dysfunction (ED) to low-intensity extracorporeal shock wave therapy (LI-ESWT): a prospective study**  
L. Quaresima, CIVITANOVA MARCHE (IT)
- P174** **The effect of combination treatment with low-intensity shockwave therapy and daily low-dose tadalafil on severe erectile dysfunction: A double-blind, randomized, sham-controlled clinical trial**  
N. Pyrgidis, München (DE)

# Lancet Commission on prostate cancer

Thematic Session

**Saturday 6 April**  
**17:15 - 19:15**

**Location** Purple Area, eURO Auditorium 2

**17:15 - 17:20**

**Introduction and welcome**

P. Albers, Düsseldorf (DE)

**17:20 - 17:25**

**Lancet opening remarks**

V. Wisdom, London (GB)

**17:25 - 17:35**

**Overview of the key findings**

N. James, London (GB)

**17:35 - 17:45**

**Global oncology perspective**

I.F. Tannock, Toronto (CA)

**17:45 - 17:55**

**Urological perspective**

J. N'Dow, Aberdeen (GB)

**17:55 - 18:05**

**Oncological perspective**

S. Gillesen Sommer, Bellinzona (CH)

**18:05 - 18:35**

**Panel discussion Key findings from point of view of Commission members**

*Moderator*

V. Wisdom, London (GB)

*Panel*

E. Compérat, Vienna (AT)

O. Fatiregun, Ikeja (NG)

M. Jalloh, Dakar (SN)

N. James, London (GB)

S. Loeb, New York (US)

J. N'Dow, Aberdeen (GB)

**18:35 - 19:10**

**Panel discussion key findings from Global Health point of view**

*Moderator*

R. Horton, London (GB)

*Panel*

P. Albers, Düsseldorf (DE)

R. Casolino, Geneva (CH)

J. Dunn, Spring Hill (AU)

K. Fizazi, Villejuif (FR)

N. James, London (GB)

**19:10 - 19:15**

**Closing remarks**

P. Albers, Düsseldorf (DE)

V. Wisdom, London (GB)

**Saturday 6 April**  
**17:15 - 18:45**

**Location** Purple Area, N01

**Chairs** J. Angulo Cuesta, Getafe (ES)  
J.C. Goddard, Leicester (GB)  
D. Schultheiss, Giessen (DE)

We encourage participants in this session to view the abstracts before the session. All abstract bodies, posters, videos and webcasts can be viewed on the EAU(N)24 Resource Centre or at the digital screens in front of the Purple Area, EGPT.

**17:15 - 17:17**

**Introduction**

A0409

**Of Monkeys and Men: Britain's rejuvenators and the decade of the testicle**  
J. Hill, Portsmouth (GB)

A0421

**Abacadabra! Bladder Stones, Birds` Eggs, Wild Horses and Joseph-Émile Cornay**  
J.K. Badawi, Luzern (CH)

A0415

**Fernand Cathelin (1873-1960): eminent urologist and pioneer of sacral anaesthesia**  
D. Schultheiss, Giessen (DE)

A0411

**Sir Peter Freyer: The man who popularized prostatectomy and his love affair with India**  
P. Sharma, Gurugram (IN)

A0420

**Revision of the case of the first human kidney transplantation: the original article by Yurii Voronoy**  
J. Medina-Polo, Madrid (ES)

A0418

**Nudity and sexual symbology in Romanesque baptismal fonts in medieval Spain**  
J. Angulo Cuesta, Getafe (ES)

A0417

**Historicization in Urology: The Viennese and Austrian Model**  
F. Moll, Stolberg (DE)

A0416

**August Socin (1837 –1899) a pioneer in Urology from a small University**  
D. Tausky, Montreal (CA)

A0405

**history and evolution of percutaneous nephrolithotomy**  
A. Chatar, Meknes (MA)

A0413

**A pioneer turkish urologist-medical historian and his one-century-old review about prostate with integration effort of Turkish republic to Europe**  
A. Verit, Istanbul (TR)

A0410

**Charles Brenton Huggins: a historical review of the Nobel laureate's pioneering contributions to hormonal treatment for prostate cancer**  
F. Saad, Montréal (CA)



A0408

**Historical aspects of the relationship between Peruvian and French urology**

J. Corrales Riveros, Lima (PE)

---

A0414

**What is new at the deepest point of human civilization for andrologic point of view?**

A. Verit, Istanbul (TR)

---

A0406

**Bhutan: The divine madman and his phallic legacy.**

A. Baby, Redhill (GB)

# Improved risk stratification before local treatment of prostate cancer

Abstract session 18

**Saturday 6 April**  
**17:15 - 18:45**

**Location** Green Area, W06

**Chairs** R.J. Karnes, Rochester (US)  
Z. Krstanoski, Slovenj Gradec (SI)  
R. Sosnowski, Warsaw (PL)

We encourage participants in this session to view the abstracts before the session. All abstract bodies, posters, videos and webcasts can be viewed on the EAU(N)24 Resource Centre or at the digital screens in front of the Purple Area, EGPT.

**17:15 - 17:17**

**Introduction**

**17:17 - 17:32**

**Type of treatment and outcome**

**A0428**

**The Impact of Radical Prostatectomy versus Radiation Therapy on Cancer-Specific-Mortality for Non-Metastatic Prostate Cancer: analysis of an Other-Cause-Mortality Matched Cohort**

M. Finati, Foggia (IT)

**A0422**

**The impact of radical prostatectomy versus radiation therapy on cancer-specific mortality for patients with localized prostate cancer and positive nodal disease: an analysis of other cause mortality weighted cohort.**

F. Abdollah, Detroit (US)

**17:32 - 17:47**

**Defining risk**

**A0431**

**Impact of time interval between diagnosis and radical prostatectomy on treatment outcome**

C.H. Yee, Hong Kong (HK)

**A0435**

**The Impact of Omitting Contralateral Systematic Biopsy on the Surgical Planning of Patients with a Unilateral Suspicious Lesion on Pre-operative MRI undergoing Robot-Assisted Radical Prostatectomy for Prostate Cancer**

D.L. van den Kroonenberg, Amsterdam (NL)

**A0429**

**Long-Term Oncological Outcomes of Surgically Managed Very High-Risk Prostate Cancer Patients According to the STAMPEDE Trial Definition: Implications for the Selection of Candidates for Clinical Trials**

A. Pellegrino, Milan (IT)

**17:47 - 18:42**

**Staging of the lymph nodes**

**A0425**

**A novel machine learning-based model predicting lymph node metastasis at robotic assisted radical prostatectomy**

D. Fuligni, Ancona (IT)

**A0437**

**PSMA PET/CT and nodal staging in prostate cancer: comparison between the diagnostic accuracy of different PSMA- ligand radiopharmaceuticals. A single institutional analysis**

P. Arena, Pieve Emanuele MI (IT)

- A0430** External Validation of the Available Nomograms for the Identification of Candidates for a Staging Extended Pelvic Lymph Node Dissection at the Time of Radical Prostatectomy in Prostate Cancer Patients Preoperatively Staged with PSMA PET  
F.M. Barletta, Milan (IT)
- A0423** The early oncological effect of extended pelvic lymph node dissection in men with at PSMA PET/CT N0M0 intermediate/high-risk prostate cancer - an international cohort study  
P.J. Van Leeuwen, Amsterdam (NL)
- A0438** A prospective randomized multicenter study on the impact of 18F-Choline PET/CT versus conventional imaging for staging intermediate- to high-risk prostate cancer  
F. Zattoni, Verona (IT)
- A0434** "The More You See the More You miss". PSMA PET/CT Is Still Affected by a Substantial Risk of Underestimation in Prostate Cancer Patients Undergoing Radical Prostatectomy  
P. Zaurito, Milan (IT)
- A0436** PSMA Radio-Guided Surgery to Detect Nodal Metastases in Prostate Cancer Patients Undergoing Robot-assisted Radical Prostatectomy and Extended Pelvic Lymph Node Dissection: Updated Results of a Planned Interim Analysis of a Prospective Phase 2 Study.  
L. Quarta, Milan (IT)
- A0433** Oncological Outcomes of pN1 Prostate Cancer Patients Treated with Radical Prostatectomy: Does Molecular Imaging Have a Prognostic Impact? Results of a Large, Multi-Institutional Series  
F.M. Barletta, Milan (IT)
- A0427** Size of lymph-node metastases in prostate cancer patients undergoing radical prostatectomy: Implication for imaging and oncologic follow-up of 2705 lymph-node positive patients  
F. Falkenbach, Hamburg (DE)
- A0426** Correlation Between the Location of the Index Tumour and the Location of Positive Lymph Nodes in High-Risk Prostate Cancer – A Monocentric Positive Lymph Node Mapping Study  
H. Decloedt, Leuven (BE)
- A0432** Prostate cancer patients with lymphatic node involvement detected by immunohistochemistry. Is the effort worthwhile?  
A. Aldaz Acin, Ejea de los Caballeros (ES)

---

**18:42 - 18:45**

**Expert summary**

# How to deal with complications?

Plenary Session

**Sunday 7 April**  
**08:00 - 10:00**

**Location** Purple Area, eURO Auditorium 2

**Chairs** J. Boormans, Rotterdam (NL)  
J. Rassweiler, Krems - Stein (AT)

## **Learning objectives**

Over the last decade, the concept of this session has been very well received by the delegates. This year we are happy to be able to invited the key opinion leaders and surgeons in their respective field to comment and discuss the management of complications in basically all important fields of minimally invasive surgery in urology. Since the possibility of personal interaction of the audience is relatively limited in a plenary session, we have chosen this format. The expert will challenge the young presenter of the respective complication and both can then discuss all important steps of managing and preventing the pitfalls.

**08:00 - 08:12**

## **Video-based PowerPoint presentation Robotic management of vascular complications**

*Speaker* C. Fankhauser, Lucerne (CH)

*Discussant* C. Schwentner, Stuttgart (DE)

**08:12 - 08:24**

## **Discussion**

**08:24 - 08:36**

## **Video-based PowerPoint presentation Rectal injury during pelvic surgery: How do I deal with it?**

*Speaker* G. Pignot, Marseille (FR)

*Discussant* P. Wiklund, Stockholm (SE)

**08:36 - 08:48**

## **Discussion**

**08:48 - 09:00**

## **Video-based PowerPoint presentation The case of ureteral avulsion during ureteroscopy and its management**

*Speaker* J. Baard, Amsterdam (NL)

*Discussant* O. Traxer, Paris (FR)

**09:00 - 09:12**

## **Discussion**

**09:12 - 09:24**

## **Video-based PowerPoint presentation Nightmares in percutaneous renal surgery**

*Speaker* S. Proietti, Milan (IT)

*Discussant* E. Liatsikos, Patras (GR)

**09:24 - 09:36**

## **Discussion**

09:36 - 09:48

**Video-based PowerPoint presentation** **What can go wrong during enucleation of the prostate?**

*Speaker*

I. Schwartzmann, Barcelona (ES)

*Discussant*

C.M. Scoffone, Turin (IT)

---

09:48 - 10:00

**Discussion**



# Personalised approaches in high-risk and metastatic prostate cancer

Plenary Session

Sunday 7 April  
08:00 - 10:00

**Location** Green Area, eURO Auditorium 1

**Chairs** A. Briganti, Milan (IT)  
S. Gillessen Sommer, Bellinzona (CH)

## Learning objectives

Learn to apply more granularity when treating patients with advanced prostate cancer in any setting from high risk localised disease to metastatic disease.

Participants should learn how to make best use of next generation imaging and how to best personalise treatment in different settings.

**08:00 - 08:10** **State-of-the-art lecture Staging high-risk prostate cancer with PET PSMA: Strengths and pitfalls**  
I. Burger, Baden (CH)

**08:10 - 08:15** **Discussion**

**08:15 - 08:42** **Case discussion Negative staging PSMA in high-risk disease: Can we skip extended PLND?**

**08:15 - 08:17** **Case presentation**  
I. Heidegger, Innsbruck (AT)

**08:17 - 08:22** **Yes, we can**  
D. Murphy, Melbourne (AU)

**08:22 - 08:27** **No, we cannot**  
A. De La Taille, Créteil (FR)

**08:27 - 08:32** **The guidelines' view**  
J. Stranne, Göteborg (SE)

**08:32 - 08:42** **Discussion**

**08:42 - 08:52** **State-of-the-art lecture Clinical and molecular stratification of men with biochemical recurrence after radical prostatectomy**  
R.C.N. Van Den Bergh, Utrecht (NL)

**08:52 - 09:19** **Case discussion High-risk biochemical recurrence after radical prostatectomy and negative PSMA PET: What to do?**

**08:52 - 08:54** **Case presentation**  
G. Gandaglia, Milan (IT)

**08:54 - 08:59** **RT + ADT in all patients**  
T. Zilli, Genève (CH)

**08:59 - 09:04** **Systemic therapy alone**  
A.S. Rannikko, Helsinki (FI)

**09:04 - 09:09** **The guidelines' view**  
D. Tilki, Hamburg (DE)

**09:09 - 09:19** **Discussion**

09:19 - 09:29	<b>State-of-the-art lecture</b> <b>How to personalise treatment in mHSPca? More than just counting metastases</b> K. Fizazi, Villejuif (FR)
09:29 - 09:39	<b>State-of-the-art lecture</b> <b>Local therapy in mHSPCa: Who really benefits?</b> A. Bossi, Villejuif (FR)
09:39 - 09:44	<b>Discussion</b>
09:44 - 10:00	<b>Case discussion</b> <b>PARP-I only for patients with alterations in DNA repair genes: Yes vs. no</b>
09:44 - 09:46	<b>Case presentation</b> S. Merler, Verona (IT)
09:46 - 09:51	<b>Yes</b> E. Castro, Madrid (ES)
09:51 - 09:56	<b>No</b> F. Saad, Montréal (CA)
09:56 - 10:00	<b>The guidelines' view</b> M. De Santis, Berlin (DE)

Sunday 7 April

08:30 - 11:30

**Location** Purple Area, E06

**Chair** T. Taily, Ghent (BE)

### Learning objectives

Urolithiasis is an increasingly prevalent worldwide disease with recurrence rates up to 50% over 5 years. Metabolic assessment to identify predisposing factors and prevention therefore play an important role in patient management. This course will address common findings on dietary and metabolic workup and highlight medical and non-medical treatment options for these metabolic abnormalities in the prevention of stone recurrence.

The goal of the course is for participants to be able to:

- Identify patients that would benefit from metabolic workup.
- Interpret standard metabolic workup, including dietary and medical history and biochemical analyses.
- Understand what the guidelines say on targeted medical treatment for prevention of urinary stone disease.
- Understand the influence of dietary changes on metabolic urinary values and provide dietary counseling.

### Who needs a metabolic evaluation and why should this be done

M. Straub, Munich (DE)

### How to do a metabolic evaluation, step-by-step

T. Taily, Ghent (BE)

### Common stone types: What abnormalities might we find on investigation?

T. Taily, Ghent (BE)

### Stone and diet: What advice should we give?

M. Straub, Munich (DE)

### Medical treatment for stones: What works?

T. Taily, Ghent (BE)

### Interactive case discussions

M. Straub, Munich (DE)

T. Taily, Ghent (BE)



**Sunday 7 April**  
**08:30 - 11:30**

**Location** Purple Area, E02

**Chair** J.F. Langenhuijsen, Nijmegen (NL)

### **Learning objectives**

To teach all about the adrenal gland minimal invasive approach; starting with the correct indications for surgery and preoperative medical preparation. The different approaches and new equipment will be shown including special instructions. The operations will be given step by step in high quality videos in detail with tips and tricks. The complication videos and intraoperative management will be discussed interactively with the experts.

### **Introduction**

J.F. Langenhuijsen, Nijmegen (NL)

### **Indications and patient preparation (medical and surgical)**

J.F. Langenhuijsen, Nijmegen (NL)

### **Surgical anatomy of adrenals**

C. Fiori, Orbassano (IT)

### **How I do it; step by step operative procedure, technical tips and tricks**

#### **- Transperitoneal**

N. Knežević, Zagreb (HR)

#### **- Retroperitoneal and prone**

J.F. Langenhuijsen, Nijmegen (NL)

#### **- Mini-laparoscopic**

C. Fiori, Orbassano (IT)

### **Partial adrenalectomy and challenging cases in adrenalectomy**

J.F. Langenhuijsen, Nijmegen (NL)

### **Complications and management**

C. Fiori, Orbassano (IT)

N. Knežević, Zagreb (HR)

### **Discussion and interaction**

C. Fiori, Orbassano (IT)

N. Knežević, Zagreb (HR)

J.F. Langenhuijsen, Nijmegen (NL)

# Percutaneous nephrolithotripsy (PCNL)

ESU Course 30

Sunday 7 April

08:30 - 11:30

**Location** Purple Area, E04

**Chair** A. Skolarikos, Athens (GR)

Voting will be available via the EAU24 App or via [www.qna.at/eau](http://www.qna.at/eau)

## Learning objectives

The aim of this course is to describe the surgical techniques of all available treatment options in percutaneous surgery of renal stones in details. In addition to tips and tricks aiming into improving the efficacy of the operation, the most common complications associated with the procedure will be reviewed focusing on prevention and proper management.

Objectives:

- describe the main indications for percutaneous nephrolithotomy and the best clinical practice based on the EAU Guidelines
- Describe the basic percutaneous nephrolithotomy techniques step by step
- Provide tips and tricks to improve the efficacy of the operation
- Identify associate complications including their management

## Guidelines on stone treatment

E.K. Bres-Niewada, Pruszkow (PL)

## PCNL instrumentation – Suite organisation, wires, dilators and lithotriptors

E.K. Bres-Niewada, Pruszkow (PL)

## From skin to stone: Step-by-step access using only fluoroscopy (Prone position)

A. Skolarikos, Athens (GR)

## From skin to stone: Step-by-step access using ultrasonography (US) and fluoroscopy (Supine position)

O. Angerri Feu, Barcelona (ES)

## MiniPerc- Indications, equipment and technique

A. Skolarikos, Athens (GR)

## Tips and tricks in PCNL

O. Angerri Feu, Barcelona (ES)

## Round table: Complications of PCNL: Diagnosis, management, prevention

O. Angerri Feu, Barcelona (ES)

E.K. Bres-Niewada, Pruszkow (PL)

A. Skolarikos, Athens (GR)

# Enhanced recovery after surgery (ERAS) in urological surgery

ESU Course 31

Sunday 7 April

08:30 - 11:30

**Location** Purple Area, E05

**Chair** J. Walz, Marseille (FR)

## Learning objectives

Enhanced recovery after surgery (ERAS) has become a mainstay in modern surgical management. The aim of this concept is to optimize and standardize perioperative management to reduce the risk of complications, and promote faster recovery and shorter hospital stays. Key elements of ERAS include increasing the use of minimally invasive surgical approaches and standardized clinical pathways starting before surgery and continuing through recovery, as well as a proactive approach to increasing patient mobilization and return to oral nutrition. ERAS is grounded in a multidisciplinary approach to proactively facilitating recovery. The course provides a detailed overview of the current standard ERAS protocols and pathways as well as practical tips on how to get started with an ERAS programme.

## The concept of ERAS

J. Walz, Marseille (FR)

## The surgical tools

C. Fankhauser, Lucerne (CH)

## The organizational tools

S. Psutka, Seattle (US)

## The anesthesia tools

J. Walz, Marseille (FR)

## Protocols for endoscopy

C. Fankhauser, Lucerne (CH)

## Protocols for nephrectomy

S. Psutka, Seattle (US)

## Protocols for radical prostatectomy

J. Walz, Marseille (FR)

## Protocols for cystectomy

C. Fankhauser, Lucerne (CH)

## Personalized risk stratification

S. Psutka, Seattle (US)

## How to get started with ERAS?

J. Walz, Marseille (FR)

## Questions and answers

Sunday 7 April

08:30 - 11:30

**Location** Purple Area, E01

**Chair** F. Montorsi, Milan (IT)

### Learning objectives

This course is aimed at critically reviewing key manuscripts published during the previous 12 months and devoted to the management of prostate cancer patients with a particular focus on basic research, screening, diagnosis, staging, and local and systemic therapies. Practice-changing manuscripts published in peer-reviewed journals will be identified and discussed for each topic. For every paper a clear take home message applicable to the every-day clinical practice will be identified and discussed. The main objective of the course is to inform participants on the latest and most significant novelties related to the contemporary management of prostate cancer patients.

### Clinical implications of basic research

F. Montorsi, Milan (IT)

### Screening: Novel biomarkers and strategies

C.P. Evans, Sacramento (US)

### Diagnosis: Role of mpMRI and PET PSMA in detecting prostate lesions. Fusion biopsies

F. Montorsi, Milan (IT)

### Staging: Imaging and predictive models

M. Graefen, Hamburg (DE)

### Treatment of localised prostate cancer: Radical prostatectomy

M. Graefen, Hamburg (DE)

### Treatment of localised prostate cancer: Focal therapy

F. Montorsi, Milan (IT)

### Treatment of localised prostate cancer: Radiation therapy

M. Graefen, Hamburg (DE)

### Management of recurrence after curative treatment

M. Graefen, Hamburg (DE)

### Management of hormone sensitive metastatic prostate cancer

C.P. Evans, Sacramento (US)

### Management of castration-resistant prostate cancer

C.P. Evans, Sacramento (US)

Sunday 7 April

08:30 - 11:30

**Location** Purple Area, E03

**Chair** J. Palou, Barcelona (ES)

## Learning objectives

The aim of this course is to describe the surgical technique of radical cystectomy. There are different approaches for radical surgery depending on the expertise and economical possibilities of the centers, and even there are some differences on the results, it is important to follow some basic principles.

The main differences according to the surgical approach will be described (open, laparoscopic and robotic).

Tips and tricks of each approach will be presented in order to show the most important steps of each procedure, and also according to execute a nerve sparing or and organ sparing procedure.

Finally the most common complications will be analysed in order prevent and improve their management.

Objectives:

- Describe the rational to choose an specific urinary diversions
- Describe the main details of the different approaches and treatment anatomy related to nerve sparing, organ sparing, intracorporeal diversion
- Provide tips and tricks to improve the efficacy and results of the operation
- Explain the complications including their prevention and management

## Introduction

J. Palou, Barcelona (ES)

## Which diversion for which patient?

J. Palou, Barcelona (ES)

## Open cystectomy in male (nerve and no nerve sparing)

B. Ali-El-Dein, Mansoura (EG)

## Laparoscopic female cystectomy (organ and non- organ sparing)

M. Karavitakis, Pagkrati - Athens (GR)

## Robotic intracorporeal ileal conduit and neobladder diversion

C. Wijburg, Arnhem (NL)

## Global tricks to decrease complications

J. Palou, Barcelona (ES)

Sunday 7 April

08:30 - 11:30

**Location** Purple Area, E07

**Chair** T.M. Kessler, Zurich (CH)

### Learning objectives

- Learn which nerve centres control the lower urinary tract, and the general principles of how functions change in neurological disease
- Understand key aspects of neuro-urological assessments as described in the EAU guidelines
- Discuss key factors when deciding on therapy

### Introduction: What can go wrong with the lower urinary tract?

T.M. Kessler, Zurich (CH)

### Neuro-urological assessments

S.T. De Cillis, Turin (IT)

### Treatment: Key issues

N. Sihra, London (GB)

### Clinical case discussion

S.T. De Cillis, Turin (IT)

T.M. Kessler, Zurich (CH)

N. Sihra, London (GB)

### Conclusion

T.M. Kessler, Zurich (CH)

# ESTs1 Exam

HOT 3.02

**Sunday 7 April**

**09:00 - 09:55**

**Location**

Orange Area, HOT 1

**Tutors**

A.C. Bouma - Houwert, Laren (NL)

P. Kallidonis, Patras (GR)

G.M. Kamphuis, Amsterdam (NL)

A. Pietropaolo, Southampton (GB)

Sunday 7 April

09:00 - 12:30

**Location** Orange Area, HOT 5

**Chair** F. Sanguedolce, Barcelona (ES)

### Learning objectives

The MRI Reading Course is designed as a half-day or full-day live or online training. This course will provide interactive teaching from expert faculty in prostate MRI reading and interpretation and help urologists to understand the role MRI plays in the management of patients with prostate cancer and how to use the information generated by prostate MRI. The course will address how to use an imaging workstation, how to understand the basic concepts/principles behind different MRI sequences (T2-weighted imaging, DWI-imaging and DCE-imaging), in which order to view the different sequences when interpreting prostate MRI, how to use the PI-RADS scoring system to score MRIs, and finally to understand what are the standards for a prostate MRI and what quality criteria need to be fulfilled. The participants will do hands on reading and assessment of prostate MRI scans on their computer via MIM-software followed by a reference reading provided by expert radiologists and pathological verification.

09:00 - 09:05

### Course Overview

F. Sanguedolce, Barcelona (ES)

09:05 - 09:15

### Lecture: The importance of prostate MRI to the Urologist

F. Sanguedolce, Barcelona (ES)

09:15 - 09:45

### Lecture: Introduction to MRI sequences, scoring systems, PI-RADS

J.A. Hernández Mancera, Barcelona (ES)

09:45 - 10:15

### Lecture: Interactive case discussion – reporting MRI using PI-RADS

V. Panebianco, Rome (IT)

10:15 - 10:20

### Introduction to the software for MRI interpretation

C.V. Kesch, Essen (DE)

10:20 - 10:50

### Diagnosis I: Practical MRI diagnosis

10:50 - 11:20

### Review of the findings I

J.A. Hernández Mancera, Barcelona (ES)

11:20 - 11:50

### Diagnosis II: Practical MRI diagnosis

11:50 - 12:20

### Review of the findings II

V. Panebianco, Rome (IT)

12:20 - 12:30

### Discussion, feedback, & closure

C.V. Kesch, Essen (DE)



# Hands-on Training in Transurethral treatment - Step 1 & 2 (TURBT/TURP)

HOT 3.03

Sunday 7 April

09:00 - 09:55

**Location** Orange Area, HOT 1

**Tutors** R.N. Brito Ramos, Lisbon (PT)

L. Osório, Porto (PT)

## **Learning objectives**

This training course combines the first and second step of the Transurethral Treatment (TUT) curriculum. It is designed for urologists who wish to improve their proficiency in key techniques and gain a fundamental understanding of transurethral resection of the bladder and prostate. This comprehensive training covers crucial basic skills including flexible and rigid cystoscopy, resection loop handling, and direct vision internal urethrotomy, as well as the resection procedure, practiced on state-of-the-art models.

The primary objective of this course is to enhance participants' skills in transurethral resection of the prostate and bladder, focusing on key aspects such as depth perception, hand-eye coordination, control, handling, and overall technique. By the end of the course, attendees should feel more competent and confident in performing this procedure.

# E-BLUS Exam

HOT 3.01

**Sunday 7 April**

**09:00 - 09:30**

**Location**

Orange Area, HOT 1

**Tutors**

A. Papatsoris, Athens (GR)

J.B. Roche, Bordeaux (FR)

# Hands-on Training in Transurethral treatment - Step 3 (ThuLEP)

HOT 3.04

Sunday 7 April

09:00 - 09:55

**Location** Orange Area, HOT 2

**Tutors** I. Kartalas Goumas, Milan (IT)

T.E. Şener, Istanbul (TR)

## **Learning objectives**

This advanced training course is the third step in the Transurethral Treatment (TUT) curriculum. It is designed to provide urologists with a fundamental understanding of thulium laser enucleation of the prostate (ThuLEP). This comprehensive training is specifically tailored for urologists who want to become proficient in ThuLEP. Using a step by step approach, experts will lead participants through the procedure on state of the art models, to build a familiarity of the process, confidence handling the equipment, and an understanding of best practice.

## **Training aim**

The primary objective of this course is to enhance participants' skills in ThuLEP, focusing on key aspects such as control, handling, and overall technique. By the end of the course, attendees should feel more competent and confident in performing this procedure.

# Hands-on Training: Office based freehand transperineal prostate biopsies under local anesthesia

HOT 3.31

**Sunday 7 April**  
**09:00 - 10:30**

**Location** Orange Area, HOT 3

**Chair** L. Budäus, Hamburg (DE)

## **Learning objectives**

Infections are a particularly relevant clinical problem in transrectal prostate biopsy. Transperineal prostate biopsy allows a significant reduction in the risk of infection, but requires good anatomical knowledge for sufficient local anesthesia and rapid workflow. During the course, innovative options for reducing the risk of infection during transrectal biopsy will be presented and transrectal and transperineal biopsy will be discussed from a diagnostic and clinical perspective.

In the hands-on part of the course, participants will be taught the practical skills required to perform a transperineal prostate biopsy under local anesthesia in an outpatient setting by using phantoms at 5 stations. Experienced tutors help to finetune each individuals biopsy skills.

**09:00 - 09:10**

## **Comparing the transrectal and transperineal approach: Transperineal only?**

L. Budäus, Hamburg (DE)

**09:10 - 09:20**

## **Different approaches for performing transperineal prostate biopsy**

C. Kastner, Cambridge (GB)

**09:20 - 09:25**

## **Transperineal in an office based setting I: Local anesthesia**

A. Bilé Silva, Lisboa (PT)

**09:25 - 09:45**

## **Hands on training phantoms I: Local anesthesia**

*Tutors*

S. Bolomytis, Bristol (GB)

L.A. Mambu, Ilford (GB)

R. Miano, Rome (IT)

A. Mohee, Manchester (GB)

R. Veeratterapillay, Newcastle Upon Tyne (GB)

**09:45 - 09:50**

## **Transperineal in an office based setting II: Biopsy taking, patient comfort**

A. Bilé Silva, Lisboa (PT)

**09:50 - 10:25**

## **Hands on training with phantoms II Biopsy taking**

*Tutors*

S. Bolomytis, Bristol (GB)

L.A. Mambu, Ilford (GB)

R. Miano, Rome (IT)

A. Mohee, Manchester (GB)

R. Veeratterapillay, Newcastle Upon Tyne (GB)

**10:25 - 10:30**

## **Q&A and conclusions**

L. Budäus, Hamburg (DE)

# E-BLUS Exam

HOT 3.05

**Sunday 7 April**

**09:30 - 10:00**

**Location**

Orange Area, HOT 1

**Tutors**

A. Papatsoris, Athens (GR)

J.B. Roche, Bordeaux (FR)

# Lymph node dissection in prostate cancer: Is the book closed?

Game changing session

Sunday 7 April

10:00 - 10:30

**Location** Purple Area, eURO Auditorium 2

**Chairs** J. Boormans, Rotterdam (NL)  
J. Rassweiler, Krems - Stein (AT)

## Learning objectives

The concept of a game changing session explains it all! We will hear the newest data on the trial comparing extended versus limited pelvic lymph node dissection in prostate cancer together with a critical discussion from one of the most experienced urologists in this field.

On the other hand, it will be also fascinating to have a closer look at the real world experiences concerning quality of life of a prostate cancer patient in Europe.

10:00 - 10:15

## Pelvic Lymph Node Dissection in Prostate Cancer: Update of the Limited vs. Extended Randomised Clinical Trial

10:00 - 10:08

### Presenter

K. Touijer, New York (US)

10:08 - 10:15

### Discussant

F.C. Hamdy, Oxford (GB)

10:15 - 10:30

## Living with a prostate cancer patient: Real-world evidence from the unprecedented Europa Uomo Prostate cancer Partners in Europe Research (EU-ProPER) study

10:15 - 10:23

### Presenter

A. Deschamps, Antwerp (BE)

10:23 - 10:30

### Discussant

M. Van Hemelrijck, London (GB)

# Prostate biopsy: Which is best?

Game changing session

**Sunday 7 April**

**10:00 - 10:15**

**Location**

Green Area, eURO Auditorium 1

**Chairs**

A. Briganti, Milan (IT)

S. Gillessen Sommer, Bellinzona (CH)

**Learning objectives**

This game changing session will focus on the ProBE-PC trial aimed at comparing transrectal and transperineal prostate biopsy for the detection of clinically significant prostate cancer with specific insights on strenghts and limitations through interactive discussion.

**10:00 - 10:15**

**Efficacy of transrectal and transperineal prostate biopsy in detecting clinically significant prostate cancer: Results of the ProBE-PC randomised clinical trial**

**10:00 - 10:08**

**Presenter**

B. Mian, Albany NY (US)

**10:08 - 10:15**

**Discussant**

B.F. Chapin, Houston (US)

# Hands-on Training in Urodynamics

HOT 3.34

**Sunday 7 April**

**10:00 - 13:00**

**Location** Orange Area, HOT 4

**Chair** A. Garcia Mora, Mexico City (MX)

## **Learning objectives**

Description:

This Hands-on Training is designed for participants to improve their skills in urodynamics, with an emphasis on practical aspects. Participants will have the opportunity to practice each step of the UDS procedure, including set up, running a test, troubleshooting, and interpretation.

## **Training aim**

The primary objective of this course is to enhance participants' skills in urodynamics, focusing on key aspects of the procedure. By the end of the course, attendees should feel more confident and competent in UDS procedures.

Voting will be available via the EAU24 App or via [www.qna.at/eau](http://www.qna.at/eau)

**10:00 - 10:20**

## **Introduction**

A. Garcia Mora, Mexico City (MX)

**10:20 - 10:40**

## **Hands-on Training: Rotation**

**10:40 - 11:10**

## **Setting Up**

A. Gammie, Bristol (GB)

**11:10 - 11:40**

## **Running a test**

F. Cancrini, Rome (IT)

**11:40 - 12:00**

## **Hands-on Training: Rotation**

**12:00 - 12:30**

## **Troubleshooting**

L. Thomas, Bristol (GB)

**12:30 - 13:00**

## **Interpretation**

B.Y. Padilla Fernandez, San Cristóbal De La Laguna (ES)



# ESTs1 Exam

HOT 3.07

**Sunday 7 April**

**10:00 - 10:55**

**Location**

Orange Area, HOT 1

**Tutors**

A.C. Bouma - Houwert, Laren (NL)

P. Kallidonis, Patras (GR)

G.M. Kamphuis, Amsterdam (NL)

A. Pietropaolo, Southampton (GB)

# Hands-on Training in Transurethral treatment - Step 1 & 2 (TURBT/TURP)

HOT 3.08

Sunday 7 April

10:00 - 10:55

**Location**

Orange Area, HOT 1

**Tutors**

L. Osório, Porto (PT)

A. Sousa Castro, Lisboa (PT)

**Learning objectives**

This training course combines the first and second step of the Transurethral Treatment (TUT) curriculum. It is designed for urologists who wish to improve their proficiency in key techniques and gain a fundamental understanding of transurethral resection of the bladder and prostate. This comprehensive training covers crucial basic skills including flexible and rigid cystoscopy, resection loop handling, and direct vision internal urethrotomy, as well as the resection procedure, practiced on state-of-the-art models.

The primary objective of this course is to enhance participants' skills in transurethral resection of the prostate and bladder, focusing on key aspects such as depth perception, hand-eye coordination, control, handling, and overall technique. By the end of the course, attendees should feel more competent and confident in performing this procedure.

# E-BLUS Exam

HOT 3.06

**Sunday 7 April**

**10:00 - 10:30**

**Location**

Orange Area, HOT 1

**Tutors**

J. Gómez Rivas, Madrid (ES)

J.B. Roche, Bordeaux (FR)

# Hands-on Training in Transurethral treatment - Step 3 (ThuLEP)

HOT 3.09

Sunday 7 April

10:00 - 10:55

**Location** Orange Area, HOT 2

**Tutors** I. Kartalas Goumas, Milan (IT)  
T.E. Şener, Istanbul (TR)

## **Learning objectives**

This advanced training course is the third step in the Transurethral Treatment (TUT) curriculum. It is designed to provide urologists with a fundamental understanding of thulium laser enucleation of the prostate (ThuLEP). This comprehensive training is specifically tailored for urologists who want to become proficient in ThuLEP. Using a step by step approach, experts will lead participants through the procedure on state of the art models, to build a familiarity of the process, confidence handling the equipment, and an understanding of best practice.

## **Training aim**

The primary objective of this course is to enhance participants' skills in ThuLEP, focusing on key aspects such as control, handling, and overall technique. By the end of the course, attendees should feel more competent and confident in performing this procedure.

# Urolithiasis: Laser, heat and pressure

Abstract session 19

Sunday 7 April  
10:30 - 12:00

**Location** Purple Area, N01

**Chairs** V.M.J. De Coninck, Brasschaat (BE)  
S. Ferretti, Modena (IT)  
A. Xhafa, Priština (XK)

We encourage participants in this session to view the abstracts before the session. All abstract bodies, posters, videos and webcasts can be viewed on the EAU(N)24 Resource Centre or at the digital screens in front of the Purple Area, EGPT.

- A0450** **A comparison between Vapor Tunnel and Virtual Basket for the treatment of proximal ureteral stones using Holmium:YAG laser (Cyber Ho): which is the best tool to reduce retropulsion?**  
D. Perri, Robecco sul naviglio (IT)
- A0453** **Pulsed Thulium:YAG laser – What is the lithotripsy ablation efficiency for stone dust from human urinary stones? Results from an in-vitro PEARLS study**  
J-L. Kwok, Singapore (SG)
- A0446** **In-Vitro Comparison of Stone Ablation Volume Using Pulsed Thulium:YAG and Modulated Pulsed Holmium:YAG Lasers**  
A.C. Bravo Balado, Barcelona (ES)
- A0449** **Prospective Evaluation of Efficacy, Safety, Cumulative Laser Energy, and Stone-Free Rates in the Post-Market Thulium Fiber Laser (SOLTIVE™ SuperPulsed Laser System) Registry: Insights from Team of Worldwide Endourological Researchers' (T.O.W.E.R.) Research Consortium**  
B.H. Chew, Vancouver (CA)
- A0455** **A prospective clinical trial on temperature profiles during flexible ureteroscopic laser lithotripsy**  
M.S.R. Asoy, Bergen (NO)
- A0456** **Impact of ureteral access sheath size on intrarenal pressure evaluated by LithoVue Elite single use ureteroscope**  
S. Kayano, Oshima-cho, Ota-shi, Gunma (JP)
- A0444** **Clinical results analysis of the first disposable intrarenal pressure measuring flexible ureteroscope in China**  
Y.B. Liu, Beijing (CN)
- A0445** **Pharmacological modulation of intrarenal pressure using a novel isoprenaline eluting guidewire ("IsoWire")**  
M. Wellmann, Cape Town (ZA)
- A0439** **A multicentre RCT assessing the influence of pressure bag versus manual-pump irrigation on intrarenal pressure during retrograde intrarenal surgery**  
S.M. Croghan, Dublin (IE)

A0441	<p><b>Expert consensus on high intra-renal pressure during ureteroscopy: A pan-European Delphi panel</b></p> <p>B. Somani, Southampton (GB)</p>
A0447	<p><b>The Dusting Utilizing Suction Technique (DUST) Ureteroscope: In vitro evaluation of a novel multichannel continuous flow ureteroscope</b></p> <p>K. Ghani, Ann Arbor (US)</p>
A0454	<p><b>Novel dual action pump (DAP) shows promise to reduce intra-renal pressure and improve irrigant flow in flexible ureteroscopy.</b></p> <p>M. Wellmann, Cape Town (ZA)</p>
A0452	<p><b>Multi-centre study comparing outcomes of RIRS using traditional suction ureteral access sheath (SUAS) and flexible-navigable suction UAS (FANS)</b></p> <p>D. Ragoori, Hyderabad (IN)</p>
A0451	<p><b>24 hours after retrograde intrarenal surgery for solitary renal calculi using a flexible and navigable suction access sheath (fans) : Results from a prospective global multicentre study by the eau section on urolithiasis (eulis)</b></p> <p>V. Gauhar, Singapore (SG)</p>
A0448	<p><b>Direct in scope suction (DISS) or suction via an ureteric access sheath (SUAS): Which is the better option for retrograde intra-renal surgery? A multi-centre validation study</b></p> <p>H.Y. Tiong, Singapore (SG)</p>
A0443	<p><b>Introducing a novel 7.5Fr single-use ureteroscope with self-vacuum suction in lowering intrarenal pressure: an in vitro study</b></p> <p>L. Linhu, Chengdu (CN)</p>
A0440	<p><b>Four dimension analysis of heat generation during Ho:YAG and thulium fiber laser activation: an in vitro thermographic study</b></p> <p>D. Robesti, Milan (IT)</p>
A0442	<p><b>Feasibility of laser lithotripsy in robotic-assisted retrograde intrarenal surgery using Zamenix in an in-vitro model</b></p> <p>S.Y. Cho, Seoul (KR)</p>

# Deciphering small renal masses: Advances in diagnosis, intervention, and active surveillance

Abstract session 20

**Sunday 7 April**  
**10:30 - 12:00**

**Location** Green Area, N03

**Chairs** To be confirmed  
P.M. Pierorazio, Philadelphia (US)  
Z. Wu, Shanghai (CN)

We encourage participants in this session to view the abstracts before the session. All abstract bodies, posters, videos and webcasts can be viewed on the EAU(N)24 Resource Centre or at the digital screens in front of the Purple Area, EGPT.

- 
- A0471**      **Reclassification of small renal masses according to the EAU Guidelines newly-proposed TNM classification for suspected renal cell carcinoma: implications for decision-making**  
C. Palumbo, Novara (IT)
- 
- A0468**      **A national study of the rate of benign pathology after partial nephrectomy for T1 renal cell carcinoma: should we be satisfied?**  
L. Van Den Brink, Amsterdam (NL)
- 
- A0464**      **Small renal masses in young adults: Insights from a large contemporary multi-institutional Registry**  
D. Amparore, Turin (IT)
- 
- A0463**      **GA68-FAPI PET/CT for the primary evaluation of a localized renal mass; a pilot study**  
T. Aviv, petach tikva (IL)
- 
- A0465**      **Diagnostic accuracy of 99mTc Sesta-MIBI SPECT/CT for preoperative differentiation of oncocytoma from renal cell carcinoma**  
U.P. Singh, Lucknow (IN)
- 
- A0462**      **Incremental value of machine learning-based radiomics for preoperative discrimination between malignant and benign small renal masses**  
Z.J. Wang, Nanjing (CN)
- 
- A0461**      **A MRI-based radiomics model for differentiation of benign and malignant small renal masses ( $\leq 4$  cm)**  
W. Dong, Guangzhou (CN)
- 
- A0459**      **Decoding Benign Renal Cortical Lesions: A Machine Learning Approach from the INMARC Registry**  
C. Saitta, Pieve Emanuele (IT)
- 
- A0458**      **Artificial intelligence links pre-operative multi-phase CT images to pathologic features, survival outcomes and biological behaviors of renal masses using real-world data**  
Y. Xiong, Shang Hai (CN)

A0469	<b>How to Perform The Optimal Renal Biopsy: a Machine Learning-Based Indication</b> F. Belladelli, Milan (IT)
A0460	<b>The role of biopsy in small renal masses &lt;4cm: A european modified delphi consensus statement</b> D.E. Bernstein, London (GB)
A0472	<b>Malignant progression outcomes of Bosniak graded renal cysts in the modern era of better imaging and uro-radiology subspecialisation</b> F. Speck, Luton (GB)
A0473	<b>Contemporary outcomes of Bosniak categorised cystic renal lesions in a cohort of 379 cases; A UK based series</b> A. Egiz, Luton (GB)
A0467	<b>Progression rates in prospective series of Small Renal Masses treated with Active Surveillance according to the newly-proposed cT1a classification</b> M. Nicolazzini, Novara (IT)
A0474	<b>Active Surveillance versus Primary Intervention for Clinical T1a Kidney Tumors: Contemporary results after Fourteen-Year Experience of the DISSRM Prospective Comparative Study</b> K. Alkhatib, Elmhurst (US)



# Radical cystectomy revisited: Prognostic factors, surgical innovations, and quality of life assessments

Abstract session 21

**Sunday 7 April**  
**10:30 - 12:00**

**Location** Purple Area, S01

**Chairs** L.S. Mertens, Amsterdam (NL)  
N. Nonomura, Osaka (JP)  
N. Vasdev, Stevenage (GB)

We encourage participants in this session to view the abstracts before the session. All abstract bodies, posters, videos and webcasts can be viewed on the EAU(N)24 Resource Centre or at the digital screens in front of the Purple Area, EGPT.

**10:30 - 10:32**

**Introduction**

**10:32 - 11:12**

**Perioperative outcomes in radical cystectomy**

A0485

**Diagnostic accuracy and inter-reader agreement of nac-VIRADS scoring system: a prospective validation study**

E. Messina, Rome (IT)

A0487

**Standardized assessment of Perioperative outcomes of robot-assisted radical cystectomy assessed using the EAU guidelines for collecting and reporting complications**

F. Pellegrino, Milan (IT)

A0490

**Early gender-related outcomes in radical cystectomy: Perioperative, postoperative and health-related quality of life outcomes comparison from a single centre randomized controlled trial**

R. Mastroianni, Rome (IT)

A0486

**Ureteroenteric strictures of open vs robot-assisted radical cystectomy with totally intracorporeal urinary diversion: single centre prospective randomised controlled trial**

R. Mastroianni, Rome (IT)

A0484

**Intraoperative ICG fluorescence as a method of prevention of postoperative strictures of ureteroileoanastomoses during robot-assisted radical cystectomy**

M. Urmantsev, Ufa (RU)

A0477

**Risk of upper urinary tract dissemination in cT3 bladder cancer patients treated with Double J stent versus nephrostomy tube prior to radical cystectomy**

M. De Angelis, Milan (IT)

A0478

**Central Venous Access and the Risk for Thromboembolic Events in Patients Undergoing Neoadjuvant Chemotherapy and Radical Cystectomy for Muscle Invasive Bladder Cancer**

H. Rydell, Umeå (SE)

**11:12 - 11:42**

**Prognostic risk factors for adverse outcome after radical cystectomy**

A0488

**Prognostic Variations Between "Primary" and "Progressive" Muscle-Invasive Bladder Cancer Following Radical Cystectomy: A Novel Propensity Score-based Multicenter Cohort Study**

C-H. Lai, Beijing (CN)

A0476	<p><b>Metformin - A Risk Factor for Metabolic Acidosis After Radical Cystectomy with Ileal Conduit or Continent Diversion? A National Claims Database Analysis</b> M. Pallauf, Salzburg (AT)</p>
A0475	<p><b>High androgen expression is linked to poor prognosis in male patients with muscle-invasive urothelial carcinoma of the bladder</b> H. Plage, Berlin (DE)</p>
A0479	<p><b>Adverse events during neoadjuvant chemotherapy for muscle invasive bladder cancer - a Swedish retrospective multicenter study</b> Y.A.M. Hüge, Norrköping (SE)</p>
A0480	<p><b>Does pre-cystectomy anemia following neoadjuvant chemotherapy in muscle invasive bladder cancer affect survival?</b> Y.A.M. Hüge, Norrköping (SE)</p>
A0483	<p><b>Pre-existing morbidity is a risk factor for mortality post-cystectomy in elderly urology patients: An Australian and New Zealand Audit of Surgical Mortality (ANZASM) study</b> S. Qin, Heidelberg (AU)</p>
<hr/>	
11:42 - 11:57	<p><b>Outcomes after radical cystectomy for muscle-invasive bladder cancer</b></p>
A0482	<p><b>Real-world oncological outcomes of a nationwide, prospective bladder cancer cohort</b> L. van Hoogstraten, Nijmegen (NL)</p> <p><b>Study Group</b> BlalZB study group(Utrecht, The Netherlands)</p>
A0491	<p><b>Stage-specific Recurrence Rates Post-Radical Cystectomy: A Path to Personalized Oncological Follow-up</b> M.S. Wettstein, Toronto (CA)</p>
A0489	<p><b>Female sexual function after radical cystectomy</b> R.V. Milling, Aarhus (DK)</p>
<hr/>	
11:57 - 12:00	<p><b>Expert summary</b></p>

# Less common urologic diseases and treatments

Abstract session 22

**Sunday 7 April**  
**10:30 - 12:00**

**Location** Purple Area, S03

**Chairs** D. Eberli, Zürich (CH)  
S. Mourad, New Cairo (EG)  
J. Rautiola, Stockholm (SE)

We encourage participants in this session to view the abstracts before the session. All abstract bodies, posters, videos and webcasts can be viewed on the EAU(N)24 Resource Centre or at the digital screens in front of the Purple Area, EGPT.

**10:30 - 10:32**

**Introduction**

**10:32 - 10:42**

**Urethral cancer**

[A0504](#)

**Outcomes of Invasive Primary Urethral Cancer in Women: An Analysis from the National Cancer Database**

M.A. Ganiyani, Miami (US)

[A0500](#)

**Treatment Strategies and Survival Outcomes in Non-Invasive Primary Urethral Cancer (NPUC): A comprehensive analysis from a large database**

M.A. Ganiyani, Miami (US)

**10:42 - 10:57**

**Uncommon prostate cancer types**

[A0494](#)

**Survival outcomes and prognostic factors in the patients with clear cell adenocarcinoma of the prostate: a case-control study for this uncommon cancer type**

Y. Wei, Fuzhou, Fujian Province (CN)

[A0495](#)

**A Comprehensive Comparative Study on Mortality and Risk Factors in Prostate Adenocarcinoma Variants and Transitional Cell Carcinoma**

Y. Wei, Fuzhou, Fujian Province (CN)

**10:57 - 11:07**

**Retroperitoneal conditions**

[A0498](#)

**Tertiary lymphoid structures in retroperitoneal sarcoma correlates with improved prognosis**

H. Kokubun, Tochigi (JP)

[A0503](#)

**Conditional cancer-specific survival in surgically treated retroperitoneal liposarcoma and leiomyosarcoma patients: a stage-specific analysis**

A. Baudo, Milano (IT)

**11:07 - 11:17**

**Less common disease types or treatments of bladder cancer**

[A0507](#)

**Neoadjuvant PD-1 inhibitor plus etoposide and cisplatin in neuroendocrine bladder carcinoma: a single-center, real-world study**

H. Chen, Shanghai (CN)

[A0499](#)

**Stapled W-shaped Hautmann orthotopic ileal neobladder. Functional results and complications over a 13-year period.**

A. Cormio, Ancona (IT)

11:17 - 11:27

**Less common uro-onco**

**A0501 Tumor size predicts survival for urachal cancer – Findings from a nationwide multicenter cohort study in Norway**

S.N. Akhtar, Bergen (NO)

**A0508 The tumor molecular characteristic and microenvironmental heterogeneity between rare non-urothelial carcinoma of bladder and urothelial carcinoma**

X. Chen, Guangzhou (CN)

---

11:27 - 11:57

**Less common benign urology miscellaneous**

**A0506 Genitourinary toxicity following radiation therapy is not just about haematuria-lessons from 7 years of a specialist radiation cystitis clinic.**

J. Kam, (AU)

**A0493 Predictive factors for failure of surgical treatment of vesicovaginal fistulas**

K. Chaker, Tunis (TN)

**A0505 Urinary incontinence is associated with the level of the demyelinating lesions in patients with multiple sclerosis: findings from a prospective cross-sectional study**

M. Tutolo, Milan (IT)

**A0496 Assessing perioperative complications in native nephrectomy as a therapeutic approach for symptomatic polycystic kidney disease: a comprehensive study**

A. Helal Birjandi, Hannover (DE)

**A0497 Fournier's gangrene prognosis: peri-umbilical cutaneous involvement as a vital warning sign.**

Y. Ouanes, Tunis (TN)

**A0502 3D augmented reality robot-assisted segmental ureterectomy with buccal mucosa graft repair: technique description and short-term outcomes**

F. Piramide, Turin (IT)

---

11:57 - 12:00

**Expert summary**

# Local salvage options for recurring prostate cancer

Abstract session 23

Sunday 7 April  
10:30 - 12:00

**Location** Green Area, W01

**Chairs** P. Hoskin, Northwood (GB)  
T. Steuber, Hamburg (DE)  
A.S. Zribi, Tunis (TN)

We encourage participants in this session to view the abstracts before the session. All abstract bodies, posters, videos and webcasts can be viewed on the EAU(N)24 Resource Centre or at the digital screens in front of the Purple Area, EGPT.

10:30 - 10:32

**Introduction**

10:32 - 11:02

**Salvage treatment for radio-recurrent prostate cancer**

A0517

**PSA response after Radiotherapy. Is there a definition of PSA persistence after RT?**

U.G. Falagario, Foggia (IT)

A0514

**Treatment free survival and the pattern of follow-up treatments after curative prostate cancer treatment, a reflection of electronic health record data**

F.B. Denijs, Rotterdam (NL)

A0520

**Multicentric evaluation of the oncological outcomes and management of recurrence after brachytherapy for prostate cancer**

Y. Benchimol, Reims (FR)

A0523

**Enhancing patient selection for salvage radical prostatectomy: a new risk-stratification model from a large retrospective cohort**

G. Callaris, Cuneo (IT)

A0510

**Current clinical practice patterns with robotic salvage radical prostatectomy: Oncological results from 10 high-volume robotic centers**

M. Wenzel, Frankfurt (DE)

11:02 - 11:27

**Focal therapy and salvage**

A0525

**Surgical and oncological outcomes of salvage radical prostatectomy after focal therapies: a matched-pair analysis**

F. Ambrosini, Veduggio (IT)

A0513

**Effect of prior focal therapy vs radiation on the outcomes of salvage robotic radical prostatectomy**

L. Storino Ramacciotti, Pasadena (US)

A0509

**HIFI-2 study: salvage HIFU for local recurrence after first-line radiotherapy for localized prostate cancer in 531 patients.**

P. Rischmann, Toulouse (FR)

**Study Group**

HiFi study group (Lyon, France)

A0515

**US-guided Targeted Focal Salvage Cryoablation: a feasible and effective treatment for prostate cancer recurrence after radiotherapy.**

E. Altobelli, Groningen (NL)

A0521

**Salvage focal ablation versus radical prostatectomy for localized radiorecurrent prostate cancer: a propensity-score matched comparison**

A. Light, London (GB)

**Study Group**

HEAT and ICE Users Group. FORECAST Trial Group. Salvage Radical Prostatectomy Consortium(London, United Kingdom)

---

11:27 - 11:57

**Salvage after radical prostatectomy**

A0516

**Time to death and clinical characteristics of patients who died for Prostate cancer after robot-assisted radical prostatectomy: 20 years' report from the EAU Robotic Urology Section (ERUS) Scientific Working Group**

U.G. Falagario, Foggia (IT)

A0522

**Long-term biochemical recurrence in patients with lymph node invasion undergoing radical prostatectomy and lymph node dissection.**

F. Preisser, Hamburg (DE)

A0519

**Identify the optimal candidates for adjuvant androgen deprivation therapy among patients with detectable PSA after radical prostatectomy.**

F. Pellegrino, Milan (IT)

A0524

**Duration of Use of Androgen Deprivation Therapy After Radical Therapy for Prostate Cancer: Nationwide, Population-based Study**

E. Lin, Uppsala (SE)

A0512

**Comparison of EAU and EMBARK criteria for high-risk biochemical recurrence after radical prostatectomy.**

G. Server Gomez, Murcia (ES)

A0511

**Age-Dependent Effect of Early Salvage Radiotherapy for Biochemical Recurrence in Prostate Cancer Patients Treated with Radical Prostatectomy**

A. Pellegrino, Milan (IT)

---

11:57 - 12:00

**Expert summary**

**Sunday 7 April**  
**10:30 - 12:00**

**Location** Green Area, W06

**Chairs** To be confirmed  
I. Heidegger, Innsbruck (AT)  
G. Marra, Turin (IT)

We encourage participants in this session to view the abstracts before the session. All abstract bodies, posters, videos and webcasts can be viewed on the EAU(N)24 Resource Centre or at the digital screens in front of the Purple Area, EGPT.

- 
- A0542** **Preclinical assessment of integrin receptors as therapeutic targets in advanced treatment-resistant prostate cancer**  
I. Tsaur, Tuebingen (DE)
- 
- A0540** **Cofilin-1 is implicated in the progression of prostate cancer under long-term exposure to leptin**  
M. Hu, Shanghai (CN)
- 
- A0541** **Cancer-associated fibroblast exosomes promote prostate cancer metastasis through miR-500a-3p/FBXW7/HSF1 axis under hypoxic microenvironment**  
Z. Liu, Beijing (CN)
- 
- A0547** **Clinical translation of the albumin-binding radioligand <sup>177</sup>Lu-(S)-Ibu-DAB-PSMA in patients with mCRPC: enhancing clinical efficacy of PSMA-targeted RLT**  
H. Nicolai, Santiago Centro (CL)
- 
- A0548** **Single-cell transcriptome analysis reveals the diverse mechanisms of castration resistance development in prostate cancer**  
Q. Peng, SHA TIN (HK)
- 
- A0545** **Epidermal growth factor-like domain 7 inhibit immune response in metastatic castration resistant prostate cancer by de-activation of endothelial intercellular adhesion molecule-1**  
S-W. Park, Yangsansi (KR)
- 
- A0544** **Characterization of the tumor microenvironment in prostate cancer progression**  
G. Thalmann, Bern (CH)
- 
- A0546** **Melatonin inhibits tumor growth and metastasis by promoting NRF2-mediated iron death activated via increase of liquid-liquid phase separation behavior of androgen receptor in prostate cancer**  
X. Yi, Chengdu (CN)
- 
- A0543** **Integrative multi-omics analysis enables a comprehensive characterization of prostate cancer and unveils metastasis-associated candidate biomarkers**  
G. Bozzini, Como (IT)
- 
- A0537** **FeS-functionalized bacteria-derived outer membrane vesicle as a novel immunotherapeutic nanodrug for prostate cancer**  
X. Du, Shanghai (CN)

A0538

**Elevated Circulating PMN-MDSC Levels Predict Prognosis in Metastatic Castration-Resistant Prostate Cancer Patients.**

T. Kobayashi, Tokyo (JP)

---

A0536

**Investigation of the tumor-macrophage crosstalk to identify palmitic acid as modulator of macrophage reprogramming in prostate cancer.**

V. Fasulo, Milano (IT)

---

A0535

**Cell-Free DNA Genomic Profiling and its Clinical Implementation in Advanced Prostate Cancer**

L. Roma, Basel-stadt (CH)

---

A0539

**Preclinical evidence for the use of anti-TROP-2 antibody-drug conjugate Sacituzumab govitecan in cerebral metastasized castration-resistant prostate cancer**

R. Weiten, Bonn (DE)

---

A0532

**ZBTB46 complex increasing intracellular Calcium level promote Epithelial-to-Mesenchymal Transition in Neuroendocrine Prostate Cancer**

Y. Ho, Taipei City (TW)

---

A0533

**Loss of glucocorticoid receptor expression in diagnostic biopsies of metastatic prostate cancer is associated with poor response to sequential docetaxel treatment**

J.M. Moll, Emmen (NL)



# The frontier of transplant urology: Robotic techniques and complex cases

Video session 08

**Sunday 7 April**  
**10:30 - 12:00**

**Location** Green Area, S04

**Chairs** A.J. Figueiredo, Coimbra (PT)  
F. McCaig, London (GB)

We encourage participants in this session to view the abstracts before the session. All abstract bodies, posters, videos and webcasts can be viewed on the EAU(N)24 Resource Centre or at the digital screens in front of the Purple Area, EGPT.

V056 (□ 7 min.)

**Robotic-assisted nephrectomy in ADPKD: a single-center experience**

C. Labate, Bari (IT)

V057 (□ 7 min.)

**Robot assisted transplant graft nephrectomy**

J. Mathew, Ernakulam (IN)

V058 (□ 8 min.)

**Orthotopic robot-assisted laparoscopic kidney transplantation with living donor: First case**

I. Al-Emadi, TOULOUSE (FR)

V059 (□ 8 min.)

**Orthotopic robot-assisted kidney transplantation: surgical technique and preliminary results**

A. Pecoraro, Firenze (IT)

V060 (□ 7 min.)

**Learning curve in Robot-Assisted Kidney Transplantation (RAKT): a single centre experience.**

S. Gerbasi, Bari (IT)

V061 (□ 8 min.)

**Approach to splitting a donor horseshoe kidney for transplantation**

J. Lu, Singapore (SG)

V062 (□ 6 min.)

**Transplanting horseshoe kidneys: A challenge for the urologist**

M. Mata Alcaraz, Madrid (ES)

V063 (□ 5 min.)

**Robot-assisted uretero-calyceal-anastomosis using native ureter as an alternative technique for treatment of complex ureteral strictures in transplanted kidney**

M. Facco, Jesolo (IT)

# Robotics at its best

Meeting of the EAU Robotic Urology Section (ERUS)

**Sunday 7 April**  
**10:30 - 12:30**

**Location** Green Area, N04

**Chair** A. Breda, Barcelona (ES)

## **Learning objectives**

To provide an update on the latest technology applications in robotic surgery as well as surgical procedures.

**10:30 - 10:35**

## **Welcome and introduction**

**10:35 - 10:58**

## **New technology**

*Moderators*  
S. Nathan, London (GB)  
H.G. Van Der Poel, Amsterdam (NL)

**10:35 - 10:44**

## **New technologies in robotic surgery**

M. Covas Moschovas, Celebration (US)

**10:44 - 10:53**

## **New robotic platforms: Who's next?**

A. Mottrie, Aalst (BE)

**10:53 - 10:58**

## **Alex Mottrie Award (AMA)**

*Moderator*  
H.G. Van Der Poel, Amsterdam (NL)

**10:58 - 11:26**

## **Prostate cancer**

*Moderators*  
B.M.C. Rocco, Milan (IT)  
C. Wagner, Gronau (DE)

**10:58 - 11:07**

## **Different approaches to RALP. How do I choose?**

A. De La Taille, Créteil (FR)

**11:07 - 11:16**

## **Retzius-sparing prostatectomy: A step-by-step approach**

S. Secco, Milan (IT)

**11:16 - 11:26**

## **Robotic radical prostatectomy using Japanese-original surgical robots "hinotori" system**

R. Shiroki, Aichi (JP)

**11:26 - 11:55**

## **Renal cancer**

*Moderators*  
B.J. Challacombe, London (GB)  
N.N. Harke, Hannover (DE)

**11:26 - 11:35**

## **Tips and tricks of retroperitoneal surgery**

A. Breda, Barcelona (ES)

**11:35 - 11:55**

## **Extreme renal surgery: Video session**

J-C. Bernhard, Bordeaux (FR)  
S. Crivellaro, Chicago (US)

11:55 - 12:27

**Bladder disease: Cancer and benign**

*Moderators*

M. Musquera Felip, Barcelona (ES)

C. Wijburg, Arnhem (NL)

11:55 - 12:03

**Single vs. multiport cystectomy**

P. Wiklund, Stockholm (SE)

12:03 - 12:11

**Female intracorporeal neobladder: Tips and tricks**

A. Minervini, Florence (IT)

12:11 - 12:19

**Fistula repair after abdominal surgery**

H. John, Winterthur (CH)

12:19 - 12:27

**Robotic sacrocolpopexy**

V. Phé, Paris (FR)

---

12:27 - 12:30

**Closing remarks**

A. Breda, Barcelona (ES)

**Sunday 7 April**  
**10:30 - 12:00**

**Location** Green Area, W03

**Chairs** A.M. AuTRAN-Gomez, Veracruz (MX)  
C. Le Magnen, Basel (CH)  
E.S. Martens-Uzunova, Rotterdam (NL)

### Learning objectives

- Discuss the generation and exploitation of patient-derived models to investigate drug response and treatment resistance mechanisms in the context of several urological malignancies.
- Obtain new insights in the role of extracellular vesicles for intercellular communication of urological cancers.

We encourage participants in this session to view the abstracts before the session. All abstract bodies, posters, videos and webcasts can be viewed on the EAU(N)24 Resource Centre or at the digital screens in front of the Purple Area, EGPT.

**10:30 - 10:33**

### Introduction

**10:33 - 11:21**

### Patient derived models for tailored therapy

A0527

#### Patient derived renal cell carcinoma organoids and isolated autologous tumor infiltrating lymphocytes as cancer in vitro models for immunotherapy agents screening

V. Hevia Palacios, Madrid (ES)

A0528

#### Identification of new therapeutic targets in penile squamous cell carcinoma using patient-derived in-vitro and in-vivo models

J. Linxweiler, Homburg/saar (DE)

A0526

#### A patient-derived bladder cancer organoid biobank for translational research and precision oncology

M. Garioni, Basel (CH)

A0529

#### Novel patient-derived organoid xenograft models emulate molecular, functional, and clinical features of advanced prostate cancer

C. Le Magnen, Basel (CH)

**11:21 - 12:00**

### The role of extracellular vesicles in cell-cell communication

11:21 - 11:28

#### State-of-the-art lecture TBD

E.S. Martens-Uzunova, Rotterdam (NL)

A0530

#### M2-like macrophage promotes prostate cancer metastasis by horizontal transfer of TXNDC5 mRNA via extracellular vesicles

C. Hu, Shanghai (CN)

A0531

#### Identification of novel snoRNA-based biomarkers from urine-derived extracellular vesicles for non-invasive detection of clear cell renal cell carcinoma

S. Füssel, Dresden (DE)

**11:52 - 12:00**

### Dicussion

# E-BLUS Exam

HOT 3.10

**Sunday 7 April**

**10:30 - 11:00**

**Location**

Orange Area, HOT 1

**Tutors**

J. Gómez Rivas, Madrid (ES)

J.B. Roche, Bordeaux (FR)

# The evolving landscape of muscle-invasive bladder cancer: Clinical trials, surgical techniques, and treatment outcomes

EGPT 08

**Sunday 7 April**  
**10:30 - 12:00**

**Location** Purple Area, EGPT

**Chairs** A.K. Czech, Kraków (PL)  
B.W.G. Van Rhijn, Amsterdam (NL)

We encourage participants in this session to view the abstracts before the session. All abstract bodies, posters, videos and webcasts can be viewed on the EAU(N)24 Resource Centre or at the digital screens in front of the Purple Area, EGPT.

**10:30 - 10:51**

## **Screen A: Translational research in muscle-invasive bladder cancer**

**P213** **Loss of MTAP expression by immunohistochemistry is a surrogate marker for homozygous 9p21.3 deletion in urothelial carcinoma**  
L. Bubendorf, Basel (CH)

**P222** **KMT2D missense mutation identifies urothelial carcinoma subtype with distinct genomic characteristics and clinical outcomes**  
Z. Xu, Shanghai (CN)

**P228** **Pathological complete response to neoadjuvant chemotherapy improves antitumor immune response through reduction of regulatory T cells in muscle-invasive bladder cancer.**  
D. Ikarashi, Morioka (JP)

**P230** **Hypoxia-induced LINC00941/IMP2 drives chemoresistance of basal/squamous bladder cancer through m6A-mediated stabilization of IPO4**  
Y. Yilin, Shanghai (CN)

**10:51 - 11:06**

## **Screen B: Clinical trials in muscle-invasive bladder cancer**

**P218** **A Prospective Multinational and Multi-institutional Analysis of Radical Cystectomy for Bladder Cancer in the Nordic Countries (NorCys – trial)**  
T. Venhomaa, turku (FI)

**P204** **The Hidden Landscape: A Lymph Node Mapping Study in Unilateral Muscle-Invasive Bladder Cancer**  
L. Baekelandt, Leuven (BE)

**P214** **Impact of neoadjuvant chemo-immunotherapy on intra and post operative outcomes in patients with bladder cancer treated with radical cystectomy and pelvic lymph node dissection: prospective surgical assessment from the NURE-Combo Trial**  
C. Re, Albairate (IT)

**P229** **A real-world study from two centers regarding the combination treatment of Disitamab vedotin and immune checkpoint inhibitors for locally advanced bladder urothelial carcinoma: a novel bladder-preserving strategy**  
Y. Wei, Fuzhou, Fujian Province (CN)

**P225** **Efficacy and safety of the combination of Cisplatin plus Nab-paclitaxel and Nivolumab with radiotherapy after maximal tumor resection in non-metastatic muscle invasive Bladder Cancer (CNN-BC trial).**  
S.K. Moosavi, Rome (IT)

11:06 - 11:27

**Screen C: Surgical techniques of radical cystectomy**

- P216 **Stentless Florence Robotic Intracorporeal Neobladder (FloRIN), a feasibility prospective randomized clinical trial.**  
L. Lambertini, Florence (IT)
- P212 **Temporal Trends in Urinary Diversion Among Patients Undergoing Radical Cystectomy from 1986 to 2022: Single-Center Evaluation of 2,224 Cases**  
G. Duwe, Mainz (DE)
- P217 **Complete Response after Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer: Is time for a paradigm shift in surgical treatment?**  
R.S. Flammia, Rome (IT)
- P205 **Oncological Impact of Perioperative Blood Transfusion in Bladder Cancer Patients Undergoing Radical Cystectomy: Do We Need to Consider Storage Time of Blood Units, Donor Age or Gender Matching?**  
B. Ebner, München (DE)
- P211 **Radical cystectomy in patients over 80 years of age: comparison of age and common preoperative geriatric assessment scores in predicting 30-days postoperative morbidity in a monocentric cohort of 429 patients**  
G. Duwe, Mainz (DE)
- P219 **Long-term follow-up of capsule-preserving radical cystectomy: a multicenter experience**  
B. Ebner, München (DE)
- P210 **Utility of intravenous indocyanine green to evaluate distal ureteral vascularity during robot-assisted radical cystectomy with intracorporeal urinary diversion**  
M. Muni I Sureda, Barcelona (ES)

11:27 - 11:57

**Screen D: Oncological outcomes of patients with muscle-invasive bladder cancer**

- P231 **Assessing Predictive Factors for Disease-Free Survival (DFS) and Overall Survival (OS) in Patients Eligible for Adjuvant Immunotherapy (IO) Following Radical Cystectomy (RC) for Muscle-Invasive Bladder Cancer (MIBC).**  
P. Russo, San Lorenzo Fraz Marina (IT)
- P208 **Comparison of the Efficacy of PD-1/L1 Antibodies in Conventional Bladder Cancer and Bladder Cancer with Histological Variations**  
H. Hu, Tianjin (CN)
- P206 **What is the real-world eligibility rate for bladder preservation treatment in patients with muscle-invasive bladder cancer?**  
Y. Abu Ghanem, London (GB)
- P226 **Addition of neoadjuvant chemotherapy to a quadrifecta composite improves the oncologic outcomes reporting of patients treated with radical cystectomy for bladder cancer**  
S. Mancon, Pieve Emanuele (IT)
- P227 **The impact of venous thromboembolism on bladder cancer patients undergoing open or minimally-invasive radical cystectomy in the united states: perioperative outcomes and health-care costs from insurance claims data**  
F. Del Giudice, Rome (IT)
- P207 **Is adjuvant immunotherapy following cystectomy a bandage for inadequate surgery?**  
E. Kjøbli, Trondheim (NO)

11:57 - 11:57

**Screen E: Oncological outcomes of patients with muscle-invasive bladder cancer**

- P203**                      **Utilization of Palliative Care in Bladder Cancer: Delineating Patterns of Care and Associated Disparities**  
D.V. Noel, Texas (US)
- P215**                      **Natural history of cN+ bladder cancer treated with radical cystectomy with or without perioperative treatment**  
M. von Deimling, Hamburg (DE)  
**Study Group**  
CLIPOLY study group collaborators(Vienna, Austria)
- P209**                      **Survival outcomes and pathological response of neoadjuvant chemotherapy with radical cystectomy in muscle-invasive bladder cancer – a propensity-matched study in octogenarians**  
A. Pon Avudaiappan, Miami (US)
- P220**                      **Treatment Approaches and Outcomes in Sarcomatoid Bladder Cancer**  
H. Hu, Tianjin (CN)



# Impact of EAU Prostate Cancer Guidelines

Thematic Session

**Sunday 7 April**  
**10:45 - 12:15**

**Location** Green Area, eURO Auditorium 1

**Chairs** P. Cornford, Liverpool (GB)  
S. Gillessen Sommer, Bellinzona (CH)

**10:45 - 10:47**

**Introduction**  
P. Cornford, Liverpool (GB)

**10:47 - 11:22**

**Case discussion Active surveillance vs. focal therapy intermediate-risk disease**

**10:47 - 10:52**

**Case presentation**  
D. Eberli, Zürich (CH)

**10:52 - 11:02**

**Active surveillance**  
S. Carlsson, New York (US)

**11:02 - 11:12**

**Focal therapy**  
H.U. Ahmed, London (GB)

**11:12 - 11:17**

**The patient perspective**  
E. Briers, Hasselt (BE)

**11:17 - 11:22**

**Conclusion: What do the guidelines say?**  
D. Eberli, Zürich (CH)

**11:22 - 12:12**

**Case discussion Management of nodal disease (N1/cN1)**

**11:22 - 11:32**

**Role of modern imaging (PSMA-PET) in managing nodal disease**  
D. Oprea-Lager, Amsterdam (NL)

**11:32 - 11:37**

**Case presentation**  
P. Cornford, Liverpool (GB)

**11:37 - 11:47**

**The role of surgery**  
D. Tilki, Hamburg (DE)

**11:47 - 11:57**

**The role of radiotherapy**  
V. Fonteyne, Ghent (BE)

**11:57 - 12:07**

**The role of systemic therapy**  
S. Gillessen Sommer, Bellinzona (CH)

**12:07 - 12:12**

**Conclusion: What do the guidelines say?**  
P. Cornford, Liverpool (GB)

**12:12 - 12:15**

**Session summary**  
P. Cornford, Liverpool (GB)

# Controversies on EAU Guidelines: Neurourology, paediatric urology and infections

Thematic Session

Sunday 7 April  
10:45 - 12:15

**Location** Purple Area, eURO Auditorium 2

**Chairs**  
B. Blok, Rotterdam (NL)  
G. Bogaert, Leuven (BE)  
G. Bonkat, Basel (CH)

## Learning objectives

Treatment of detrusor sphincter dyssynergia in patients with high spinal cord injury is challenging. Successful treatment includes preservation of renal function and prevention of complications like autonomic dysreflexia and complicated urinary tract infections. The panelists discuss different treatment options. Participants should be able after the session to choose the best individual DSD treatment.

Treatment of varicocele in adolescents is controversially. The panelists will present different scenarios and present current evidence-based data to support the various longterm treatment options. Participants should be able to leave the session with a better knowledge of how to address different presentations of adolescent varicocele.

Voting will be available via the EAU24 App or via [www.qna.at/eau](http://www.qna.at/eau)

10:45 - 10:47

## Introduction

G. Bonkat, Basel (CH)

10:47 - 11:16

## Case discussion Surgical treatment for detrusor sphincter dyssynergia (DSD) is the way to go

*Moderator* B. Blok, Rotterdam (NL)

10:47 - 10:50

## Case presentation

B. Blok, Rotterdam (NL)

10:50 - 10:58

## Yes

S. Musco, Firenze (IT)

10:58 - 11:06

## No

B.Y. Padilla Fernandez, San Cristóbal De La Laguna (ES)

11:06 - 11:16

## Discussion

11:16 - 11:45

## Case discussion Is varicocele treatment in teenagers of any benefit at all?

*Moderator* G. Bogaert, Leuven (BE)

11:16 - 11:19

## Case presentation

M.S. Skott, Aarhus (DK)

11:19 - 11:27

## Yes

J.S.L.T. Quaedackers, Groningen (NL)

11:27 - 11:35

## No

U.K. Kennedy, Zurich (CH)

11:35 - 11:45

## Discussion

11:45 - 12:14

**Case discussion Vaccination and oestrogen therapy for treatment of recurrent UTIs: Does the evidence support this?**

*Moderator*

G. Bonkat, Basel (CH)

11:45 - 11:48

**Case presentation**

G. Bonkat, Basel (CH)

11:48 - 11:56

**Evidence for vaccination**

J. Kranz, Aachen (DE)

11:56 - 12:04

**Evidence for hormone replacement**

F.M.E. Wagenlehner, Giessen (DE)

12:04 - 12:14

**Voting & discussion**

---

12:14 - 12:15

**Closing remarks**

G. Bogaert, Leuven (BE)

# Hands-on Training: Office based freehand transperineal prostate biopsies under local anesthesia

HOT 3.32

**Sunday 7 April**  
**10:45 - 12:15**

**Location** Orange Area, HOT 3

**Chair** L. Budäus, Hamburg (DE)

## **Learning objectives**

Infections are a particularly relevant clinical problem in transrectal prostate biopsy. Transperineal prostate biopsy allows a significant reduction in the risk of infection, but requires good anatomical knowledge for sufficient local anesthesia and rapid workflow. During the course, innovative options for reducing the risk of infection during transrectal biopsy will be presented and transrectal and transperineal biopsy will be discussed from a diagnostic and clinical perspective.

In the hands-on part of the course, participants will be taught the practical skills required to perform a transperineal prostate biopsy under local anesthesia in an outpatient setting by using phantoms at 5 stations. Experienced tutors help to finetune each individuals biopsy skills.

**10:45 - 10:55**

## **Comparing the transrectal and transperineal approach: Transperineal only?**

L. Budäus, Hamburg (DE)

**10:55 - 11:05**

## **Different approaches for performing transperineal prostate biopsy**

C. Kastner, Cambridge (GB)

**11:05 - 11:10**

## **Transperineal in an office based setting I: Local anesthesia**

A. Bilé Silva, Lisboa (PT)

**11:10 - 11:30**

## **Hands on training phantoms I: Local anesthesia**

*Tutors*

S. Bolomytis, Bristol (GB)

L.A. Mambu, Ilford (GB)

R. Miano, Rome (IT)

A. Mohee, Manchester (GB)

R. Veeratterapillay, Newcastle Upon Tyne (GB)

**11:30 - 11:35**

## **Transperineal in an office based setting II: Biopsy taking, patient comfort**

A. Bilé Silva, Lisboa (PT)

**11:35 - 12:10**

## **Hands on training with phantoms II Biopsy taking**

*Tutors*

S. Bolomytis, Bristol (GB)

L.A. Mambu, Ilford (GB)

R. Miano, Rome (IT)

A. Mohee, Manchester (GB)

R. Veeratterapillay, Newcastle Upon Tyne (GB)

**12:10 - 12:15**

## **Q & A and conclusions**

L. Budäus, Hamburg (DE)

# ESTs1 Exam

HOT 3.12

**Sunday 7 April**

**11:00 - 11:55**

**Location**

Orange Area, HOT 1

**Tutors**

A.C. Bouma - Houwert, Laren (NL)

P. Kallidonis, Patras (GR)

N. Macchione, Milan (IT)

A. Pietropaolo, Southampton (GB)

# E-BLUS Exam

HOT 3.11

**Sunday 7 April**

**11:00 - 11:30**

**Location**

Orange Area, HOT 1

**Tutors**

J. Gómez Rivas, Madrid (ES)

J.B. Roche, Bordeaux (FR)

# Hands-on Training in Transurethral treatment - Step 1 & 2 (TURBT/TURP)

HOT 3.13

**Sunday 7 April**

**11:00 - 11:55**

**Location** Orange Area, HOT 1

**Tutors** L. Osório, Porto (PT)  
A. Sousa Castro, Lisboa (PT)

## **Learning objectives**

This training course combines the first and second step of the Transurethral Treatment (TUT) curriculum. It is designed for urologists who wish to improve their proficiency in key techniques and gain a fundamental understanding of transurethral resection of the bladder and prostate. This comprehensive training covers crucial basic skills including flexible and rigid cystoscopy, resection loop handling, and direct vision internal urethrotomy, as well as the resection procedure, practiced on state-of-the-art models.

The primary objective of this course is to enhance participants' skills in transurethral resection of the prostate and bladder, focusing on key aspects such as depth perception, hand-eye coordination, control, handling, and overall technique. By the end of the course, attendees should feel more competent and confident in performing this procedure.

# Hands-on Training in Transurethral treatment - Step 3 (ThuLEP)

HOT 3.14

Sunday 7 April

11:00 - 11:55

**Location** Orange Area, HOT 2

**Tutors** I. Kartalas Goumas, Milan (IT)  
T.E. Şener, Istanbul (TR)

## **Learning objectives**

This advanced training course is the third step in the Transurethral Treatment (TUT) curriculum. It is designed to provide urologists with a fundamental understanding of thulium laser enucleation of the prostate (ThuLEP). This comprehensive training is specifically tailored for urologists who want to become proficient in ThuLEP. Using a step by step approach, experts will lead participants through the procedure on state of the art models, to build a familiarity of the process, confidence handling the equipment, and an understanding of best practice.

## **Training aim**

The primary objective of this course is to enhance participants' skills in ThuLEP, focusing on key aspects such as control, handling, and overall technique. By the end of the course, attendees should feel more competent and confident in performing this procedure.



# E-BLUS Exam

HOT 3.15

**Sunday 7 April**

**11:30 - 12:00**

**Location**

Orange Area, HOT 1

**Tutors**

A. Papatsoris, Athens (GR)

J.B. Roche, Bordeaux (FR)

# Joint Session of the EAU and the Advanced Prostate Cancer Consensus (APCCC)

Thematic Session

**Sunday 7 April**  
**13:30 - 15:30**

**Location** Green Area, eURO Auditorium 1

**Chairs** S. Gillessen Sommer, Bellinzona (CH)  
B. Tombal, Brussels (BE)

## **Learning objectives**

APCCC is the largest consensus conference on advanced prostate cancer worldwide. In this session, we will review through a series of cases how expert consensus may guide the treatment of patients.

Attendees may be able to learn about the most recent strategies on the selected cases.

**13:30 - 13:35**

## **Introduction and background**

S. Gillessen Sommer, Bellinzona (CH)

**13:35 - 14:50**

## **Synchronous mHSPC: What are the treatment options and what are the goals of treatment?**

**13:35 - 13:40**

### **Case presentation**

F. Turco, Turin (IT)

**13:40 - 13:50**

## **What is the evidence for systemic therapy in synchronous low-volume mHSPC?**

K. Fizazi, Villejuif (FR)

**13:50 - 14:00**

## **What is the evidence for RT?**

T. Zilli, Genève (CH)

**14:00 - 14:10**

## **What is the evidence for surgery?**

N. Fossati, Lugano (CH)

**14:10 - 14:20**

## **Germline genetic testing necessary and/or helpful?**

E. Castro, Madrid (ES)

**14:20 - 14:30**

## **What to test before start of hormonal treatment and what to monitor**

A. Omlin, Zürich (CH)

**14:30 - 14:40**

## **How to treat a frail and elderly patient in the same situation?**

S. Chowdhury, London (GB)

**14:40 - 14:45**

## **Summary**

B. Tombal, Brussels (BE)

**14:45 - 14:50**

## **Q&A**

**14:50 - 15:20**

## **PSA persistence after radical prostatectomy**

**14:50 - 14:55**

### **Case presentation**

P. Rajwa, Zabrze (PL)

**14:55 - 15:05**

## **Is all PSA persistence created equal? Definition and diagnostic work-up**

D. Tilki, Hamburg (DE)

**15:05 - 15:15**

## **Optimal treatment in the case of PSA persistence**

N. James, London (GB)

15:15 - 15:20

**Summary and Q&A**


K. Fizazi, Villejuif (FR)

---

15:20 - 15:30

**Outlook for APCCC 2024**

S. Gillessen Sommer, Bellinzona (CH)



# Kidney transplant: Andrology issues, research, paediatric KT, surgical and clinical scenarios to teach young urologists

Meeting of the EAU Section of Transplantation Urology (ESTU)

**Sunday 7 April**  
**13:30 - 16:30**

<b>Location</b>	Green Area, W01
<b>Chairs</b>	F.J. Burgos Revilla, Madrid (ES) E. Lledó García, Madrid (ES) M. Musquera Felip, Barcelona (ES)

## **Learning objectives**

In this session, international experts on kidney transplantation will share their experiences in a moderated setting. The session will cover kidney transplantation in the context of: andrological issues, research, and immunosuppression. Additionally, the session will feature a moderated conversation with a true master of transplantation, a special series of talks for young urologists and of course the awarding of the 2024 René Küss Prize.

**13:30 - 13:35**

## **Welcome and introduction**

**13:35 - 14:20**

## **Kidney transplant and andrology issues**

<i>Moderators</i>	C. Bettocchi, Foggia (IT) E. Lledó García, Madrid (ES) K. Van Renterghem, Hasselt (BE)
-------------------	--

**13:35 - 13:45**

## **Prevalence or erectile dysfunction in patients before/after kidney transplant**

G.I. Russo, Catania (IT)

**13:45 - 13:55**

## **Male infertility in ESRD patients: What are the best options for treatment?**

J.M. Corral Molina, Barcelona (ES)

**13:55 - 14:05**

## **Surgical treatment in erectile dysfunction KT patients: Still the third line?**

P. Capogrosso, Varese (IT)

**14:05 - 14:15**

## **Female sexual dysfunction with ESRD/Kidney Tx**

A. Zachariou, Ioannina (GR)

**14:15 - 14:20**

## **Conclusions**

**14:20 - 14:45**

## **Kidney transplant and research: The lab and the clinic**

<i>Moderators</i>	J.D.J.M. Branchereau, Nantes (FR) V. Gomez Dos Santos, Madrid (ES)
-------------------	---

**14:20 - 14:30**

## **Artificial intelligence and kidney transplantation**

B. Mesnard, Nantes (FR)

**14:30 - 14:40**

## **New options in organ perfusion preservation**

S. Hosgood, Cambridge (GB)

**14:40 - 14:45**

## **Conclusions**

**14:45 - 15:10**

## **Kidney transplant and nephrological issues**

14:45 - 15:05

## **The immunosuppression of the 21st century**

J. Pascual, Madrid (ES)

15:05 - 15:10

## **Conclusions**

15:10 - 15:40

## **Kidney transplant and the young urologists: Urological and nephrological problems**

*Moderators*

J. Gómez Rivas, Madrid (ES)

J.D. Olsburgh, London (GB)

J. Pascual, Madrid (ES)

A. Territo, Barcelona (ES)

15:10 - 15:20

## **NHBD initially non-functioning KT: How to manage?**

A. Pecoraro, Firenze (IT)

15:20 - 15:30

## **Urinary leak in the first week: Surgery vs. non-surgery?**

M.I Dönmez, Istanbul (TR)

15:30 - 15:40

## **Hypertension 2 years after kidney transplant: An arterial stenosis**

L. Peri Cusi, Barcelona (ES)

15:40 - 16:00

## **Conference of the big master**

*Moderators*

A.J. Figueiredo, Coimbra (PT)

V. Hevia Palacios, Madrid (ES)

E. Lledó García, Madrid (ES)

15:40 - 16:00

## **My journey in kidney transplant**

G. Ciancio, Miami (US)

16:00 - 16:15

## **Rene-Küss Prize 2024**

*Moderator*

F.J. Burgos Revilla, Madrid (ES)

C. Larose, Vandoeuvre (FR)

16:15 - 16:30

## **Closing remarks**

# How to individualise therapy in uro-oncology

Joint meeting of the EAU Section of Uro-pathology (ESUP) and the EAU Section of Urological Research (ESUR)

**Sunday 7 April**  
**13:30 - 16:30**

**Location** Green Area, W03

**Chairs** M. Colecchia, Milan (IT)  
C. Jeronimo, Porto (PT)

## **Learning objectives**

This meeting is a joint session by the EAU Sections of Uro-pathology and Urological Research, two complementary entities within the EAU. Major topics to be discussed by international experts are the clinical and biological rationale of combination therapies in RCC; the role of chemo- and radiation therapy for intracavernosal injection in bladder cancer and innovative approaches to individualizing therapy. Expect a lot of discussion on these hot topics, new insights and audience interaction.

**13:30 - 13:35**

## **Welcome and introduction**

C. Jeronimo, Porto (PT)

**13:35 - 14:25**

## **Clinical and biological rationale of combination therapies in renal cell carcinoma**

*Moderators* M. Colecchia, Milan (IT)  
K. Junker, Homburg (DE)

**13:35 - 13:47**

## **Checkpoint inhibition and TKI: Clinical evidence**

R. Pichler, Innsbruck (AT)

**13:47 - 13:59**

## **Immunological rationale of combination with VEGF/VEGFR inhibition**

E. Nossner, Munich (DE)

**13:59 - 14:11**

## **Any advance with the new WHO classification of renal tumours?**

A. Lopez-Beltran, Lisbon (PT)

**14:11 - 14:25**

## **Discussion**

**14:25 - 15:00**

## **The role of chemo- (and radiation) therapy for ICI in bladder cancer: Sequence or combination?**

*Moderators* M. Colecchia, Milan (IT)  
K. Junker, Homburg (DE)

**14:25 - 14:37**

## **Clinical evidence**

T. Powles, London (GB)

**14:37 - 14:49**

## **Biological rationale**

S. Lerner, Houston (US)

**14:49 - 15:00**

## **Discussion**

**15:00 - 16:20**

## **New approaches to individualise therapy**

*Moderators* J. Linxweiler, Homburg/saar (DE)  
R. Montironi, Ancona (IT)  
K.A. Tasken, Oslo (NO)

**15:00 - 15:10**

## **Histological subtyping: The role of the molecular pathologist**

M. Brunelli, Verona (IT)

15:10 - 15:20

**Artificial Intelligence in Digital Pathology of urological tumors: Hype or Hope**

F. Khoraminia, Rotterdam (NL)

15:20 - 15:30

**Spatial transcriptomics/proteomics: Understanding the tumour complexity**

M. Eckstein, Erlangen (DE)

15:30 - 15:50

**Discussion**

15:50 - 16:00

**In vitro model systems to select the best therapy for each patient**

C. Le Magnen, Basel (CH)

16:00 - 16:10

**In vivo model systems to select the best therapy for each patient**

J. Paramio, Madrid (ES)

16:10 - 16:20

**Discussion**

---

16:20 - 16:30

**Closing remarks**

M. Colecchia, Milan (IT)

# New developments and innovations in endourology

Meeting of the EAU Section of Urolithiasis (EULIS)

**Sunday 7 April**  
**13:30 - 15:30**

**Location** Purple Area, N01

**Chair** C.C. Seitz, Vienna (AT)

## **Learning objectives**

Continuous technological innovation alongside with the effective application in endourology influences treatment concepts. This EULIS session takes a close look at new insights particularly on stone recurrences, metabolomics and future orientated developments and their application in practice demonstrated by experts sharing their tips and tricks

**13:30 - 13:31**

## **Welcome and introduction**

C.C. Seitz, Vienna (AT)

**13:31 - 13:52**

## **Developments in stone metabolics**

*Moderators* O.R. Durutovic, Belgrade (RS)  
C.A. Wagner, Zurich (CH)

**13:31 - 13:38**

## **Definition and prediction of kidney stone recurrence**

J. Sayer, Newcastle upon Tyne (GB)

**13:38 - 13:45**

## **The role of metabolomics in kidney stone disease**

P.M. Ferraro, Verona (IT)

**13:45 - 13:52**

## **What does the urologist need to know about new developments in hyperoxaluria?**

C.A. Wagner, Zurich (CH)

**13:52 - 14:20**

## **Challenging the guidelines**

*Moderators* A. Bujons Tur, Barcelona (ES)  
B. Somani, Southampton (GB)

**13:52 - 13:59**

## **Should we use cumulative stone diameter or stone volume for guidance in stone treatment?**

T. Tailly, Ghent (BE)

**13:59 - 14:06**

## **Quality of life in endourology: Impact on treatment decisions?**

G. Mazzon, Bassano del Grappa (IT)

**14:06 - 14:13**

## **Are fluoroscopy-free procedures to come in endourology?**

A. Skolarikos, Athens (GR)

**14:13 - 14:20**

## **Follow-up imaging strategies - Overdetection of fragments: An issue?**

V. Jahrreiss, Vienna (AT)

**14:20 - 14:48**

## **Evolution of percutaneous nephrolithotomy**

*Moderators* G.M. Kamphuis, Amsterdam (NL)  
E. Liatsikos, Patras (GR)

**14:20 - 14:27**

## **Lapaxy in percutaneous nephrolithotomy: From physics to the OR**

E. De Lorenzis, Milan (IT)



14:27 - 14:34	<b>Non-papillary puncture: An evolutionary step for percutaneous nephrolithotomy</b> P. Kallidonis, Patras (GR)
14:34 - 14:41	<b>Is there still a place for percutaneous nephrolithotomy in current times? From classic to special indications</b> A. Budía Alba, Valencia (ES)
14:41 - 14:48	<b>Robotic surgery complementary or an alternative to percutaneous nephrolithotomy?</b> E. Montanari, Milan (IT)
<hr/>	
14:48 - 15:18	<b>Advances in technology</b> <i>Moderators</i> P.J.S. Osther, Vejle (DK) A. Pietropaolo, Southampton (GB)
14:48 - 14:58	<b>Debate Is vacuum-assisted stone surgery a game changer in endourology?</b> Yes V. Gauhar, Singapore (SG) No M. Straub, Munich (DE)
14:58 - 15:03	<b>Robotics in ureteroscopy</b> L.B. Dragoş, Cambridge (GB)
15:03 - 15:08	<b>Optimal laser settings for stones</b> E.X. Keller, Zürich (CH)
15:08 - 15:13	<b>Precision medicine: Robotic-guided percutaneous access, never have a stressed puncture again?</b> U. Nagele, Hall in Tirol (AT)
15:13 - 15:18	<b>Burst-wave lithotripsy: All set?</b> M. Özsoy, Vienna (AT)
<hr/>	
15:18 - 15:28	<b>Video presentations: Ureteroscopy/percutaneous nephrolithotomy</b> <i>Moderators</i> C.C. Seitz, Vienna (AT) M. Özsoy, Vienna (AT)
15:18 - 15:23	<b>Flexible ureteroscopy: Traditional ureteral access sheath vs. Suction ureteral access sheath?</b> G.H. Zeng, Guangzhou (CN)
15:23 - 15:28	<b>Percutaneous nephrolithotomy - Puncture</b> W. Gamal, Sohag (EG)
<hr/>	
15:28 - 15:30	<b>Closing remarks</b> C.C. Seitz, Vienna (AT)

# Uro-Technology welcomes computer-assisted systems and artificial intelligence applications

Meeting of the EAU Section of Uro-Technology (ESUT)

**Sunday 7 April**  
**13:30 - 15:30**

**Location** Green Area, N04

**Chair** J. Rassweiler, Krems - Stein (AT)

## **Learning objectives**

This year ESUT has chosen a very hot topic concerning future technologies in Urology. First we will get an update, how current and future imaging technology together with AI may impact our surgical planning in the OR. Furthermore, the value and limits of miniaturisation of surgical robots for laparoscopy and endourology will be discussed. Basically all new robotic devices will be presented.

**13:30 - 13:35**

## **Introduction**

J. Rassweiler, Krems - Stein (AT)

**13:35 - 14:03**

## **Current Innovations and minimally-invasive therapy options in laparoscopy (New technologies in laparoscopy theatre)**

*Moderators*

F. Porpiglia, Turin (IT)

D. Veneziano, New York (US)

**13:35 - 13:42**

## **Mentoring platforms and their applications in surgical training**

D. Veneziano, New York (US)

**13:42 - 13:49**

## **The Place of Metaverse 3D surgical planning in minimally-invasive laparoscopic surgery**

C. Fiori, Orbassano (IT)

**13:49 - 13:56**

## **Intra-operative visual guidance through artificial Intelligence**

P. De Backer, Ghent (BE)

**13:56 - 14:03**

## **New computer-assisted miniaturised surgical platforms: Is this the future?**

J. Rassweiler, Krems - Stein (AT)

**14:03 - 14:52**

## **New technologies and innovations in endoscopic surgery**

*Moderators*

T. Knoll, Sindelfingen (DE)

J. Rassweiler, Krems - Stein (AT)

**14:03 - 14:10**

## **Computer-aided platforms for percutaneous kidney access**

P. Kallidonis, Patras (GR)

**14:10 - 14:17**

## **Computer-assisted, image-guided waterjet ablation of the prostate**

N. Barber, Camberley (GB)

**14:17 - 14:24**

## **ILY robotic ureteroscopy**

W. Krajewski, Wrocław (PL)

**14:24 - 14:31**

## **Avicenna Roboflex ureteroscopy robot**

J. Rassweiler, Krems - Stein (AT)

**14:31 - 14:38**

## **Virtuoso, mini endoscopic-robotic arms for transurethral surgeries**

D. Herrell, Nashville (US)

**14:38 - 14:45**

## **Endoluminal surgical system and applications in urology**

B. Geavlete, Bucharest (RO)

14:45 - 14:52

**Auris Monarch platform for advanced endoscopic stone surgery**

M.M. Desai, Los Angeles (US)

---

14:52 - 15:30

**Computer-assisted imaging and navigation in urology**

*Moderators*

G. Bozzini, Como (IT)

P.J. Zondervan, Amsterdam (NL)

14:52 - 14:59

**Image-guided focal therapy in urology: What is new**

E. Barret, Paris (FR)

14:59 - 15:06

**Artificial intelligence applications and imaging for bladder pathologies during endoscopic operations**

G.M. Kamphuis, Amsterdam (NL)

15:06 - 15:13

**Virtual biopsy for urologic malignancies**

G. Cacciamani, Los Angeles (US)

15:13 - 15:20

**Artificial intelligence-based visual intelligence systems**

F. Porpiglia, Turin (IT)

15:20 - 15:30

**Discussion and closing remarks**

J. Rassweiler, Krems - Stein (AT)

# Take 'that' antibiotic away!

Thematic Session

Sunday 7 April  
13:45 - 15:15

**Location** Purple Area, eURO Auditorium 2

**Chairs** G. Bonkat, Basel (CH)  
Z. Tandođdu, London (GB)

13:45 - 14:20	<b>Combatting antimicrobial resistance in urology: Innovations, challenges, and strategies for a resilient future</b>
13:45 - 13:50	<b>Case presentation: Introduction, background and urosepsis with MDR pathogens</b> H.M. Çek, Edirne (TR)
13:50 - 14:00	<b>Point of diagnosis to direct treatment: Emerging technologies</b> R. Ahmad, Hamar (NO)
14:00 - 14:10	<b>State-of-the-art lecture Non-antibiotic options for management of rUTIs: New evidence from a RCT</b> C. Harding, Newcastle upon Tyne (GB)
14:10 - 14:20	<b>Do we need more evidence to change practice for the guidelines? Methanime hippurate the old kid back on the block</b> F.M.E. Wagenlehner, Giessen (DE)
14:20 - 14:40	<b>Case discussion Management of rUTIs: Strategies to employ to reduce burden of antibiotics</b>
14:20 - 14:25	<b>Case presentation I &amp; II</b> E. Day, London (GB) M. Vallée, Poitiers (FR)
14:25 - 14:40	<b>Discussion</b> <i>Panel</i> T.E. Bjerklund Johansen, Oslo (NO) C. Harding, Newcastle upon Tyne (GB) F.M.E. Wagenlehner, Giessen (DE)
14:40 - 14:45	<b>Implementation of the EAU Guidelines on infection: IMAGINE</b> N.M. Pereira Azevedo, Porto (PT)
14:45 - 15:15	<b>How to avoid complications and sepsis due to prostate biopsies</b>
14:45 - 14:50	<b>Guidelines recommendation: Transperineal</b> R.C.N. Van Den Bergh, Utrecht (NL)
14:50 - 14:55	<b>Challenge the guidelines: Transrectal is still safe enough</b> P. Albers, Düsseldorf (DE)
14:55 - 15:00	<b>Statement on current literature and trials in progress</b> J. Kranz, Aachen (DE)
15:00 - 15:15	<b>Discussion</b>

**Sunday 7 April**  
**13:45 - 15:15**

**Location** Green Area, N03

**Chairs** M.C. Lapitan, Manila (PH)  
M.I. Omar, Aberdeen (GB)  
M.J. Ribal Caparros, Barcelona (ES)

We encourage participants in this session to view the abstracts before the session. All abstract bodies, posters, videos and webcasts can be viewed on the EAU(N)24 Resource Centre or at the digital screens in front of the Purple Area, EGPT.

**13:45 - 13:47**

## **Introduction**

**A0857**

### **Quality of information and appropriateness of ChatGPT outputs for urological trauma**

G. Gallo, Roma (IT)

**A0850**

### **The role of artificial intelligence in urological cancers: An overview of systematic reviews.**

V. Sakalis, Thessaloniki (GR)

**A0855**

### **Prostate cancer detection percentages of repeat biopsy in patients with positive multiparametric MRI (PIRADS/Likert 3-5) and negative initial biopsy. A systematic review**

N. Grivas, Ioannina (GR)

**A0852**

### **Development of Prostate Cancer Typical Case Presentations and Their Usage in OPTIMA's Guideline Based Decision Support Tool**

K. Beyer, Rotterdam (NL)

**A0844**

### **Active Surveillance Follow-Up for Prostate Cancer: From Guidelines to Real-World Clinical Practice**

G. Chiarelli, Milan (IT)

**A0856**

### **Patient- and tumour-related prognostic factors for urinary incontinence after radical prostatectomy for nonmetastatic prostate cancer: A systematic review and meta-analysis**

N. Grivas, Ioannina (GR)

**A0851**

### **Critical Appraisal of Systematic Reviews Cross-Referenced by the European Association of Urology (EAU) 2023 Guidelines on Prostate Cancer 2023 with AMSTAR 2 Tool**

A. AlEbraheem, Aberdeen (GB)

**A0859**

### **AGREE II Quality Assessment of National and International Clinical Practice Guidelines on Prostate Cancer**

K. Beyer, Rotterdam (NL)

A0853	<p><b>OPTIMA prostate cancer care pathways - bridging clinical practice guidelines, real world evidence and artificial intelligence to enhance decision-making</b></p> <p>I. Anselmo da Costa Santiago, Berlin (DE)</p>
A0849	<p><b>Oncologic surveillance after surgical treatment for clinically localized kidney cancer – time for a revision? (OroCCR N.129)</b></p> <p>A. Martini, Houston (US)</p>
A0854	<p><b>Consistencies in follow-up after radical cystectomy for bladder cancer: A practice-based framework by collaborative EAU bladder cancer guideline panels</b></p> <p>R. Contieri, Pieve Emanuele (IT)</p>
A0858	<p><b>The diagnostic accuracy of cystoscopy for detecting bladder cancer in adults presenting with haematuria: A Systematic Review from the European Association of Urology Guidelines Office</b></p> <p>M.I. Omar, Aberdeen (GB)</p>
A0847	<p><b>Clinical Application of Bladder MRI and Vesical Imaging-Reporting And Data System</b></p> <p>M. Pecoraro, Rome (IT)</p>
A0845	<p><b>Individual Patient Data Validation of the Definitions of BCG Failure in Patients with Non-muscle Invasive Urothelial Carcinoma of the Bladder: an international multi-centre retrospective study</b></p> <p>P. Gontero, Turin (IT)</p>
A0846	<p><b>Systematic Review of the Incidence of and Risk Factors for Urothelial Cancers and Renal Cell Carcinoma Among Patients with Haematuria</b></p> <p>M.I. Omar, Aberdeen (GB)</p>
A0848	<p><b>Mirabegron versus Placebo and other therapeutic modalities in the treatment of patients with Overactive Bladder Syndrome – A Systematic Review</b></p> <p>A. Dey, Aberdeen (GB)</p>
15:07 - 15:10	<p><b>Expert summary</b></p>

# Prostate cancer diagnosis: Genetics, liquid biomarkers, node staging

Abstract session 26

Sunday 7 April

13:45 - 15:15

**Location** Purple Area, S01

**Chairs** P.K-F. Chiu, Hong Kong (HK)  
B. Malavaud, Toulouse (FR)  
F. Preisser, Hamburg (DE)

We encourage participants in this session to view the abstracts before the session. All abstract bodies, posters, videos and webcasts can be viewed on the EAU(N)24 Resource Centre or at the digital screens in front of the Purple Area, EGPT.

13:45 - 13:47

**Introduction**

13:47 - 14:12

**Genetics for classification**

A0562

**First description of a Collagen score outperforming PSA, age and mpMRI in diagnosis of significant prostate cancer**

I. Heidegger, Innsbruck (AT)

A0557

**Gene expression-based molecular classifier is associated with biochemical recurrence and proves independent of heterogeneity in primary prostate cancer**

K. Axcrone, Lørenskog (NO)

A0558

**Insights into the impact of neuropsychiatric disorders on prostate diseases: A two-sample Mendelian randomization study**

Z. Han, Chengdu (CN)

A0552

**Evaluation of Chimeric RNA Expression in Urine Samples as a Non-invasive Method for the Detection and Molecular Classification of Prostate Cancer**

H. Huang, Guangzhou (CN)

A0560

**The 17-gene Genomic Prostate Score test as a predictor of treatment selection in men with favorable intermediate-risk prostate cancer**

E. Uchio, Newport Beach (US)

14:12 - 14:47

**Liquid biomarkers**

A0553

**Diagnostic Accuracy of Liquid Biomarkers for Clinically Significant Prostate Cancer Detection: A Systematic Review and Diagnostic Meta-analysis of Multiple Thresholds**

T. Kawada, Okayama (JP)

A0561

**Platelet RNAs as Potential Biomarkers in Prostate Cancer Detection: Highlighting Differential Expression of hsa-miR-627, hsa-miR-22, and hsa-miR-190**

X.K. Wang, London (GB)

A0563

**A Novel Approach to Identify Aggressive Prostate Cancer via DNA-Methylation Signatures from Prostate Needle Biopsy**

M. Kaneko, Glendale (US)

A0549

**Clinical Significance of SCHLAP1:UBE2E3 Gene Fusion Compared to TMPRSS2:ERG Gene Fusion in Localized Prostate Cancer: Insights from a Korean Cohort**

B. Kang, Busan (KR)

- A0555 **A Highly Sensitive Methylation Assay for Prostate Cancer Diagnosis**  
X.Y. Zhong, Wuhan (CN)
- A0565 **Assessing the Potential of Cystatin 4 as a Blood Biomarker for Prostate Cancer Diagnosis and Prognosis: A Prospective Single-center Study**  
A. Keles, Istanbul (TR)
- A0550 **Real-world utilization, patient characteristics, and treatment patterns among men with localized prostate cancer tested with the 17-gene Genomic Prostate Score assay**  
S. Canfield, Houston (US)
- 

14:47 - 15:12

**Node staging**

- A0551 **The conventional Briganti 2018 nomogram is superior to its side-specific adaptation in identifying candidates for extended pelvic lymph node dissection at radical prostatectomy**  
G. Ortner, Innsbruck (AT)
- A0554 **POPCORN Study: Application of the “One-Step Nucleic Acid Amplification” (OSNA) Method for the Detection of Nodal Metastasis in Patients with Prostate Cancer**  
M. Cuadras Sole, Barcelona (ES)
- A0559 **More Micrometastases, More Recurrence? Assessing the Role of Quantitative rtPCR of PSA from Lymph Nodes Post-Prostatectomy in Predicting Biochemical Recurrence - An Experimental Study**  
J. Troidl, Magdeburg (DE)
- A0564 **Modified use of Briganti 2019 nomogram to assess lymph node metastasis risk in patients with in-bore biopsy detected prostate cancer**  
S. Madendere, Istanbul (TR)
- A0556 **The diagnostic performance of indocyanine green for sentinel node biopsy in prostate cancer: a systematic review and meta-analysis**  
S. Ma, Wuhan (CN)
- 

15:12 - 15:15

**Expert summary**



**Sunday 7 April**  
**13:45 - 15:15**

**Location** Purple Area, S03

**Chairs** C.F.S. Jensen, Herlev (DK)  
To be confirmed  
N. Sofikitis, Ioannina (GR)

We encourage participants in this session to view the abstracts before the session. All abstract bodies, posters, videos and webcasts can be viewed on the EAU(N)24 Resource Centre or at the digital screens in front of the Purple Area, EGPT.

**13:45 - 13:47**

**Introduction**

**13:47 - 14:05**

**Interrogating the tissue micro-environment in andrology**

A0568

**Targeting and enhancing digestive capacity in Sertoli cells to ameliorate late-onset hypogonadism**

L. Zhao, Zhuhai (CN)

A0566

**Anatomical transcriptome atlas of the male mouse Anatomical Transcriptome Atlas of the Male Mouse Reproductive System During Aging**

Y. Huang, Shanghai (CN)

A0567

**A single-cell analysis deciphers the molecular characteristics of low semen quality in seminoma**

G. Chen, Chengdu (CN)

**14:02 - 14:05**

**Summary**

**14:05 - 14:25**

**Translational research in testicular function**

A0577

**Physio-pharmacological Mechanisms Underlying Ejaculation in Human Seminal Vesicle**

T. Okada, Fukuoka (JP)

A0573

**Epididymal RNase T2 contributes to astheno-teratozoospermia and intergenerational metabolic disorder through epididymosome-sperm interaction**

Z. Xin, Shanghai (CN)

A0574

**Testosterone Synthesis Pathway in Non-Obstructive Azoospermic Men: Aberrant CYP17A1/HSD17B3 activity**

I-S. Huang, Taipei (TW)

A0582

**The expression of PDE11A in sperm and the potential role of its inhibitors in sperm motility regulating**

Z-J. Zi-Jue, Shanghai (CN)

**14:25 - 14:55**

**Translational research in erectile function**

A0576

**Comprehensive analysis of biological landscape of oxidative stress-related genes in diabetic erectile dysfunction**

P. Yuan, Wuhan (CN)

- A0570 **Erectile dysfunction in non-bacterial chronic prostatitis is induced via suppressing PI3K/AKT/CREB and Nrf2/Keap1 pathways**  
Y. Xiong, Chengdu (CN)
- A0575 **Studies on the mechanism of methyltransferase METTL3 regulating GLP-1R m6A modification in the pathogenesis of diabetic erectile dysfunction**  
T. Sun, Zhengzhou (CN)
- A0569 **Acute sleep deprivation impairs erectile function via activating RhoA/ROCK signaling pathway**  
Y. Xiong, Chengdu (CN)
- A0579 **Orexin receptors in paraventricular nucleus influence sexual behavior via regulating the sympathetic outflow in males**  
N. Song, Nanjing (CN)
- A0580 **New biomarker for erectile dysfunction: soluble tumor necrosis factor-like weak inducer of apoptosis (sTWEAK)**  
A. Iplikci, Istanbul (TR)
- 

14:55 - 15:15

**Preclinical evidence for novel therapeutics**

- A0578 **Lacosamide alleviates bilateral cavernous nerve injury-induced erectile dysfunction in the rat model by ameliorating pathological changes in the corpus cavernosum**  
N. Song, Nanjing (CN)
- A0571 **Role of adipose-derived stem cells in healing of surgically induced trauma of rat's tunica albuginea**  
A. Sharqawi, Manchester (GB)
- A0572 **Effects of different doses of human umbilical cord-derived mesenchymal stem cells on the recovery of erectile function in rats**  
W. Wei, XUZHOU (CN)
- A0581 **Effect of near-infrared laser treatment on improving erectile function in aging rats**  
L. Yang, Xian (CN)
- 

15:15 - 15:17

**Expert summary**

**Sunday 7 April**  
**13:45 - 15:15**

**Location** Green Area, W06

**Chairs** To be confirmed  
T. Strandgaard, Aarhus (DK)  
T. Zuiverloon, Rotterdam (NL)

We encourage participants in this session to view the abstracts before the session. All abstract bodies, posters, videos and webcasts can be viewed on the EAU(N)24 Resource Centre or at the digital screens in front of the Purple Area, EGPT.

**13:45 - 13:47**

**Introduction**

- 
- A0597** **Results from SunRISe-1 in patients with Bacillus Calmette–Guérin-unresponsive high-risk non–muscle-invasive bladder cancer receiving TAR-200 monotherapy**  
A. Necchi, Milan (IT)
- 
- A0595** **SunRISe-3: TAR-200 plus cetrelimab or TAR-200 versus intravesical Bacillus Calmette–Guérin in patients with BCG-naive high-risk non–muscle-invasive bladder cancer**  
F. Guerrero-Ramos, Madrid (ES)
- 
- A0596** **First safety and efficacy results of the TAR-210 erdafitinib intravesical delivery system in patients with non–muscle-invasive bladder cancer with select FGFR alterations**  
F. Guerrero-Ramos, Madrid (ES)
- 
- A0583** **Efficacy of intravesical nadofaragene firadenovec-vncg for patients with Bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer: 36-month follow-up from a phase 3 trial**  
C. Dinney, Houston (US)
- 
- A0599** **Intravesical instillation of nanoparticle-loaded toll like receptor (TLR) 3/9 agonists triggers a tumor-preventing immune environment in an orthotopic mouse bladder cancer model.**  
C-H. Lai, Beijing (CN)
- 
- A0594** **Comprehensive analysis of immune activation and suppression markers in peripheral blood and tumor tissue in NMIBC.**  
E.M. Albers, Madrid (ES)
- 
- A0590** **Validation of FGFR screening by uromonitor® and therascreen in FFPE tissue in bladder cancer in the context of the clinical-pathological real-world registry study "Bladder BRIDGister"**  
T. Ecke, Bad Saarow (DE)
- 
- A0591** **Multiple activation of apoptosis, ferroptosis cuproptosis and disulfidptosis by iridium based complex for bladder cancer therapy**  
N. Yu, Jinan (CN)

---

A0586	<b>A novel molecular classification of non-muscle-invasive bladder cancer based on HLA class I expression: Associations with immune infiltration and prognosis</b> M. Yu, Birmingham (GB)
A0585	<b>Analysis of the tumor microenvironment (TME) in High-Grade Ta (HG Ta) Bladder Cancer reveals an immune and stromal enriched subtype which demonstrates poor prognosis with concurrent carcinoma-in situ (CIS)</b> F. Mark, New York (US)
A0593	<b>The novel Immunotherapy for BCG-resistant Bladder Cancer by ImmuneNanoVaccine</b> P. Huang, Okayama (JP)
A0598	<b>Guiding adjuvant instillation in intermediate risk non-muscle invasive bladder cancer by drug screens in patient derived organoids</b> M. Egger, Biel (CH)
A0592	<b>A pre-clinical organoid model to select suitable bladder cancer patients for targeting EZH2 treatment</b> H. Zhao, Hongkong (HK)
A0589	<b>Development and evaluation of gemcitabine-loaded liposomes in an orthotopic mouse bladder cancer model</b> I.H. Chang, Seoul (KR)
15:12 - 15:15	<b>Expert summary</b>

---

# Advances in genital reconstruction

Video session 09

**Sunday 7 April**  
**13:45 - 15:15**

**Location** Green Area, S04

**Chairs** T.J. Greenwell, London (GB)  
S.C. Morgenstern, Frankfurt am Main (DE)

We encourage participants in this session to view the abstracts before the session. All abstract bodies, posters, videos and webcasts can be viewed on the EAU(N)24 Resource Centre or at the digital screens in front of the Purple Area, EGPT.

V064 (□ 8 min.)

**Transmeatal Dorsal Inlay Buccal Mucosa Graft Augmentation for Fossa Navicularis Strictures: Technical Nuances and Short-term Functional Outcomes.**  
B.T. Enganti, Hyderabad (IN)

V066 (□ 8 min.)

**Medium to Long Term Outcomes of Female VOBMG Urethroplasty**  
B. Toia, London (GB)

V067 (□ 5 min.)

**Robot-assisted gonadal vein excision for chronic abdominal pain after varicocele embolization: a case series**  
E. Panio, Florence (IT)

V068 (□ 6 min.)

**Configuration of pudendal thigh flap in recurring perineal urethroscopy stenosis**  
M. Falcone, Torino (IT)

V069 (□ 5 min.)

**Urethral polyps: Hidden flow obstructors after PFUI repair**  
J. Navarro, San Miguel de Tucumán (AR)

V070 (□ 7 min.)

**Gender affirmation vulvovaginoplasty with inverted penile skin, scrotal graft and peritoneal flap technique**  
L. Freton, Rennes (FR)

V071 (□ 7 min.)

**The outcomes of inflatable penile prosthesis implantation in the context of GGAS in AFAB patients: a comparative study between cis-gender modified and single cylinder transgender PP**  
M. Falcone, Torino (IT)

# Hands-on Training in Non-Technical Skills (NTS)

HOT 3.35

**Sunday 7 April**

**13:45 - 15:30**

**Location** Orange Area, HOT 4

**Chair** N. Raison, London (GB)

## **Learning objectives**

Non-technical skills encompass the cognitive, personal, and social abilities critical for safe and effective surgery. It is recognised that the majority of surgical errors and complications occur as a result of non technical factors. Technical skill alone is insufficient to maintain safe and effective care but like technical skills, NTS require dedicated, focussed training.

The course will introduce delegates to the key concepts of non-technical skills for surgeons. An expert faculty will highlight the key learning points and pitfalls in common emergency and difficult clinical scenarios to teach the necessary NTS skills to navigate them safely. Training will utilise simulation bases scenarios. Delegates will have the opportunity to participate and practice key skills such as communicating effectively, work collaboratively, maintain situational awareness, and making timely and informed decisions.

## **Training aim**

The objective of this course is to provide a foundation for the development non-technical skills. Participants will be introduced to the key aspects of effective NTS including situational Awareness, Decision Making, Communication and Leadership and how these lead to effective, safe surgical practice. By the end of the course, attendees will have a understanding of the key concepts of non technical skills and will be able to apply them to their own surgical practice.

**13:45 - 13:55**

## **Introduction to Non-Technical Skills**

N. Raison, London (GB)

**13:55 - 14:05**

## **Principles of Non-Technical Skills**

S.M. Haensel, Rotterdam (NL)

**14:05 - 15:10**

## **Hands-on Training**

**15:10 - 15:30**

## **Debrief**

G. Zanovello, Verona (IT)

Sunday 7 April  
13:45 - 15:15

**Location** Purple Area, EGPT

**Chairs** C. Gratzke, Freiburg (DE)  
I. Heidegger, Innsbruck (AT)

We encourage participants in this session to view the abstracts before the session. All abstract bodies, posters, videos and webcasts can be viewed on the EAU(N)24 Resource Centre or at the digital screens in front of the Purple Area, EGPT.

13:45 - 13:54

## Screen A: Initial diagnosis

- P251** **Pre-diagnostic prostate-specific antigen testing and clinical characteristics in men deceased from Prostate Cancer**  
M. Arvendell, Stockholm (SE)
- P243** **Cost effectiveness of prostate cancer testing incorporating Stockholm3 and MRI versus standard of care**  
O. Mcleod, Solna (SE)
- P239** **Worry about prostate cancer and risk perception among middle-aged men: results from the PROBASE trial**  
V.H. Meissner, Munich (DE)

13:54 - 14:06

## Screen B: Local management with active surveillance and focal therapy

- P247** **Do Incidental Prostate Cancer Patients Managed with Active Surveillance Exhibit Different Disease Features and Outcomes Compared to Their Biopsy-Diagnosed Counterparts? Results of a Multi-Institutional Study**  
R. Lenj, Milan (IT)  
**Study Group**  
EAU-YAU Prostate Cancer Working Group(Arnhem, The Netherlands)
- P236** **Validation of a Blood-Based Sphingolipid Panel for Men with Prostate Cancer on Active Surveillance**  
J.R. Gregg, Houston (US)
- P232** **Initial non-curative treatment for favorable intermediate-risk prostate cancer: Findings from a population-based database**  
X. Shangguan, Shanghai (CN)
- P241** **MRI-guided transurethral ultrasound ablation (TULSA) for the treatment of organ-confined primary prostate cancer: A single-center retrospective clinical service evaluation of 300 patients**  
L. Engelage, Bielefeld (DE)

14:06 - 14:27

## Screen C: Local management with surgery

- P253** **Radical Prostatectomy for non-metastatic Prostate Cancer in Renal Transplant Recipients: outcomes from a large contemporary cohort and matched-paired analysis with non-transplanted patients**  
S. Tappero, Genova (IT)

- P242** **The risk of venous thromboembolic events in men operated with laparoscopic or open radical prostatectomy - A nationwide population-based cohort study**  
J. Björklund, Stockholm (SE)
- P256** **Learning Curve For Single-Port Robot-Assisted Urological Surgery: Implications for Surgical Adoption**  
A. Pellegrino, Milan (IT)
- P255** **The relationship between mental wellbeing and functional outcomes in the first year of a prostate cancer diagnosis**  
O. Brunckhorst, London (GB)
- P252** **Predictors for improvement of lower urinary tract symptoms (LUTS) in prostate cancer patients treated with robot assisted laparoscopic prostatectomy (RALP)**  
V. Berge, Oslo (NO)
- P258** **A Randomized Comparison of 9 months' Maximum Androgen Blockage versus Bicalutamide 150 mg as Adjuvant Therapy for High-risk Localized Prostate Cancer: Long-Term Update of the CU1005**  
K. Chang, Shanghai (CN)
- P383** **LuTectomy Translational Correlatives: The Immune Landscape Responses to Upfront LuPSMA in High-risk Localized Prostate Ca**
- Authors**  
Eapen R.<sup>1</sup>, Chalmers H.<sup>2</sup>, Crock P.<sup>2</sup>, Thio N.<sup>2</sup>, MacDonald S.<sup>2</sup>, Nguyen T.<sup>2</sup>, Molden-Hauer T.<sup>2</sup>, Keam S.<sup>2</sup>, Au L.<sup>3</sup>, Buteau J.P.<sup>4</sup>, Oon S.F.<sup>5</sup>, Jackson P.<sup>6</sup>, Mitchell C.<sup>7</sup>, Sandhu S.<sup>3</sup>, Azad A.A.<sup>3</sup>, Williams S.G.<sup>8</sup>, Sharma G.<sup>9</sup>, Haskali M.B.<sup>10</sup>, Scalzo M.J.<sup>9</sup>, Moon D.<sup>1</sup>, Lawrentschuk N.<sup>1</sup>, Hofman M.S.<sup>4</sup>, Murphy D.G.<sup>1</sup>, Neeson P.J.<sup>2</sup>
- Institutions**  
<sup>1</sup>Peter MacCallum Cancer Centre, Genitourinary Oncology, Melbourne, Australia, <sup>2</sup>Peter MacCallum Cancer Centre, Immunology, Melbourne, Australia, <sup>3</sup>Peter MacCallum Cancer Centre, Medical Oncology, Melbourne, Australia, <sup>4</sup>Peter MacCallum Cancer Centre, Nuclear Medicine, Melbourne, Australia, <sup>5</sup>Peter MacCallum Cancer Centre, Radiology, Melbourne, Australia, <sup>6</sup>Peter MacCallum Cancer Centre, Medical Physics, Melbourne, Australia, <sup>7</sup>Peter MacCallum Cancer Centre, Pathology, Melbourne, Australia, <sup>8</sup>Peter MacCallum Cancer Centre, Radiation Oncology, Melbourne, Australia, <sup>9</sup>Peter MacCallum Cancer Centre, Prostate Theranostics and Imaging Centre of Excellence, Melbourne, Australia, <sup>10</sup>Peter MacCallum Cancer Centre, Radiopharmacy, Melbourne, Australia

---

**14:27 - 14:45**

**Screen D: Estimate outcome**

- P260** **Radiomics-based prognostic model guided by artificial intelligence to predict lymph node invasion and biochemical recurrence in patients with high-grade prostate cancer**  
N. Touma, Laval (CA)
- P234** **Does prostate cancer without cribriform pattern have metastatic potential?**  
L. Kroon, Rotterdam (NL)
- P254** **Prostatic ductal adenocarcinoma and comparison to high-risk acinar adenocarcinoma of the prostate in patients undergoing robotic radical prostatectomy (RARP): A prostate cancer referral centre review**  
M. Covas Moschovas, Celebration (US)
- P257** **Impact of RAS Inhibitors on prostate cancer aggressiveness – a retrospective multicenter analysis by the Young academic urologists Prostate cancer group**  
N. Artamonova, Innsbruck (AT)



P259	<b>Association of Area Deprivation Index and Race with Prostate Cancer-Specific Mortality among Non-Hispanic Black and Non-Hispanic White men in a contemporary North American population.</b> M. Finati, Foggia (IT)
P248	<b>Assessment of Significant Clinical and Pathological Tumor Volume Cutoffs Pre vs Post RARP</b> H. Yeagyeong, Orange (US)
<hr/>	
<b>14:45 - 14:57</b>	<b>Screen E: Recurrent prostate cancer</b>
P238	<b>Incidence and management of radiation cystitis after pelvic radiotherapy for prostate cancer: Analysis from a national database</b> E. Bologna, Rome (IT)
P244	<b>Detection of prostate cancer recurrences with Prostate-Specific Membrane Antigen Positron Emission Tomography after curative radiotherapy: a call for reconsideration of the Phoenix Criteria.</b> M.L. Korbee, Amsterdam (NL)
P245	<b>Strong association between the intraoperative numeric gamma probe signal and the maximum standardized uptake value (SUVmax) on PSMA PET/CT in patients with recurrent prostate cancer</b> A.C. Berrens, Amsterdam (NL)
P250	<b>Assessing The Impact and Timing of Salvage Radiation Therapy In Men With Biochemically Recurrent Prostate Cancer After Radical Prostatectomy and Negative PSMA PET</b> D. Cannoletta, Milano (IT)
<hr/>	
<b>14:57 - 15:12</b>	<b>Screen F: Metastatic prostate cancer</b>
P249	<b>Inter-lesional response heterogeneity in paired PSMA and FDG PET strongly associated with conventional progression-free survival in metastatic castration resistant prostate cancer treated with abiraterone: a prospective study</b> J. Pan, Shanghai (CN)
P235	<b>Cardiovascular Risk associated with LHRH analogue treatment and assessing those at risk: A Retrospective Cohort Study</b> J. Gibson, Manchester (GB)
P233	<b>Patient and Physician Preferences for Treatments of Metastatic Castrate Resistant Prostate Cancer</b> S. Machtens, Bergisch Gladbach (DE)
P240	<b>Comparative Analysis of the Expression of Clinically Available Contemporary Antibody-Drug Conjugate Targets in Varied Prostate Cancer Types</b> Y. Mulati, Beijing (CN)

**Sunday 7 April**  
**14:00 - 17:00**

**Location** Orange Area, HOT 3

**Chairs** P. Martino, Bari (IT)  
V. Scattoni, Milan (IT)

### **Learning objectives**

#### **Description:**

The Hands-on Training in Urological ultrasound is designed to provide healthcare professionals with a thorough understanding of urology diagnostics. The course blends expert presentations and practical hands-on sessions, offering participants a solid foundation in urological ultrasound examinations.

By the end of this course, participants will be equipped with the necessary baseline training to implement abdominal ultrasound as well as transrectal ultrasound of the prostate as a routine diagnostic tool in daily practice. The training covers urological ultrasound examinations following standardised procedures, accurately identify normal and pathological findings, and confidently conduct assessments of the urinary tract and genital organs, as well as valuable insights and skills that can be immediately applied to enhance patient care and diagnostic accuracy.

#### **Training aim**

- Understanding standard operating procedures
- Proficiency in imaging techniques
- Identification of normal anatomy
- Recognition of pathological findings
- Integration of innovative ultrasound technologies
- Practical hands-on experience

**14:00 - 14:05**

#### **Introduction**

P. Martino, Bari (IT)

**14:05 - 14:20**

#### **Standard operating procedure for ultrasound examination urinary tract: Kidney and bladder**

V. Scattoni, Milan (IT)

**14:20 - 14:40**

#### **Innovative ultrasound of the kidney and bladder: Normal and pathological findings**

A.B. Galosi, Ancona (IT)

**14:40 - 15:00**

#### **Standard operating procedure for ultrasound examination genital organs: Prostate and testis**

P. Martino, Bari (IT)

**15:00 - 15:15**

#### **Innovative ultrasound of prostate and testis: Normal and pathological findings**

T. Loch, Flensburg (DE)

15:15 - 17:00

**Hands-on Training: Kidney and bladder / Prostate & testis**

*Tutors*

A.B. Galosi, Ancona (IT)

T. Loch, Flensburg (DE)

C.B. Maccagnano, Milan (IT)

P. Martino, Bari (IT)

V. Scattoni, Milan (IT)

K.F. Stock, Munich (DE)

# ESTs1 Exam

HOT 3.17

**Sunday 7 April**

**14:00 - 14:55**

**Location**

Orange Area, HOT 1

**Tutors**

K. Ahmed, London (GB)

B. Ballesta Martinez, Alicante (ES)

N. Macchione, Milan (IT)

# E-BLUS Exam

HOT 3.16

**Sunday 7 April**

**14:00 - 14:30**

**Location**

Orange Area, HOT 1

**Tutors**

A. Papatsoris, Athens (GR)

T.M. Ribeiro De Oliveira, Lisbon (PT)

# Hands-on Training in Transurethral treatment - Step 1 & 2 (TURBT/TURP)

HOT 3.18

**Sunday 7 April**

**14:00 - 14:55**

**Location**

Orange Area, HOT 1

**Tutors**

A.J. Antunes Loureiro Nunes, Lisbon (PT)

R.N. Brito Ramos, Lisbon (PT)

**Learning objectives**

This training course combines the first and second step of the Transurethral Treatment (TUT) curriculum. It is designed for urologists who wish to improve their proficiency in key techniques and gain a fundamental understanding of transurethral resection of the bladder and prostate. This comprehensive training covers crucial basic skills including flexible and rigid cystoscopy, resection loop handling, and direct vision internal urethrotomy, as well as the resection procedure, practiced on state-of-the-art models.

The primary objective of this course is to enhance participants' skills in transurethral resection of the prostate and bladder, focusing on key aspects such as depth perception, hand-eye coordination, control, handling, and overall technique. By the end of the course, attendees should feel more competent and confident in performing this procedure.

# Hands-on Training in Transurethral treatment - Step 3 (ThuLEP)

HOT 3.19

Sunday 7 April

14:00 - 14:55

**Location** Orange Area, HOT 2

**Tutors** I. Kartalas Goumas, Milan (IT)  
T.E. Şener, Istanbul (TR)

## **Learning objectives**

This advanced training course is the third step in the Transurethral Treatment (TUT) curriculum. It is designed to provide urologists with a fundamental understanding of thulium laser enucleation of the prostate (ThuLEP). This comprehensive training is specifically tailored for urologists who want to become proficient in ThuLEP. Using a step by step approach, experts will lead participants through the procedure on state of the art models, to build a familiarity of the process, confidence handling the equipment, and an understanding of best practice.

## **Training aim**

The primary objective of this course is to enhance participants' skills in ThuLEP, focusing on key aspects such as control, handling, and overall technique. By the end of the course, attendees should feel more competent and confident in performing this procedure.

Sunday 7 April  
14:30 - 17:30

**Location** Purple Area, E05

**Chair** B.A. Hadaschik, Essen (DE)

### **Learning objectives**

Recently theranostics, the combination of diagnosis and treatment based on the same concept, was introduced in the management of prostate cancer based on nuclear medicine technologies. This is an emerging field with promising clinical data being published very recently. The concept of theranostics has the potential to change the management of prostate cancer and to become an essential part of our armamentarium. The aim of the course is to provide an in-depth overview on these new concepts and to critically assess their performance, efficacy and limitations.

### **Diagnosis and initial staging of prostate cancer**

#### **Diagnosis of the primary**

B.A. Hadaschik, Essen (DE)

#### **Initial staging of prostate cancer**

W.J.G. Oyen, Arnhem (NL)

#### **The EAU guidelines perspective on early PET imaging**

P. Cornford, Liverpool (GB)

---

### **Biochemical recurrence**

#### **Staging of biochemical recurrence with PET imaging**

W.J.G. Oyen, Arnhem (NL)

#### **Treatment options and risk stratification for salvage treatment**

B.A. Hadaschik, Essen (DE)

#### **What to do with the information?**

P. Cornford, Liverpool (GB)

---

### **Metastatic disease**

#### **Use of PET in the management of metastatic prostate cancer**

B.A. Hadaschik, Essen (DE)

#### **Radioligand treatment for metastatic prostate cancer**

W.J.G. Oyen, Arnhem (NL)

#### **The place of radioligand treatment in the M1 prostate cancer arena**

P. Cornford, Liverpool (GB)



# Retropubic radical prostatectomy: Tips, tricks and pitfalls

ESU Course 34

Sunday 7 April

14:30 - 17:30

**Location** Purple Area, E01

**Chair** G. Thalmann, Bern (CH)

## Learning objectives

In many parts of Europe, open retropubic radical prostatectomy remains an alternative to robotic prostatectomy for treating localised prostate cancer for practical and financial reasons. Novel competitive treatment options should encourage urologists to optimally perform the surgical resection. This teaching course offers a refresher on the anatomy, a step-by-step demonstration of the important stages of the intervention and how to cope with specific complications. The course may benefit the elder resident and the younger urologist as well as trained urologists who do not treat many patients with localised prostate cancer.

## Introduction

G. Thalmann, Bern (CH)

## Surgical anatomy

I. Varkarakis, Athens (GR)

## Step by step radical retropubic prostatectomy

G. Thalmann, Bern (CH)

## Tips, tricks and pitfalls

I. Varkarakis, Athens (GR)

## Treatment of complications

G. Thalmann, Bern (CH)

## Discussion and interaction

I. Varkarakis, Athens (GR)

Sunday 7 April  
14:30 - 17:30

**Location** Purple Area, E02

**Chair** T.R.W. Herrmann, Frauenfeld (CH)

## Learning objectives

Subject of the course is the content of the surgical chapter of the EAU Non Neurogenic Male Luts Guidelines.

The Course will display:

- The surgical treatment algorithm of the EAU Guidelines
- The Rational behind the subdivision in Vaporisation, Resection and Enucleation
- Positioning and leverage of each surgical modality and evidence
- Enucleating modalities: endoscopic enucleation, vs Robotic / laparoscopic adenomectomy vs. Open adenomectomy
- Treatment related side effects, esp. QOL, sexual function

## Surgical treatment of BPO: Current EAU guidelines.

L. Lusuardi, Salzburg (AT)

## What (not) to know about lasers for BPO treatment?

T.R.W. Herrmann, Frauenfeld (CH)

## Is there still a role for TUIP and TURP?

L. Lusuardi, Salzburg (AT)

## Endoscopic Enucleation of the Prostate: Surgical principles & outcomes

T.R.W. Herrmann, Frauenfeld (CH)

## Defining the role of laparoscopic and robotic surgery in BPO surgery

N. Barber, Camberley (GB)

## Ejaculation-preserving techniques: TURP & EEP vs. MIST-techniques

T.R.W. Herrmann, Frauenfeld (CH)

## Minimally invasive surgical (ablative) techniques (Rezum & Aquablation)

N. Barber, Camberley (GB)

## Minimally invasive surgical (non-ablative) techniques (i-Tind, Urolift, PAE)

L. Lusuardi, Salzburg (AT)

## Interactive case discussions

N. Barber, Camberley (GB)

T.R.W. Herrmann, Frauenfeld (CH)

L. Lusuardi, Salzburg (AT)

# Advanced course on upper tract laparoscopy: Kidney, ureteropelvic junction (UPJ), ureter and stones

ESU Course 40

Sunday 7 April  
14:30 - 17:30

**Location** Purple Area, E07

**Chair** F. Porpiglia, Turin (IT)

## Learning objectives

Surgery of the kidney by means of laparoscopy is standard of care, and has replaced open surgery to a great extent.

Approach: Transperitoneal, retroperitoneoscopy, posterior, direct through the mesentery of the colon. Each approach has specific advantages also depending on the procedure to be performed.

Procedures: Ablative, reconstruction, stone surgery.

Presentation: Power-point, interactive, videos, tips and tricks, complications.

- For surgery of the kidney, the da Vinci robot is often overkill. Also it is not available everywhere. Therefore standard laparoscopy is still of importance and should be mastered by every endoscopic surgeon.
- Choice of the perfect approach makes the respective surgery easier and safer.
- Standard laparoscopy is greatly facilitated by 3D vision.
- When mastering both laparoscopic surgical skills as well as the surgical concept of the respective procedure complications can either be avoided or managed appropriately.

## Approach: Transperitoneal, retroperitoneoscopy

B. Petrut, Cluj Napoca (RO)

## Kidney: Nephrectomy, management of cysts

M.C. Mir Maresma, Valencia (ES)

## Ureter: Nephroureterectomy, end-to-end anastomosis, replacement

F. Porpiglia, Turin (IT)

## Pyeloplasty: Indication – techniques – problems

F. Porpiglia, Turin (IT)

## Stone surgery

M.C. Mir Maresma, Valencia (ES)

## Complication management

B. Petrut, Cluj Napoca (RO)

## Questions, tips and tricks

M.C. Mir Maresma, Valencia (ES)

B. Petrut, Cluj Napoca (RO)

F. Porpiglia, Turin (IT)

Sunday 7 April  
14:30 - 17:30

**Location** Purple Area, E06

**Chair** E.N. Xylinas, Paris (FR)

## Learning objectives

Our main objective is to not only enrich what you know about NMIBC, but to also equip you with frontline strategies when dealing with common and complex patient cases.

This course will commence with discussions on NMIBC diagnostic opportunities and then proceed to the best practices and the pitfalls to avoid in transurethral resection (TUR). Get to know the techniques, tips and tricks, potential problems/complications, TUR with enhanced imaging, en-bloc resection and more through videos and lively discussions with key opinion leaders.

Further into the course, you will familiarise yourself with the new modalities and the limitations of recommendations on additional risk-adapted intravesical treatment. These will be followed by deliberations on typical problems encountered, complications during and after intravesical therapy, and strategies on how you can prevent them.

Another course highlight you can look forward to is how you can deal with abnormal cytology including locations outside the bladder.

## Introduction

E.N. Xylinas, Paris (FR)

## Diagnosis, markers and innovations

E.N. Xylinas, Paris (FR)

## TUR technique: Tips and tricks; problems; En bloc resection; TUR and the location, including diverticula, ureteral meatus; Re-TUR; PDD, SPIES, NBI etc.: With several cases and videos

P. Gontero, Turin (IT)

## Complications during surgery and what to do: Obturator nerve contraction, intra and extraperitoneal perforation, bleeding etc.

L.S. Mertens, Amsterdam (NL)

## Risk groups and guideline treatment: What is clearly established

P. Gontero, Turin (IT)

## Standard of care treatment including BCG shortage and new treatment modalities on the block

E.N. Xylinas, Paris (FR)

## Complications of intravesical therapy, including case

L.S. Mertens, Amsterdam (NL)

## Follow-up of NMIBC

P. Gontero, Turin (IT)

## **How to deal with abnormal cytology including locations outside the bladder (UUT and urethra) and its limitations**

L.S. Mertens, Amsterdam (NL)

---

### **Questions, answers and conclusion**

E.N. Xylinas, Paris (FR)

# Lower urinary tract dysfunction and urodynamics

ESU Course 37

Sunday 7 April

14:30 - 17:30

**Location** Purple Area, E04

**Chair** S. Musco, Firenze (IT)

## **Learning objectives**

Having attended the course, the attendee should: • Understand the basic physical principles referable to urodynamics. • Be able to assess the quality of a urodynamic trace. • Recognise common artefacts and know how to correct them. • Know the indications for urodynamic studies in men, women and neurological patients.

## **Urodynamics: Philosophy, scientific basis and technique**

M. Przydacz, Cracow (PL)

---

## **Urodynamics in men**

S. Musco, Firenze (IT)

---

## **Urodynamics in female urology**

M. Przydacz, Cracow (PL)

---

## **Urodynamics in neurourology**

S. Musco, Firenze (IT)

Sunday 7 April  
14:30 - 17:30

**Location** Purple Area, E03

**Chair** T.J. Greenwell, London (GB)

## Learning objectives

Clinicians involved in the care of female patients should know vaginal surgery. A specific goal of the faculty is to employ scientific principles, published information and clinical experience to describe and position newly developed techniques in current management of urinary incontinence. Special attention will be given to new techniques that use synthetics tapes in SUI surgery. This course will also cover the management of complications of surgery for stress incontinence and mesh complications. Treatment of recurrent urinary incontinence and incontinence with mixed symptoms also will be under discussion. Management of vesicovaginal fistulae, urethral diverticula and some rare conditions will be shown both during podium and video presentations. An interactive course means active participation by the audience and participants are encouraged to prepare and present interesting and challenging clinical cases for consultation by the faculty. After this course, participants should know how to apply the newest technique in patients with stress incontinence, urethral loss and iatrogenic injuries of lower urinary tract. This course will facilitate the decision making process for those who are just starting their careers and for advanced surgeons.

## Introduction

T.J. Greenwell, London (GB)

## Mostly vaginal surgery for stress urinary incontinence (SUI)

T. Tarcan, Üsküdar/ İstanbul (TR)

## Mostly vaginal repair of pelvic organ prolapse (POP)

K-D. Sievert, Detmold (DE)

## Management of mesh complications

K-D. Sievert, Detmold (DE)

## Surgery for female urethral stricture and loss

T. Tarcan, Üsküdar/ İstanbul (TR)

## Surgery for urethral diverticulum

T.J. Greenwell, London (GB)

## Vesico-vaginal fistulae

T.J. Greenwell, London (GB)

## Discussion and conclusions

T.J. Greenwell, London (GB)

# E-BLUS Exam

HOT 3.20

**Sunday 7 April**

**14:30 - 15:00**

**Location**

Orange Area, HOT 1

**Tutors**

A. Papatsoris, Athens (GR)

T.M. Ribeiro De Oliveira, Lisbon (PT)



# ESTs1 Exam

HOT 3.22

**Sunday 7 April**

**15:00 - 15:55**

**Location**

Orange Area, HOT 1

**Tutors**

B. Ballesta Martinez, Alicante (ES)

N. Macchione, Milan (IT)

T. Tokas, Hall In Tirol (AT)

# E-BLUS Exam

HOT 3.21

**Sunday 7 April**

**15:00 - 15:30**

**Location**

Orange Area, HOT 1

**Tutors**

K. Ahmed, London (GB)

T.M. Ribeiro De Oliveira, Lisbon (PT)

# Hands-on Training in Transurethral treatment - Step 1 & 2 (TURBT/TURP)

HOT 3.23

**Sunday 7 April**

**15:00 - 15:55**

**Location**

Orange Area, HOT 1

**Tutors**

A.J. Antunes Loureiro Nunes, Lisbon (PT)

R.N. Brito Ramos, Lisbon (PT)

**Learning objectives**

This training course combines the first and second step of the Transurethral Treatment (TUT) curriculum. It is designed for urologists who wish to improve their proficiency in key techniques and gain a fundamental understanding of transurethral resection of the bladder and prostate. This comprehensive training covers crucial basic skills including flexible and rigid cystoscopy, resection loop handling, and direct vision internal urethrotomy, as well as the resection procedure, practiced on state-of-the-art models.

The primary objective of this course is to enhance participants' skills in transurethral resection of the prostate and bladder, focusing on key aspects such as depth perception, hand-eye coordination, control, handling, and overall technique. By the end of the course, attendees should feel more competent and confident in performing this procedure.

# Hands-on Training in Transurethral treatment - Step 3 (ThuLEP)

HOT 3.24

Sunday 7 April

15:00 - 15:55

**Location** Orange Area, HOT 2

**Tutors** I. Kartalas Goumas, Milan (IT)

T.E. Şener, Istanbul (TR)

## **Learning objectives**

This advanced training course is the third step in the Transurethral Treatment (TUT) curriculum. It is designed to provide urologists with a fundamental understanding of thulium laser enucleation of the prostate (ThuLEP). This comprehensive training is specifically tailored for urologists who want to become proficient in ThuLEP. Using a step by step approach, experts will lead participants through the procedure on state of the art models, to build a familiarity of the process, confidence handling the equipment, and an understanding of best practice.

## **Training aim**

The primary objective of this course is to enhance participants' skills in ThuLEP, focusing on key aspects such as control, handling, and overall technique. By the end of the course, attendees should feel more competent and confident in performing this procedure.

# Responsible and affordable medicine

Thematic Session

**Sunday 7 April**  
**15:30 - 17:00**

**Location** Purple Area, S01

**Chairs** R. Hovhannisyanyan, Yerevan (AM)  
G. Karazanashvili, Tbilisi (GE)

## **Learning objectives**

The session is about to make medical care widely affordable without compromising the highest standards of medical care

**15:30 - 15:35**

### **Introduction: Value-based health care & oncology**

R. Hovhannisyanyan, Yerevan (AM)

**15:35 - 15:40**

### **When there is no MRI for PCa diagnosis: Extended biopsy?**

R. Sosnowski, Warsaw (PL)

**15:40 - 15:45**

### **When there is no MRI for PCa diagnosis: Ultrasound?**

G. Karazanashvili, Tbilisi (GE)

**15:45 - 15:55**

### **Added value of expensive oncological medication, non-histology based medical oncological treatment**

B. Tombal, Brussels (BE)

**15:55 - 16:15**

### **Debate Upfront orchiectomy for metastatic PCa**

**15:55 - 16:05**

#### **Pro**

M. Arslan, Istanbul (TR)

**16:05 - 16:15**

#### **Con**

R.J.A. Van Moorselaar, Amsterdam (NL)

**16:15 - 16:25**

### **Telemonitoring allows better and cheaper patient contact and patient care as compared to face to face visits**

H. Borgmann, Brandenburg an der Havel (DE)

**16:25 - 16:35**

### **Understanding the urology needs of countries with limited access to resources**

S.M. Gueye, Dakar (SN)

**16:35 - 16:55**

### **Debate Disposable cystoscope**

**16:35 - 16:45**

#### **No**

M. Baboudjian, Marseille Cedex (FR)

**16:45 - 16:55**

#### **Yes**

B. Somani, Southampton (GB)

**16:55 - 17:00**

### **Closing remarks**

G. Karazanashvili, Tbilisi (GE)

# European Urology Surgery in Motion: Novel robotic approaches for challenging benign cases

Thematic Session

**Sunday 7 April**  
**15:30 - 17:00**

**Location** Purple Area, eURO Auditorium 2

**Chairs**  
A. Briganti, Milan (IT)  
R. De Groote, Aalst (BE)  
N.N. Harke, Hannover (DE)  
A. Mottrie, Aalst (BE)

## **Learning objectives**

This session will deal with the extension of indications of robotic surgery, mainly in the field of challenging benign cases. We aim to widen your interest in robotics so that you will adopt minimally invasive surgery, also for non-oncological surgery for the benefit of your patients. Experts will give tips and tricks on how to optimally set the indication and perform the surgery.

**15:30 - 15:35**

**Welcome and introduction**

**15:35 - 16:15**

**Modern management of ureteric strictures**

**15:35 - 15:45**

**Proximal ureteric strictures**

B. McGuire, Dublin (IE)

**15:45 - 15:55**

**Is there still a place for ureteral reimplantation and how?**

R. Nair, London (GB)

**15:55 - 16:05**

**Extended ureteral stricture: Ileal interposition**

A. Minervini, Florence (IT)

**16:05 - 16:15**

**Extended ureteral stricture: Renal autotransplantation**

A. Breda, Barcelona (ES)

**16:15 - 16:25**

**Use of technology in benign robotic surgery: ICG, Augmented reality, Tilepro and stapling**

A. Mottrie, Aalst (BE)

**16:25 - 16:55**

**Prosthetic surgery in the robotic era**

**16:25 - 16:35**

**Male bladder neck AUS**

M.A. Perrouin Verbe, Nantes (FR)

**16:35 - 16:45**

**Female AUS**

B. Peyronnet, Rennes (FR)

**16:45 - 16:55**

**Mesh sacrocolpopexy**

E. Costantini, Perugia (IT)

**16:55 - 17:00**

**Conclusion**

# Intensifying treatment for better prostate cancer control

Abstract session 29

**Sunday 7 April**  
**15:30 - 17:00**

**Location** Green Area, N03

**Chairs** J. Gadu Campos Salcedo, Mexico City (MX)  
W. Loidl, Linz (AT)  
A.S. Rannikko, Helsinki (FI)

We encourage participants in this session to view the abstracts before the session. All abstract bodies, posters, videos and webcasts can be viewed on the EAU(N)24 Resource Centre or at the digital screens in front of the Purple Area, EGPT.

**15:30 - 15:32**

**Introduction**

**15:32 - 15:47**

**Neoadjuvant treatment**

A0602

**Three-year oncological outcomes of the randomized phase II trial ARNEO: Neoadjuvant degarelix with or without apalutamide prior to radical prostatectomy for high-risk prostate cancer.**

G.T. Devos, Kortrijk (BE)

A0604

**Two-year quality of life (QoL) outcomes of the randomized phase II trial ARNEO: neoadjuvant degarelix with or without apalutamide prior to radical prostatectomy for high-risk prostate cancer**

A. Giesen, Leuven (BE)

A0613

**Neoadjuvant pamiparib plus abiraterone and ADT for high-risk/very high-risk localized prostate cancer: results of a prospective study.**

J. Zhuang, Nanjing (CN)

**15:47 - 16:12**

**Adjuvant treatment**

A0608

**Which Is the Optimal Multimodal Management of pN1 Patients with PSA Persistence After Radical Prostatectomy and Extended Nodal Dissection? Results of a Large, Multi-Institutional Database**

S.L.A. Scuderi, Milan (IT)

A0614

**Early oncological outcomes following radical prostatectomy of patients with pelvic lymph node-positive prostate cancer at preoperative PSMA PET/CT**

L.G. Zuur, Amsterdam (NL)

A0605

**Natural history of pN1 prostate cancer after radical prostatectomy: competing risk analysis from a large multi-institutional series**

A. Giesen, Leuven (BE)

**Study Group**

European Multicenter Prostate Cancer Clinical and Translational research group (Leuven, Belgium)

A0609	<p><b>Adjuvant or Early Salvage Radiotherapy in Node Positive Prostate Cancer Patients: Development of a Novel Risk Score to Identify the Optimal Candidate for Early Intensification Approaches Based on a Large, Multi-Institutional Series.</b></p> <p>F.M. Barletta, Milan (IT)</p> <p><b>Study Group</b></p> <p>Young Academic Urologists Prostate Cancer Working Group(Arnhem, The Netherlands)</p>
A0601	<p><b>Incidence of cardiovascular death in localized prostate cancer and its relationship to androgen blockade: Long-term data from two phase III trials</b></p> <p>A. Nabid, Sherbrooke (CA)</p>
<b>16:12 - 16:27</b>	<b>Time and PSA kinetics for risk stratification for biochemical recurrence</b>
A0611	<p><b>Avoiding Overtreatment using PSA Doubling Time Kinetics: Long-Term Management of BCR Following RARP</b></p> <p>T. Ahlering, Orange (US)</p>
A0612	<p><b>PSA Doubling Time Thresholds in Predicting Clinical Recurrence after Biochemical Recurrence in Surgically Treated Prostate Cancer Patients. The Impact of Nodal Status and Adjuvant Radiotherapy</b></p> <p>L. Nocera, Milan (IT)</p>
A0615	<p><b>The impact of the time elapsed between primary treatment and BCR on cancer specific mortality in patients who experienced BCR after primary treatment.</b></p> <p>F. Pellegrino, Milan (IT)</p>
<b>16:27 - 16:57</b>	<b>Metastasis directed therapy and recurrence</b>
A0603	<p><b>PSMA-PET guided intensification of salvage radiotherapy after radical prostatectomy: a phase 2 randomized controlled trial</b></p> <p>C. Belliveau, Montreal (CA)</p>
A0610	<p><b>Identifying the optimal definition of PSA response after metastasis directed therapy in Men With oligo-recurrent prostate cancer detected at PSMA PET.</b></p> <p>E. Mazzone, Milan (IT)</p>
A0616	<p><b>Prostate-specific Membrane Antigen-radioguided Surgery Salvage Lymph Node Dissection: Experience with Fifty Oligorecurrent Prostate Cancer Patients in a Single Center</b></p> <p>R. Mayr, Regensburg (DE)</p>
A0600	<p><b>PSICHE trial (NCT05022914): PSMA guided approach for biochemical relapse after prostatectomy- a prospective trial</b></p> <p>G. Francolini, Florence (IT)</p>
A0607	<p><b>Prognostic factors of long-term survival rates after PSMA/PET-based salvage whole pelvic radiotherapy for recurrent prostate cancer.</b></p> <p>N. Grivas, Ioannina (GR)</p>
A0606	<p><b>Prostate re-irradiation after previous definitive or salvage radiotherapy (RE-START). A study on behalf of Italian Association of Radiotherapy and Clinical Oncology (AIRO)</b></p> <p>G. Francolini, Florence (IT)</p>
<b>16:57 - 17:00</b>	<b>Expert summary</b>



**Sunday 7 April**  
**15:30 - 17:00**

**Location** Purple Area, S03  
**Chairs** M. Eto, Fukuoka (JP)  
To be confirmed  
G. Pignot, Marseille (FR)

We encourage participants in this session to view the abstracts before the session. All abstract bodies, posters, videos and webcasts can be viewed on the EAU(N)24 Resource Centre or at the digital screens in front of the Purple Area, EGPT.

- 
- A0628** **Renal function after CT-guided cryoablation of small renal tumours in patients with solitary kidney - An Analysis of European Multinational Prospective EuRECA Registry**  
B.W. Lagerveld, Amsterdam (NL)
- 
- A0619** **A detailed analysis about perioperative complications, length of stay, readmission rates and treatment time after percutaneous thermal ablation for small renal masses**  
M.L. Piccinelli, Milan (IT)
- 
- A0627** **Comparison of survival outcomes following surgical treatment and local nonsurgical treatment of kidney cancer patients with a history of radical nephrectomy: a population study based on the SEER database**  
R.Y. Deng, Beijing (CN)
- 
- A0623** **Quality metrics for renal cell carcinoma (RCC) surgical care: Insights from a large contemporary multi-institutional Registry**  
R. Campi, Florence (IT)
- 
- A0633** **Prospective quality assessment using Patient Reported Outcomes (PROMS) of nurse-led coordinated pathways of care for Robotic Assisted Partial Nephrectomy (RAPN) (UroCCR 25)**  
G. Margue, Bordeaux (FR)
- 
- A0631** **Exploring the associations between hospital volume and complications in renal cancer surgery**  
J. Akerlund, Mölndal (SE)
- 
- A0626** **Urinary fistulae after robotic partial nephrectomy – analysis of a multicenter database**  
C. Fuhrmann, Hannover (DE)
- 
- A0624** **SAFE: Multi-institutional study of time to complications after robot-assisted partial nephrectomy, selection of a population eligible for outpatient management (UroCCR 90)**  
F. Barthe, Cernoy (FR)

A0622	<p><b>Robotic partial nephrectomy is associated with a significantly decreased rate of postoperative pseudoaneurysm as compared to open and laparoscopic partial nephrectomy</b></p> <p>H. Mahmud, TEL AVIV (IL)</p>
A0620	<p><b>Does robot-assisted partial nephrectomy / nephrectomy has favourable perioperative cytokine response compared to laparoscopic / open renal surgery? : A Prospective study .</b></p> <p>U. Mete, Chandigarh (IN)</p>
A0618	<p><b>Incidence and risk factors for urinary fistula in patients undergoing partial nephrectomy: results of a single-center cohort study (UroCCR n°170)</b></p> <p>G. Margue, Bordeaux (FR)</p>
A0621	<p><b>Clinical characteristics of patients with renal cancer do impact more than ischemia time on post-operative renal function</b></p> <p>G. Rosiello, Bacoli (IT)</p>
A0629	<p><b>Surgical Experience and Functional Outcomes after Laparoscopic and Robot-Assisted Partial Nephrectomy: Results from a Multi-Institutional Collaboration</b></p> <p>C.A. Bravi, London (GB)</p>
A0617	<p><b>Comparative analysis of mortality and progression to end-stage renal disease between surgically induced-chronic kidney disease versus medical chronic kidney disease - Multicenter hospital-based cohort study</b></p> <p>G. Jung, Seoul (KR)</p>
A0634	<p><b>Development and temporal external validation of a simple risk classification tool with location index and tumor volume for the prediction of renal function after robotic partial nephrectomy</b></p> <p>H. Ohsugi, Hirakata (JP)</p>
A0630	<p><b>Predictors of renal function improvement after partial nephrectomy</b></p> <p>J. Afari, San Diego (US)</p>
A0632	<p><b>Incorporating C-Reactive Protein into the Trifecta: Implications for Survival and Functional Outcomes Following Partial Nephrectomy</b></p> <p>J. Afari, San Diego (US)</p>
A0625	<p><b>The effect of metabolic syndrome on long-term renal function after partial nephrectomy</b></p> <p>G. Rosiello, Bacoli (IT)</p>

# Metastatic prostate cancer

Abstract session 31

Sunday 7 April  
15:30 - 17:00

**Location** Green Area, W06

**Chairs** G. Baciarello, Rome (IT)  
B.F. Chapin, Houston (US)  
F. Rozet, Paris (FR)

We encourage participants in this session to view the abstracts before the session. All abstract bodies, posters, videos and webcasts can be viewed on the EAU(N)24 Resource Centre or at the digital screens in front of the Purple Area, EGPT.

15:30 - 16:05

**mHSPC**

A0644

**PEACE V – Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): 24-months toxicity results of a randomized phase II trial**  
T. Zilli, Genève (CH)

**Study Group**  
PEACE-V STORM(Ghent and Geneva, Belgium)

A0639

**Impact of Disease Volume on Survival Efficacy of Triplet Therapy for Metastatic Hormone-Sensitive Prostate Cancer: A Systematic Review, Meta-analysis, and Network Meta-analysis**  
A. Matsukawa, Tokyo (JP)

A0643

**Development of a predictive model for death amongst patients with metastatic Hormone Sensitive Prostate Cancer (mHSPC) treated with one of the approved treatment plans, on characteristics present at admission using Big data: preliminary results from the European network of excellence for big data in prostate cancer (PIONEER).**  
R. Nicoletti, Florence (IT)

A0641

**Analysis of clinical characteristics in metastatic hormone-sensitive prostate cancer. A comparative study of patients from cal trials to patients from real life using 'Big Data'.**  
L. Ibanez Vazquez, Madrid (ES)  
**Study Group**  
PIONEER consortium(Arnhem, The Netherlands)

A0638

**Understanding variation in treatment intensification for de novo metastatic castration sensitive prostate cancer (mCSPC): A population-based cohort study**  
C.J.D. Wallis, Toronto (CA)

A0645

**Fracture-related hospitalisations in de novo advanced or metastatic hormone-sensitive prostate cancer: secondary analysis of the STAMPEDE abiraterone acetate plus prednisone +/- enzalutamide and M1|RT phase 3 trials using health systems data**  
C. Jones, Cheshire (GB)

A0647

**Efficacy and safety of darolutamide in combination with androgen-deprivation therapy and docetaxel in European patients from the phase 3 ARASENS trial**  
B. Tombal, Brussels (BE)

16:05 - 16:25

**mCRPC**

A0635	<b>PARP Inhibitor Plus Androgen Receptor Pathway Inhibitor Combinations for 1st Line mCRPC: A Systematic Review and Meta-Analysis</b> R. Sayyid, Toronto (CA)
A0636	<b>Exploring homologous recombination deficiency threshold for predicting response to PARP inhibitor in prostate cancer</b> J. Wang, Guangzhou (CN)
A0642	<b>Design, Synthesis, and Preclinical Study of Dual Inhibitors Targeting AR-Vs and PARP1/2 in Prostate Cancer Therapy</b> Z. Sihan, Wuhan (CN)
A0646	<b>PPIA-regulated crotonylation of stat3 governs the immunological milieu in bone metastasis of castration-resistant prostate cancer</b> C. Zheng, Wuhan (CN)
<b>16:25 - 16:40</b>	<b>Side effects of treatment</b>
A0648	<b>FRAX Spain may overestimate the need for anti-osteoporotic treatment compared to bone densitometry (DEXA) in patients with prostate cancer undergoing androgen deprivation therapy (ADT) and new antiandrogens signalling-inhibitors generation (ASI)</b> V. Lozano, L'Hospitalet de Llobregat (ES)
A0637	<b>Cardiovascular risks of androgen receptor targeted agents in prostate cancer: a systematic review and meta-analysis</b> Y.X.T. Law, Singapore (SG)
A0640	<b>Evaluation of Cardiovascular Events Among Men with Prostate Cancer Treated with Androgen Receptor Signaling Inhibitors: A Systematic Review, Meta-analysis, and Network Meta-analysis</b> A. Matsukawa, Tokyo (JP)
<b>16:40 - 16:55</b>	<b>Nodal disease</b>
A0649	<b>Effect of metastasis directed therapy (MDT) in men with PSMA PET detected recurrent prostate cancer according to time from primary treatment. Do men with late recurrences really benefit from MDT? Results from a large, single institution series.</b> E. Mazzone, Milan (IT)
A0650	<b>Oncologic Outcomes of Template vs. Radio-Guided Salvage Lymph Node Dissection for Node-Only Recurrent Prostate Cancer: Results from a Multi-Institutional Collaboration.</b> C.A. Bravi, London (GB)
A0651	<b>Prostatectomy vs radiotherapy for regional node positive prostate cancer</b> G. Reitano, Acireale (IT)

# Exploring options in minimally-invasive ureteroplasty

Video session 10

**Sunday 7 April**  
**15:30 - 17:00**

**Location** Green Area, S04

**Chairs** G. Gakis, Halle (DE)  
B. Peyronnet, Rennes (FR)

We encourage participants in this session to view the abstracts before the session. All abstract bodies, posters, videos and webcasts can be viewed on the EAU(N)24 Resource Centre or at the digital screens in front of the Purple Area, EGPT.

V072 (□: 6 min.)

**Intravesical Laparoscopic Cohen's cross trigonal bilateral ureteric reimplant**  
M. Thangarasu, Chennai (IN)

V073 (□: 7 min.)

**Robot Assisted Excisional Tapering and Ureteric Re-implantation: Surgical tips and tricks**  
G.S. Bora, Chandigarh (IN)

V074 (□: 8 min.)

**Robot-assisted surgical treatment for ureteral stenosis: Comparison of different techniques**  
F. Chiaramonti, Terni (IT)

V079 (□: 7 min.)

**Techniques and Outcomes of Minimally Invasive Augmentation Ureteroplasty using Buccal Mucosal Graft for Ureteric Strictures**  
P. Nanavati, Hyderabad (IN)

V076 (□: 7 min.)

**Robot-assisted pyeloplasty with direct pyelo-ureteral anastomosis for retrocaval ureter**  
A. Mottaran, Bologna (IT)

V077 (□: 8 min.)

**Laparoscopic appendiceal interposition techniques for the management of ureteral stricture disease.**  
M. Karavitakis, Pagkrati - Athens (GR)

V078 (□: 5 min.)

**Robotic-assisted laparoscopic ureteroplasty using a non-transecting side-to-side technique for distal ureteral strictures.**  
B. Flynn, Aurora (US)

V075 (□: 8 min.)

**Robotic-assisted repair of complex ureteral stricture after kidney transplantation. 3D virtual models and intraoperative laparoscopic ultrasound are essential tools in the planning and performance of surgery**  
F.J. Burgos Revilla, Madrid (ES)

# E-BLUS Exam

HOT 3.25

**Sunday 7 April**

**15:30 - 16:00**

**Location**

Orange Area, HOT 1

**Tutors**

K. Ahmed, London (GB)

T.M. Ribeiro De Oliveira, Lisbon (PT)

**Sunday 7 April**  
**15:30 - 17:00**

**Location** Purple Area, EGPT

**Chairs** F. Claps, Trieste (IT)  
M. Rouprêt, Paris (FR)

We encourage participants in this session to view the abstracts before the session. All abstract bodies, posters, videos and webcasts can be viewed on the EAU(N)24 Resource Centre or at the digital screens in front of the Purple Area, EGPT.

**15:30 - 15:51**

**Screen A: Urinary diagnostics in non-muscle invasive bladder cancer**

**P289** **Effect of hematuria on the Performance of BTA stat®, UBC® Rapid Test and NMP22® as urine-based biomarker for bladder cancer detection**  
S. Weiß, Berlin (DE)

**P267** **Detection of Molecular Recurrence in Early-Stage Bladder Cancer Patients using a Urinary Tumor DNA Assay after Transurethral Resection of Bladder Tumor (TURBT)**  
R. Zhang, Shanghai (CN)

**P262** **The urine DNA methylation assay facilitates whole course management of urothelial carcinoma in a large multicentric, prospective China cohort**  
X. Chen, Guangzhou (CN)

**P272** **An Innovate Segmentation System by Implementing Dilated Convolution and Red Channel Enhanced Images in Cystoscopic Images**  
J. Mutaguchi, Fukuoka (JP)

**P264** **Development of a sensitive digital droplet PCR screening assay for the detection of GPR126 non-coding mutations in bladder cancer urine liquid biopsies**  
A. Tivtikyan, Moscow (RU)

**P271** **Universal Cancer-Only Marker SIX6 for the Diagnosis Universal Cancer-Only Marker SIX6 for the Diagnosis and Monitoring Early Recurrence of Urothelial Carcinoma**  
W. Yu, Shanghai (CN)

**P279** **The bladder microbiome of NMIBC and MIBC patients revealed by 2bRAD-M**  
X.Y. Zhong, Wuhan (CN)

**15:51 - 16:03**

**Screen B: Developments for the treatment of non-muscle invasive bladder cancer**

**P275** **Imaging-guided photothermal therapy for bladder cancer lesions smaller than 1 millimeter expressing marker of bladder CIS**  
M. Alfano, Milan (IT)

**P261** **Development of a porcine model of bladder cancer using the Oncopig.**  
A. Aulitzky, Innsbruck (AT)

**P285** **Subsequent therapies after intravesical BCG in patients with bladder cancer: Analysis of real-world treatment patterns**  
B. Linghu, Brisbane (US)

**16:03 - 16:18**

**Screen C:**

P277	<p><b>Is there a role for Bacillus Calmette-Güerin in very high-risk Non-Muscle Invasive Bladder carcinoma? Multicenter analysis of oncological outcomes and risk dynamics</b></p> <p>J.D. Subiela Henriquez, Madrid (ES)</p> <p><b>Study Group</b> European Association of Urology-Young Academic Urologists Urothelial carcinoma working group(., Spain)</p>
P274	<p><b>Trends in the the use of immediate postoperative intravesical chemotherapy following TURBT</b></p> <p>A. Dahmen, Chicago, Illinois (US)</p>
P280	<p><b>No impact of detrusor muscle absence in pTaHG urothelial bladder carcinoma first TURB</b></p> <p>G. Tissot, Paris (FR)</p>
P276	<p><b>Replacing ReTUR with Cystoscopy in High-Grade T1 NMIBC Patients: Confirmatory Results from the HuNIRE Trial</b></p> <p>A. Finocchiaro, Catania (IT)</p>
<b>16:18 - 16:33</b>	
<b>Screen D:</b>	
P382	<p><b>A phase III trial of a single post-operative dose of intravesical chemotherapy (pirarubicin) to reduce the risk of bladder recurrence after radical nephroureterectomy (RNU) for upper tract urothelial carcinoma (UTUC) (JCOG1403, UTUC THP Phase III)</b></p> <p>A. Ito, Sendai (JP)</p> <p><b>Study Group</b> Urologic Oncology Study Group of the Japan Clinical Oncology Group(Tokyo, Japan)</p>
P383	<p><b>A preoperative intravesical instillation with Mitomycin C reduces the risk of intravesical recurrence after radical surgery for upper urinary tract urothelial carcinoma: a multicenter phase II clinical trial.</b></p> <p>T. van Doeveren, Rotterdam (NL)</p>
P281	<p><b>Multi-institutional European outcomes of supervised unexperienced resident in transurethral resection of bladder cancer: the importance of a standardized program, the ENTRY project working group</b></p> <p>P. Diana, Barcelona (ES)</p>
P290	<p><b>Proposal for an additional histologic grading approach for stage pT1 non-muscle-invasive bladder cancer (NMIBC) correlating with disease aggressiveness and patient outcomes</b></p> <p>M. Haas, Regensburg (DE)</p>
P269	<p><b>Benchmarking Flemish centers for quality control indicators for transurethral resection of the bladder tumor</b></p> <p>M. Akand, Leuven (BE)</p> <p><b>Study Group</b> CaBLLe Group(Leuven, Belgium)</p>
<b>16:33 - 16:48</b>	
<b>Screen E: Upper Urinary Tract Cancer</b>	
P286	<p><b>Impact of delay in diagnosis and extirpative surgery in upper tract urothelial carcinomas – a population-based study</b></p> <p>J. Bobjer, Malmö (SE)</p>



P283	<b>Characteristics of bladder cancer after radiotherapy for prostate cancer</b> A. Descazeaud, Limoges (FR)
P263	<b>Pembrolizumab in BCG Refractory Non-Muscle Invasive Bladder Cancer is Associated with High Rates of Adverse Events and Discontinuation of Treatment</b> B. Golijanin, providence (US)
P278	<b>Prognosis and Pathological Characteristics Analysis of Same-Patient Metachronous and Synchronous Upper Tract and Bladder Urothelial Carcinoma</b> W. Zuo, Beijing (CN)
P265	<b>From survival to longevity: assessing upper tract urothelial carcinoma impact on life expectancy and economic strain in taiwan</b> W-S. Hu, Taichung (TW)
<hr/>	
<b>16:48 - 16:59</b>	<b>Screen F:</b>
P284	<b>Urological follow-up of Lynch Syndrome: UTUC incidence and mutational patterns in a dedicated outpatient clinic</b> F. Cattafi, Milan (IT)
P288	<b>Risk factors of subsequent upper urinary tract carcinoma treated with intravesical bacillus Calmette-Guerin therapy for non-muscle-invasive bladder cancer: from multiple Japanese hospitals</b> K. Numakura, Akita (JP)
P270	<b>Integrated analysis reveals molecular features of upper tract urothelial carcinoma and prognostic value of neutrophil infiltration for adjuvant chemotherapy</b> J. Shengming, Shanghai (CN)
P268	<b>Oncologic Outcomes in Patients with Variant Histologies of Upper Tract Urothelial Cancer: Results from an International Multicenter Cohort</b> M. Pallauf, Salzburg (AT)

# Has focal therapy for prostate cancer come of age?

Abstract session 33

**Sunday 7 April**  
**15:45 - 17:15**

**Location** Purple Area, N01

**Chairs** E. Barret, Paris (FR)  
L. Hakim, Surabaya (ID)  
P.B. Østergren, Copenhagen (DK)

We encourage participants in this session to view the abstracts before the session. All abstract bodies, posters, videos and webcasts can be viewed on the EAU(N)24 Resource Centre or at the digital screens in front of the Purple Area, EGPT.

**15:45 - 15:47**

**Introduction**

**15:47 - 16:07**

**Selection of candidates**

[A0668](#)

**The accuracy of PSMA PET/CT for assessing intraprostatic lesions in patients with prostate cancer: an evaluation of the PI-RADS, PRIMARY and PSMA-expression score**

E. Donck, Gent (BE)

[A0675](#)

**Natural History of PIRADS-2 Lesions on Serial Multiparametric Magnetic Resonance Imaging: Real-Life Data from an Academic Center**

B. Esen, Istanbul (TR)

[A0674](#)

**Oncologic Outcomes of Partial Gland Ablation using Focal Intensity Focused Ultrasound after Additional Confirmatory Transperineal Mapping Biopsy in Men with Prostate Cancer**

J. Lee, Changwon (KR)

[A0680](#)

**Lessons learned: Improved selection and treatment outcomes for Focal Therapy for early adoption to latest experience.**

A. Rodríguez Serrano, Madrid (ES)

**16:07 - 16:32**

**HIFU**

[A0676](#)

**A randomized non-inferiority clinical trial comparing focal ablation and radical prostatectomy in patients with unilateral clinical significant prostate cancer. A Two-year follow-up.**

E. Baco, Oslo (NO)

[A0682](#)

**A novel multi-imaging based focal therapy program for prostate cancer with High Intensity Focused Ultrasound: early oncological outcomes of a single-center experience.**

D. Maffei, Villa Lagarina (IT)

[A0679](#)

**High Intensity Focused Ultrasounds vs Radical Prostatectomy: carcinologic results of the HIFI study**

G. Ploussard, Toulouse (FR)

**Study Group**

HiFi study group(Lyon, France)

A0678

**Safety, Efficacy and Quality of Life Outcomes of MRI-guided transurethral ultrasound ablation for localized prostate cancer: 12-month outcomes**

E.H.M. Yli-Pietilä, Turku (FI)

A0683

**HIFU vs Radical Prostatectomy: functional results of the HIFI study**

P. Coloby, Cergy Pontoise (FR)

**Study Group**

HiFi study group(Lyon, France)

---

**16:32 - 16:57**

**Cryo, IRE and other energies**

A0672

**Focal HIFU and cryotherapy for prostate cancer: a HEAT and ICE analysis of 15-year usage trends in the United Kingdom**

A. Light, London (GB)

**Study Group**

HEAT and ICE Users Group(London, United Kingdom)

A0677

**A Phase 1 Safety, PK and Preliminary Efficacy Study of Localized Therapy using Biolen (Bicalutamide) Implants for Early-Stage Prostate Cancer**

P.A. Pinto, Bethesda (US)

A0670

**ProFocal® - novel, cooled Laser Focal Therapy. Pivotal trial results of 100 men with localised prostate cancer**

J. Kam, (AU)

A0673

**Irreversible Electroporation for Localized Prostate Cancer: Prospective Cohort Study Evaluating Local Tumor Control and Quality of Life**

S.A. Rhew, Seoul (KR)

A0669

**When does focal LDR brachytherapy fail? Early lessons from Australia's LIBERATE registry**

E. Anderson, Melbourne (AU)

---

**16:57 - 17:12**

**Follow-up**

A0671

**The Trans-Atlantic Recommendations for prostate Gland Evaluation with MRI after focal Therapy (TARGET) international consensus recommendations**

A. Light, London (GB)

**Study Group**

TARGET Working Group(London, United Kingdom)

A0681

**Diagnostic performance of PI-FAB (Prostate Imaging after Focal Ablation): validation of the scoring system for multiparametric MRI performed after ablative techniques for prostate cancer**

M. Ferriero, Rome (IT)

A0684

**The role of PSA kinetics in evaluating treatment failure after focal therapy using high-intensity focused ultrasound for primary localised prostate cancer**

S. Moretto, Milano (IT)

---

**17:12 - 17:15**

**Expert summary**

**Sunday 7 April**  
**15:45 - 17:15**

**Location** Green Area, N04

**Chairs** J.H. Kim, Seoul (KR)  
S. Malde, London (GB)  
S. Secco, Milan (IT)

We encourage participants in this session to view the abstracts before the session. All abstract bodies, posters, videos and webcasts can be viewed on the EAU(N)24 Resource Centre or at the digital screens in front of the Purple Area, EGPT.

- 
- A0686** **New minimally invasive techniques versus gold standard approach for middle volume (30-80 ml) prostates: a multicentre prospective randomized study**  
A.L. Pastore, Rome (IT)
- 
- A0702** **Benign prostatic hyperplasia surgical retreatment: A retrospective cohort analysis of a nationwide database**  
C. Manfredi, Naples (IT)
- 
- A0689** **Postoperative urinary incontinence following BPH surgery: insights from a comprehensive U.S. database analysis**  
L.C. Licari, Sciacca (IT)
- 
- A0700** **Water Vapor Thermal Therapy vs. TURP for the treatment of benign prostatic obstruction: A Multicenter Propensity-Score Matched Pair "tetrafecta" Analysis (URAN Collaborative Group)**  
M.G.R. Asmundo, Catania (IT)
- 
- A0699** **The Rezum water vapor thermal therapy for benign prostate hypertrophy : Risk of unsuccessful trial without catheter after 7 days in a large population**  
M. Al Barajaji, Brussels (BE)
- 
- A0695** **Transurethral Intraprostatic Injections of Anesthetics (TUIA) and cortisone before rezum treatment shows full pain control and it improves post-operative dysuria**  
M. Lo Re, Florence (IT)
- 
- A0697** **Pre-operative prostate artery embolization before transurethral resection of prostate for prostate glands larger than 80 milliliters – a randomised controlled trial**  
Y.A. Lee, Singapore (SG)
- 
- A0692** **Multicenter study evaluating the safety and feasibility of Transurethral Intraprostatic Injections of Anesthetics (TUIA) delivered via an innovative catheter to perform minimally invasive surgical techniques for benign prostatic obstructions**  
S. Secco, Milan (IT)
- 
- A0693** **Transperineal Laser Ablation (TPLA) and convective water vapor ablation (CWVA) for minimally invasive treatment of benign prostatic hyperplasia: a randomized controlled trial**  
M. Pacini, Pistoia (IT)

A0688	<b>Trans-Perineal Laser Ablation of the Prostate for the treatment of Benign Prostatic Obstruction in high surgical risk patients. One-year results from a prospective cohort of "extreme" patients</b> M. Sibona, Torino (IT)
A0690	<b>Transperineal Fusion Laser Ablation for BPH: 100 consecutive patients with 1 year results</b> G. Maiolino, Perugia (IT)
A0698	<b>Efficacy and safety of ultrasonography guided transperineal percutaneous laser ablation for treating benign prostatic hyperplasia: a randomized controlled clinical trial compared with transurethral resection of the prostate.</b> Q. Fu, Shanghai (CN)
A0691	<b>Treatment of benign prostatic hyperplasia (BPH) using 3D Ultrasound-guided transperineal targeted microwave ablation (TMA): the first safety and feasibility study (BETTY trial)</b> P.K-F. Chiu, Hong Kong (HK)
A0694	<b>MRI-guided transurethral ultrasound ablation (TULSA) for the treatment of benign prostatic hyperplasia: 12-month outcomes of a phase 1-2 study</b> M.H.J. Anttinen, Turku (FI)
A0687	<b>Flow rate and symptom improvements maintained long-term after treatment of prostatic hypertrophy with a novel combination drug/device</b> S.A. Kaplan, New York (US)
A0701	<b>A drug-coated ballon treatment for urethral stricture: a multicenter Italian real-life study.</b> R. Castellucci, Pescara (IT)
A0696	<b>Impact of treatment of BPH-related LUTS with second generation temporary implantable nitinol device (iTIND) on serum PSA: results from a multicenter prospective study (MT-06-study)</b> S.T. De Cillis, Turin (IT)
A003	<b>Minimally Invasive Surgery (MIS) vs Medication in the initial Treatment of LUTS Secondary to BPH: Preliminary RCT Analysis</b> C. Roehrborn, Dallas (US)

# Prostate cancer screening at its best

Abstract session 32

**Sunday 7 April**  
**15:45 - 17:15**

**Location** Green Area, eURO Auditorium 1

**Chairs** A.P. Auvinen, Tampere (FI)  
C.H. Bangma, Rotterdam (NL)  
S. Carlsson, New York (US)

We encourage participants in this session to view the abstracts before the session. All abstract bodies, posters, videos and webcasts can be viewed on the EAU(N)24 Resource Centre or at the digital screens in front of the Purple Area, EGPT.

**15:45 - 15:47**

## **Introduction**

A0666

### **Why is there a need to re-think Prostate Cancer early detection?**

K. Beyer, Rotterdam (NL)

A0661

### **Prevalence and determinants of shared decision-making for psa testing in the United States**

N. Bhojani, Montreal (CA)

A0659

### **Organised prostate cancer testing in Sweden – Results from the first three years of inviting 50-year-old men**

A. Lantz, Danderyd (SE)

A0665

### **Understanding the barriers to Prostate Cancer population-based early detection programs: the PRAISE-U BEST survey**

K. Beyer, Rotterdam (NL)

A0652

### **The Man Van Project: Second Phase Interim Results**

M. Moghul, London (GB)

A0663

### **Effect of age at first protocolled screening on long-term outcomes in prostate cancer screening: results from a cross-sectional screening study**

I.I. de Vos, Rotterdam (NL)

A0667

### **Superiority of midlife baseline prostate-specific antigen value over psa doubling time and velocity in the prediction of lethal prostate cancer development, and mortality: A system wide analysis of a racially diverse north american cohort**

G.O. Cirulli, Roma (IT)

A0662

### **Differences in quality of curative treatment and outcome in men with localised prostate cancer in the screening and control arms of the ERSPC Rotterdam**

I.I. de Vos, Rotterdam (NL)

A0664

### **Multiplex blood-test and magnetic resonance imaging (MRI) for prostate cancer screening: Results from the 2nd screening round in the STHLM3-MRI trial**

T. Nordström, Stockholm (SE)

A0657	<p><b>The Association of County-Level Prostate-Specific Antigen Screening with metastatic prostate cancer and prostate cancer mortality</b></p> <p>D.K. Filipas, Hamburg (DE)</p>
A0656	<p><b>Can we reduce unnecessary prostate biopsies in patients with PI-RADS 3 lesions? Role of PSA density and the Stockholm 3 test</b></p> <p>A. Abbadi, Stockholm (SE)</p>
A0655	<p><b>A 20 years Follow-up Results of the Modena Screening Program for Prostate Cancer (PCa) "Progetto Uomo"(PU)</b></p> <p>M. Brausi, Modena (IT)</p>
A0653	<p><b>PROSPET-BX trial: [68Ga]PSMA PET/CT vs. mpMRI in patients with suspicion of prostate cancer and previous negative biopsy.</b></p> <p>V. Fasulo, Milano (IT)</p>
A0654	<p><b>The role of PSA density in the follow up of men with a negative MRI in the Göteborg 2 trial</b></p> <p>F. Möller, Gothenburg (SE)</p>
A0658	<p><b>The impact of prostate volume on prostate cancer detection: comparing MRI with TRUS in biopsy-naïve men</b></p> <p>Y. Jianjun, Chengdu (CN)</p>
A0660	<p><b>Assessing the mid-term impact of enhanced prostate cancer screening in Caucasian men with germline DNA repair pathogenic variants.</b></p> <p>M. Aljoulani, Capriate San Gervasio (IT)</p>
A001	<p><b>First screening round results of the ProScreen trial with PSA, kallikrein panel and MRI</b></p> <p>A.S. Rannikko, Helsinki (FI)</p>
<b>17:11 - 17:14</b>	<b>Expert summary</b>

# Hands-on Training in Non-Technical Skills (NTS)

HOT 3.36

**Sunday 7 April**

**15:45 - 17:30**

**Location** Orange Area, HOT 4

**Chair** N. Raison, London (GB)

## **Learning objectives**

Non-technical skills encompass the cognitive, personal, and social abilities critical for safe and effective surgery. It is recognised that the majority of surgical errors and complications occur as a result of non technical factors. Technical skill alone is insufficient to maintain safe and effective care but like technical skills, NTS require dedicated, focussed training.

The course will introduce delegates to the key concepts of non-technical skills for surgeons. An expert faculty will highlight the key learning points and pitfalls in common emergency and difficult clinical scenarios to teach the necessary NTS skills to navigate them safely. Training will utilise simulation bases scenarios. Delegates will have the opportunity to participate and practice key skills such as communicating effectively, work collaboratively, maintain situational awareness, and making timely and informed decisions.

## **Training aim**

The objective of this course is to provide a foundation for the development non-technical skills. Participants will be introduced to the key aspects of effective NTS including situational Awareness, Decision Making, Communication and Leadership and how these lead to effective, safe surgical practice. By the end of the course, attendees will have a understanding of the key concepts of non technical skills and will be able to apply them to their own surgical practice.

**15:45 - 15:55**

## **Introduction to Non-Technical Skills**

N. Raison, London (GB)

**15:55 - 16:05**

## **Principles of Non-Technical Skills**

S.M. Haensel, Rotterdam (NL)

**16:05 - 17:10**

## **Hands-on Training**

**17:10 - 17:30**

## **Debrief**

G. Zanovello, Verona (IT)



# ESTs1 Exam

HOT 3.27

**Sunday 7 April**

**16:00 - 16:55**

**Location**

Orange Area, HOT 1

**Tutors**

K. Ahmed, London (GB)

B. Ballesta Martinez, Alicante (ES)

N. Macchione, Milan (IT)

T. Tokas, Hall In Tirol (AT)

# E-BLUS Exam

HOT 3.26

**Sunday 7 April**

**16:00 - 16:30**

**Location**

Orange Area, HOT 1

**Tutor**

T.M. Ribeiro De Oliveira, Lisbon (PT)

# Hands-on Training in Transurethral treatment - Step 1 & 2 (TURBT/TURP)

HOT 3.28

Sunday 7 April

16:00 - 16:55

**Location** Orange Area, HOT 1

**Tutors** A.J. Antunes Loureiro Nunes, Lisbon (PT)  
R.N. Brito Ramos, Lisbon (PT)

## **Learning objectives**

This training course combines the first and second step of the Transurethral Treatment (TUT) curriculum. It is designed for urologists who wish to improve their proficiency in key techniques and gain a fundamental understanding of transurethral resection of the bladder and prostate. This comprehensive training covers crucial basic skills including flexible and rigid cystoscopy, resection loop handling, and direct vision internal urethrotomy, as well as the resection procedure, practiced on state-of-the-art models.

The primary objective of this course is to enhance participants' skills in transurethral resection of the prostate and bladder, focusing on key aspects such as depth perception, hand-eye coordination, control, handling, and overall technique. By the end of the course, attendees should feel more competent and confident in performing this procedure.

# Hands-on Training in Transurethral treatment - Step 3 (ThuLEP)

HOT 3.29

Sunday 7 April

16:00 - 16:55

**Location** Orange Area, HOT 2

**Tutors** I. Kartalas Goumas, Milan (IT)  
T.E. Şener, Istanbul (TR)

## **Learning objectives**

This advanced training course is the third step in the Transurethral Treatment (TUT) curriculum. It is designed to provide urologists with a fundamental understanding of thulium laser enucleation of the prostate (ThuLEP). This comprehensive training is specifically tailored for urologists who want to become proficient in ThuLEP. Using a step by step approach, experts will lead participants through the procedure on state of the art models, to build a familiarity of the process, confidence handling the equipment, and an understanding of best practice.

## **Training aim**

The primary objective of this course is to enhance participants' skills in ThuLEP, focusing on key aspects such as control, handling, and overall technique. By the end of the course, attendees should feel more competent and confident in performing this procedure.

# E-BLUS Exam

HOT 3.30

**Sunday 7 April**

**16:30 - 17:00**

**Location**

Orange Area, HOT 1

**Tutors**

G. Bozzini, Como (IT)

T.M. Ribeiro De Oliveira, Lisbon (PT)

# Kidney transplantation

Abstract session 60

Sunday 7 April  
16:45 - 18:15

**Location** Green Area, W01

**Chairs** To be confirmed  
K. Decaestecker, Ghent (BE)  
J.D. Olsburgh, London (GB)

We encourage participants in this session to view the abstracts before the session. All abstract bodies, posters, videos and webcasts can be viewed on the EAU(N)24 Resource Centre or at the digital screens in front of the Purple Area, EGPT.

- 
- A0945** **Impact of the number of organs retrieved during multiple organ procurement on short and long term renal graft function.**  
T. Ghestem, (FR)
- 
- A0936** **Analysing rejected kidney offers - are your own rules justified?**  
J. Putz, Dresden (DE)
- 
- A0943** **TransplantAFUF: Impact of BMI and the ilio-cutaneous distance on renal transplant prognosis.**  
C. Joncour, La Rochelle (FR)
- 
- A0938** **Questioning minimum annual caseload requirements for kidney transplantation (KT): low-volume centers show better graft function after deceased-donor KT in German total population quality assurance data from 2006 to 2021**  
P. Reimold, Marburg (DE)
- 
- A0929** **Kidney transplant in patients with unique blood transfusion preferences: a study of ethical and clinical aspects at a specialized institution**  
N. García Formoso, Santander (ES)
- 
- A0931** **Proposal of a Standardized Training Curriculum for Open and Robot-assisted Kidney Transplantation**  
A. Pecoraro, Firenze (IT)
- 
- A0933** **Implementation of robot-assisted kidney transplantation in surgical practice at referral European transplant Centres: An audit within the ERUS-RAKT working group**  
A. Pecoraro, Firenze (IT)
- 
- A0934** **Robot-assisted kidney transplantation: 8-year European experience**  
A. Territo, Barcelona (ES)
- 
- A0932** **Trifecta in robot-assisted kidney transplantation (RAKT) from living donors: the ERUS-RAKT experience**  
A. Gallioli, Barcelona (ES)
- 
- A0940** **Orthotopic Robot-Assisted Kidney Transplantation: Experience from the ERUS-RAKT Group**  
B.R. Etcheverry Giadrosich, Barcelona (ES)

A0935	<b>Post-operative surgical complications of renal transplantation in the elderly</b> A. Beretta, (FR)
A0939	<b>Complications and outcomes of percutaneous drainage in the treatment of lymphocele after renal transplantation.</b> O. Boiko, Castro Urdiales (ES)
A0944	<b>Evaluation of oxygenation modalities for marginal renal transplants in a porcine model.</b> T. Prudhomme, Toulouse (FR)
A0937	<b>Assessment of kidney graft quality during normothermic machine perfusion using NMR spectroscopy as a valuable tool</b> J. Putz, Dresden (DE)
A0941	<b>Assessment of compliance with recommendations for the use of renal infusion machines and the consequences of their non-application</b> C. Larose, Vandoeuvre (FR)
A0946	<b>Robot-assisted pyelo-ureterostomy for complex ureteral strictures in kidney transplant patients: A very successful option</b> J. Vangeneugden, Ghent (BE)
A0942	<b>Robotic Surgery for the Management of Urinary Tract Complications Following Kidney Transplantation</b> V. Lozano, L'Hospitalet de Llobregat (ES)
A0930	<b>Impact of Timing of Rejection Cardiovascular Events in Living Donor Kidney Transplantation: A Multicenter Retrospective Study</b> T. Hamaya, Hirosaki (JP)

# Hot research topics II

Abstract session

**Sunday 7 April**  
**16:45 - 18:15**

**Location** Green Area, W03

**Chairs** L. Dyrskjøt, Aarhus (DK)  
M. Eckstein, Erlangen (DE)  
C. Jeronimo, Porto (PT)

We encourage participants in this session to view the abstracts before the session. All abstract bodies, posters, videos and webcasts can be viewed on the EAU(N)24 Resource Centre or at the digital screens in front of the Purple Area, EGPT.

**16:45 - 16:48**

**Introduction**

**16:48 - 16:55**

**State-of-the-art lecture Technological advances and potential clinical impact**  
T. Strandgaard, Aarhus (DK)

**16:55 - 17:31**

**From bulk to single cell spatial analysis**

[A0707](#)

**The infiltration of MALT B cells could predict a poor prognosis in clear cell renal carcinoma: results from single-cell transcriptomics and spatial transcriptome**  
S. Zhu, Shanghai (CN)

[A0703](#)

**Spatial mapping reveals the transcriptome and anatomic heterogeneity of human and rat corpus cavernosum**  
L. Zhao, Zhuhai (CN)

[A0708](#)

**Spatial transcriptomic clonal deconvolution identifies the 'lethal clone' in prostate cancer (PCa) as defined by ability to metastasize to lymph nodes**  
W. Yin, Oxford (GB)

**17:31 - 18:15**

**Liquid biopsy: prognostic evaluation and treatment selection**

[A0705](#)

**Genomic profiling and clinical utility of circulating tumor DNA in metastatic renal cell carcinoma: Nationwide SCRUM-Japan MONSTAR SCREEN project**  
T. Kato, Suita (JP)

[A0704](#)

**Rapid feedback on the effects of anticancer mitochondrially targeted tamoxifen using circulating tumor cells**  
P. Klézli, Prague 10 (CZ)

[A0706](#)

**Prognostic value of circulating tumor cells and cell-free DNA in upper tract urothelial carcinoma**  
B. Padulles Castello, Barcelona (ES)

**18:07 - 18:15**

**Discussion**



# Biopsy indication: The role of MRI and risk calculators

Abstract session 35

**Sunday 7 April**  
**17:15 - 18:45**

**Location** Green Area, N03

**Chairs** P. Nyirády, Budapest (HU)  
M. Salazar, Floridablanca (CO)  
F. Sanguedolce, Barcelona (ES)

We encourage participants in this session to view the abstracts before the session. All abstract bodies, posters, videos and webcasts can be viewed on the EAU(N)24 Resource Centre or at the digital screens in front of the Purple Area, EGPT.

**17:15 - 17:45**

## **Risk stratification and imaging**

A0717

**EAU Risk stratification for prostate cancer according to systematic biopsy, target biopsy and combined biopsy results and final pathology concordance. Results from the PROMOD Study Group**

A. Ninivaggi, Foggia (IT)

A0726

**A new approach to data integration with AI to enhance the specificity of prostate cancer diagnosis**

N. Vasdev, Stevenage (GB)

A0712

**PSA-density, DRE, and PI-RADS 5: Potential surrogates for omitting prostate biopsy?**

F. Falkenbach, Hamburg (DE)

A0718

**To biopsy or not to biopsy, that is the prostate-blem: The utility of Prostate Health Index in men with PIRADS 3 lesions**

K. Wang, Singapore (SG)

A0709

**Risk Stratification for Avoiding Unnecessary Prostate Biopsy After Atypical Small Acinar Proliferation Detection**

M. Kaneko, Glendale (US)

**17:45 - 18:30**

## **Risk calculators and markers**

A0719

**Development and external validation of new biopsy indication using Prostate Health Index Density and Prostate Image Report and Data System score**

J.K. Nam, Yangsan (KR)

A0722

**Added Value of The Rotterdam Prostate Cancer Risk Calculator After a Negative Pre-Biopsy Magnetic Resonance Imaging: How many Clinically Significant Prostate Cancers Are Overlooked?**

A.C. Tagalos Munoz, Madrid (ES)

A0711

**Intercenter variability in the accuracy of Risk calculators based on MRI parameters: Extensive external validation of 7 contemporary risk calculators.**

E. Tocci, Foggia (IT)

A0710

**Pre-biopsy meeting as a foundation to the diagnostic prostate cancer pathway: A single unit review**

S. Fleville, Craigavon (GB)

A0721

**The Ongoing Role of DRE in the Diagnostic Pathway for Men with Suspected Prostate Cancer**

C. Richards, Stockport (GB)

- A0725 **Stockholm3 validation in a multi-Ethnic cohort for Prostate cancer (SEPTA) detection: A multicentered, prospective trial**  
H.T. Vigneswaran, Stockholm (SE)
- A0715 **The importance of high volume providers in the diagnostic pathways of prostate cancer. Results from large, single Institution series**  
P. Scilipoti, Milan (IT)
- A0713 **Stockholm3 to predict post-operative risk and biochemical recurrence after radical prostatectomy: Evidence from the STHLM3 trial**  
H.T. Vigneswaran, Stockholm (SE)
- A0714 **Stockholm3 in older men; PSA values, MRI- and biopsy results.**  
M.N. Vigmostad, Stavanger (NO)
- 

**18:30 - 18:45**

**Markers PSA-PSAD**

- A0723 **Lower than expected? Establishing a PSA density threshold**  
J. Dawson, Liverpool (GB)
- A0724 **Repeat PSA testing improves biopsy outcome predictions in men undergoing MRI and targeted biopsies**  
P. Davik, (NO)
- A0716 **Does the accuracy of PSA density change according to prostate volume? Assessing the diagnostic accuracy at the extreme values of prostate volume in a large single institution series.**  
L. Quarta, Milan (IT)
- 

- A004 **PSA density as a selection tool before MRI – a post hoc analysis within the STHLM3MRI screening trial**  
L. Björnebo, Stockholm (SE)

**Sunday 7 April**  
**17:15 - 18:45**

**Location** Purple Area, S03

**Chairs** A.M. Kamat, Houston (US)  
G. Kramer, Vienna (AT)  
A. Masson-Lecomte, Paris (FR)

We encourage participants in this session to view the abstracts before the session. All abstract bodies, posters, videos and webcasts can be viewed on the EAU(N)24 Resource Centre or at the digital screens in front of the Purple Area, EGPT.

**17:15 - 17:17**

## **Introduction**

A0732

### **Active surveillance for recurrent non-muscle invasive bladder cancer**

E. Tokarski, Paris (FR)

A0742

### **The International Bladder Cancer Group Intermediate-risk Non-muscle Invasive Bladder Cancer (IBCG IR-NMIBC) scoring system predicts the need for intervention for patients on active surveillance.**

R. Contieri, Pieve Emanuele (IT)

A0729

### **Outpatient laser coagulation of low-grade intermediate risk bladder tumor compared with TUR-BT, 12 months and long-term follow-up of a noninferiority RCT**

G.L. Pedersen, Herlev (DK)

A0734

### **Repeat Transurethral Resection for Non-muscle Invasive Bladder Cancer: An Updated Systematic Review and Meta-analysis in the Contemporary Era**

T. Yanagisawa, Tokyo (JP)

A0740

### **Correlation of quality control indicators for transurethral resection of the bladder tumor with oncological outcomes: Results from a Flemish prospective registry**

M. Akand, Leuven (BE)

A0730

### **Does audit, feedback and education improve quality indicator achievement and reduce early recurrence rates in TURBT surgery for NMIBC? Results from the RESECT cluster randomised trial.**

K.M. Gallagher, Edinburgh (GB)

A0737

### **Impact of risk factors on oncologic outcomes in intermediate-risk non-muscle-invasive bladder cancer**

E. Laukhtina, Vienna (AT)

A0733

### **Intravesical instillations in octagenarian high grade, non muscle-invasive bladder cancer patients: could they offer a real survival advantage?**

G. Guano, Genova (IT)

A0727

### **Cumulative incidence of and risk factors for BCG-infection after adjuvant BCG-instillations**

F. Liedberg, Malmö (SE)

A0739	<p><b>Challenging the paradigm of “BCG Unresponsive” Bladder Cancer: Does additional BCG have an effect?</b></p> <p>A. Myers, Houston (US)</p>
A0736	<p><b>No clinical benefit from Sequential Combination of Mitomycin C Plus Bacillus Calmette- Guérin (BCG) than BCG alone in the adjuvant treatment of high risk non muscle invasive bladder cancer: result of a planned interim analysis of a prospective randomized trial (NCT03790384)</b></p> <p>A.F.M. Cicione, Roma (IT)</p>
A0738	<p><b>TRUCE04: A Phase II Clinical Trial of RC48 for High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) 24)</b></p> <p>H. Hu, Tianjin (CN)</p>
A0731	<p><b>First results of the phase Ib-II BladderGATE clinical trial: intravenous Atezolizumab + intravesical bacillus Calmette-Guérin (BCG) upfront combination in BCG-naïve high risk non-muscle invasive bladder cancer patients</b></p> <p>F. Guerrero-Ramos, Madrid (ES)</p>
A0741	<p><b>Intravesical administration of Durvalumab to patients with high risk non muscle invasive bladder cancer who experience BCG failure. Final results from a phase II study by the Hellenic GU Cancer Group.</b></p> <p>C. Fragkoulis, Athens (GR)</p>
A0728	<p><b>Intravesical electromotive mitomycin for primary high risk non-muscle invasive bladder cancer after intravesical bacillus Calmette-Guérin failure: a single arm phase II multicenter prospective study.</b></p> <p>S.K. Moosavi, Rome (IT)</p>
A0735	<p><b>Unveiling the necessity: Should (Very) high-risk NMIBC patients undergoing RC Opt for pelvic lymph node dissection? —A prospective cohort study</b></p> <p>Q. Lyu, Nanjing (CN)</p>
A0743	<p><b>Impact of Systemic Therapy in Clinical T1 Small-cell Neuroendocrine Carcinoma of the Bladder</b></p> <p>A. Myers, Houston (US)</p>
18:42 - 18:45	<p><b>Expert summary</b></p>

# Metastatic urothelial cancer

Abstract session 37

**Sunday 7 April**  
**17:15 - 18:45**

**Location** Green Area, W06

**Chairs** B. Ali-El-Dein, Mansoura (EG)  
A.J Birtle, Preston (GB)  
M. Vukovic, Podgorica (ME)

We encourage participants in this session to view the abstracts before the session. All abstract bodies, posters, videos and webcasts can be viewed on the EAU(N)24 Resource Centre or at the digital screens in front of the Purple Area, EGPT.

**17:15 - 17:30**

## Antibody drug conjugates (ADC's)

A0750

**Membranous NECTIN-4 expression in metastasis versus matched primary tumor more accurately predicts enfortumab vedotin response**

T. Büttner, Bonn (DE)

A0744

**Side effects of antibody-drug conjugates in the new era of tailored therapy in urologic malignancies**

K.H. Tully, Herne (DE)

A1107

**Enfortumab vedotin and pembrolizumab (EV+P) versus chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC): Results from the global phase 3 EV-302/KEYNOTE-A39 study**

J. Bedke, Tübingen (DE)

**17:30 - 17:50**

## Immune checkpoint inhibition

A0753

**First-line maintenance therapy in patients with locally advanced or metastatic urothelial carcinoma in routine care in Germany: Preliminary results of the prospective CARAT registry**

P.J. Goebell, Erlangen (DE)

A0745

**Analysing resistance and progression patterns to immune checkpoint inhibitors in urothelial carcinoma**

T. Powles, London (GB)

A0751

**Pembrolizumab after platinum-based chemotherapy for treatment of metastatic bladder cancer**

A. Richters, Nijmegen (NL)

### Study Group

ProBCI Study Group(Utrecht, The Netherlands)

A0755

**Impact of antacids on the prognosis of patients with metastatic urothelial carcinoma treated with pembrolizumab: a retrospective multicenter study**

T. Sekito, Okayama (JP)

**17:50 - 18:25**

## Prognosticators and predictors

A0752

**Gustave Roussy Immune Score Predicts Survival Outcome of Patients with Metastatic Urothelial Carcinoma Treated with Pembrolizumab: A multicenter Study of 321 patients (YUSHIMA study)**

K. Tanabe, Saitama (JP)

A0754

**Predictors of developing cisplatin ineligibility in a contemporary cohort of bladder cancer patients treated with radical cystectomy at an Italian National Cancer Center**

U. Anceschi, Rome (IT)

A0757

**TP53 disruptive mutation predicts platinum-based chemotherapy and PD-1/PD-L1 blockade response in urothelial carcinoma**

J. Kaifeng, Shanghai (CN)

A0748

**Impact of radiation therapy to the recurrence sites on oncological outcomes in patients who experienced local recurrence and/or pelvic lymph node metastases after radical cystectomy: A multicenter retrospective study**

N. Fujita, Hirosaki (JP)

A0756

**A clinically practical model for the preoperative prediction of lymph node metastasis in bladder cancer: a multicohort study**

J. Lu, Guangzhou (CN)

A0747

**Germline HLA-DQB1\*03:01 is an independent prognostic factor for clinical outcomes in patients with urothelial cancer treated with pembrolizumab**

M. Mori, Akita (JP)

---

**18:25 - 18:30**

**Trial in progress**

A0746

**Phase 3 study of disitamab vedotin with pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial carcinoma that expresses HER2 (DV-001; trial in progress)**

T. Powles, London (GB)

# Award session: New horizons in robotics and AI

Video session 11

**Sunday 7 April**  
**17:15 - 18:45**

**Location** Purple Area, eURO Auditorium 2

**Chairs** G. Shaw, London (GB)  
F. Van Der Aa, Leuven (BE)

We encourage participants in this session to view the abstracts before the session. All abstract bodies, posters, videos and webcasts can be viewed on the EAU(N)24 Resource Centre or at the digital screens in front of the Purple Area, EGPT.

V080 (□ 2 min.)

**AI Guidance in Robotic Surgery: Preliminary Video Analysis of Enhanced Surgical Performance**

L.A. Morgantini, Chicago (US)

V081 (□ 8 min.)

**The Single Port (SP) robotic surgical “toolbox”: a primer for beginners**

F. Ditunno, Verona (IT)

V082 (□ 7 min.)

**A pure single port DaVinci SP Robotic partial nephrectomy integrated with a fully functional assistant port: iFAP trocar configuration technique**

Y.H. Ko, Daegu (KR)

V083 (□ 8 min.)

**A novel single-port robotic surgical system in RNRS-RARP**

W. Yong, Tianjin (CN)

V084 (□ 7 min.)

**Single Port radical prostatectomy comparing Shurui and da Vinci SP robots: technology illustration and intraoperative performances**

Z. Wu, Shanghai (CN)

V085 (□ 8 min.)

**Robot-assisted radical cystectomy with ureterocutaneostomy: surgical technique, perioperative and oncologic outcomes**

L. Misuraca, Rome (IT)

V086 (□ 7 min.)

**A preliminary experience with metaverse surgical planning for robotic partial nephrectomy**

E. Checcucci, Candiolo (IT)

V022 (□ 8 min.)

**Feasibility of image-guided navigation during robotic-assisted surgery: a prospective study**

L. Aguilera Saiz, Amsterdam (NL)

**18:42 - 18:45**

**Closing remarks and handover prizes**

# Urothelial cancer treatment: From endoscopy to robotic-assisted surgery

Video session 12

**Sunday 7 April**  
**17:15 - 18:45**

**Location** Purple Area, S01

**Chairs** M. Musquera Felip, Barcelona (ES)  
B. Pradere, Toulouse (FR)

We encourage participants in this session to view the abstracts before the session. All abstract bodies, posters, videos and webcasts can be viewed on the EAU(N)24 Resource Centre or at the digital screens in front of the Purple Area, EGPT.

V088 (□ 8 min.)

**A novel transurethral resection approach: a study of rotatable bi-channel en bloc resection of bladder tumor in ex vivo and in vivo porcine models**

Q. Yao, Suzhou (CN)

V089 (□ 7 min.)

**Outpatient treatment of low and intermediate risk non-muscle invasive bladder tumors using transurethral ablation with diode laser (TULA). Initial experience**

P. Zamora Voorn, Gijón (ES)

V090 (□ 5 min.)

**Robot-assisted radical cystectomy with Hugo RAS system: Description of the setup and initial outcomes for two Italian centres**

B.M.C. Rocco, Milan (IT)

V091 (□ 7 min.)

**Fully sexual-sparing robot-assisted cystectomy: a step-by-step surgical technique**

C. Vaccaro, Milano (IT)

V085 (□ 8 min.)

**Robot-assisted radical cystectomy with ureterocutaneostomy: surgical technique, perioperative and oncologic outcomes**

L. Misuraca, Rome (IT)

V093 (□ 8 min.)

**Robotic Radical Cystectomy and Nephroureterectomy for UC in double Renal Transplant Recipient with FloRIN reconstruction**

F. Lavagno, Turin (IT)

V094 (□ 7 min.)

**"Bordeaux Neobladder": illustration of surgical tricks and evaluation of perioperative outcomes in a referred center.**

B. Bianchi, Cortona (IT)

V095 (□ 7 min.)

**Prone position posterior retroperitoneal robotic nephroureterectomy: A new approach requiring NO patient repositioning**

Q. Lyu, Nanjing (CN)



# Complex robotic renal surgery

Video session 13

**Sunday 7 April**  
**17:15 - 18:45**

**Location** Green Area, S04

**Chairs** J.L. Hoepffner, Bordeaux (FR)  
P.J. Zondervan, Amsterdam (NL)

We encourage participants in this session to view the abstracts before the session. All abstract bodies, posters, videos and webcasts can be viewed on the EAU(N)24 Resource Centre or at the digital screens in front of the Purple Area, EGPT.

V096 (□: 8 min.)

**The novel strategy of robotic-assisted partial nephrectomy for renal sinus tumors**  
P. Shao, Nanjing (CN)

V097 (□: 6 min.)

**Redo partial nephrectomy for local recurrence after previous nephron sparing surgery. Surgical insights and oncologic results from a high-volume robotic centre.**  
F. Di Maida, Florence (IT)

V098 (□: 8 min.)

**Primary Renal cell carcinoma in cross-fused ectopia in chronic kidney disease: Robot-assisted Nephron sparing surgery for a rare entity.**  
G.K. Pooleri, Kochi (IN)

V099 (□: 7 min.)

**Retroperitoneal robot-assisted partial nephrectomy with Hugo RAS System: Surgical settings and preliminary results**  
A. Uleri, Barcelona (ES)

V100 (□: 7 min.)

**Robotic surgery for treatment of a renal tumor with level III vena cava tumor thrombus**  
L. Puig, Barcelona (ES)

V101 (□: 8 min.)

**Challenging scenarios and problem-solving in robot-assisted inferior vena cava thrombectomy for Mayo level III-IV thrombi**  
P. Dell'Oglio, Milan (IT)

V102 (□: 7 min.)

**Re-do robot-assisted vena cava thrombectomy: Feasibility and results**  
G. Margue, Bordeaux (FR)

**Sunday 7 April**  
**17:15 - 18:45**

**Location** Purple Area, EGPT

**Chairs** P. Albers, Düsseldorf (DE)  
R. Hogenhout, Rotterdam (NL)

We encourage participants in this session to view the abstracts before the session. All abstract bodies, posters, videos and webcasts can be viewed on the EAU(N)24 Resource Centre or at the digital screens in front of the Purple Area, EGPT.

**17:15 - 17:24**

## Screen A

- P291** **Differential impact of Prostate-Specific Antigen screening pattern on prostate cancer-mortality Among Non-Hispanic Black and Non-Hispanic White men: A large, urban health system cohort analysis**  
G.O. Cirulli, Roma (IT)
- P296** **Prostate cancer testing in Stockholm; comparing compliance to follow up of men with elevated PSA vs elevated Stockholm3 in clinical practice between 2018 to 2020**  
T. Palsdottir, Solna (SE)
- P293** **External validation of the Rotterdam Prostate Cancer risk calculators with and without including PHI for detection of clinically significant prostate cancer.**  
L. Rius Bilbao, Galdakano Usansolo (ES)  
**Study Group**  
Basque PHI study group(Basque country, Spain)
- 
- P305** **Developing and comparing prostate cancer screening specific performance indicators for PRAISE-U**  
M.J. van Harten, Utrecht (NL)

**17:27 - 17:45**

## Screen B

- P311** **Towards a tailored use of PSA density to decide when to avoid prostate biopsy in men with PIRADS 3 lesions according to the location of the index lesion at mp-MRI. Results of a large, multi-institutional series**  
L. Quarta, Milan (IT)
- P320** **Contemporary Patterns Prostate Cancer Screening Patterns Among LGBTQ+ Patients**  
K. Alkhatib, Elmhurst (US)
- P292** **Incidence and mortality of prostate cancer, a cohort of 564,975 patients, France 2010-2021**  
H. Crespín, Tours (FR)
- P309** **Advancing prostate cancer risk stratification: is predicting positive magnetic resonance imaging (MRI) findings the preferred approach?**  
M.J. Hagens, Amsterdam (NL)

P313	<b>Comparing PSA Screening Patterns and their role as predictor of Prostate Cancer Incidence and Mortality: a system wide analysis of a contemporary North American cohort.</b> G.O. Cirulli, Roma (IT)
P303	<b>Is strict PSA Surveillance necessary for patients with a negative PI-RADS 4 lesion following MRI-Fusion targeted and saturation biopsies of prostate</b> K.W. Lai, Singapore (SG)
<b>17:45 - 17:54</b>	<b>Screen C</b>
P298	<b>Comparing the Performance of Digital Rectal Examination and PSA as a Screening Test for Prostate Cancer: A Systematic Review and Meta-analysis</b> A. Matsukawa, Tokyo (JP)
P314	<b>Testing Free PSA Percentage as a tool in predicting future risk of developing Prostate Cancer: a system wide analysis of a contemporary North American cohort.</b> G.O. Cirulli, Roma (IT)
P319	<b>Diagnostic validation of real world prostate cancer screening algorithms</b> M. Thüring, Zürich (CH)
P310	<b>Artificial intelligence-aided detection for prostate cancer with multi-modal routine health check-up data: a multi-center study</b> R. Chen, Shanghai (CN)
<b>18:00 - 18:15</b>	<b>Screen D: Trials in progress</b>
P304	<b>ARASAFE - A randomized, phase 3 trial comparing 3-weekly Docetaxel 75 mg/m<sup>2</sup> (in a 3-week cycle) versus 2-weekly Docetaxel 50 mg/m<sup>2</sup> (in a 4-week cycle) in combination with Darolutamide + ADT in patients with mHSPC.</b> A. Roessler, Jena (DE)
P312	<b>Phase 2 KEYNOTE-057 cohort C: Coformulations of pembrolizumab (pembro) and favezelimab or vibostolimab for patients with bacillus Calmette-Guérin (BCG)-unresponsive high-risk (HR) non-muscle-invasive bladder cancer (NMIBC)</b> G. Kulkarni, Toronto (CA)
P299	<b>A phase II clinical trial of neoadjuvant sasanlimab and stereotactic body radiation therapy as an in situ vaccine for cisplatin ineligible muscle invasive bladder cancer</b> R. Satkunasivam, Toronto (CA)
P302	<b>A precise diagnostic method for urothelial carcinomas based on novel dual methylated DNA markers</b> Y. Wu, Beijing (CN)
P307	<b>ProstACT GLOBAL: A Phase 3 Study Best Standard of Care With and Without 177Lu-DOTA-rosopatamab (TLX591) for Patients with PSMA Expressing Metastatic Castration-resistant Prostate Cancer Progressing Despite Prior Treatment With a Novel Androgen Axis Drug</b> E. Debret, Petit-Lancy-Genève (CH)
<b>18:15 - 18:27</b>	<b>Screen E</b>
P306	<b>RJBLC-NEBC001: A prospective, single-arm study on neoadjuvant addebrelimab plus etoposide and cisplatin in neuroendocrine bladder carcinoma</b> Q. Lei, Shanghai (CN)

P318	<b>WUTSUP-02-II-Neo-Dis-Tis: Investigating the efficacy and safety of neoadjuvant tislelizumab plus disitamab vedotin with adjuvant tislelizumab in upper urinary tract carcinoma—A phase II multi-center study.</b> Y. Bao, Chengdu (CN)
P316	<b>RJBLC-A2A008: An open-label, single-arm, multi-center study on RC48-ADC combined with toripalimab and radiotherapy as bladder-preserving therapy in HER2 overexpression muscle-invasive bladder cancer</b> R. Zhang, Shanghai (CN)
P308	<b>SOGUG-NEOWIN: A Phase 2, open-label, multi-centre, multi-national interventional trial evaluating the efficacy and safety of erdafitinib (ERDA) monotherapy and ERDA and cetrelimab (CET) as neoadjuvant treatment in cisplatin-ineligible patients with muscle-invasive bladder cancer (MIBC) whose tumours express FGFR gene alterations</b> A. Necchi, Milan (IT)
<b>18:27 - 18:45</b>	<b>Screen F</b>
P315	<b>Impact of radical prostatectomy on pelvic floor muscles: An electromyography and perineometric assessment</b> M. Tiwari, Raipur (IN)
P295	<b>Avoiding Risks of Thrombosis and bleeding in Surgery (ARTS): An international, multicentre, randomised pragmatic trial</b> K.A.O. Tikkinen, Helsinki (FI)
P301	<b>Open-label randomised clinical trial investigating whether robot-assisted kidney transplantation can reduce surgical complications compared to open kidney transplantation (ORAKTx): Study protocol for a randomised clinical trial</b> M. Ortvad, Copenhagen (DK)
P317	<b><sup>89</sup>Zr-DFO-girentuximab for PET imaging of solid tumors likely to express high levels of carbonic anhydrase IX</b> S. Dalleau, Herstal (BE)
P294	<b>MicroUltraSound In Cancer – Active Surveillance (MUSIC-AS)</b> P. Albers, Edmonton (CA)
P300	<b>Preliminary results of the CONFIRM trial: role of PSMA PET/CT in newly diagnosed prostate cancer in active surveillance prior to confirmatory biopsy</b> J. Liu, Melbourne (AU)

# Semi-live session: Focal therapy for prostate cancer - How, why, when?

Thematic Session

**Sunday 7 April**  
**17:30 - 18:30**

**Location** Green Area, eURO Auditorium 1

**Chairs** S. Crouzet, Lyon (FR)  
L. Rodriguez-Sanchez, Paris (FR)

## **Learning objectives**

By the end of the session, participants should have acquired expertise in the following:

- Understanding why focal treatments should be considered as a valid alternative option for localised prostate cancer in well-selected patients.
- Selecting a patient for potential focal therapy based on patient and prostate cancer characteristics.
- Gaining insight into the potential treatment options available for focal therapy and being aware of their limitations.
- Demonstrating proficiency in performing focal therapy using various energies or a surgical approach through four semi-live surgeries.

**17:30 - 17:40**

## **Semi-live video presentation Irreversible electroporation**

C. Orczyk, London (GB)

**17:40 - 17:50**

## **Semi-live video presentation Cryotherapy**

E. Barret, Paris (FR)

**17:50 - 18:00**

## **Semi-live video presentation HIFU**

H.U. Ahmed, London (GB)

S. Crouzet, Lyon (FR)

**18:00 - 18:10**

## **Semi-live video presentation Partial surgical ablation**

J. Olivier, Lille (FR)

**18:10 - 18:15**

## **Why not radical prostatectomy?**

M. Graefen, Hamburg (DE)

**18:15 - 18:30**

## **Do we need focal therapy?**

*Moderator*

J. Stranne, Göteborg (SE)

**18:15 - 18:30**

## **Panel discussion**

*Panel*

H.U. Ahmed, London (GB)

E. Barret, Paris (FR)

S. Crouzet, Lyon (FR)

M. Graefen, Hamburg (DE)

J. Olivier, Lille (FR)

C. Orczyk, London (GB)

# Urolithiasis: Shock wave lithotripsy and stents

Abstract session 38

Sunday 7 April  
17:30 - 19:00

**Location** Purple Area, N01

**Chairs** U. Mete, Chandigarh (IN)  
To be confirmed  
J. Vesper, Vienna (AT)

We encourage participants in this session to view the abstracts before the session. All abstract bodies, posters, videos and webcasts can be viewed on the EAU(N)24 Resource Centre or at the digital screens in front of the Purple Area, EGPT.

- A0775** **Is it safe and effective to increase the total accumulated energy by increasing the number of shock waves per session in extracorporeal shock wave lithotripsy? A prospective randomized study**  
A.J. Beviá Romero, San Vicente del Raspeig (ES)
- A0771** **Post-SWL urinary osteopontin level and ion-activity product of CaOx are Associated with Stone Recurrence after 5-year Follow-up**  
C-M. Liu, Tainan (TW)
- A0768** **Break Wave™ Lithotripsy for Urolithiasis: Results of the First-In-Human International Multicenter Clinical Trial**  
B.H. Chew, Vancouver (CA)
- A0762** **Comparison of Symptom questionnaire, Stone Clearance rate, Passive Ureter Dilatation using 4.5 French vs 6 French Double J stenting for passive dilatation of unfavorable ureter**  
M.K. Nagabhairava, bengaluru (IN)
- A0760** **Safety and Tolerability of Single-J vs. Double-J Stents After Ureterorenoscopy – A Randomized Trial**  
C. Laranjo Tinoco, Braga (PT)
- A0764** **Is shorter better? Associations between pain intensity, ureteral stent indwell time and patient factors from an international prospective registry**  
B.H. Chew, Vancouver (CA)
- A0773** **Fast track treatment of ureteral stones by short-term preoperative and postoperative stenting (FaST 6): A randomized prospective study**  
V. Hoffmann, Bochum (DE)
- A0763** **Efficiency of self-expanding stents in endoscopic treatment of ureteral strictures.**  
F. Kowalski, Bydgoszcz (PL)
- A0758** **Patients undergoing double J substitution with a pigtail suture stent report a significant decrease of stent-related symptoms. Results from a prospective multicenter longitudinal trial**  
A. Bosio, Torino (IT)

A0766

**Tria™ Ureteral Stents offer improved comfort: Results from an international prospective study**

B.H. Chew, Vancouver (CA)

---

A0774

**Update on the use of Pigtail Suture Stents: an ongoing experience**

E. Alessandria, Turin (IT)

---

A0767

**In vitro and in vivo studies on bacteria and encrustation resistance of PLA-Ciprofloxacin-coating ureteral stent application**

Z. Wang, Nanjing (CN)

---

A0769

**STONE (STent Or NEphrostomy) Study: Patient-Reported Outcome Measures**

H.W. Schuil, Leiderdorp (NL)

---

A0770

**Decompression of an obstructed, infected kidney- how urgent is urgent?**

O. Hemo, Tel Aviv (IL)

---

A0759

**Impact of the timing of percutaneous nephrostomy on the prognosis in patients with obstructive urolithiasis with sepsis**

D.H. Koh, Daejeon (KR)

---

A0765

**Retrograde ureteric stent and percutaneous nephrostomy for upper urinary tract obstruction: findings from a national consensus survey**

V. Quaresma, Coimbra (PT)

---

A0772

**A new innovative EPR (electronic patient records) integrated Ureteric Stent Register**

D. Harry, London (GB)

**Sunday 7 April**  
**17:30 - 19:00**

**Location** Green Area, N04

**Chairs** D. Elterman, Toronto (CA)  
E. Finazzi Agrò, Rome (IT)  
K. Jehle, Cape Town (ZA)

We encourage participants in this session to view the abstracts before the session. All abstract bodies, posters, videos and webcasts can be viewed on the EAU(N)24 Resource Centre or at the digital screens in front of the Purple Area, EGPT.

**17:30 - 17:50**

## OAB Basic research

A0792

### Immuno-Modulatory Imide Drugs (IMiDs) Inhibit Human Bladder Smooth Muscle Contraction: a Novel Drug Class in LUTS?

A. Tamalunas, Munich (DE)

A0789

### Silencing of Rac1 and Arf6 reduces time-dependent and carbachol-induced contractions, proliferation, survival and growth in human bladder smooth muscle cells: monomeric GTPases as novel regulators of OAB-relevant bladder functions

S. Qian, Munich (DE)

A0781

### Interaction between periaqueductal gray and Barrington's nucleus during strong desire to void using 7 Tesla functional MRI

A. Knops, Maastricht (NL)

A0783

### Genetics Of OAB Syndrome

N. Raison, London (GB)

**17:50 - 18:05**

## Storage LUTS epidemiology

A0785

### The Impact of Urge Urinary Incontinence on Mortality in U.S. population

S. Kim, Namyangju-si (KR)

A0786

### Biological age acceleration is positively associated with overactive bladder

W. Huang, Chengdu (CN)

A0778

### Longitudinal changes in urinary incontinence and quality of life in older community-dwelling men: 11 year data from the CHAMP study

L. Chan, Sydney (AU)

**18:05 - 18:35**

## OAB clinical

A0791

### Role of Body Shape and metabolic syndrome in symptoms persistence in patients undergoing transurethral resection of the prostate

A. Guidotti, Rome (IT)

A0793

### Prostate shape and intravesical prostatic protrusion assessed by Magnetic Resonance Imaging are related to urinary symptoms

R. Lombardo, Rome (IT)

A0787

### Differences in recovery of lower urinary tract symptoms between patients with storage-positive vs. storage-negative symptoms after laser enucleation of the prostate

C. Cano Garcia, Frankfurt am Main (DE)



A0780

**Intravesical instillations of hyaluronic acid in the management of lower urinary tract symptoms after transurethral resection of non-muscle invasive bladder cancers: a randomized, controlled clinical study.**

A. Finocchiaro, Catania (IT)

A0776

**The inhibition of uninhibited detrusor contractions through distraction task: a novel approach for characterizing detrusor overactivity during filling cystometry**

B. Peyronnet, Rennes (FR)

A0782

**A preliminary analysis of the Comparing UroLift Experience Against Rezūm (CLEAR) randomized controlled trial (RCT) suggests a superior early patient experience with UroLift**

M. Rochester, Norwich (GB)

---

**18:35 - 19:00**

**Neuromodulation**

A0777

**Predictive Factors for Long-Term Response to Sacral Neuromodulation in patients with Refractory Idiopathic Overactive Bladder**

S. Hafez, Nantes (FR)

A0788

**Device programming, MRI utilization and safety of sacral neuromodulation through 24 months in a global post-market study**

M.A. Perrouin Verbe, Nantes (FR)

A0790

**Acute autonomic nervous system response to direct sacral nerve root stimulation in lower urinary tract dysfunction: A new approach to understand the mechanism of action of sacral nerve modulation**

X. Biardeau, Lille (FR)

A0779

**New TENS+ device for transcutaneous posterior tibial nerve stimulation: a prospective, multicenter post-market clinical study**

J-N.L. Cornu, Rouen (FR)

A0784

**Algorithm based programming of a novel implantable tibial neuromodulation system for urge urinary incontinence**

M.A.C. Smits, Maastricht (NL)

# Living with advanced kidney cancer and urothelial cancer

Plenary Session

Monday 8 April  
08:00 - 10:30

**Location** Purple Area, eURO Auditorium 2

**Chairs** S. Gillessen Sommer, Bellinzona (CH)  
M.C. Mir Maresma, Valencia (ES)

## Learning objectives

We will be discussing some of the current hot topics for urologists in locally-advanced and first-line metastatic kidney cancer. We will hold a debate on the real-life indications for adjuvant immunotherapy for high-risk patients after nephrectomy, including a life patient and a legal concerns of usage. We will also direct our attention toward treatment intensification for first-line metastatic RCC including a debate on recent result from triplet therapy trials. Finally a state-of-the-art lecture on the use of surgery and the upcoming role of SBRT in the context of oligometastatic RCC will be articulated.

08:00 - 08:01

**Welcome and introduction**

08:01 - 08:11

**Confederación Americana de Urología (CAU) lecture Redefining the role of surgery in advanced kidney cancer**

F. Rodriguez-Covarrubias, Mexico City (MX)

08:11 - 08:21

**State-of-the-art lecture Advancements in cutting-edge SBRT therapy for oligometastatic kidney cancer**

S. Siva, Melbourne (AU)

08:21 - 08:54

**Debate Moving towards intensified treatment paradigms in first-line metastatic kidney cancer: Triplet combinations at any cost - is more always better?**

08:21 - 08:24

**Case presentation**

C.H.J. Muselaers, Nijmegen (NL)

08:24 - 08:34

**Yes, the more the merrier**

L. Albiges, Villejuif (FR)

08:34 - 08:44

**No, less is more**

S. Psutka, Seattle (US)

08:44 - 08:54

**Discussion**

*Panel*

L. Albiges, Villejuif (FR)

C.H.J. Muselaers, Nijmegen (NL)

S. Psutka, Seattle (US)

08:54 - 09:04

**State-of-the-art lecture Embracing the digital frontier: Symptom management through E-Health monitoring**

R. Pereira Mestre, Bellinzona (CH)

09:04 - 09:14

**State-of-the-art lecture Illuminating the resilient journey of kidney cancer survivorship**

I. Duran, Santander (ES)

09:14 - 09:49

**Debate** Adjuvant immunotherapy in the legal landscape: Navigating use of IO in high-risk kidney cancer following nephrectomy - is it worth the trade-off?

09:14 - 09:19

**Case presentation**

L. Marandino, London (GB)

09:19 - 09:49

**Discussion**

*Panel*

W. Everaerts, Leuven (BE)

B. Leigh, London (GB)

T.S. O'Brien, London (GB)

09:49 - 09:57

**State-of-the-art lecture** New standard treatment for metastatic bladder cancer based on EV-302/KEYNOTE-A39?

A. Necchi, Milan (IT)

09:57 - 10:00

**Discussion**

10:00 - 10:30

**Practice-changing trials in locally-advanced bladder cancer**

10:00 - 10:05

**LEA lymph node dissection trial update**

J.E. Gschwend, Munich (DE)

10:05 - 10:16

**SWOG S1011: A phase III surgical trial to evaluate the benefit of a standard versus an extended lymphadenectomy performed at time of radical cystectomy for muscle-invasive urothelial cancer**

S. Lerner, Houston (US)

10:16 - 10:30

**Discussion**

J.A. Witjes, Nijmegen (NL)

# Male LUTS: Prevention, attention, intervention

Plenary Session

**Monday 8 April**  
**08:00 - 10:00**

**Location** Green Area, eURO Auditorium 1

**Chairs** J-N.L. Cornu, Rouen (FR)  
C. Gratzke, Freiburg (DE)

## **Learning objectives**

The session will delve into the role of genetic predisposition, epidemiology, prevention and multidimensional impact of male LUTS. Transitioning to clinical aspects, the best experts in the field will debate on optimal medical treatments, advancements in medical management, discussing efficacy and side effects of combination therapies. Then, innovations in MiST for male LUTS will take centre stage. Experts will engage in debates regarding the comparative advantages and limitations of these innovative therapies, and their role as alternative to medications or conventional surgery. The final segment will revolve around surgical interventions, as a definitive therapy for male LUTS/BPO eventually after failed MiST.

**08:00 - 08:25**

## **Epidemiology and prevention**

**08:00 - 08:10**

### **Non-pharmacologic prevention of BPH: Truth and lies**

M. Gacci, Florence (IT)

**08:10 - 08:15**

### **Genetic predisposition for BPH: Where do we stand?**

M. Hennenberg, Munich (DE)

**08:15 - 08:25**

### **Epidemiology of male LUTS: Not only the prostate**

M. Drake, London (GB)

**08:25 - 08:49**

## **Case discussion Clinical issues and daily medical challenges**

**08:25 - 08:28**

### **Case presentation: Mixed symptoms in a 60 yo, 60 grams benign prostate**

T. Hüscher, Mainz (DE)

**08:28 - 08:35**

### **Try alpha-blockers first / follow the leader**

M. Baboudjian, Marseille Cedex (FR)

**08:35 - 08:42**

### **Try another option / think different**

F. Fusco, Naples (IT)

**08:42 - 08:49**

### **Société Internationale d'Urologie (SIU) lecture A critical review: Additive effects of combination therapy - Myth or reality?**

S. Gravas, Nicosia (CY)

**08:49 - 09:15**

## **Debate Refining the indication of interventional therapies for male LUTS**

**08:49 - 08:51**

### **Minimally-invasive Surgical Therapies (MIST): What are we talking about?**

S. Malde, London (GB)

**08:51 - 08:58**

### **MIST are super pills**

R. Eapen, Melbourne (AU)

**08:58 - 09:05**

### **MIST are alternatives to TURP**

D. Abt, Biel-Bienne (CH)

**09:05 - 09:15**

## **Discussion: Bridging medical treatment and ablative surgery**

---

<b>09:15 - 09:55</b>	<b>Case discussion</b> The end of the journey: Best options for BPO relief
<b>09:15 - 09:17</b>	<b>Case presentation: A failed case of MIST with BPO and indication for ablative surgery - 80 gram prostate</b> M. Creta, Solopaca (IT)
<b>09:17 - 09:24</b>	<b>Perseverate: MIST after another</b> D. Elterman, Toronto (CA)
<b>09:24 - 09:31</b>	<b>Stay standard: Resection and vaporisation</b> S. Madersbacher, Vienna (AT)
<b>09:31 - 09:38</b>	<b>Enucleate: AEEP against all odds</b> T.R.W. Herrmann, Frauenfeld (CH)
<b>09:38 - 09:45</b>	<b>Innovate: Aquablation and robotics</b> N. Barber, Camberley (GB)
<b>09:45 - 09:55</b>	<b>Discussion</b>
<hr/>	
<b>09:55 - 10:00</b>	<b>Wrap-up by chairs</b>

# Renal transplantation: Technical aspects, diagnosis and management of early and late urological complications

ESU Course 45

Monday 8 April  
08:30 - 11:30

**Location** Purple Area, E05

**Chair** M. Musquera Felip, Barcelona (ES)

## Learning objectives

The objectives of this course are essentially to update medical-surgical knowledge in kidney transplantation. As an area of interdisciplinary knowledge, it is important that the urologist acquires preparation for the main nephrological and urological aspects of these patients that allow to provide the best assistance. Preparation of the patient, procurement techniques, preservation, open and robotic surgery, immunosuppression therapy, diagnosis and treatment of medical & surgical complications, and prognosis in the mid and long term.

## Introduction

M. Musquera Felip, Barcelona (ES)

## Selection and urological preparation of transplant recipients

R. Boissier, Marseille (FR)

## Surgical aspects of deceased donor nephrectomy

J.D.J.M. Branchereau, Nantes (FR)

## Living donor nephrectomy: Technical alternatives and controversies

M. Musquera Felip, Barcelona (ES)

## Preservation

R. Boissier, Marseille (FR)

## Renal transplantation. Surgical options: Tips and tricks

J.D.J.M. Branchereau, Nantes (FR)

M. Musquera Felip, Barcelona (ES)

## Inmunosuppression

J. Pascual, Madrid (ES)

## How to diagnose and manage postoperative and long-term complications following renal transplantation. Long term survival

R. Boissier, Marseille (FR)

J. Pascual, Madrid (ES)

Monday 8 April

08:30 - 11:30

**Location** Purple Area, E03

**Chair** V. Phé, Paris (FR)

## Learning objectives

The objective of this course is to provide a complete overview of pelvic organ prolapse diagnosis, investigations (place of urodynamics) and treatment including conservative management and surgeries from open to laparoscopic and robotic approaches.

Clinical cases of POP, POP associated with stress and urge urinary incontinence and complications of surgeries will be discussed methodically.

At the end, the participants will know the diagnostic strategies, the techniques to perform POP surgeries and how to counsel the patients.

- To learn about clinical diagnosis of POP
- To learn about urodynamics and indications
- To learn step by step how to perform a sacrocolpopexy and tips and tricks
- To learn how to manage POP surgery complications

## What can go wrong in the female pelvic floor support

### Evaluation of female pelvic floor and basic anatomical concepts

F. Cancrini, Rome (IT)

### Pelvic organ prolapse (POP) classifications and its clinical usefulness

F. Cancrini, Rome (IT)

---

## Anterior prolapse

### Pessaries

V. Phé, Paris (FR)

### Vaginal approach

V. Phé, Paris (FR)

### Open, laparoscopic and robotic sacrocolpopexy

V. Phé, Paris (FR)

---

## POP and urinary incontinence

### Stress incontinence and POP

F. Cancrini, Rome (IT)

### Urge urinary incontinence and POP

F. Cancrini, Rome (IT)

### Place of urodynamics

F. Cancrini, Rome (IT)

---

## Complications of POP surgery

### One case of pelvic pain

V. Phé, Paris (FR)

### **One case of erosion**

F. Cancrini, Rome (IT)

---

### **Interactive discussion on different clinical scenarios**

F. Cancrini, Rome (IT)

V. Phé, Paris (FR)



**Monday 8 April**  
**08:30 - 11:30**

**Location** Purple Area, E04

**Chair** A. Mottrie, Aalst (BE)

### **Learning objectives**

The panel have introduced new content to build on this popular course delivered in 2023. This is a video-based interactive course which will demonstrate techniques, tricks and practical surgical management for a variety of advanced urological conditions. The panel will bring the audience through these videos, with discussion and interaction on topics as they occur.

## **Part 1: Pyleoplasty – Unusual variations**

### **Re-do Pyeloplasty**

- B. McGuire, Dublin (IE)
- B. Peyronnet, Rennes (FR)

### **Ureterocalycostomy**

- B. McGuire, Dublin (IE)

### **Unusual anatomy**

- B. McGuire, Dublin (IE)
- A. Mottrie, Aalst (BE)

### **Horseshoe**

- B. McGuire, Dublin (IE)

---

### **Modern management of proximal ureteric strictures**

- B. McGuire, Dublin (IE)

---

### **Modern management of distal ureteric strictures (Psoas hitch, Boari Flap, Non-diverting)**

- B. McGuire, Dublin (IE)
- A. Mottrie, Aalst (BE)

---

## **Part 2:**

---

### **Redo anastomosis after failed RARP**

- A. Mottrie, Aalst (BE)

---

### **Bladder Neck Plasty for post prostatectomy stricture**

- B. Peyronnet, Rennes (FR)

---

### **Bladder augmentation and catheterisable channel**

- B. Peyronnet, Rennes (FR)

---

### **Robotic Urachal Cancer/Cyst**

- B. McGuire, Dublin (IE)

---

### **Sling excision and Autologous POP and SUI repair**

- B. McGuire, Dublin (IE)

---

**RASP (Robotic Assisted Simple Prostatectomy)**

A. Mottrie, Aalst (BE)

---

**Bladder diverticulectomy**

A. Mottrie, Aalst (BE)

---

**Vesicovaginal fistula**

B. Peyronnet, Rennes (FR)

---

**Vesicorectal fistula**

A. Mottrie, Aalst (BE)

---

**Conclusions**

A. Mottrie, Aalst (BE)

---



# Flexible ureterorenoscopy and retrograde intrarenal surgery: Instrumentation, technique, tips, tricks and indications

ESU Course 42

Monday 8 April  
08:30 - 11:30

**Location** Purple Area, E02

**Chair** O. Traxer, Paris (FR)

## Learning objectives

The aims and objectives of this course is to provide a complete overview of instruments, endoscopes, indications, technique and special tips and tricks concerning Retrograde IntraRenal Surgery (RIRS) using flexible ureterorenoscopes and Holmium YAG lasers. At the end the participants will know the equipment and the technique to perform flexible ureterorenoscopy in the best conditions. • To learn about equipment. • To learn about technique and indications. • To learn how to use an Holmium Laser. • To learn tips and tricks for special circumstances.

## Welcome and introduction

O. Traxer, Paris (FR)

## Instrumentation: Endoscopes

O. Traxer, Paris (FR)

## Instrumentation: Laser and lithotripsy devices

B. Somani, Southampton (GB)

## Instrumentation: Disposable (wires, retrieving devices, ureteral access sheath (UAS), irrigation devices and others)

H.U. Jung, Vejle (DK)

## Technique: Stones

O. Traxer, Paris (FR)

## Technique: Urothelial tumours and strictures

B. Somani, Southampton (GB)

## Tips and tricks and special circumstances

O. Traxer, Paris (FR)

## Indications (guidelines) and clinical cases

H.U. Jung, Vejle (DK)

## Conclusions

O. Traxer, Paris (FR)

# Prostate cancer screening and active surveillance – Where are we now?

ESU Course 41

**Monday 8 April**  
**08:30 - 10:30**

**Location** Purple Area, E01

**Chair** S. Carlsson, New York (US)

Voting will be available via the EAU24 App or via [www.qna.at/eau](http://www.qna.at/eau)

## **Learning objectives**

- Prostate cancer is a global public health concern. While large randomised trials have shown a reduction in prostate cancer mortality with regular prostate-specific antigen (PSA) screening, there is potential for negative effects from over-diagnosis and treatment, making screening a controversial topic. This course will provide an overview of the evidence of both benefits and harm from the randomised trials as well as data from epidemiological studies illustrating the global incidence and mortality trends.
- Today's challenges include the age when to start screening, screening intervals and the optimal use of "smarter screening". This course will cover the EAU-ESTRO-SIOG Guidelines and other risk-stratified approaches to screening based on age, health and PSA-values, family history, ethnicity and genetic risk.
- Active surveillance (AS) is now widely accepted as a management strategy for low-risk prostate cancer with definitive treatment used if there is evidence that the patient is at increased risk for disease progression. Several AS studies have consistently shown a low rate of progression to metastatic disease or death from prostate cancer with AS, with the majority of patients remaining free from definitive therapy for many years.
- Clinical and pathological factors influencing the risk of disease progression in patients with low risk prostate cancer under AS, surveillance strategy, role of repeat biopsy, inclusion criteria, and the use of MRI will be discussed.
- The course will be interactive and include illustrative and practical clinical case discussions.

## **Prostate cancer screening: Where are we now?**

S. Carlsson, New York (US)

## **Prostate cancer active surveillance: Where are we now?**

R.C.N. Van Den Bergh, Utrecht (NL)

**Monday 8 April**  
**09:00 - 12:30**

**Location** Orange Area, HOT 5

## **Learning objectives**

The MRI Reading Course is designed as a half-day or full-day live or online training. This course will provide interactive teaching from expert faculty in prostate MRI reading and interpretation and help urologists to understand the role MRI plays in the management of patients with prostate cancer and how to use the information generated by prostate MRI. The course will address how to use an imaging workstation, how to understand the basic concepts/principles behind different MRI sequences (T2-weighted imaging, DWI-imaging and DCE-imaging), in which order to view the different sequences when interpreting prostate MRI, how to use the PI-RADS scoring system to score MRIs, and finally to understand what are the standards for a prostate MRI and what quality criteria need to be fulfilled. The participants will do hands on reading and assessment of prostate MRI scans on their computer via MIM-software followed by a reference reading provided by expert radiologists and pathological verification.

**09:00 - 09:05**

## **Course Overview**

C.V. Kesch, Essen (DE)

**09:05 - 09:15**

## **Lecture: The importance of prostate MRI to the Urologist**

C.V. Kesch, Essen (DE)

**09:15 - 09:45**

## **Lecture: Introduction to MRI sequences, scoring systems, PI-RADS**

J.A. Hernández Mancera, Barcelona (ES)

**09:45 - 10:15**

## **Lecture: Interactive case discussion – reporting MRI using PI-RADS**

V. Panebianco, Rome (IT)

**10:15 - 10:20**

## **Introduction to the software for MRI interpretation**

E. Barret, Paris (FR)

**10:20 - 10:50**

## **Diagnosis I: Practical MRI diagnosis**

**10:50 - 11:20**

## **Review of the findings I**

J.A. Hernández Mancera, Barcelona (ES)

**11:20 - 11:50**

## **Diagnosis II: Practical MRI diagnosis**

**11:50 - 12:20**

## **Review of the findings II**

V. Panebianco, Rome (IT)

**12:20 - 12:30**

## **Discussion, feedback, & closure**

E. Barret, Paris (FR)

# Hands-on Training in Urological ultrasound

HOT 4.01

Monday 8 April

09:30 - 12:30

**Location** Orange Area, HOT 3

**Chairs** P. Martino, Bari (IT)  
V. Scattoni, Milan (IT)

## Learning objectives

### Description:

The Hands-on Training in Urological ultrasound is designed to provide healthcare professionals with a thorough understanding of urology diagnostics. The course blends expert presentations and practical hands-on sessions, offering participants a solid foundation in urological ultrasound examinations.

By the end of this course, participants will be equipped with the necessary baseline training to implement abdominal ultrasound as well as transrectal ultrasound of the prostate as a routine diagnostic tool in daily practice. The training covers urological ultrasound examinations following standardised procedures, accurately identify normal and pathological findings, and confidently conduct assessments of the urinary tract and genital organs, as well as valuable insights and skills that can be immediately applied to enhance patient care and diagnostic accuracy.

### Training aim

- Understanding standard operating procedures
- Proficiency in imaging techniques
- Identification of normal anatomy
- Recognition of pathological findings
- Integration of innovative ultrasound technologies
- Practical hands-on experience

09:30 - 09:35

### Introduction

P. Martino, Bari (IT)

09:35 - 09:50

### Standard operating procedure for ultrasound examination urinary tract: Kidney and bladder

V. Scattoni, Milan (IT)

09:50 - 10:10

### Innovative ultrasound of the kidney and bladder: Normal and pathological findings

K.F. Stock, Munich (DE)

10:10 - 10:30

### Standard operating procedure for ultrasound examination genital organs: Prostate and testis

P. Martino, Bari (IT)

10:30 - 10:45

### Innovative ultrasound of prostate and testis: Normal and pathological findings

T. Loch, Flensburg (DE)

10:45 - 12:30

**Hands-on Training: Kidney and bladder / Prostate & testis**

*Tutors*

A.B. Galosi, Ancona (IT)

T. Loch, Flensburg (DE)

C.B. Maccagnano, Milan (IT)

P. Martino, Bari (IT)

V. Scattoni, Milan (IT)

K.F. Stock, Munich (DE)

# Smartphone-based treatment for benign prostate enlargement: A novel approach

Game changing session

**Monday 8 April**

**10:00 - 10:15**

**Location** Green Area, eURO Auditorium 1

**Chair** J-N.L. Cornu, Rouen (FR)

## **Learning objectives**

The objective of this session is to unveil a game-changing approach for monitoring and treating male LUTS / benign prostate enlargement. This innovative method, utilising cutting-edge technologies, aims to redefine patient care standards by offering precise treatment monitoring and potentially revolutionising current management strategies for this prevalent urological condition.

**10:00 - 10:15**

**App-based therapeutics of lower urinary tract symptoms (LUTS) with or without benign prostate enlargement (BPE): Results of the randomised controlled BEST (Bladder Emptying DiSorder Therapy) trial**

**10:00 - 10:08**

## **Presenter**

C. Gratzke, Freiburg (DE)

**10:08 - 10:15**

## **Discussant**

J-N.L. Cornu, Rouen (FR)



# Controversies on EAU Guidelines: NMIBC, RCC and strictures

Thematic Session

**Monday 8 April**  
**10:45 - 12:15**

**Location** Purple Area, eURO Auditorium 2

**Chairs**  
A. Bex, London (GB)  
P. Gontero, Turin (IT)  
N. Lumen, Ghent (BE)

## **Learning objectives**

The participants should be able to:

- Reflect on the grading system(s) in NMIBC
- Reflect on the need for adjuvant treatment in very high-risk RCC
- Reflect on the use of drug-coated balloon dilatation for recurrent short bulbar strictures

**10:45 - 10:47**

## **Introduction**

P. Gontero, Turin (IT)

**10:47 - 11:16**

**Case discussion NMIBC: The LG/HG grading system is the one that best fits clinical practice when treating non-muscle invasive urothelial carcinoma**

**10:47 - 10:50**

## **Case presentation**

P. Gontero, Turin (IT)

**10:50 - 10:58**

## **LG/HG is the way to go**

E. Compérat, Vienna (AT)

**10:58 - 11:06**

## **A three-tier system better captures tumour biology**

A. Masson-Lecomte, Paris (FR)

**11:06 - 11:16**

## **Discussion**

P. Gontero, Turin (IT)

**11:16 - 11:45**

**Case discussion RCC: Offer adjuvant treatment only in patients with very high-risk for recurrence as patients with sarcomatoid dedifferentiation**

**11:16 - 11:19**

## **Case presentation**

S. Dabestani, Lund (SE)

**11:19 - 11:27**

## **Yes**

J. Bedke, Tübingen (DE)

**11:27 - 11:35**

## **No**

A. Bex, London (GB)

**11:35 - 11:45**

## **Discussion**

**11:45 - 12:14**

**Case discussion The recurrent short bulbar urethral stricture urethroplasty or drug-coated balloon dilatation**

**11:45 - 11:48**

## **Case presentation**

M. Waterloos, Gent (BE)

11:48 - 11:56

**Urethroplasty is the first choice**

R. Dahlem, Hamburg (DE)

11:56 - 12:04

**Drug-coated balloon dilatation should be attempted**

S.P. Elliott, Minneapolis (US)

12:04 - 12:14

**Discussion**

M. Waterloos, Gent (BE)

---

12:14 - 12:15

**Closing remarks**

N. Lumen, Ghent (BE)



# Overactive bladder in special situations

Thematic Session

Monday 8 April

10:45 - 12:15

**Location** Purple Area, S01

**Chairs** E. Chartier-Kastler, Paris (FR)  
J. Heesakkers, Maastricht (NL)

## Learning objectives

Overactive Bladder is a symptom complex that, according to the definition, has one obligatory symptom (urgency) and three facultative symptoms (frequency, nocturia and urgency incontinence). This implies that the disorder has various ways of showing itself and the cause of the symptoms are not identified by putting the OAB label on a patient. The consequences are that causes and treatments differ according to the patient profile and that the effect of treatment on the various OAB symptoms and the syndrome as a whole varies from patient to patient.

The objective of this thematic session is to elucidate these aspect in patients with a neurogenic disease and in typical, difficult to treat, non-neurogenic clinical situations.

10:45 - 10:55

**Overactive bladder in neurological diseases**

10:45 - 10:55

**State-of-the-art lecture** **Panorama of OAB neurological dysfunction: The bladder and the brain - what does the urologist need to know?**

T.M. Kessler, Zurich (CH)

10:55 - 11:36

**Rapid-fire debate** **The current neurogenic OAB patient journey: What's new?**

10:55 - 11:02

**The role of medications**

L.P.W. Witte, Zwolle (NL)

11:02 - 11:09

**Botulinum Toxin A injections: Until when should we inject?**

H-C. Kuo, Hualien (TW)

11:09 - 11:16

**Is there any role for neuromodulation in neurogenic OAB?**

X. Biardeau, Lille (FR)

11:16 - 11:36

**Discussion**

11:36 - 12:11

**Rapid-fire debate** **Daily challenges in non-neurogenic OAB: Key messages on clinical issues**

11:36 - 11:43

**OAB in the irradiated bladder**

A. Sahai, London (GB)

11:43 - 11:50

**OAB and endometriosis**

J-N.L. Cornu, Rouen (FR)

11:50 - 11:57

**Persistent OAB after BPO surgery in males**

M. Rieken, Zürich (CH)

11:57 - 12:04

**How can we cure diabetic OAB?**

C. De Nunzio, Rome (IT)

12:04 - 12:11

**OAB after a mid-urethral sling**

S. Arlandis, Valencia (ES)

12:11 - 12:15

**Closing remarks**



# Fertility frustrations: 9 Dilemmas in men's reproductive health

Thematic Session

**Monday 8 April**  
**10:45 - 12:15**

**Location** Green Area, W01

**Chairs** Z. Kopa, Budapest (HU)  
A. Salonia, Milan (IT)

**10:45 - 10:52** **Isolated teratozoospermia: Causes, work-up and management**  
M. Dinkelman-Smit, Rotterdam (NL)

**10:52 - 10:55** **Discussion**

**10:55 - 11:02** **Failed TESE: Repeat or explore donor insemination?**  
C.F.S. Jensen, Herlev (DK)

**11:02 - 11:05** **Discussion**

**11:05 - 11:12** **Ejaculatory duct obstruction: Desobstruct or TESE?**  
T. Stasinou, Manchester (GB)

**11:12 - 11:15** **Discussion**

**11:15 - 11:22** **Should you perform orchidopexy in adults with cryptorchidism discovered at infertility work-up?**  
T. Diemer, Giessen (DE)

**11:22 - 11:25** **Discussion**

**11:25 - 11:32** **Should you prescribe hormonal agents to optimise sperm-retrieval?**  
J.M. Dupree, Ann Arbor (US)

**11:32 - 11:35** **Discussion**

**11:35 - 11:42** **Should you treat asymptomatic positive semen culture?**  
L. Boeri, Milan (IT)

**11:42 - 11:45** **Discussion**

**11:45 - 11:52** **Should you treat varicocele in implantation failure?**  
N. Sofikitis, Ioannina (GR)

**11:52 - 11:55** **Discussion**

**11:55 - 12:02** **Should we give nutritional supplements to men with OAT?**  
G.I. Russo, Catania (IT)

**12:02 - 12:05** **Discussion**

12:05 - 12:12


**Should we be administering any therapy that had not shown improved live birth rate?**

S. Minhas, London (GB)

---

12:12 - 12:15

**Discussion**



Monday 8 April  
10:45 - 12:15

**Location** Purple Area, N01

**Chairs** T. Antunes Lopes, Porto (PT)  
L. Cindolo, Salerno (IT)  
C-H. Liao, New Taipei City (TW)

We encourage participants in this session to view the abstracts before the session. All abstract bodies, posters, videos and webcasts can be viewed on the EAU(N)24 Resource Centre or at the digital screens in front of the Purple Area, EGPT.

- 
- A0802**  **$\beta$ -Arrestin-2-mediated promotion of contractility and stromal growth, evidenced by silencing, and correlation of  $\beta$ -arrestin-2 expression with voiding symptoms in patients undergoing surgery for BPH opposes predicted  $\beta$ -arrestin-2 functions in the prostate**  
M. Hennenberg, Munich (DE)
- 
- A0809** **Phosphodiesterase Type 5 Inhibitor Tadalafil Reduces Prostatic Fibrosis via MiR-3126-3p/FGF9 Axis in Benign Prostatic Hyperplasia**  
Y. Zhang, Shanghai (CN)
- 
- A0797** **Verteporfin and fasudil suppress inflammation-induced benign prostatic hyperplasia by regulating ROCK1/YAP1 pathway**  
D. Lin, Wuhan (CN)
- 
- A0799** **Activation of the cGMP/PKG/ERK signaling pathway associated with PDE5Is inhibits fibroblast activation by downregulating autophagy in early progressive benign prostatic hyperplasia**  
S. Jin, Beijing (CN)
- 
- A0798** **Human Umbilical Cord-Derived Mesenchymal Stem Cells Improve Bladder Contractility and Compliance in Rats with Partial Bladder Outlet Obstruction**  
T-N. Lee, Taipei (TW)
- 
- A0801** **YAP and TAZ regulate gene splicing and differentiation of urinary bladder smooth muscle cells**  
L. Liu, Lund (SE)
- 
- A0810** **TGF $\beta$ 1 and LIM kinases: Novel Insights into Overactive Bladder Secondary to Benign Prostate Hyperplasia**  
Q. Yu, Guangzhou (CN)
- 
- A0811** **Post-surgery medication usage through 5 years is similar between PUL, TURP and GreenLight: a US Healthcare Claims analysis**  
S.A. Kaplan, New York (US)
- 
- A0805** **Effects Of Preoperative Treatment With Phenolmicine P3 And Boisexil Dietary Supplement on Postoperative Irritative Symptoms In Patients With Middle Prostate Volume Undergoing Transurethral Prostate Surgery**  
F.M. Valenzi, Latina LT (IT)

A0796	<b>A prospective, randomized, open-label, parallel trial comparing the efficacy of <math>\alpha</math>-blocker or 5<math>\alpha</math>-reductase inhibitor withdrawal to continued combination therapy on the maintenance of lower urinary tract symptoms in men with benign prostatic hyperplasia</b> S. Bang, Seoul (KR)
A0808	<b>A real-world study to evaluate disease control based on symptoms severity in Greek patients with benign prostatic hyperplasia (BPH) after 6 months of treatment under fixed dose combination (FDC) with dutasteride/tamsulosin. The PROSPERITY I study</b> G. Tsioumas, Athens (GR)
A0806	<b>A randomized controlled trial comparing tadalafil/solifenacin versus tamsulosin/solifenacin combination for the treatment of benign prostatic hyperplasia with overactive bladder</b> M. Hegazy, Mansoura (EG)
A0804	<b>A randomised, placebo-controlled study to assess the efficacy &amp; safety of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia</b> S. Morsy, cairo (EG)
A0794	<b>Efficacy and safety of fixed dose combination of silodosin and tadalafil in Indian patients with benign prostatic hyperplasia and erectile dysfunction: A phase 3 randomized clinical study</b> S. Saha, Mumbai (IN)
A0803	<b>Can pyridostigmine bromide 60 mg improve BPH symptoms in Diabetic patients?</b> M.S. Eladawy, Giza (EG)
A0795	<b>Tadalafil treatment might be effective for BPH patients with metabolic syndrome.</b> S. Inamura, Fukui (JP)
A0800	<b>Voiding dysfunction that developed during hospitalization improve with rehabilitation</b> A. Ohtsubo, Sasebo (JP)



# Pushing the limits of active surveillance for prostate cancer

Abstract session 41

Monday 8 April

10:45 - 12:15

**Location** Green Area, N03

**Chairs** M. Baboudjian, Marseille Cedex (FR)

To be confirmed

T. Nordström, Stockholm (SE)

We encourage participants in this session to view the abstracts before the session. All abstract bodies, posters, videos and webcasts can be viewed on the EAU(N)24 Resource Centre or at the digital screens in front of the Purple Area, EGPT.

10:45 - 10:47

**Introduction**

10:47 - 11:07

**Real world data**

A0828

**FINPRO – A Nationwide Registry Study on Localized Prostate Cancer in Finland**

A.S. Rannikko, Helsinki (FI)

A0816

**Reasons for Discontinuation of Active Surveillance and Subsequent Outcome on Radical Prostatectomy Pathology**

I.I. de Vos, Rotterdam (NL)

**Study Group**

PRIAS Consortium(Rotterdam, The Netherlands)

A0821

**Real world data of active surveillance protocols in low-risk prostate cancer. Intensity of follow-up may be reduced according to a 14 years' experience.**

S. Nazzani, Milan (IT)

A0814

**Active Surveillance for Prostate Cancer in “Real-World” Setting: Exploring Racial Disparities in Surveillance Intensity and Cancer Control Outcomes**

G. Chiarelli, Milan (IT)

11:07 - 11:42

**De-Escalation in follow up**

A0815

**MRI-guided active surveillance without re-biopsy in patients with ISUP 1 and 2 prostate cancer – Results of Radical Prostatectomy and Mid-term Follow up of the prospective PROMM-AS study**

J.P. Radtke, Düsseldorf (DE)

A0813

**De-escalation of monitoring for prostate cancer active surveillance: Results of the GAP3 consortium**

Y. Tohi, Kita-gun (JP)

**Study Group**

Global Action Plan prostate cancer active surveillance consortium(Rotterdam, The Netherlands)

A0826

**MRI-guided Active Surveillance in patients with ISUP 1 prostate cancer – A multi-institutional validation of the discrimination of the PRECISE Score**

J.P. Radtke, Düsseldorf (DE)

- A0818 **A novel PRECISE implemented predictive model to assess the risk of long-term disease reclassification in men on active surveillance. Results from a large, single institution series.**  
A. Stabile, Milan (IT)
- A0812 **Does The PRECISE Score Improves PI-RADS Ability to Predict Grade Reclassification in Men on Active Surveillance for Early Prostate Cancer?**  
R. Leni, Milan (IT)
- A0823 **Should patients with PIRADS 5 lesions be recommended against active surveillance? A multicenter retrospective European study**  
A. Peyrottes, Paris (FR)
- A0820 **PRECISE v2: Updated recommendations for reporting prostate MRI in patients on active surveillance**  
C. Englman, London (GB)
- 

11:42 - 12:12

**Long term outcome**

- A0822 **Does multiparametric (mp)MRI and MRI-informed biopsy improve risk allocation of men at inclusion in Active Surveillance for low-risk prostatic cancer? Results of per-protocol population of the prospective single institution SPRINT trial**  
M.A. Catanzaro, Milano (IT)
- A0824 **Adherence to recommendations in prostate cancer guidelines: Nationwide population-based study**  
A.W. Orrason, Uppsala (SE)
- A0819 **Comparing functional outcomes between active surveillance vs radical prostatectomy as initial approach in newly diagnosis ISUP 1 prostate cancer.**  
R.S. Flammia, Rome (IT)
- A0817 **Long-term sexual health of men on active surveillance for low-risk prostate cancer – results of the Movember GAP3 consortium**  
L.D.F. Venderbos, Rotterdam (NL)  
**Study Group**  
Global Active surveillance data research Platform GAP3(Rotterdam, The Netherlands)
- A0825 **25-year outcomes for men on active surveillance after screen detected prostate cancer in the Göteborg-1 trial**  
E. Palmstedt, Lidköping (SE)
- A0827 **Long-term outcomes of a multicenter prospective observational study of active surveillance for early-stage prostate cancer: the PRIAS-JAPAN study**  
T. Kato, Kagawa (JP)  
**Study Group**  
PRIAS-JAPAN study group(Miki-cho, Japan)
- 

12:12 - 12:15

**Expert summary**

**Monday 8 April**  
**10:45 - 12:15**

**Location** Green Area, N04

**Chairs**  
A. Bex, London (GB)  
R. Flippot, Villejuif (FR)  
M. Hiroš, Sarajevo (BA)

We encourage participants in this session to view the abstracts before the session. All abstract bodies, posters, videos and webcasts can be viewed on the EAU(N)24 Resource Centre or at the digital screens in front of the Purple Area, EGPT.

**10:45 - 10:47**

**Introduction**

A0840

**Differences in other-cause mortality in metastatic renal cell carcinoma according to partial vs. radical nephrectomy**

C. Siech, Frankfurt Am Main (DE)

A0832

**Delayed partial nephrectomy following complete response to immunotherapy: feasibility and results (UroCCR n°157)**

G. Margue, Bordeaux (FR)

A0829

**Prognostic factors for overall survival (OS) in patients receiving first-line (1L) nivolumab plus ipilimumab (NIVO+IPI) for advanced/metastatic renal cell carcinoma (aRCC) in a real-world setting in Germany**

J. Bedke, Tübingen (DE)

A0838

**Outcome of patients with synchronous metastatic renal cell carcinoma treated with nivolumab and ipilimumab and the primary tumour in place**

L. Jurascheck, London (GB)

A0842

**The role of cytoreductive nephrectomy in metastatic clear cell carcinoma: analysis of an other-cause mortality matched population from the contemporary immunotherapy era.**

M. Finati, Foggia (IT)

A0843

**Impact of tumor volume on prognosis in IMDC poor risk renal cell carcinoma patients underwent cytoreductive nephrectomy**

H. Naito, Kagawa (JP)

A0831

**Improved survival in contemporary actively treated community-based metastatic clear-cell renal cell carcinoma patients**

R.B. Incesu, Hamburg (DE)

A0833

**Real clinical outcomes of nivolumab plus ipilimumab for renal cell carcinoma in patients over 75 years old**

K. Numakura, Akita (JP)

A0835

**Association between age and efficacy of first-line immunotherapy-based combination therapies for mRCC: a meta-analysis**

T. Yanagisawa, Tokyo (JP)

A0830	<p><b>The effect of treatment dose intensification on other-cause mortality in clear-cell metastatic renal cell carcinoma patients</b></p> <p>R.B. Incesu, Hamburg (DE)</p>
A0837	<p><b>Breaking boundaries: Exploring extended pembrolizumab in first-line treatment of renal cell carcinoma with axitinib-pembrolizumab combination.</b></p> <p>C. Aydogdu, München (DE)</p>
A0839	<p><b>Papillary Renal Cell Carcinoma (pRCC): Outcomes Of Patients Receiving First-Line Immune-Based Combinations Or Tyrosine Kinase Inhibitors (TKIs) From The ARON-1 Study</b></p> <p><b>Papillary Renal Cell Carcinoma (pRCC): Outcomes Of Patients Receiving First-Line Immune-Based Combinations Or Tyrosine Kinase Inhibitors (TKIs) From The ARON-1 Study</b></p> <p>V. Mollica, Bologna (IT)</p>
A0836	<p><b>Comparison of the Efficacy of First-line Combinations for Metastatic Clear Cell Renal Cell Carcinoma: A Propensity Score-matched Analysis of Japanese Multicenter Database</b></p> <p>T. Yanagisawa, Tokyo (JP)</p>
A0834	<p><b>Development and internal validation of a nomogram to predict five-years chest metastasis in surgically treated non metastatic renal cell carcinoma</b></p> <p>R.S. Flammia, Rome (IT)</p>
A0841	<p><b>Delayed nephrectomy after immunotherapy for metastatic renal cell carcinoma : oncological outcomes and predictive factors of surgical difficulties.</b></p> <p>G. Pignot, Marseille (FR)</p>
12:02 - 12:05	<p><b>Expert summary</b></p>

# Basic research and trials: locally advanced and metastatic bladder cancer

Abstract session 43

**Monday 8 April**  
**10:45 - 12:15**

**Location** Green Area, W03

**Chairs**  
S. Lerner, Houston (US)  
R. Seiler, Bern (CH)  
A. Vlahou, Athens (GR)

We encourage participants in this session to view the abstracts before the session. All abstract bodies, posters, videos and webcasts can be viewed on the EAU(N)24 Resource Centre or at the digital screens in front of the Purple Area, EGPT.

**10:45 - 10:47**

## **Introduction**

- 
- A0871** **Bladder Cancer Patient-Derived Organoids: a new frontier for personalized therapy**  
R. Mastroianni, Rome (IT)
- 
- A0870** **Patient-Derived Organoids: 3D miniature models of Bladder Cancer**  
R. Mastroianni, Rome (IT)
- 
- A0872** **Prospective standardization of organoid-based pharmacotyping in urothelial carcinoma**  
M.K. Melzer, Ulm (DE)
- 
- A0869** **Bladder cancer organoids: a reliable tool for validation of in vitro new therapeutic approaches.**  
A-S. Bajeot, TOULOUSE (FR)
- 
- A0876** **Cancer vaccine improves the efficacy of immune checkpoint inhibitor against refractory cancers**  
S. Ueda, Fukuoka (JP)
- 
- A0866** **Dynamic transition from NMIBC to MIBC in the bladder cancer rely on stiffness microenvironment determined methionine metabolism**  
C. Yang, Shanghai (CN)
- 
- A0862** **A miRNA signature defines invasiveness with high accuracy and is associated with molecular subtypes in bladder cancer**  
K. Junker, Homburg (DE)
- 
- A0867** **Germline variants linked to ovarian and bladder cancer in females: Is ovary sparing radical cystectomy an option?**  
L. Davis, Cleveland (US)
- 
- A0865** **Tumor infiltrating CD39+ CD8+ T cells mediate anti-tumor immunity and determine better prognosis in bladder cancer**  
R. Yang, Nanjing (CN)

A0874	<p><b>The role of androgen response pathway in association with tumor biology and response to neoadjuvant immune-checkpoint inhibitors (ICI) in muscle-invasive urothelial bladder carcinoma (MIBC)</b></p> <p>A. Cigliola, Milan (IT)</p>
A0861	<p><b>Molecular characterization of upper urinary tract urothelial carcinoma and paired bladder cancer recurrences</b></p> <p>J.A. Nakauma-González, Rotterdam (NL)</p>
A0868	<p><b>Amiodarone, an anti-arrhythmic drug, is a new repurposed drug for bladder cancer therapy</b></p> <p>N.C.H. van Creijl, Innsbruck (AT)</p>
A0873	<p><b>Single-cell RNA-seq analysis reveals the role of tumor-associated neutrophils and neutrophil extracellular traps in upper tract urothelial carcinoma</b></p> <p>Y. Wang, Guangzhou (CN)</p>
A0875	<p><b>Comprehensive genomic profiling (CGP) of clinical T2-4N0M0 muscle-invasive bladder cancer (MIBC) treated with neoadjuvant pembrolizumab or cisplatin-based chemotherapy before radical cystectomy (RC)</b></p> <p>C. Mercinelli, Milan (IT)</p>
A0860	<p><b>Assessment of cancer cell invasion and high-throughput screenings in a novel ex vivo murine bladder tissue model</b></p> <p>C. Gunes, Ulm (DE)</p>
A0863	<p><b>Urachal (U) and Non-Urachal (NU) adenocarcinomas (adenoCA) of the bladder: A comparative comprehensive genomic profiling (CGP) study</b></p> <p>A. Cigliola, Milan (IT)</p>
12:12 - 12:15	<p><b>Expert summary</b></p> <p><i>Speaker</i> R. Seiler, Bern (CH)</p>

# Andrology: Male infertility and hypogonadism

Abstract session 44

Monday 8 April

10:45 - 12:15

**Location** Green Area, W06

**Chairs** B. García Gómez, Madrid (ES)  
W.J. Huang, Taipei (TW)  
E.C. Şerefoğlu, Istanbul (TR)

We encourage participants in this session to view the abstracts before the session. All abstract bodies, posters, videos and webcasts can be viewed on the EAU(N)24 Resource Centre or at the digital screens in front of the Purple Area, EGPT.

10:45 - 10:47

**Introduction**

10:47 - 11:12

**Diagnostic innovation**

A0883

**DeepSperM: A machine learning based model that facilitates sperm identification through touch print smear cytology of testicular specimen from patients with azoospermia**

K-S. Su, Taipei City (TW)

A0890

**Innovation in clinical diagnosis of male infertility: validation study and a 6-month experience using whole exome sequencing**

K.W. D'Hauwers, Nijmegen (NL)

A0882

**Karyotype alterations and Y chromosome microdeletion prevalence among patients with nonobstructive azoospermia - findings from a large multi-center cross-sectional study**

E. Pozzi, Milan (IT)

A0879

**Predictors of Abnormal DNA Fragmentation Index and Successful Pregnancy**

V. Nguyen, San Diego (US)

A0887

**Potential of testis-derived circular RNAs in seminal plasma to predict the outcome of microdissection testicular sperm extraction in patients with idiopathic non-obstructive azoospermia**

N. Song, Nanjing (CN)

11:12 - 11:45

**Male infertility in context**

A0877

**May Assisted Reproductive Techniques outcomes impact on overall health parameters in infertile men?**

M. Raffo, Milan (IT)

A0885

**Revealing the disability and illness burden in infertile men: key findings from a long-term longitudinal study utilizing the Years Lived with Disability metric**

F. Negri, Milan (IT)

A0888

**Long-term comorbidity trends among men with primary infertility: findings from a long term comprehensive longitudinal study**

A. Bertini, Milan (IT)

A0884

**The incidence of male breast cancer in Klinefelter's syndrome and its proposed mechanisms**

B.D. Cook, London (GB)

A0881	<p><b>Exploring the landscape of idiopathic Non-Obstructive Azoospermia at two tertiary referral centers: BMI as a Significant Predictor of Hormonal Profiles and Implications for Medical Intervention</b></p> <p>E. Pozzi, Milan (IT)</p>
A0878	<p><b>Unravelling familial ties: elevated sperm DNA fragmentation index in infertile men and familial cancer susceptibility</b></p> <p>M. Raffo, Milan (IT)</p>
A1106	<p><b>Cardiac structure and function in men with erectile dysfunction</b></p> <p>E. Durukan, Herlev (DK)</p>
<b>11:45 - 11:50</b>	<b>Outcomes</b>
A0889	<p><b>Reproductive outcomes in infertile couples undergoing intracytoplasmic sperm injection with a male partner exhibiting chromosomal translocation or inversion</b></p> <p>Y-L. Wu, Taipei City (TW)</p>
<b>11:50 - 12:10</b>	<b>Hypogonadism and testosterone therapy</b>
A0893	<p><b>Are reference intervals for free testosterone in healthy men reliable also in men with erectile dysfunction? Findings from a cross-sectional study</b></p> <p>L. Boeri, Milan (IT)</p>
A0880	<p><b>Effectiveness of long-term testosterone therapy for up to 15 years on erectile function and sexual activity in men with functional hypogonadism</b></p> <p>K.S. Haider, Bremerhaven (DE)</p>
A0891	<p><b>Is testosterone replacement therapy effective and safe even for eugonadal men with symptom of late onset hypogonadism?</b></p> <p>K. Ishikawa, Urayasu (JP)</p> <p><b>Study Group</b> Juntendo University Urayasu Hospital(Urayasu, Japan)</p>
A0892	<p><b>Chatbots vs andrologists : testing 25 clinical cases</b></p> <p>O. Perrot, Maison Alfort (FR)</p>
<b>12:10 - 12:15</b>	<b>Hormones and gender</b>
A0886	<p><b>Transgender men can achieve adequate muscular development through low-dose testosterone therapy: A Long-term Study on Body Composition Changes</b></p> <p>Y. Tominaga, Okayama (JP)</p>
<b>12:15 - 12:18</b>	<b>Expert summary</b>



# Innovations in biopsy and focal therapy in prostate cancer

Video session 14

**Monday 8 April**  
**10:45 - 12:15**

**Location** Purple Area, S03

**Chairs** G. Cacciamani, Los Angeles (US)  
J.I. Martínez Salamanca, Madrid (ES)

We encourage participants in this session to view the abstracts before the session. All abstract bodies, posters, videos and webcasts can be viewed on the EAU(N)24 Resource Centre or at the digital screens in front of the Purple Area, EGPT.

V103 (□ 5 min.)

**Holomedicine: The use of a mixed reality device to aid in transperineal prostate biopsies**

A. Kesavan, Singapore (SG)

V104 (□ 7 min.)

**An extended reality (XRD) headset designed as a wearable monitor for transperineal procedures: applications for remote training**

N. Stone, Vail (US)

V105 (□ 5 min.)

**MRI-TRUS Fusion Guided Prostate Biopsy: should we continue to do it? Our first hundred cases experience**

F. Arborea, Altamura (IT)

V106 (□ 5 min.)

**Transperineal biopsies using micro-ultrasound for prostate cancer.**

M.E. Rodríguez Socarrás, Madrid (ES)

V107 (□ 7 min.)

**A single center evaluation of single use, disposable transperineal prostate biopsy guide with pivot feature**

C.G. Rogers, Detroit (US)

V108 (□ 6 min.)

**The use of spacer in focal cryotherapy for rectal protection**

C.H. Yee, Hong Kong (HK)

V109 (□ 5 min.)

**Targeted Microwaves Ablation for Localized Prostate Cancer (FOSTINE 1b): a Prospective Ablate-and-Resect Study**

A. Peltier, Brussels (BE)

V110 (□ 8 min.)

**Single setting 3D MRI-US guided frozen section and focal cryoablation of the index lesion: oncologic and functional outcomes**

L. Misuraca, Rome (IT)

# Challenging practice in continence surgery

Video session 15

**Monday 8 April**  
**10:45 - 12:15**

**Location** Green Area, S04

**Chairs** H. Gresty, London (GB)  
M.A. Perrouin Verbe, Nantes (FR)

We encourage participants in this session to view the abstracts before the session. All abstract bodies, posters, videos and webcasts can be viewed on the EAU(N)24 Resource Centre or at the digital screens in front of the Purple Area, EGPT.

V111 (□ 7 min.)

**Robot-assisted laparoscopic artificial urinary sphincter insertion in 12 years old boy with neurogenic stress urinary incontinence**

T. Loubersac, Nantes (FR)

V112 (□ 8 min.)

**Robotic-assisted laparoscopic implantation of artificial urinary sphincter in men with neurogenic stress urinary incontinence-Step by step technique**

M.A. Perrouin Verbe, Nantes (FR)

V113 (□ 8 min.)

**A comparative journey of Laparoscopic vs. Robotic approaches in Female Artificial Urinary Sphincter implantation**

A. Sanchez, Madrid (ES)

V114 (□ 5 min.)

**The ABCs of Complicated Artificial Urinary Sphincter Insertion: The Tunical Flap Technique**

H. Al Saffar, Melbourne (AU)

V115 (□ 6 min.)

**AMS800 artificial urinary sphincter: a novel modified easier technique**

L. Ola, Torino (IT)

V116 (□ 8 min.)

**The adjustable sling ATOMS SSP proximal implantation technique - Updated outcome of revised patients and step by step surgery video**

F. Queißert, Münster (DE)

V117 (□ 7 min.)

**Operative technique of the retro-urethral transobturator bulbar support sling**

P. Rehder, Innsbruck-Igls (AT)

V118 (□ 5 min.)

**Vulko the New Adjustable Sling for Male Incontinence - Preliminary Results**

W.A. Hübner, Korneuburg (AT)

# Best of EAU24 Abstracts: An expert discussion

Special session

**Monday 8 April**  
**10:45 - 12:15**

**Location** Green Area, eURO Auditorium 1

**Chairs** P. Albers, Düsseldorf (DE)  
A. Stenzl, Tübingen (DE)

## Learning objectives

This session contains abstracts selected by the Scientific Congress Office (SCO) to be discussed further. The selected abstracts will be discussed by a member of the SCO or a specialist in the field. By this, the selected abstracts will be highlighted and their content will be commented. In addition, the prize-winning abstracts will be presented and discussed by a member of the SCO.

[We encourage participants in this session to view the abstracts before the session. All abstract bodies, posters, videos and webcasts can be viewed on the EAU\(N\)24 Resource Centre or at the digital screens in front of the Purple Area, EGPT.](#)

**10:45 - 11:21**

## Oncology abstracts discussed

**10:45 - 11:00**

### Renal cancer

M.C. Mir Maresma, Valencia (ES)

**A0271** Enhancing immunotherapy in renal cell carcinoma by engineering cytotoxic T lymphocytes with chimeric costimulatory switch proteins - Dr. J. Linxweiler, Homburg/Saar (DE)

**A0474** Active Surveillance versus Primary Intervention for Clinical T1a Kidney Tumors: Contemporary results after Fourteen-Year Experience of the DISSRM Prospective Comparative Study - Dr. K. Alkhatib, Elmhurst (US)

**A0471** Reclassification of small renal masses according to the EAU Guidelines newly-proposed TNM classification for suspected renal cell carcinoma: implications for decision-making - Dr. C. Palumbo, Novara (IT)

**A0270** A potential tumor-marker from urinary microbiota – focusing on renal cell carcinoma - Prof. Dr. Dr. S. Kajioka, Fukuoka (JP)

**A0458** Artificial intelligence links pre-operative multi-phase CT images to pathologic features, survival outcomes and biological behaviors of renal masses using real-world data - Dr. Y. Xiong, Shang Hai (CN)

**11:00 - 11:09**

### Urothelial cancer

J. Boormans, Rotterdam (NL)

**A0352** Development and external validation of an artificial intelligence-based tool for PROgression Risk assessment in Non-muscle invasive Bladder Cancer (PROGRxN-BCa) - Dr. J. Kwong, Toronto (CA)

**A0876** Cancer vaccine improves the efficacy of immune checkpoint inhibitor against refractory cancers - Dr. S. Ueda, Fukuoka (JP)

**A0148** Development and validation of a highly specific digital PCR test using hypermethylated circulating tumour DNA in invasive urothelial carcinoma - Dr. D. Prost, Paris (FR)

11:09 - 11:21

## Prostate cancer

D. Tilki, Hamburg (DE)

**A0563** A novel approach to identify aggressive prostate cancer via DNA-Methylation signatures from prostate needle biopsy - Dr. M. Kaneko, Glendale (US)

**A0659** Organised prostate cancer testing in Sweden – results from the first three years of inviting 50-year-old men - Ass. Prof. A. Lantz, Danderyd (SE)

**A0679** High intensity focused ultrasounds vs. radical prostatectomy: Carcinologic results of the HIFI study - Dr. G. Ploussard, Toulouse (FR)

**A0645** Fracture-related hospitalisations in de novo advanced or metastatic hormone-sensitive prostate cancer: Secondary analysis of the STAMPEDE abiraterone acetate plus prednisone +/- enzalutamide and M1|RT phase 3 trials using health systems data - Mr. C. Jones, Cheadle (GB)

---

11:21 - 11:48

## Non-oncology abstracts discussed

11:21 - 11:36

### Functional urology

J-N.L. Cornu, Rouen (FR)

**A0240** Unveiling the long-term survival outcomes of artificial urinary sphincter: A twelve-year study from the French National Health Insurance database - Dr. L. Lenfant, Paris (FR)

**A0782** A preliminary analysis of the comparing UroLift Experience Against Rezūm (CLEAR) randomized controlled trial (RCT) suggests a superior early patient experience with UroLift - Dr. M. Rochester, Norwich (GB)

**A0379** A prospective paired comparison trial on mirabegron and anticholinergics in patients with low bladder compliance - Dr. H.S. Son, Seoul (KR)

**A0918** Volume variability in orthotopic neobladder: the Impact of the ileal width and the AADAPT formula tested on the animal model - Dr. F. Annino, Arezzo (IT)

**A0927** Novel 3D bioprinting for urethral reconstruction - Dr. A.T. Olsen Ekerhult, Gothenburg (SE)

11:36 - 11:45

### Urolithiasis

T. Knoll, Sindelfingen (DE)

**A0768** Break wave lithotripsy for urolithiasis: Results of the first-in-human international multicenter clinical trial - Ass. Prof. B.H. Chew, Vancouver (CA)

**A0400** Comparison of the intestinal microbiota of patients with primary hyperparathyroidism with and without urinary system stone disease - Dr. A. Gudeloglu, Ankara (TR)

**A0455** A prospective clinical trial on temperature profiles during flexible ureteroscopic laser lithotripsy - Mr. M.S.R. Asoy, Bergen (NO)

11:45 - 11:48

### Andrology

M. Albersen, Leuven (BE)

**A1092** Treatment of Erectile Dysfunction using Digital Health Applications (DiGA) - Results of a Prospective, Randomized, Controlled, Single-Blind Study (RCT) (EDDIG Study) - Prof. Dr. M. Zitzmann, Münster (DE)

---

11:48 - 12:14

## Discussion of prize-winning abstracts

11:48 - 12:01

### Oncology

*Discussant*

A. Villers, Lille (FR)

**First prize A0603 PSMA-PET guided intensification of salvage radiotherapy after radical prostatectomy: A phase 2 randomized controlled trial - C. Belliveau, et al., Montreal (CA)**

**Second prize A0825 25-year outcomes for men on active surveillance after screen detected prostate cancer in the Göteborg-1 trial - E. Palmstedt, et al., Gothenburg (SE)**

12:01 - 12:14

**Third prize A0526 A patient-derived bladder cancer organoid biobank for translational research and precision oncology - M. Garioni, et al., Basel (CH)**

**Non-Oncology**

C. Gratzke, Freiburg (DE)

**First prize P375 PUrE RCT 1: Clinical and cost-effectiveness of flexible ureterorenoscopy and extracorporeal shockwave lithotripsy for lower pole stones  $\leq 10$  mm - O. Wiseman, et al., Cambridge (GB)**

**Second prize A1013 LIM kinase inhibitor: A novel pharmacological strategy in the treatment of mixed symptoms in mixed LUTS? - Dr. Q. Yu, et al., Guangzhou (CN)**

**Third prize A0111 Efficacy and safety of mirabegron compared with solifenacin in treatment of non-neurogenic voiding dysfunction in children: A randomized controlled trial - Dr. I. Mansour, et al., Mansoura (EG)**

Monday 8 April

10:45 - 12:15

**Location** Purple Area, EGPT

**Chairs** R.J. Bryant, Oxford (GB)  
G. Gandaglia, Milan (IT)

We encourage participants in this session to view the abstracts before the session. All abstract bodies, posters, videos and webcasts can be viewed on the EAU(N)24 Resource Centre or at the digital screens in front of the Purple Area, EGPT.

10:45 - 10:57

## Screen A: Significance of Intraductal or cribriform patterns at biopsy

- P347** **Cribriform pattern associated lymphatic metastases detected by prostate-specific membrane antigen in post-radical prostatectomy biochemically recurrent patients**  
R.M. Marques Bernardino, TORONTO (CA)
- P333** **The expression of prostate-specific membrane antigen in intraductal carcinoma of the prostate: from whole mount histology to [68Ga]Ga-PSMA-11 PET/CT**  
H. Zheng, Nanjing (CN)
- P346** **Intraductal Prostate Cancer Affinity for Lymphatic-Predominant Metastases through 18F-DCFPyL-PSMA-PET/CT Scans in Pre-Treatment Prostate Cancer Patients**  
R.M. Marques Bernardino, TORONTO (CA)

10:57 - 11:15

## Screen B: Imaging and prediction of adverse pathology events

- P321** **Association between PSMA PET intraprostatic SUVmax and post radical prostatectomy pathology: A systematic review and meta-analysis**  
D. Chen, Melbourne (AU)
- P343** **Radical Prostatectomy Without Prior Biopsy in Selected Patients Evaluated by 18F-labeled PSMA-ligand positron emission tomography/computed tomography and multiparameter magnetic resonance imaging: A Single-centre, Prospective, Single-arm Trial**  
S. Niu, Beijing (CN)
- P340** **Combining MRI PI-RADS and PSMA-PET/CT PRIMARY score in a composite (P) score for more accurate diagnosis of clinically significant Prostate cancer.**  
L. Emmett, Sydney (AU)
- P342** **Correlation of intraprostatic SUVmax during PSMA PET/CT and adverse pathology at radical prostatectomy.**  
F. Preisser, Hamburg (DE)
- P330** **PSMA-PET vs. conventional imaging for preoperative staging high-risk PCa patients underwent surgery for cN0M0 disease**  
L. Bianchi, Bologna (IT)

11:15 - 11:30

## Screen C: Imaging and risk of progression

- P327** **Validation of the EAU Risk Groups for Radical Prostatectomy Prostate Cancer Patients Who Experienced Biochemical Recurrence Restaged with PSMA PET Imaging and Development of a Novel Tool**  
M. Longoni, Milan (IT)

P323	<b>PI-RADS score 5 is a strong predictor for rapid prostate cancer specific death</b> T.D. Laajala, Turku (FI)
P349	<b>Multi-Institutional Development and Validation of a Radiomic Model to Predict Prostate Cancer Recurrence following Radical Prostatectomy</b> L. Huynh, Orange (US)
P338	<b>Can We Rely on Available Models Predicting Pathological Outcomes in Prostate Cancer Patients Staged With 68-Ga PSMA-PET/CT? External Validation of the Existing Nomograms for Extracapsular Extension and Seminal Vesicle Invasion at Radical Prostatectomy and Development of a Novel Tool Including Intraprostatic SUVmax</b> S.L.A. Scuderi, Milan (IT)
P331	<b>Accuracy of the MRI 5-point Likert score to predict extra-prostatic extension and seminal vesicle invasion in patients undergoing radical prostatectomy for prostate cancer and development of a new MRI-based nomogram.</b> F. Pellegrino, Milan (IT)
<hr/>	
<b>11:30 - 11:48</b>	<b>Screen D: Imaging for detection</b>
P332	<b>The value of 68Ga-PSMA PET/MRI for classifying PI-RADS 3 lesions on multiparametric MRI: a prospective single-center study</b> J. Shi, Nanjing (CN)
P337	<b>DEPROMP-Study: PSMA-PET/CT Prior to Prostate Biopsy: Enhancing Prostate Cancer Detection and Personalized Management</b> P. Krausewitz, Bonn (DE)
P322	<b>Comparison of the Incidence of Clinically Significant Prostate Cancer in Patients With Isolated Peripheral vs Transitional Zone PIRADS 3 Lesions</b> K. Malshy, Providence, Rhode Island (US)
P350	<b>Do 5-alpha reductase inhibitors influence the features of suspicious lesions on magnetic resonance imaging and targeted biopsy results for prostate cancer diagnosis?</b> Z. Savin, Tela Aviv (IL)
P326	<b>Decoding Clinically Significant Prostate Cancer in Biopsy Naïve Patients: A Machine Learning Approach from a tertiary referral center</b> F. Dagnino, Pieve Emanuele (IT)
P329	<b>How can we reduce the rates of false positive findings at mpMRI? The pivotal role of Urologist expertise assessed in a large, single center series</b> A. Pellegrino, Milan (IT)
<hr/>	
<b>11:48 - 12:00</b>	<b>Screen E: Imaging for local staging</b>
P341	<b>Determining an optimal SUVmax cut-off for detection of intra-prostatic radiorecurrent prostate cancer using 68Ga-PSMA-11 PET/CT</b> N. Mayor, London (GB)
P324	<b>Impact of magnetic resonance imaging scan and image acquisition protocol in detecting clinically significant prostate cancer at biopsy: results from the PROMOD working group</b> A. Fanelli, Taranto (IT)

- P345**      **Development and external validation of a novel nomogram to predict the probability of pelvic lymph-node metastases in prostate cancer patients using magnetic resonance imaging and molecular imaging with prostate-specific membrane antigen positron emission**  
A. Vis, Haarlem (NL)
- P336**      **The Next Generation Trial: Assessing 18F-PSMA-1007 Positron Emission Tomography and Magnetic Resonance Imaging in the primary staging of prostate cancer patients**  
N. Mookerji, Edmonton (CA)
- 
- 12:00 - 12:15**      **Screen F: Suspicious imaging and negative biopsies**
- P328**      **What happens to patients with a PI-RADS 5 lesion and a negative prostate biopsy? Long term follow up of a single institutional experience.**  
L. Cella, Milan (IT)
- P334**      **Negative MRI rules out clinically significant prostate cancer regardless of PI-RADS era**  
T. Shadbahr, Helsinki (FI)
- P339**      **Negative fusion biopsy in PIRADS 3-5 cases: what comes next in real world clinical practice?**  
R.S. Flammia, Rome (IT)
- P344**      **Long-Term follow-up after initial negative prostate biopsy: Comparison of conventional TRUS against mpMRI-fusion biopsies**  
T. Scherer, Zürich (CH)
- P325**      **PROSPET-BX trial: [G8Ga]PSMA PET/CT vs. mpMRI in patients with suspicion of prostate cancer and previous negative biopsy**  
D. Maffei, Villa Lagarina (IT)



# Surgical, non-surgical and systemic treatment of localised muscle-invasive bladder cancer

Abstract session 58

Monday 8 April  
11:00 - 12:30

**Location** Purple Area, E01

**Chairs** H. Abol-Enein, Mansoura (EG)  
G. Marcq, Lille (FR)  
P. Mariappan, Edinburgh (GB)

We encourage participants in this session to view the abstracts before the session. All abstract bodies, posters, videos and webcasts can be viewed on the EAU(N)24 Resource Centre or at the digital screens in front of the Purple Area, EGPT.

11:00 - 11:02

**Introduction**

11:02 - 11:47

**Peri-operative systemic therapy in MIBC**

A0910

**The impact of cigarette smoking on response rate and survival in patients with muscle-invasive bladder cancer undergoing neoadjuvant chemotherapy and radical cystectomy**

J. Krauter, Vienna (AT)

A0897

**Thromboprophylaxis during neoadjuvant chemotherapy before cystectomy is associated with a lower risk of venous thromboembolism and bleeding, a multicentric retrospective study**

L. Antonelli, bovezzo (IT)

A0900

**Feasibility and oncological outcome of patients achieving non-invasive down-staging after transurethral resection of bladder tumor plus systemic chemotherapy for bladder preservation strategy in muscle-invasive bladder cancer**

T. Onishi, Ise (JP)

A0903

**Impact of maximal transurethral resection prior to neoadjuvant chemotherapy on oncological outcomes in patients who undergo radical cystectomy: A multicenter retrospective study**

N. Fujita, Hiroasaki (JP)

A0901

**First results of NURE-Combo: A phase 2 study of neoadjuvant nivolumab (NIVO) and nab-paclitaxel (ABX) followed by postsurgical adjuvant NIVO in patients (pts) with muscle-invasive bladder cancer (MIBC).**

C. Mercinelli, Milan (IT)

A0904

**Tislelizumab in combination with gemcitabine plus cisplatin as neoadjuvant therapy for lymph node-positive bladder cancer: results of a prospective study**

X. Yang, Nanjing (CN)

A0896

**The optimal number of induction chemotherapy cycles in cN+ bladder cancer**

M. von Deimling, Hamburg (DE)

**Study Group**

CLIPOLY Study Group(Vienna, Austria)

A0902

**Stratifying the risk of disease progression among surgically treated muscle invasive bladder cancer eligible for adjuvant nivolumab**

R.S. Flammia, Rome (IT)

A0894	<b>Dissecting the genomic, immunophenotypic and therapeutic implications of FAT1 loss muscle-invasive bladder cancer</b> Z. Wang, Shanghai (CN)
<b>11:47 - 11:57</b>	<b>Bladder-sparing treatment in patients with MIBC</b>
A0908	<b>Radical Cystectomy versus Trimodal Therapy for Non-metastatic Muscle-Invasive Bladder Cancer: analysis of an Other-cause Mortality Matched Cohort</b> M. Finati, Foggia (IT)
A0907	<b>Tetramodal bladder-preservation therapy incorporating induction chemoradiotherapy and consolidative partial cystectomy with pelvic lymphnode dissection for muscle-invasive bladder cancer: long-term oncologic outcomes of 201 patients</b> H. Tanaka, Tokyo (JP)
<b>11:57 - 12:27</b>	<b>Surgical techniques of radical cystectomy for MIBC</b>
A0899	<b>The effect of hospital caseload on perioperative mortality, morbidity and costs in bladder cancer patients undergoing radical cystectomy: Results from the GRAND study</b> G.B. Schulz, Munich (DE)
A0905	<b>The effect of Robot-Assisted Radical Cystectomy (RARC) on peritoneal metastasis in patients with muscle-invasive bladder cancer</b> F. Yoneyama, Hirosaki (JP)
A0909	<b>Surgical technique and perioperative outcomes of Robot-Assisted Radical Cystectomy with the Hugo™ RAS: is it ready for prime time?</b> F. Prata, Rome (IT)
A0898	<b>DaBlaCa-16: The MOSAIC trial - A randomized study investigating retrosigmoid versus conventional ileal conduit in robot-assisted radical cystectomy - feasibility and 90-day postoperative complications</b> S. Brandt, Århus N (DK)
A0895	<b>Impact of transvaginal specimen extraction on urinary continence after robot-assisted radical cystectomy and intracorporeal orthotopic neobladder</b> R. Mastroianni, Rome (IT)
A0906	<b>Systematic review of clinical outcomes and step-by-step description of orthotopic bladder reconstruction following robot-assisted radical cystectomy</b> F. Piramide, Turin (IT)
<b>12:27 - 12:30</b>	<b>Expert summary</b>

**Monday 8 April**  
**12:00 - 13:30**

**Location** Purple Area, E02

**Chairs** L. De Kort, Utrecht (NL)  
S. Kulkarni, Pune (IN)  
K-D. Sievert, Detmold (DE)

We encourage participants in this session to view the abstracts before the session. All abstract bodies, posters, videos and webcasts can be viewed on the EAU(N)24 Resource Centre or at the digital screens in front of the Purple Area, EGPT.

**12:00 - 12:25**

## Urethral Strictures: Basic Research

A0924

**The superiority of hypoxic to normoxic adipose-derived stem cells culture in inducing IL-10, FGF-2 and preventing fibrotic tissue formation in a urethra model**  
I.B.P. Pramana, KOTA DENPASAR (ID)

A0916

**Single-cell transcriptome profiling of foreskin lesions from male genital lichen sclerosus urethral strictures patients**  
R. Zhang, Shanghai (CN)

A0912

**Transcriptomic analysis reveals inflammatory and oxidative stress subtypes in prepuce lesions of Male Genital Lichen Sclerosus-Associated Urethral Stricture patients and explores their histological and clinical correlations**  
X. Xianjie, Shanghai (CN)

A0923

**Establishment of epithelial organoids for urethral tissue engineering purposes**  
P. De Graaf, Utrecht (NL)

A0927

**Novel 3D bioprinting for urethral reconstruction**  
A.T. Olsen Ekerhult, Gothenburg (SE)

**12:25 - 12:35**

## Gender affirmation surgery

A0913

**Evaluation of urethral complications in a large cohort following transmasculine gender affirmation surgery**  
W.G. Lee, London (GB)

A0914

**Quality of life and sexual satisfaction after metoidioplasty in transmen**  
B. Stojanovic, Belgrade (RS)

**12:35 - 13:15**

## Urethral strictures: Clinic

A0911

**Kulkarni versus the standard dorsal Approach for Buccal Mucosal Graft Urethroplasty: Does Sexual Function Matter?**  
A. Tharwat Abdelghafour, Faqous (EG)

A0919

**Incidence and management of BPH surgery-related urethral stricture: results from a large U.S. database**  
L.C. Licari, Sciacca (IT)

A0915

**28 Years of Expertise: Optimizing Treatment Strategies for Pelvic Fractures and Complex Urethral Injuries with a Comprehensive Approach**  
M.A. Ocampo, Bogota (CO)

A0926	<p><b>Elimination of post-operative oral care pathways does not increase complications in buccal mucosal graft urethroplasty</b></p> <p>K. Sury, Durham (US)</p>
A0922	<p><b>The Optilume® Drug Coated Balloon for recurrent anterior urethral strictures: ROBUST III study 3-year results</b></p> <p>S.P. Elliott, Minneapolis (US)</p> <p><b>Study Group</b></p> <p>ROBUST III Study Group(Plymouth, United States of America)</p>
A0920	<p><b>Results of oral mucosa graft urethroplasty in the penil urethra with or without reconstruction of the meatus</b></p> <p>M. Borisenkov, Hof (DE)</p>
A0917	<p><b>Effect of Inferior Alveolar plus Buccal Nerve Block on Postoperative Morbidity at Buccal Mucosal Graft Harvest Site: A Prospective Double-Blind Randomised Controlled Trial</b></p> <p>V. Tarigopula, Bhubaneswar (IN)</p>
<b>13:15 - 13:30</b>	<b>Reconstructive urology: miscellaneous</b>
A0918	<p><b>Volume variability in orthotopic neobladder: the Impact of the ileal width and the AADAPT formula tested on the animal model.</b></p> <p>F. Annino, Arezzo (IT)</p>
A0921	<p><b>Comparative Effectiveness of Surgical Treatments for Recurrent Obstruction Following Failed Pyeloplasty: A Multicenter, Prospective Registry Study</b></p> <p>S. Xiong, Beijing (CN)</p>
A0925	<p><b>Ex-vivo bladder model for evaluation of optimum applied pressure and number of artificial urinary sphincter cuffs to achieve continence</b></p> <p>P. Shokri, tehran (IR)</p>
A005	<p><b>The Artificial Urinary Sphincter Improves Depression, Anxiety and Overall Emotional Health in Men with Stress Urinary Incontinence; Analysis of the Artificial Urinary Sphincter Clinical Outcomes Trial (AUSCO)</b></p> <p>A.C. Peterson, DURHAM (US)</p>

# How can we get away from positive surgical margins during prostatectomy?

Abstract session 61

**Monday 8 April**  
**12:00 - 13:30**

**Location** Purple Area, E04

**Chairs** S. Knipper, Berlin (DE)  
M. Moussa, Beirut (LB)  
D. Murphy, Melbourne (AU)

We encourage participants in this session to view the abstracts before the session. All abstract bodies, posters, videos and webcasts can be viewed on the EAU(N)24 Resource Centre or at the digital screens in front of the Purple Area, EGPT.

**12:00 - 12:02**

**Introduction**

**12:02 - 12:17**

**Margins and Retzius-sparing RP**

A0948

**Predictors of positive surgical margins and site-specific analysis after Retzius-sparing and antegrade robotic radical prostatectomy in trainees' cohorts: results of a multicentric experience**

U. Anceschi, Rome (IT)

A0958

**Retzius-sparing robot-assisted radical prostatectomy for large prostate volumes: surgical and functional outcomes**

A. Olivero, Milan (IT)

A0949

**Modified Retzius-sparing robot-assisted radical prostatectomy for cases with anterior tumor: a propensity score matched analysis**

J. Qian, Nanjing (CN)

**12:17 - 12:47**

**MRI and augmented reality**

A0957

**Preoperative MRI to assess the anatomical location of positive surgical margin at robot-assisted radical prostatectomy (RARP)**

S.H. van der Graaf, Amsterdam (NL)

A0951

**Is it safe to perform contralateral nerve sparing in high-risk prostate cancer with unilateral lesions on multiparametric magnetic resonance image?**

Y. Cheng, Nanjing (CN)

A0955

**Deep learning model for real-time semantic segmentation during intraoperative robotic prostatectomy**

S. Pak, Seoul (KR)

A0953

**A phase III prospective randomized trial to evaluate the impact of augmented reality during robot-assisted radical prostatectomy on the rates of postoperative surgical margins**

S. Luzzago, Milan (IT)

A0952

**A prospective randomized controlled study on reducing positive surgical margin in robot assisted radical prostatectomy using holographic imaging intraoperative navigation guided intraoperative frozen section technology: Preliminary results**

X. Wang, Beijing (CN)

A0950

**The effect of preoperative MRI on oncological outcomes following radical prostatectomy: a 12-year follow-up of a randomized controlled trial**

D. Noor, Finstadjordet (NO)

12:47 - 13:22

## Real time evaluation of margins and new technology

A0962

**Diffuse reflectance spectroscopy during prostatectomy; towards intraoperative margin assessment.**

L.M. de Roode, Amsterdam (NL)

A0954

**Intraoperative evaluation of surgical margins during robot-assisted radical prostatectomy: comparison between fluorescence confocal microscopy and frozen section analysis with final pathology as standard reference**

S. Luzzago, Milan (IT)

A0961

**Centralized prostatectomy with intra-operative NeuroSAFE surgical margin assessment improves surgical margin control**

L. Kroon, Rotterdam (NL)

A0959

**Five-year oncological results of intra-operative frozen section (Neurosafe) during robotic-assisted radical prostatectomy**

P. Fonseca, Stevenage (GB)

A0960

**Accuracy of fluorescence confocal microscopy for detecting positive surgical margins during robot-assisted radical prostatectomy: blind assessment and inter-rater agreement**

R. Almeida-Magana, London (GB)

A0947

**Robot-assisted radical prostatectomy with Hugo™ RAS System: perioperative outcomes from the largest multicentric series.**

F. Prata, Rome (IT)

A0956

**Evaluation of the minimum volume standard for radical prostatectomies in the Netherlands: centralization of care and surgical outcomes over time**

C.M. van der Starre, Utrecht (NL)

---

13:22 - 13:25

## Expert summary

# Urolithiasis: Percutaneous nephrolithotomy

Abstract session 62

Monday 8 April  
12:00 - 13:30

**Location** Purple Area, E05

**Chairs** B.H. Chew, Vancouver (CA)  
A. Sierra Del Rio, Barcelona (ES)  
A. Tsaturyan, Yerevan (AM)

We encourage participants in this session to view the abstracts before the session. All abstract bodies, posters, videos and webcasts can be viewed on the EAU(N)24 Resource Centre or at the digital screens in front of the Purple Area, EGPT.

- 
- A0970**      **Application of optical tracking sensing technology in fusion of image puncture and 3D navigation lithotripsy of ultrasound-guided PCNL**  
Y.B. Liu, Beijing (CN)
- 
- A0966**      **The utility of Augmented Reality in planning renal access for PCNL**  
R. Lasmanovich, Ramat Gan (IL)
- 
- A0969**      **Ultrasonographic guided Robotic-assisted percutaneous renal puncture: a feasibility study.**  
A. Piro, Modena (IT)
- 
- A0978**      **Impact of Renal Access Angles and Speed of Nephroscope Retrieval Movements on the Vortex Effect**  
B. Whiles, Kansas City (US)
- 
- A0967**      **Comparing anterior and posterior calyx approach in supine percutaneous nephrolithotomy**  
A. Ricapito, Foggia (IT)
- 
- A0964**      **Supine Tubeless Upper Pole PCNL under Spinal Anaesthesia: Safety, Feasibility and Outcomes from a Tertiary Endourology centre**  
N. Kumar, Patna (IN)
- 
- A0968**      **A comparison on safety and efficacy between 24 Fr versus 18 Fr pneumatic balloon dilators for percutaneous treatment of renal stones between 10 and 20 mm: results from a contemporary cohort**  
D. Perri, Robecco sul naviglio (IT)
- 
- A0972**      **Prospective Comparative study of Thulium Fiber Laser Vs Holmium laser with Moses technology for kidney stone in Percutaneous Nephrolithotomy: A Randomised controlled single-center trial**  
A. Singh, Naidad (IN)
- 
- A0974**      **Vacuum-assisted mini-percutaneous nephrolithotomy is associated with lower rates of infectious complications compared to standard procedures in low-risk patients: a single-center experience**  
S.P. Zanetti, Milan (IT)

A0975	<b>Effect of tranexamic acid irrigation on perioperative blood loss during mini-percutaneous nephrolithotomy: A double-blind, randomized controlled clinical trial</b> O. Prohsoontorn, pathumthani (TH)
A0971	<b>Nomogram Predicting Acute Kidney Injury Following Percutaneous Nephrolithotomy: An Observational Study.</b> A.K. Chawla, Manipal (IN)
A0976	<b>Frailty impact on post-operative complications and resource utilization following mini-PCNL using the modified 5 item frailty index (MFI-5) score</b> S. Sureka, Lucknow (IN)
A0979	<b>Impact of duration of pre-operative antibiotics on SIRS / urosepsis rates following PNL for non-staghorn renal stones: A randomized controlled study</b> U. Mete, Chandigarh (IN)
A0973	<b>Stone cultures performed during PCNL could accurately predict post-operative septic complications: a single tertiary centre experience</b> F. Ripa, London (GB)
A0963	<b>Significance of renal pelvis urine gram stain, systemic inflammation index, white blood cell ratios and guy stone score in predicting post operative fever after mpcnl: A prospective observational study</b> T.M. Yanga, Zamboanga City (PH)
A0965	<b>Intraoperative cone beam computed tomography increases single procedure stone free rates in percutaneous nephrolithotomy: results of a randomized controlled trial.</b> R.A. Kingma, Groningen (NL)
A0977	<b>Totally X-ray-free tubeless mini-percutaneous nephrolithotomy in supine position: Is tomorrow already here?</b> Y. Safaev, Tashkent (UZ)
A0980	<b>Enhancing Patient Understanding and Satisfaction through Video Consent in Percutaneous Nephrolithotomy (PCNL)</b> L. Cacciatore, (IT)



# The cutting edge of partial nephrectomy: Robotic precision, surgical advances, and virtual realities

Abstract session 63

Monday 8 April  
12:00 - 13:30

**Location** Purple Area, E03

**Chairs** M.A. Corrales Acosta, Briançon (FR)  
T. Takagi, Tokyo (JP)  
A. Volpe, Novara (IT)

We encourage participants in this session to view the abstracts before the session. All abstract bodies, posters, videos and webcasts can be viewed on the EAU(N)24 Resource Centre or at the digital screens in front of the Purple Area, EGPT.

12:00 - 12:02

**Introduction**

- A0993** **Off-clamp versus on-clamp robotic partial nephrectomy: A systematic review and meta-analysis of randomized trials and matched studies**  
K.Y. Fong, Singapore (SG)
- A0996** **Does the single-layer technique with soft coagulation versus the double-layer technique in robot-assisted partial nephrectomy affect postoperative outcomes for complex tumors?**  
K. Shiozaki, tokushima (JP)
- A0986** **Preclinical survival study comparing a new poly (2-oxazoline) based hemostatic sealing patch vs. standard renorrhaphy after partial nephrectomy.**  
R.J. Farinha, Gent (BE)
- A0990** **Investigating the impact of suture-less technique on percentage of preserved parenchyma after off-clamp robot-assisted partial nephrectomy**  
R.S. Flammia, Rome (IT)
- A0991** **Comparisons of surgical outcomes of robot-assisted laparoscopic partial nephrectomy according to reconstruction methods, including single-layer and double-layer renorrhaphy: Analyses of an experienced surgeon**  
T. Takagi, Tokyo (JP)
- A0984** **Single-port vs multi-port robot-assisted partial nephrectomy: a single center propensity-score matched analysis**  
L.C. Licari, Sciacca (IT)
- A0994** **Prospective comparison between da vinci and hugo ras platforms in robot-assisted partial nephrectomy**  
V. Hevia Palacios, Madrid (ES)
- A0982** **Robot-assisted partial nephrectomy using the new Hugo™ RAS System versus traditional Da Vinci platform: a propensity score-matched comparison of perioperative and functional outcomes.**  
F. Prata, Rome (IT)

A0989	<b>Transperitoneal and retroperitoneal robot-assisted partial nephrectomy with a novel robotic system: initial experience from a tertiary care referral centre</b> F. Chierigo, Genova (IT)
A0997	<b>Outcomes of the MP1000 system for robot-assisted partial nephrectomy: A multicenter randomized controlled trial</b> G. Yu, Beijing (CN)
A0995	<b>Robot-assisted partial nephrectomy with the on demand Dexter™ robotic system: the first twenty cases</b> D. Thillou, Saint-Georges-des-Coteaux (FR)
A0983	<b>Real-time feature tracking and segmentation in urologic robotic assisted surgery: an artificial intelligence based platform</b> S. Crivellaro, Chicago (US)
A0992	<b>A novel 3D deep learning model to automatically demonstrate renal vasculature segmentation and its validation in nephron-sparing surgery</b> P. Shao, Nanjing (CN)
A0985	<b>Deep-learning approach to renal parenchyma detection: a first step towards augmented reality to guide robot-assisted partial nephrectomy</b> A. Khaddad, Bordeaux (FR)
A0987	<b>Deep Learning Automated Phase Recognition in Robot-Assisted Partial Nephrectomy</b> P. De Backer, Ghent (BE)
A0988	<b>Robotic Assisted Partial Nephrectomy with Metaverse based surgical planning: a single center preliminary experience</b> F. Piramide, Turin (IT)
A0981	<b>Surgeon skill is associated with positive surgical margins in robot-assisted partial nephrectomy: Results of a video-based evaluation</b> C.G. Rogers, Detroit (US)

# Restoration of lower urinary tract functioning after oncological treatments

Thematic Session

Monday 8 April

12:30 - 14:00

**Location** Purple Area, S01

**Chairs** F.C. Burkhard, Bern (CH)  
C. Harding, Newcastle upon Tyne (GB)

## Learning objectives

This session will explore three commonly encountered scenarios in functional and reconstructive urology:

- Post-prostatectomy incontinence
- Mesh insertion in patients with previous radiation treatment
- Reconstruction after radical cystectomy in the female patient

Attendees will learn about the treatment options available and factors which may influence the choice of surgery and hear from experts regarding their preferences. Patient factors which influence treatment choice will also be highlighted. The eagerly awaited data from the SATURN registry will be presented.

12:30 - 13:02

**Rapid-fire debate** Difficult post-prostatectomy incontinence

12:30 - 12:32

**Case presentation: Post-prostatectomy incontinence + radiation therapy and proven UUI an SUI**

L. Moris, Leuven (BE)

12:32 - 12:37

**Medical and non-invasive solutions are the best and the safest**

F. Cruz, Porto (PT)

12:37 - 12:42

**Try Pro-ACT balloons**

W.A. Hübner, Korneuburg (AT)

12:42 - 12:47

**Male slings are possible**

M. Tutolo, Milan (IT)

12:47 - 12:52

**Sphincter is the best**

F. Van Der Aa, Leuven (BE)

12:52 - 13:02

**Discussion**

13:02 - 13:12

**State-of-the-art lecture** Results of SATURN trial on complicated PPI treatment

L. De Kort, Utrecht (NL)

13:12 - 13:27

**Case discussion** SUI surgery in female with pelvic radiation history: Are synthetic mid-urethral sling indicated?

13:12 - 13:14

**Case presentation**

M.A. Cerruto, Verona (IT)

13:14 - 13:19

**Yes**

G. Karsenty, Marseille (FR)

13:19 - 13:24

**No**

P.E. Zimmern, Dallas (US)

13:24 - 13:27

**Conclusion**

M.A. Cerruto, Verona (IT)

13:27 - 13:35

**Urological Association of Asia (UAA) Continent catheterisable channels – options for the continent diversion**

D. Winkle, South Brisbane (AU)

---

13:35 - 13:50

**Rapid-fire debate Reconstruction after radical cystectomy in females**

13:35 - 13:40

**Introduction: Reconstruction after radical cystectomy in females, from pelvic exenteration to organ-sparing**

V. Phé, Paris (FR)

13:40 - 13:45

**Privilege ileal conduit**

N. Thiruchelvam, Cambridge (GB)

13:45 - 13:50

**Propose neobladder**

S.T. De Cillis, Turin (IT)

---

13:50 - 14:00

**Neobladder with continent urinary diversion: Why, when and how?**

T.J. Greenwell, London (GB)

# Familial and hereditary cancer syndromes in urology

Thematic Session

**Monday 8 April**  
**12:30 - 14:00**

**Location** Purple Area, eURO Auditorium 2

**Chairs** P. Albers, Düsseldorf (DE)  
C.H. Bangma, Rotterdam (NL)

## Learning objectives

Genetic factors may contribute to the initiation and progression of various urologic malignancies based on germline mutations. Some of these urologic cancers are related to a larger syndromes involving multiple organs. For the urologic clinician it is important to know in which cases to initiate genetic screening. In this session the relationship between a positive family history and germline related urologic malignancies is highlighted for prostate, kidney, and bladder cancer. Based on best available knowledge, this will provide recommendations for genetic work-up, treatment, and follow-up in patients and their family members.

12:30 - 12:32	<b>Introduction: Relevance and epidemiology of familial cancer syndromes in urology</b> C.H. Bangma, Rotterdam (NL)
12:32 - 12:40	<b>What is the relation between family history and germline mutation?</b> K. Hemminki, Heidelberg (DE)
12:40 - 12:48	<b>What does a urologist need to know starting germline screening?</b> M. Ausems, Utrecht (NL)
12:48 - 13:08	<b>Familial prostate cancer</b>
12:48 - 12:56	<b>Familial prostate cancer</b> A. Morgans, Boston (US)
12:56 - 12:58	<b>Case presentation: 35 yrs, BRCA 2 +, no previous history</b> P. Rajwa, Zabrze (PL)
12:58 - 13:08	<b>Panel discussion Genetic work-up, treatment, follow-up recommendation</b> <i>Panel</i> M. Ausems, Utrecht (NL) K. Hemminki, Heidelberg (DE) A. Morgans, Boston (US) P. Rajwa, Zabrze (PL)
13:08 - 13:28	<b>Familial kidney cancer</b>
13:08 - 13:16	<b>Familial kidney cancer</b> P. Mulders, Nijmegen (NL)
13:16 - 13:18	<b>Case presentation: 45 yrs, history of papRCC I with organ-preserving surgery, now recurrence in both kidneys</b> E. Roussel, Leuven (BE)

13:18 - 13:28

**Panel discussion Genetic work-up, treatment, follow-up recommendation**

*Panel*

M. Ausems, Utrecht (NL)

K. Hemminki, Heidelberg (DE)

P. Mulders, Nijmegen (NL)

E. Rousset, Leuven (BE)

---

13:28 - 13:48

**Lynch syndrome**

13:28 - 13:36

**Lynch syndrome**

M. Gebauer Madsen, Aarhus N (DK)

13:36 - 13:38

**Case presentation: 30 yrs, HNPCC**

E. Laukhtina, Vienna (AT)

13:38 - 13:48

**Panel discussion Urological work-up, interdisciplinary care, follow-up recommendations**

*Panel*

M. Ausems, Utrecht (NL)

M. Gebauer Madsen, Aarhus N (DK)

K. Hemminki, Heidelberg (DE)

E. Laukhtina, Vienna (AT)

---

13:48 - 13:56

**Overview Routine genetic testing for familial cancer syndromes**

A.S. Rannikko, Helsinki (FI)

---

13:56 - 14:00

**Discussion**

*Panel*

M. Ausems, Utrecht (NL)

K. Hemminki, Heidelberg (DE)

A.S. Rannikko, Helsinki (FI)

# Rapid-fire debates: Kidney cancer

Thematic Session

**Monday 8 April**  
**12:30 - 14:00**

**Location** Green Area, eURO Auditorium 1

**Chairs**  
A. Breda, Barcelona (ES)  
M.C. Mir Maresma, Valencia (ES)

**12:30 - 12:45**

**cT1a SRM turns into pT3a with positive margins, what's next?**

*Moderator* Z. Wu, Shanghai (CN)

**12:30 - 12:31**

**Case presentation**

Z. Wu, Shanghai (CN)

**12:31 - 12:35**

**Surveillance**

P.M. Pierorazio, Philadelphia (US)

**12:35 - 12:39**

**Radical nephrectomy**

V. Ficarra, Messina (IT)

**12:39 - 12:45**

**Discussion/Q&A**

---

**12:45 - 13:00**

**How do we manage a patient with complex cystic renal mass (Bosniak III/IV)?**

*Moderator* S. Dabestani, Lund (SE)

**12:45 - 12:46**

**Case presentation**

S. Dabestani, Lund (SE)

**12:46 - 12:50**

**Surveillance**

E. Roussel, Leuven (BE)

**12:50 - 12:54**

**Surgery**

R. Campi, Florence (IT)

**12:54 - 13:00**

**Discussion/Q&A**

---

**13:00 - 13:15**

**Follow-up after pT1a clear cell RCC: Do we save lives with intense follow-up imaging?**

*Moderator* A. Volpe, Novara (IT)

**13:00 - 13:01**

**Case presentation**

A. Volpe, Novara (IT)

**13:01 - 13:05**

**No imaging at all**

C. Beisland, Bergen (NO)

**13:05 - 13:09**

**Guidelines imaging**

L. Oliveira Marconi, Coimbra (PT)

**13:09 - 13:15**

**Discussion/Q&A**

---

**13:15 - 13:30**

**Should we do lymph node dissection for clinical high-risk RCC: What template is appropriate?**

*Moderator* U. Capitanio, Milan (IT)

13:15 - 13:16

**Case presentation**

U. Capitano, Milan (IT)

13:16 - 13:20

**No**

T. Kuusk, London (GB)

13:20 - 13:24

**Unilateral RPLND**

C. Palumbo, Novara (IT)

13:24 - 13:30

**Discussion/Q&A**

---

13:30 - 13:45

**Adjuvant immunotherapy after pT3a F IV /N0 at nephrectomy: Is it considered high-risk for all individuals?**

*Moderator*

M-O. Grimm, Jena (DE)

13:30 - 13:31

**Case presentation**

M-O. Grimm, Jena (DE)

13:31 - 13:35

**Yes**

T. Powles, London (GB)

13:35 - 13:39

**No**

L. Albiges, Villejuif (FR)

13:39 - 13:45

**Discussion/Q&A**

---

13:45 - 14:00

**Does scalpel play a role in intermediate risk metastatic RCC?**

*Moderator*

R. Flippot, Villejuif (FR)

13:45 - 13:46

**Case presentation**

R. Flippot, Villejuif (FR)

13:46 - 13:50

**Upfront CN**

C.K. Bensalah, Rennes (FR)

13:50 - 13:54

**dCN**

A. Bex, London (GB)

13:54 - 14:00

**Discussion/Q&A**



# Transgender surgery

Thematic Session

**Monday 8 April**  
**12:30 - 14:00**

**Location** Green Area, W01

**Chairs** R. Djinovic, Belgrade (RS)  
S.C. Morgenstern, Frankfurt am Main (DE)

## **Learning objectives**

This session provides an overview of surgical options and complication management in transgender surgery. It covers vaginoplasty techniques for transwomen and various phalloplasty techniques for transmen and provides tips and tricks for this unique surgery. A special emphasis is put on some of the greatest challenges in transfeminine surgery: the redo- vaginoplasty as well as in transmasculine surgery: neourethral stricture management and penile implants in phalloplasty.

**12:30 - 12:32**

## **Introduction**

**12:32 - 13:06**

## **Male-to-Female: Sex Reassignment Surgery (SRS)**

**12:32 - 12:40**

### **An overview**

N. Morel Journal, Lyon (FR)

**12:40 - 12:48**

### **M2F SRS: Penile Inversion Surgery - Techniques**

F. Zorzi, Trieste (IT)

**12:48 - 12:56**

### **Re-do Vaginoplasty - Rectosigmoid, Skin, Peritoneum...**

S. Krege, Essen (DE)

**12:56 - 13:06**

## **Discussion**

**13:06 - 13:40**

## **Female-to-Male: Sex Reassignment Surgery (SRS)**

**13:06 - 13:14**

### **Male genital reconstruction - Metoidioplasty: New advances**

W.G. Lee, London (GB)

**13:14 - 13:22**

### **Radial forearm flap phalloplasty: Advantages and disadvantages**

M. Falcone, Torino (IT)

**13:22 - 13:30**

### **Latissimus dorsi phalloplasty**

B. Spiridonescu, Bucharest (RO)

**13:30 - 13:40**

## **Panel discussion**

**13:40 - 13:48**

### **Urethral reconstruction and complications in total phalloplasty**

G. Pigot, Amsterdam (NL)

**13:48 - 13:56**

### **Prosthesis implantation in total phalloplasty: Options and complications**

D.J. Ralph, London (GB)

**13:56 - 14:00**

## **Discussion and closure**

**Monday 8 April**  
**12:30 - 14:00**

**Location** Green Area, N03

**Chairs** A. Chkhotua, Tbilisi (GE)  
R. Järvinen, Helsinki (FI)  
S. Shariat, Vienna (AT)

We encourage participants in this session to view the abstracts before the session. All abstract bodies, posters, videos and webcasts can be viewed on the EAU(N)24 Resource Centre or at the digital screens in front of the Purple Area, EGPT.

- 
- A1020** **A Fully Automated Novel Urine Cytology Support Artificial Intelligence System for the Prediction of Histological High-grade Urothelial Carcinoma: External Validation Study**  
M. Kaneko, Glendale (US)
- 
- A1019** **A viable alternative to Urine Cytology in Urothelial Cancer Detection: a non-inferiority trial**  
S. Morselli, San Felice Sul Panaro (IT)
- 
- A1032** **A prospective, comparative, within-patient controlled multicenter phase III study comparing blue light cystoscopy versus white light cystoscopy for the detection of bladder cancer using modern HD 4K equipment**  
H. Hu, Tianjin (CN)
- 
- A1027** **Photodynamic diagnosis (PDD) directed biopsies vs white light bladder mapping in patients with positive cytology and negative preoperative workup: an international multicenter retrospective study On behalf of the European Association of Urology Young Academic Urologist Urothelial Working Group**  
C.F. Colucci, Torino (IT)
- 
- A1028** **Leveraging deep learning for real-time detection of bladder tumor in cystoscopy: a multi-center retrospective study**  
Y. Li, Beijing (CN)
- 
- A1021** **A breakthrough non-invasive tool for early detection of bladder cancer in human urine: evaluation of a novel compact spectrometer.**  
F. Prata, Rome (IT)
- 
- A1018** **A novel Bladder Cancer diagnostic technique based on urine multimodal spectroscopy**  
S. Morselli, San Felice Sul Panaro (IT)
- 
- A1023** **The impact of centralized uropathology review in the management of bladder cancer patients at the time of transurethral resection of the bladder**  
D. Robesti, Milan (IT)
- 
- A1026** **Unlocking the potential of urinary mutation and methylation biomarkers: A Game-Changing approach to optimizing candidates of NMIBC for Repeated TURBT - A prospective multicenter study**  
X. Yang, Nanjing (CN)

A1031	<b>Molecular subtyping, ADC assessment and FGFR testing reveals potential for co-targeting of FGFR3 with TROP2 &amp; NECTIN4 – preview of Bladder BRIDGister.</b> R. Wirtz, Cologne (DE)
A1030	<b>Prognostic Value of Micrometric Substaging in pT1 Bladder Cancer Patients Treated with En Bloc Transurethral Resection</b> T. Yanagisawa, Tokyo (JP)
A1035	<b>The importance of being grade 3 in primary non-muscle invasive bladder cancer</b> I.J. Beijert, Ouderkerk aan de Amstel (NL)
A1025	<b>The genetic information of non muscle invasive bladder cancer associated with recurrence</b> K.J. Oh, Gwangju (KR)
A1022	<b>Charlson-Deyo Comorbidity Index as a Novel Predictor for Recurrence in Non-Muscle Invasive Bladder Cancer</b> L. Scheipner, Graz (AT)
A1024	<b>Pragmatic Clinico-pathological sub-classification of Intermediate Risk Non-Muscle Invasive Bladder Cancer (IR-NMIBC) with multicentre validation</b> P. Mariappan, Edinburgh (GB)
A1029	<b>Lymphovascular invasion as prognostic factor in patients with T1 high-grade non-muscle-invasive bladder cancer</b> E. Laukhtina, Vienna (AT)

# Male LUTS diagnosis - clinical issues

Abstract session 45

Monday 8 April  
12:30 - 14:00

**Location** Purple Area, N01

**Chairs** J. Chueh, Taipei (TW)  
M. Creta, Solopaca (IT)  
To be confirmed

We encourage participants in this session to view the abstracts before the session. All abstract bodies, posters, videos and webcasts can be viewed on the EAU(N)24 Resource Centre or at the digital screens in front of the Purple Area, EGPT.

- 
- A1000** **Evaluation Of Nocturia In Patients Affected By Severe Obstructive Sleep Apnea Syndrome By Nocturnal Bladder Capacity Index.**  
A.L. Pastore, Rome (IT)
- 
- A1006** **Regular sleep habits with appropriate bedtime prolong hours to undisturbed sleep and reduce nocturnal urine volume per hour.**  
Y. Okumura, Fukui (JP)
- 
- A1010** **The association between testosterone deficiency and nocturia in patients over 60 years with cardiovascular diseases**  
S. Kim, Namyangju-si (KR)
- 
- A1011** **Causal relationship between lower urinary tract symptoms and frailty: The chicken or the egg dilemma**  
S. Hosogoe, Hirosaki (JP)
- 
- A1012** **Mobile app-based versus conventional uroflowmetry: Is your home toilet the new uroflowmetry lab?**  
K. Manoj, Delhi (IN)
- 
- A1014** **Transitional Voided volume: a new parameter for assessing home uroflowmetry**  
G. De Win, Edegem (BE)
- 
- A1009** **Twelve-year follow-up observation of idiopathic detrusor underactivity in the elderly living in community: Treatment and urodynamic changes**  
S.J. Jeong, Seongnam, Gyeonggi (KR)
- 
- A1002** **Developing Dual AI Models Using Non-Invasive Clinical Parameters to Aid in Male Bladder Outlet Obstruction Diagnosis and Minimize the Need for Invasive Video-Urodynamic Studies**  
C-Y. Tsai, New Taipei City (TW)
- 
- A1007** **Can Clinical Prostate Score (CLIPS) be used as a useful adjunct for predicting success in minimal invasive surgical therapy (MIST) of the prostate?**  
W.C. Tsang, Singapore (SG)
- 
- A1016** **In how many patients invasive urodynamics should be omitted? Data from a single center database analysed on the basis of the UPSTREAM trial findings.**  
E. Rosato, (IT)

A0999	<b>The diagnostic role of prostatic urethral angle in diagnosis of bladder neck dysfunction in men with lower urinary tract symptoms and small prostate volume</b> T-L. Chang, Hualien (TW)
A1005	<b>Voiding symptoms are aggravated by decreasing glandular content and by increasing stromal/epithelial ratio in patients undergoing surgery for BPH, independently from prostate size</b> P. Keller, Munich (DE)
A1008	<b>Identification of programmed cell death (PCD) associated genes in diagnosing benign prostatic hyperplasia and prostate cancer by integrated bioinformatics analysis and machine learning</b> C. Jie, Chengdu (CN)
A1003	<b>Both activator and inhibitor of transient receptor potential mucolipin 1 (TRPML1) inhibit contractions induced by various stimuli in human prostate smooth muscle</b> S. Hu, Munich (DE)
A1015	<b>Novel Concepts of Post-receptor Signaling: Phospholipase C (PLC) Plays an Important Role in Prostate Cell Proliferation, Viability, and Cytoskeletal Organization</b> A. Tamalunas, Munich (DE)
A1004	<b>Concentration-dependent antagonism of <math>\alpha</math>1-adrenergic smooth muscle contractions in human prostate tissues, and bidirectional effects on stromal cell growth by the dual <math>\beta</math>- and <math>\alpha</math>1-adrenergic antagonist carvedilol</b> S. Hu, Munich (DE)
A1001	<b>Phospholipase C (PLC) is a crucial mediator of agonist-induced smooth muscle contraction in the lower urinary tract</b> A. Tamalunas, Munich (DE)
A0998	<b>Over-expression of LEDGF/p75 in HEp-2 cells enhances autoimmune IgG response in patients with benign prostatic hyperplasia - a novel diagnostic approach with therapeutic consequence?</b> D. Roggenbuck, Senftenberg (DE)
A1013	<b>LIM kinase inhibitor: a novel pharmacological strategy in the treatment of mixed symptoms in mixed LUTS?</b> Q. Yu, Guangzhou (CN)

# Frontiers in renal cell carcinoma management: Surgical strategies and prognostic insights

Abstract session 47

Monday 8 April  
12:30 - 14:00

**Location** Green Area, N04

**Chairs** C.K. Bensalah, Rennes (FR)  
A. Galloli, Barcelona (ES)

We encourage participants in this session to view the abstracts before the session. All abstract bodies, posters, videos and webcasts can be viewed on the EAU(N)24 Resource Centre or at the digital screens in front of the Purple Area, EGPT.

- 
- A1052** **Sutureless purely off-clamp Robot-assisted partial nephrectomy in solitary kidney: comparison of perioperative, pathologic and functional outcomes with renorrhaphy technique**  
G. Tuderti, Roma (IT)
- 
- A1038** **Management and predictive factors of unplanned open conversion during minimally invasive renal tumor surgery**  
N. Branger, Marseille (FR)
- 
- A1046** **Robotic partial nephrectomy in patients with a solitary kidney – a multicenter analysis**  
C. Fuhrmann, Hannover (DE)
- 
- A1047** **Impact of Positive Surgical Margin after Radical and Partial Nephrectomy for Renal Cell Carcinoma: A Multicenter Analysis.**  
C. Saitta, Pieve Emanuele (IT)
- 
- A1041** **Comparison of outcomes between radical nephrectomy and partial nephrectomy in cT2 renal cell carcinoma: a KORCC registry propensity score matching**  
Y.S. Chung, Seongnam (KR)
- 
- A1051** **Outcomes of partial and radical nephrectomy in patients with pathological T3a upstaging of clinical T1 renal cell carcinoma: an analysis from the International Marker Consortium for Renal Cancer (INMARC) Cohort**  
S. Fukuda, Tokyo (JP)
- 
- A1040** **Comparative analysis of oncological and functional outcomes of radical and partial nephrectomy in pT3aN0M0 renal cell carcinoma: A multicenter propensity score-matched analysis**  
C. Saitta, Pieve Emanuele (IT)
- 
- A1048** **Prognostic Significance of the Site of Invasion in pT3a Renal Cell Carcinoma**  
H.Y. Lee, seoul (KR)
- 
- A1053** **On-Clamp vs Off-Clamp Robotic Partial Nephrectomy to Treat pT3a Renal Cancers: A Multicenter Analysis**  
A. Brassetti, Rome (IT)

A1045	<b>Node positive non-clear cell renal cell carcinoma: oncological outcomes and genomic insights</b> L. Eismann, Munich (DE)
A1049	<b>Renal cell carcinoma with tumor thrombus growing against the direction of venous return: an indicator of complicated surgery and poor prognosis</b> Z. Liu, Beijing (CN)
A1044	<b>Prognostic factor and cancer-specific survival of the surgically managed renal cell carcinoma with venous thrombus: Thirty-year experience of single tertiary medical center</b> H.Y. Lee, seoul (KR)
A1042	<b>The impact of histological variants on oncological outcomes after surgical resection of a Nonmetastatic Renal Cell Carcinoma with Tumor Thrombus: A Multi-Institutional Study</b> R. Fleury, Rennes (FR)
A1037	<b>Defining a caseload threshold for safe management of inferior vena cava tumor thrombus in renal cell carcinoma patients: German total population data with 3,700 cases from 2006 to 2020.</b> C. Groeben, Marburg (DE)
A1039	<b>Robotic versus Open Level III-IV Inferior Vena Cava Thrombectomy: A Matched Group Comparative Analysis</b> G. Liangyou, Beijing (CN)
A1036	<b>NODESAFE nomogram: A novel score system to predict lymph node involvement at the time of nephrectomy or nodal recurrence in non-metastatic renal cell carcinoma</b> C. Cerrato, (IT)
A1050	<b>The comparison of prognostic models accuracy in non-metastatic papillary renal cell carcinoma undergoing curative surgical treatments: An analysis from international multi-institutional papillary renal cell carcinoma database</b> S. Erdem, Istanbul (TR)

# Biopsy route and methods of targeting

Abstract session 48

**Monday 8 April**  
**12:30 - 14:00**

**Location** Purple Area, S03

**Chairs** B.A. Inman, London (CA)  
M. Kincius, Vilnius (LT)  
T. Roumeguere, Brussels (BE)

We encourage participants in this session to view the abstracts before the session. All abstract bodies, posters, videos and webcasts can be viewed on the EAU(N)24 Resource Centre or at the digital screens in front of the Purple Area, EGPT.

**12:30 - 12:32**

**Introduction**

**12:32 - 12:42**

**MRI/US Fusion methods**

A1068

**Transperineal prostatic targeted biopsy utilizing fusion technique: An institutional case series**

G. Abatangelo, Vicenza (IT)

A1061

**Comparative study between cognitive fusion targeted prostate biopsy technique and software-based magnetic resonance imaging-ultrasonography image-fusion targeted prostate biopsy technique in a high-volume hospital**

C. Calzas Montalvo, Pinto (ES)

**12:42 - 13:32**

**Biopsy route**

A1057

**Transperineal prostate biopsy: An international Delphi consensus for best clinical practices**

L. Storino Ramacciotti, Pasadena (US)

A1062

**Comparison between 14G and 18G needle in performing transperineal prostate biopsies: preliminary results on sample quality, patient discomforts and complications rates from a non-inferiority randomized trial**

A. Panunzio, Brindisi (IT)

A1069

**Freehand Single-Port Access Transperineal Ultrasound Guided Biopsy versus Transrectal Ultrasound Guided Prostate Biopsy Under Local Anesthesia: A Randomized Prospective, Cross-Sectional Study**

J.E.G. Yadao, quezon city (PH)

A1054

**MRI/TRUS fusion-guided transperineal versus transrectal prostate biopsy: A large, multiracial and ethnically diverse cohort**

L. Storino Ramacciotti, Pasadena (US)

A1063

**Retrospective analysis of the learning curve for transperineal robotic-assisted prostate biopsy**

R.J. Himmelsbach, Freiburg (DE)

A1070

**Grid-based cognitive diagnostic transperineal prostatic biopsies without transrectal ultrasound imaging**

D.S. Sahni, Glasgow (GB)

A1058

**Learning Curve Analysis in Transperineal MRI/TRUS Fusion Prostate Biopsy: Impact and Outcomes**

M. Kaneko, Glendale (US)



- A1056 **Trans perineal precision point prostate biopsies: A paradigm shift in prostate cancer diagnosis. A retrospective analysis of 1000 cases.**  
B. Anwar, Blackpool (GB)
- A1060 **Prospective per-target analysis of the added value of probe-tethered access cannulas in cognitive transperineal prostate biopsy of MRI targets**  
L. Orecchia, Roma (IT)
- A1059 **Transperineal vs. Transrectal MRI/TRUS Fusion Biopsy: A Comparative Analysis of Index Cancer Characterization in Radical Prostatectomy Specimens**  
M. Kaneko, Glendale (US)
- 

**13:32 - 13:57**

**Trans perineal biopsy route and anesthesia**

- A1064 **Does inhalational methoxyflurane (Pentrox®) improve pain control during local anaesthetic transperineal biopsy of the prostate?**  
D. Whiting, Ash Vale (GB)
- A1066 **Perineal infiltration of bupivacaine at the time of transperineal prostate biopsy. Does it reduce pain in the recovery bay?**  
A. Al-Khanaty, Strathmore Heights (AU)
- A1065 **Transperineal fusion biopsies in the office setting: Impact of Sufentanil**  
A. Pluchino, Miami Lakes (US)
- A1055 **Local anaesthetic transperineal prostate biopsy: what is the learning curve?**  
N. Mayor, London (GB)
- A1067 **Clinical evaluation of office-based MR-guided transperineal prostate biopsies without the use of antibiotic prophylaxis**  
L. Boesen, Herlev (DK)
- 

**13:57 - 14:00**

**Expert summary**

**Monday 8 April**  
**12:30 - 14:00**

**Location** Green Area, W03

**Chairs** M.E. Alvarez-Maestro, Madrid (ES)  
To be confirmed  
G. Van Der Pluijm, Leiden (NL)

We encourage participants in this session to view the abstracts before the session. All abstract bodies, posters, videos and webcasts can be viewed on the EAU(N)24 Resource Centre or at the digital screens in front of the Purple Area, EGPT.

- 
- A1073** **Population genetics identifies distinct subsets of prostate cancer risk variants between men of European, African and East Asian ancestry**  
C. Molokwu, Bradford (GB)
- 
- A1078** **Folate receptor 2-positive tumor-associated macrophages exert immunosuppressive function in prostate cancer**  
Q. Zhou, Shanghai (CN)
- 
- A1079** **Urinary-exosomal transcript markers for discriminating indolent from aggressive disease of prostate cancer patients under active surveillance**  
K. Erdmann, Dresden (DE)
- 
- A1084** **Analysis of transcriptomic data reveals the landscape of cholesterol metabolism in prostate cancer and impact of related signature on survival.**  
Y. An, Wuhan (CN)
- 
- A1082** **The Interplay between Zonal Microenvironments and Cancer Development in the Prostate**  
A. Ali, Manchester (GB)
- 
- A1086** **Whole exome sequencing analysis in low-risk prostate cancer patients with known family history. Implication for active surveillance.**  
V. Cucchiara, Milan (IT)
- 
- A1087** **Utilizing patient-derived organoids of prostate cancer to predict functional homologous recombination repair deficiency and targeted therapy response**  
S.J. Oh-Hohenhorst, Hamburg (DE)
- 
- A1074** **Endothelial-mesenchymal transition in the cancer microenvironment promotes neuroendocrine differentiation of prostate cancer**  
T. Kageyama, Tsu (JP)
- 
- A1071** **Cholesterol metabolism reprogramming induces the secretion of MDK to promote M2 polarization of macrophages and promotes the progression of prostate cancer**  
H. Huang, Guangzhou (CN)
- 
- A1083** **Assessing Epigenetic Features Associated with Lymph Node Metastases in Prostate Cancer**  
M. Bandini, Milan (IT)

A1081	<b>Variable anti-cancer effects of statins in androgen-insensitive prostate cancer and increased sensitivity of docetaxel-resistant cells to lipophilic statins via the AKT pathway</b> S.J. Oh-Hohenhorst, Hamburg (DE)
A1085	<b>Mimicking physiological conditions to optimize the development of prostate cancer patient-derived organoids</b> R. Parmentier, Basel (CH)
A1075	<b>Development and validation of a novel prostate-specific membrane antigen-targeted near infrared imaging agent S0456@PBP-EVs for fluorescence guided surgery in prostate cancer</b> J. Sun, Wuhan (CN)
A1080	<b>Targeting cofilin 1 reverses the immunotherapy-induced cold phenotype in prostate cancer through cellular cytoskeletal reorganization</b> L. Le, Wuhan (CN)
A1077	<b>Investigating the STING pathway in the prostate cancer tumour immune microenvironment and radiosensitivity</b> R.J. Bryant, Oxford (GB)
A1076	<b>Enhancing novel multimodality therapy for prostate cancer, combining radiotherapy, vascular-targeted photodynamic therapy, and anti-CD73 immunotherapy</b> R.J. Bryant, Oxford (GB)
A1072	<b>Single-cell Secretion Analysis Unveils Autocrine IL11-mediated Resistance to Docetaxel in Prostate Cancer via Activation of the JAK3/STAT4 Pathway.</b> H. Huang, Guangzhou (CN)
A006	<b>Comparison of total PSA and free PSA values in capillary blood and serum blood: A study with 308 patients</b>

**Monday 8 April**  
**12:30 - 14:00**

**Location** Green Area, W06

**Chairs** A. Kadioglu, Istanbul (TR)  
R.B. Meacham, Aurora (US)  
M. Skrodzka, London (GB)

We encourage participants in this session to view the abstracts before the session. All abstract bodies, posters, videos and webcasts can be viewed on the EAU(N)24 Resource Centre or at the digital screens in front of the Purple Area, EGPT.

**12:30 - 12:45**

**RCTs in andrology: can we change practice?**

A1103

**Early Recovery of Erectile Function After Intrafascial Nerve Sparing Robotic-Assisted Radical Prostatectomy: A Prospective Randomized Comparison of PDE5Is vs. Prostaglandin (PG) vs. Combination Therapy (PGE + PDE5Is)**

G. Candita, Latina (IT)

A1094

**PREPED study: a randomised, double-blind controlled trial to evaluate the efficacy of intracavernosal infusion of platelet rich plasma (PRP) against control (platelet poor plasma) in the treatment of vasculogenic erectile dysfunction. Preliminary results**

E. Fernandez Pascual, Madrid (ES)

A1092

**Treatment of Erectile Dysfunction using Digital Health Applications (DiGA) - Results of a Prospective, Randomized, Controlled, Single-Blind Study (RCT) (EDDIG Study)**

M. Zitzmann, Münster (DE)

**12:45 - 13:20**

**Erectile dysfunction and its clinical correlates**

A1098

**A Novel Machine Learning-based Risk Classification For Vascular Damage In Men With Erectile Dysfunction**

F. Belladelli, Milan (IT)

A1096

**Reassessing Cardiovascular Risk Stratification in Men with Erectile Dysfunction: Beyond the Princeton Consensus**

J. Lorigo, Quiaios (PT)

A1091

**A paradoxical association between asthma and erectile dysfunction: A bidirectional Mendelian randomization study**

X.Y. Lyu, Chengdu (CN)

A1095

**Erectile Dysfunction after COVID-19 Infection in Egyptian Individuals: An Observational Longitudinal Study.**

A. Zoair, TANTA (EG)

A1090

**Artificial Intelligence in Andrology. Can we predict long-term erectile dysfunction following COVID-19?**

F. Natal, Bilbao (ES)

A1105

**More negative sexual self-concept in middle-aged men with sexual dysfunctions: results of the Bavarian Men's Health-Study**

K. Herkommer, München (DE)

A1089

**Limitations of IIEF-15 in the preoperative assessment of patients undergoing surgery for prostate disease**

G. Maiolino, Perugia (IT)

---

**13:20 - 13:35**

**Assessing the effects of therapy beyond erectile hardness**

A1097

**The Effects of PDE5i on Psychological Well-Being in ED Patients**

F. Belladelli, Milan (IT)

A1099

**Duration of untreated ED is associated with overall impoverishment of male sexual function**

M. Malvestiti, Gallarate (IT)

A1104

**Treatment adherence disparities in men with primary erectile dysfunction: a comparative study of psychogenic and organic cases**

C. Corsini, Milan (IT)

---

**13:35 - 14:00**

**Premature ejaculation**

A1100

**Premature and delayed ejaculation: an update of latency time and comparison between male and female perception in the largest cohort of study up to day**

M. Lo Re, Florence (IT)

A1088

**Ejaculatory duct obstruction: A single centre experience over 14 years**

A. Schirrmann, Boulogne-Billancourt (FR)

A1093

**Prospective and comparative study to evaluate the impact of the male masturbation device "Controleyac®" by Androgenital® on premature ejaculation: Functional results, safety, and satisfaction assessment**

M. Alonso Isa, Madrid (ES)

A1102

**Multicentre Study On Premature Ejaculation Treatment with Pelvic Floor Muscle Rehabilitation: Analysis of 5 Years Results.**

A.L. Pastore, Rome (IT)

A1101

**Evaluation of factors associated with premature ejaculation: logistical regression on the largest cohort of male patients ever studied**

M. Lo Re, Florence (IT)

# Identifying, preventing and managing complications

Video session 16

**Monday 8 April**  
**12:30 - 14:00**

**Location** Green Area, S04

**Chairs** R. Gaston, Bordeaux (FR)  
S. Joniau, Leuven (BE)

We encourage participants in this session to view the abstracts before the session. All abstract bodies, posters, videos and webcasts can be viewed on the EAU(N)24 Resource Centre or at the digital screens in front of the Purple Area, EGPT.

V119 (□ 5 min.)

**Nightmare surgical scenario during robotic nephroureterectomy for unexpected ureteral endometriosis infiltrating the external iliac artery**

L. Roggero, Verona (IT)

V120 (□ 4 min.)

**Variations in Promontory Anatomy Complicating Robotic Sacrocolpopexy**

P.E. Zimmern, Dallas (US)

V121 (□ 5 min.)

**Robotic parastomal hernia repair after radical cystectomy**

M. Fabregas Drnda, L'Hospitalet de Llobregat (ES)

V122 (□ 8 min.)

**Face-To-Face Robot-Assisted and Laparoscopic Complex Vesicovaginal Fistula Repair**

M. Miranda, Lisboa (PT)

V123 (□ 8 min.)

**Robotic re-exploration in post robot assisted radical cystectomy mechanical bowel obstruction: It is feasible**

A. Khanna, New delhi (IN)

V124 (□ 8 min.)

**Buccal Mucosa Endo-laparoscopic repair of Vesico-urethral stenosis after Radical Prostatectomy**

H. Smets, Utrecht (NL)

V125 (□ 7 min.)

**Robot assisted retzius sparing trans-vesical pull-through technique for reconstruction of vesicourethral anas**

A. Koshmelev, Moscow (RU)

V126 (□ 8 min.)

**Robotic Vesico-Urethral Anastomosis Re-fashioning after Urinary Leak following Radical Robotic Prostatectomy**

E. Day, London (GB)

Monday 8 April  
12:30 - 14:00

**Location** Purple Area, EGPT

**Chairs** T. Knoll, Sindelfingen (DE)  
To be confirmed

We encourage participants in this session to view the abstracts before the session. All abstract bodies, posters, videos and webcasts can be viewed on the EAU(N)24 Resource Centre or at the digital screens in front of the Purple Area, EGPT.

12:30 - 12:54

## Screen A: Outcome of intervention

P356

**Comparison of STONE, CROES, and RIRS Scoring Systems in Predicting Outcomes of Retrograde Intrarenal Surgery in Horseshoe Kidneys: A Single-Center Experience**

A. Keles, Istanbul (TR)

P358

**Which is a better predictor for the safety and efficacy of retrograde intrarenal surgery; stone size or volume? A study of rirsearch study group**

H. Cakir, Istanbul (TR)

P369

**A Machine Learning Approach Using Stone Volume to Predict Stone-Free Status after Ureteroscopy for Kidney Stones**

F. Ripa, London (GB)

P351

**Perioperative outcomes of same-session bilateral versus unilateral ureteroscopy for stone removal: Results from the GRAND study**

N. Pyrgidis, München (DE)

P354

**Incidence, risk factors and persistence of acute kidney injury following ureteroscopy and laser lithotripsy: Results from a tertiary care referral center**

L. Candela, Milan (IT)

P363

**Is Bladder Catheterization Necessary After Ureteroscopy and DJ Stent Placement? A Randomized Prospective YAU Endourology & Urolithiasis Study**

M. Cetin, Istanbul (TR)

### Study Group

Young Academic Urologists Endourology and Urolithiasis Working Party(Arnhem, The Netherlands)

P364

**"Who's at risk? New postoperative hydronephrosis in ureteroscopy patients without prior hydronephrosis"**

G. Fernandez Moncaleano, Royal Oak (US)

### Study Group

for the Michigan Urological Surgery Improvement Collaborative(Ann Arbor MI, United States of America)

P359

**Video gaming and surgical proficiency: Investigating the impact of video gaming experience to Flexible Ureteroscopy (FURS) among post-graduate medical interns**

T.M. Yanga, Zamboanga City (PH)

12:54 - 13:21

## Screen B: The battle between thulium fiber and Holmium: YAG laser

P370	<p><b>Safety and Outcomes of Ureterorenoscopy with High-Power Thulium Yag Laser for Urolithiasis: First Case Series in our High-Volume institution</b></p> <p>L. Cacciatore, (IT)</p>
P367	<p><b>Prospective randomized trial comparing high power Holmium:YAG and thulium fiber laser for retrograde ureteroscopy: preliminary clinical results, environmental noise analysis, and surgeon satisfaction</b></p> <p>L. Vergamini, Kansas City (US)</p>
P373	<p><b>Who is the winner? Superpulsed Thulium Fiber Laser Vs. Pulse Modulated High Power Holmium:YAG Laser For Retrograde Intrarenal Surgery: A Randomized Control Trial</b></p> <p>A. Ricapito, Foggia (IT)</p>
P360	<p><b>Thulium:YAG (Yttrium Aluminium Garnet) pulsed laser vs Holmium:YAG laser in RIRS (retrograde intrarenal surgery): a comparative prospective study</b></p> <p>B. Carbonaro, Cuneo (IT)</p>
P376	<p><b>Tantalizing Thulium vs Hallowed Holmium : A Prospective Randomized Controlled Trial comparing The Efficacy &amp; Efficiency of Thulium Fiber Laser And Holmium: Yttrium Aluminium Garnet Laser for Stone Lithotripsy during Retrograde Intrarenal Surgery for Renal Calculus of 1 to 2 cm</b></p> <p>P. Nanavati, Hyderabad (IN)</p>
P368	<p><b>Thulium fiber laser versus high-power Holmium:YAG laser in mini-endoscopic combined intrarenal surgery for treatment of kidney stones: a practical comparison</b></p> <p>L. Vergamini, Kansas City (US)</p>
P357	<p><b>Thulium Laser Lithotripsy for Retrograde Intra-Renal Surgeries : YAG or Fiber ? a prospective evaluation</b></p> <p>F. Panthier, Paris (FR)</p> <p><b>Study Group</b> GRC 20 Groupe de Recherche Clinique sur la Lithiase Urinaire Hopital Tenon Sorbonne University(Paris, France)</p>
P355	<p><b>Holmium versus Thulium laser for Renal Stone Lithotripsy during Retrograde Intrarenal Surgery: Outcomes from a prospective multicenter study</b></p> <p>F. Cabrera Meiras, Madrid (ES)</p>
P362	<p><b>Is “kidney stone calculator” efficient in predicting ureteroscopic lithotripsy duration? A ho:yag and thulium fiber lasers comparative analysis</b></p> <p>M. Chicaud, Dax (FR)</p>
<hr/>	
<b>13:21 - 13:39</b>	<b>Screen C: New technology</b>
P361	<p><b>The ILY® robotic system for flexible ureteroscopy: first italian case series in a single center</b></p> <p>A. Quarà, Baldissero Torinese (IT)</p>
P378	<p><b>Stone size guidance of robotic RIRS, Zamenix</b></p> <p>K-S. Song, Daejeon (KR)</p>
P366	<p><b>Retrograde intrarenal surgery using the ILY robotic flexible ureteroscope: a single centre experience</b></p> <p>W. Krajewski, Wrocław (PL)</p>
P353	<p><b>Comparative analysis of light sources and illumination in flexible ureteroscopy: fundamental findings from a PEARLS analysis</b></p> <p>J-L. Kwok, Singapore (SG)</p>



- P379 **Washing out stone dust: does ureteroscopic irrigation work?**  
B. Yang, Oxford (GB)
- P371 **Fluid dynamics within the renal cavities during endoscopic stone surgery: Does the position of the flexible ureteroscope and ureteral access sheath affect the outflow rate?**  
A. Tsaturyan, Yerevan (AM)  
**Study Group**  
EAU Young Academic Urologists Urolithiasis and Endourology Working Group(Arnhem, The Netherlands)
- 
- 13:39 - 14:00** **Screen D: What is the best approach for stones?**
- P375 **PUR RCT 1: Clinical and cost-effectiveness of Flexible Ureterorenoscopy and Extracorporeal Shockwave Lithotripsy for lower pole stones ≤10 mm**  
To be confirmed
- P380 **PUR RCT 2: Clinical and cost-effectiveness of FURS and Percutaneous Nephrolithotomy for lower pole stones 10-25mm**  
R.D. Smith, London (GB)
- P352 **Retrograde Intrarenal Surgery (RIRS) Versus Mini-Percutaneous Nephrolithotripsy (Mini-PCNL) In Treatment Of Renal Stones 1.5 to 2 cm in Diameter Using Holmium Laser : A Prospective Randomized Study**  
H.M. Singh, Chennai (IN)
- P377 **Efficacy and Patient Satisfaction Of Flexible Ureteroscopy, Semirigid Ureteroscopy And Extracorporeal Shockwaves Lithotripsy In The Management Of Proximal Ureteric Stones .5 to 1.5 cm: A Randomized Trial**  
A. Tharwat Abdelghafour, Faqous (EG)
- P374 **Miniaturized percutaneous nephrolithotomy versus retrograde intrarenal surgery in the treatment of renal calculi larger than 20 mm: A propensity score-matched analysis**  
A. Sakly, Monastir (TN)
- P372 **Laparoendoscopic Rendezvous Ureterolithotomy for Unilateral Upper Tract Stones in the Galdakao Modified Supine Valdivia Position**  
C.H. Huang, Kaohsiung City (TW)
- P365 **Comparison of Transperitoneal Laparoscopic Ureterolithotomy, Retrograde Flexible Ureteroscopy, and Mini- percutaneous Antegrade Ureteroscopic Lithotripsy in the Management of Large Proximal Ureteral Stones (1.5-2 cm): A Prospective Randomized Trial.**  
A. Zoair, TANTA (EG)

# Best of EAU24: Take Home Messages

Special Session

**Monday 8 April**

**14:15 - 16:15**

**Location** Green Area, eURO Auditorium 1

**Chairs** P. Albers, Düsseldorf (DE)  
A. Stenzl, Tübingen (DE)

**Learning objectives**

This session summarises the scientific highlights of the Annual EAU Congress.

**14:15 - 14:20**

**Welcome and introduction**

**14:20 - 14:30**

**Prostate cancer**

A. Villers, Lille (FR)

**14:30 - 14:40**

**Paediatric urology**

A-F. Spinoit, Ghent (BE)

**14:40 - 15:00**

**Bladder cancer & Upper Tract TCC**

J. Boormans, Rotterdam (NL)

**15:00 - 15:10**

**Renal cancer**

M.C. Mir Maresma, Valencia (ES)

**15:10 - 15:20**

**BPH/LUTS**

J-N.L. Cornu, Rouen (FR)

**15:20 - 15:30**

**Functional urology**

J. Heesakkers, Maastricht (NL)

**15:30 - 15:40**

**Imaging**

J. Walz, Marseille (FR)

**15:40 - 15:50**

**Stones**

T. Knoll, Sindelfingen (DE)

**15:50 - 16:00**

**Andrology**

M. Albersen, Leuven (BE)

**16:00 - 16:10**

**Testis/Penile cancer**

M. Albersen, Leuven (BE)

**16:10 - 16:15**

**Closing remarks by the EAU Scientific Congress Committee Chair**

P. Albers, Düsseldorf (DE)